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ABSTRACT 
Parkinson’s disease (PD) is a progressive and debilitating neurodegenerative disorder, characterized 
by a distinct motor phenotype and the selective loss of dopaminergic neurons in the substantia nigra. 
While the etiology of PD is not fully understood, it is thought to involve a combination of different 
genetic, cellular and environmental factors that independently or concurrently contribute to 
neurodegeneration. To date, several PD-causing genes have been identified, and investigations of their 
function have provided novel insights into the pathobiology of disease. Particularly interesting among 
the known PD genes is parkin, mutations in which are the most common genetic cause of early onset 
PD. Parkin is an E3 ligase that ubiquitinates protein substrates and targets such substrates for 
degradation via the ubiquitin proteasome system (UPS). Therefore, the loss of parkin may result in the 
deleterious accumulation or dysregulation of parkin substrates and neurotoxicity. Parkin’s enzymatic 
activity has also been implicated in the maintenance of mitochondrial health, and mitochondrial 
dysfunction is commonly reported in cellular and animal models of parkin deficiency.  
This study aimed to investigate parkin and its role in PD on various levels. Initially, genetic screening 
approaches were used to assess the contribution of parkin mutations to PD in a group of 229 South 
African patients. It was concluded that parkin mutations are rare in the South African PD population, 
being present in only seven (3.1%) patients in the study group. Interestingly, this study identified two 
of only three Black African PD patients with mutations in a known PD-causing gene to date. The low 
frequency of known PD genes raises the interesting possibility that the unique South African ethnic 
groups may harbor mutations in novel PD-causing genes.  
Although many parkin-interacting proteins have been identified in the literature, it is anticipated that 
novel, pathologically-relevant parkin substrates remain to be discovered. Hence, this study used a 
yeast two-hybrid (Y2H) approach to identify novel parkin interactions. This yielded 29 putative 
parkin interactors, of which four, namely ATPAF1, SEPT9, actin and 14-3-3η, were prioritized for 
verification by co-localization and co-immunoprecipitation experiments. Interestingly, two of the 
parkin interactors (ATPAF1 and SEPT9) were found to accumulate in the absence of parkin, 
supporting their role as authentic parkin substrates. The identification of these two intriguing proteins 
implicates parkin in the regulation of mitochondrial ATP synthase assembly and septin filament 
dynamics, which may be of significant relevance to our understanding of processes underlying 
neurodegeneration.   
Moreover, it was aimed to assess various markers of mitochondrial function in a parkin-deficient 
cellular model, as previous studies had reported conflicting results regarding mitochondrial 
impairments in patient-derived cells with parkin mutations. Hence, dermal fibroblasts were obtained 
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from PD patients with homozygous parkin mutations, after which cell growth and viability, 
mitochondrial membrane potential, respiratory rates and the integrity of the mitochondrial network 
were assessed. Surprisingly, it was found that cell growth was significantly higher in the parkin-
mutant fibroblasts compared to wild-type controls fibroblasts under basal conditions (p=0.0001), 
while exhibiting a greater inhibition of cell growth in the presence of the mitochondrial toxin CCCP 
(p=0.0013). Furthermore, whereas the mitochondrial networks of patient-derived fibroblasts were 
more fragmented than controls (p=0.0306), it was found that mitochondrial respiratory rates were 
paradoxically higher in the patients (p=0.0355). These unanticipated findings are suggestive of a 
compensatory response to the absence of parkin. 
The parkin-deficient cellular model was also used in a pilot study of the functional effects of vitamin 
K2 treatment, which has recently been identified as a promising PD therapeutic modality. It was found 
that treatment with vitamin K2 resulted in more interconnected mitochondrial networks (p=0.0001) 
and enhanced respiratory rates (p=0.0459) in both parkin-mutant and wild-type control cells. While 
these results need to be studied further, it suggests that vitamin K2 supplementation may be of use as a 
general promoter of mitochondrial integrity and function.  
In conclusion, this dissertation highlights some novel interactions of the parkin protein and some 
interesting phenotypes of parkin deficiency. It is hoped that further investigation of parkin and its role 
in PD will, ultimately, aid in the development of therapeutic strategies to treat this debilitating and 
poorly-understood disorder.  
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
OPSOMMING 
 
Parkinson se siekte (PS) is 'n progressiewe en aftakelende neurodegeneratiewe kondisie, wat 
gekarakteriseer word deur 'n kenmerkende bewegingsfenotipe en die selektiewe afsterwing van 
dopaminergiese neurone in die substantia nigra. Terwyl die etiologie van PS nie ten volle verstaan is 
nie, behels dit waarskynlik 'n kombinasie van verskillende genetiese, sellulêre en omgewings-faktore 
wat onafhanklik of gelyktydig lei tot senuwee-afsterwing. Tot op hede is daar al verskeie PS-
veroorsakende gene geïdentifiseer, en die bestudering van hul funksie het nuwe insigte in die 
patobiologie van hierdie siekte verskaf. Onder meer hierdie PS gene is parkin van besondere belang, 
aangesien mutasies in parkin die mees algemene genetiese oorsaak van vroeë-aanvang PS is. Parkin is 
'n E3 ligase-ensiem wat proteïen substrate ubiquitineer en teiken vir degradasie via die ubiquitien 
proteasoomstelsel (UPS). Dus kan die verlies van parkin lei tot die beskadigende opeenhoping of 
wanregulasie van parkin substrate en senuwee-afsterwing. Parkin se ensiematiese aktiwiteit is ook 
betrokke by die instandhouding van mitokondriale gesondheid, en mitokondriale afwykings word 
dikwels gerapporteer in sellulêre en diermodelle van parkin tekort. 
Hierdie studie het gepoog om parkin en sy rol in PS op verskillende vlakke te ondersoek. Aanvanklik 
is genetiese siftingsbenaderinge gebruik om die bydrae van parkin mutasies tot PS in 'n groep van 229 
Suid-Afrikaanse pasiënte te evalueer. Die gevolgtrekking is bereik dat parkin mutasies skaars is in die 
Suid-Afrikaanse PS bevolking, aangesien dit teenwoordig is in net sewe (3.1%) pasiënte in die studie 
groep. Interessant genoeg, hierdie studie het twee van slegs drie gevalle van Swart Afrika-pasiënte 
met mutasies in 'n bekende PS geen to op datum geïdentifiseer. Die lae frekwensie van bekende PS 
gene versterk die stimulerende moontlikheid dat die unieke Suid-Afrikaanse sub-populasies dalk 
mutasies in nuwe PS-veroorsakende gene mag koester. 
Alhoewel baie parkin proteïen-interaksies reeds in die literatuur geïdentifiseer is, word daar verwag 
dat nuwe, patologies-relevante parkin substrate nog wag om ontdek te word. Dus het hierdie studie 'n 
gis twee-hibried (G2H) benadering gebruik om nuwe parkin interaksies te identifiseer. Hierdie het 29 
vermeende parkin interaktors opgelewer, waarvan vier, naamlik ATPAF1, SEPT9, aktien en 14-3-3η, 
geprioritiseer is vir verifikasie deur mede-lokalisering en mede-immunopresipitasie eksperimente. 
Interessant genoeg, daar is gevind dat twee van die parkin interaktors (ATPAF1 en SEPT9) ophoop in 
die afwesigheid van parkin, wat hul rol as werklike parkin substrate ondersteun. Die identifisering van 
hierdie twee interessante proteïene impliseer parkin in die regulering van mitokondriale ATP sintase 
vervaardiging en septienfilament dinamika, wat moontlik van beduidende belang is vir ons begrip van 
die onderliggende prosesse wat senuwee-afsterwing veroorsaak. 
Stellenbosch University  https://scholar.sun.ac.za
Verder is daar daarop gemik om verskeie aanwysigings van mitokondriale funksie in 'n parkin-
gebrekkige sellulêre model te evalueer, aangesien vorige studies teenstrydige resultate rapporteer 
rakende mitokondriale afwykings in pasiënt-selle met parkin mutasies. Dus is daar dermale 
fibroblaste verkry van PS pasiënte met homosigotiese parkin mutasies, waarna sel-groei en 
lewensvatbaarheid, mitokondriale membraanpotensiaal, respiratoriese tempo en die integriteit van die 
mitokondriale netwerk geëvalueer is. Daar is verbasend gevind dat sel-groei aansienlik hoër is die 
parkin-mutante fibroblaste in vergelyking met wilde-tipe kontrole fibroblaste onder basale kondisies 
(p=0.0001), terwyl hulle 'n groter inhibisie van sel-groei in die teenwoordigheid van die mitokondriale 
toksien CCCP ondergaan (p=0.0013). Verder, terwyl die mitokondriale netwerke van pasiënt 
fibroblaste meer gefragmenteer is as die van kontroles (p=0.0306), is daar gevind dat mitokondriale 
respiratoriese tempo’s, paradoksaal-gewys, hoër is in die pasiënte (p=0.0355). Hierdie onverwagte 
bevindinge is suggestief van die aanskakeling van 'n vergoedende respons-proses in die afwesigheid 
van parkin. 
Die parkin-gebrekkige sellulêre model is ook gebruik in 'n voorlopige studie van die funksionele 
effekte van vitamiene K2 behandeling, wat onlangs geïdentifiseer is as 'n belowende terapeutiese 
moontlikheid vir PS. Daar is gevind dat sel-behandeling met vitamiene K2 lei tot meer 
geïnterkonnekteerde mitokondriale netwerke (p=0.0001) en verbeterde respiratoriese fuksie 
(p=0.0459) in beide parkin-mutante en wilde-tipe kontrole selle. Terwyl hierdie resultate verder 
bestudeer sal moet word, dui dit daarop dat vitamiene K2-aanvulling moontlik gebruik kan word as 'n 
algehele promotor van mitochondriale integriteit en funksie. 
Ten slotte, hierdie verhandeling beklemtoon ‘n paar nuwe interaksies van die parkin proteïen en 'n 
paar interessante fenotipes van parkin tekort. Daar word gehoop dat verdere ondersoek van parkin en 
parkin se rol in PS sal, uiteindelik, steun in die ontwikkeling van terapeutiese strategieë om hierdie 
aftakelende en swak-verstaande wanorde beter te behandel. 
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OUTLINE OF THE DISSERTATION  
 
This dissertation involves a genetic and functional investigation of parkin and its role in Parkinson’s 
disease (PD). As such, it examines the contribution of parkin mutations to PD in South African 
patients, highlights novel parkin-interacting proteins and evaluates cellular function in a parkin-
deficient cell model. Furthermore, it explores the therapeutic compound vitamin K2 as a possible PD 
treatment modality.  
This dissertation is divided into four chapters: 
Chapter one provides an overview of what is currently known about PD, with a particular emphasis 
on the genetics and pathobiology of this disease. As this dissertation will be specifically focusing on 
the role of parkin in PD, a review of the literature on parkin is provided. Previous studies on the 
therapeutic potential of vitamin K2 for PD will also be highlighted. Lastly, the overall aims and 
objectives of this study will be outlined. 
Chapter two details the methodological approaches used in this dissertation, and is organized into 
three parts. The first part describes a molecular genetic screen of parkin for pathogenic mutations, the 
second part entails experimental procedures used to identify and characterize parkin-interacting 
proteins, and the third part provides methods employed in the functional evaluation of cellular health 
in a model of parkin deficiency.  
Chapter three relays the results obtained from the present study. It includes the findings on the 
frequency of parkin mutations South African PD patients, the identification and verification of four 
parkin interactors, interesting cellular phenotypes observed in a parkin-deficient cell model and 
describes the effect of treatment with vitamin K2 on several parameters of cellular health.  
Chapter four provides a discussion of the important findings of this dissertation, and highlights the 
possible relevance of these findings to PD research. It furthermore advises on proposed future work 
that may expand our current understanding of parkin and its role in PD. 
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CHAPTER ONE: INTRODUCTION 
 
PART ONE: PARKINSON’S DISEASE (PD) 
 
1.1 PD – HISTORICAL CONTEXT 
Almost two centuries ago, the English apothecary James Parkinson provided the first clear medical 
description of the disorder which now bears his name, in “An Essay on the Shaking Palsy” (Parkinson 
1817). In this landmark publication, Parkinson described six patients with “involuntary tremulous 
motion, with lessened muscular power, in parts not in action and even when supported; with a 
propensity to bend the trunk forwards, and to pass from a walking to a running pace: the senses and 
the intellects being uninjured”. The French neurologist Jean-Martin Charcot later expanded on the 
formal clinical description of this disorder and named it Parkinson’s disease (PD), in recognition of 
the work of James Parkinson (Charcot 1880). However, Parkinson himself acknowledged that 
parkinsonism-like symptoms were noticed by several earlier authors, including Galen, Sylvius de la 
Boë, Boissier de Sauvages and Juncker (Parkinson 1817). For example, Galen described a condition 
involving tremors that occurred only at rest, postural instability and paralysis, whereas Sauvages 
described festination, a term for the gait abnormalities characteristic of PD (Raudino 2012). 
Ayurvedic Indian texts dating from the tenth century BC and ancient Chinese sources included 
descriptions highly reminiscent of PD, suggesting that this disorder was known to several ancient 
civilizations (Manyam 1990; Zhang et al. 2006). Nonetheless, the great merit of Parkinson’s essay 
was its focused and careful description of PD’s cardinal symptoms, accurate account of the course of 
the malady as well as in distinguishing PD from similar disorders. The contribution of Parkinson’s 
work is increasingly recognized and his birthday, 11 April, is celebrated as World PD Day.   
Parkinson’s expressed hope that his monograph would spur pathologists to find the anatomical 
substrate of PD had to wait 80 years. After Paul Blocq and Georges Marinesco published their case 
report of a tuberculomatous lesion in the midbrain which resulted in parkinsonism (Blocq and 
Marinesco 1894), Edouard Brissaud speculated that an ischemic lesion of the substantia nigra might 
be principally responsible for PD (Brissaud 1895). Brissaud’s hypothesis was later confirmed by 
Konstantin Tretiakoff, who consistently observed substantia nigral degeneration in autopsied PD 
patients and also found associated “senile lesions” in the affected areas (Tretiakoff 1919). 
Furthermore, a majority of the PD brains also had “corps de Lewy”, neuronal inclusions described 
seven years earlier by Frederic Lewy (Lewy 1912). Despite Tretiakoff’s study, severe damage to the 
substantia nigra was not generally accepted as the critical pathological hallmark of PD until later 
confirmatory work of Rolf Hassler (1938) and then John Greenfield and Frances Bosanquet (1953) 
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was published. Further noteworthy historical advances include elucidation of the biochemical basis of 
PD, centered on the newly discovered role of the neurotransmitter dopamine in PD (Carlsson et al. 
1958), the introduction of dopamine replacement via levodopa therapy for the management of motor 
symptoms, and the discovery of genetic factors that contribute to PD (Polymeropoulos et al. 1997).  
After two centuries since the publication of Parkinson’s seminal monograph, and great leaps and 
bounds in our understanding of the anatomical and molecular pathology of this disorder, many key 
questions concerning PD pathogenesis remain unanswered, and PD remains without a cure. It is 
hoped that a wider and deeper understanding of the genes, proteins and pathways involved in PD will 
aid in the development of neuroprotective or therapeutic interventions that may prevent or treat the 
underlying pathology of this debilitating disorder. 
 
1.2 EPIDEMIOLOGY OF PD 
Published estimates of the prevalence and incidence of PD vary greatly according to the applied 
methodology, which complicates cross-study comparisons. Epidemiological studies are particularly 
sensitive to differences in diagnostic criteria and case-finding strategies; record-based studies and 
studies performed in clinical settings do not include patients who failed to seek medical attention and 
therefore generally underestimate the prevalence or incidence in the general population. Nonetheless, 
the quantity of publications on PD epidemiology, over 80 prevalence and 25 incidence studies, allow 
for confident estimations of PD prevalence and incidence (at least for developed nations) (Wirdefeldt 
et al. 2011).  
 
1.2.1 Prevalence 
The reported prevalence of PD ranges from 100 to 5703 per 100 000, with studies on the elderly 
population (typically over the age of 60) reporting the highest figures (Kuopio et al. 1999; de Rijk et 
al. 2000; Barbosa et al. 2006; Peters et al. 2006; Racette et al. 2009). A meta-analysis of twelve high-
quality North American and European studies estimated the prevalence of PD in the population over 
the age of 65 at 950 per 100 000 (Hirtz et al. 2007). A further study that reviewed data from six 
European prevalence studies and country-specific population structure data estimated the worldwide 
total number of PD patients over the age of 50 at between 4.1 and 4.6 million in 2005; this number 
was projected to double to between 8.7 and 9.3 million by the year 2030 (Dorsey et al. 2007). 
Age is a significant risk factor for PD: it is very rare before the age of 40 and the prevalence increases 
steeply after the age of 60, with up to and above 4000 per 100 000 reported in the highest age groups 
(de Rijk et al. 1995; Clavería et al. 2002; Benito-León et al. 2003). Most cases of PD manifest around 
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the age of 60 years (Jankovic 2008). Some studies report a decline in prevalence rates in the age group 
above 80 years (Wang et al. 1991; Benito-León et al. 2003), but this is probably an artefact resulting 
from PD misdiagnosis due to disease comorbidity, patient loss to follow-up or smaller patient sample 
sizes (de Rijk et al. 2000).     
Geographic and ethnic variation in PD prevalence is interesting from an etiological point of view, as 
such variation might result from differences in environmental exposures or distribution of 
susceptibility alleles (de Lau and Breteler 2006). Several studies have reported lower prevalence 
figures in Africa (Schoenberg et al. 1988), Asia (Wang et al. 1991), and South America (Melcon et al. 
1997) than Europe. This is supported by calculations of age-standardized prevalence proportions 
which found a 13-fold difference in age-standardized prevalence across populations; the study found 
the lowest prevalence in China, Japan and Africa (Zhang and Román 1993). However, more recent 
studies report PD prevalence in China (Zhang et al. 2005) and South America (Barbosa et al. 2006) as 
being similar to European populations. The previously reported differences may result from 
methodological and case-ascertainment concerns, rather than true ethnic differences (Alves et al. 
2008). The low PD prevalence in Africa may be due to a shorter life expectancy in comparison to the 
developed world (McInerney-Leo et al. 2004). Indeed, PD prevalence estimates in Africa are lowest 
in countries of Eastern and Western Africa, where life expectancy is lowest, while Northern African 
countries have reported prevalences comparable to developed countries (Okubadejo et al. 2006). 
Another plausible reason for low prevalence in Africa is the relative underdiagnosis of PD in Africa 
due to socioeconomic and cultural factors (McInerney-Leo et al. 2004). 
 
1.2.2 Incidence  
Comparatively fewer PD incidence than prevalence studies have been published. Overall, these 
studies report annual incidence estimates for all age groups ranging from 2 to 22 per 100 000 
(Mayeux et al. 1995; Bower et al. 1999; de Lau et al. 2004), with studies restricted to the elderly (over 
the age of 65) reporting estimates of 410 to 529 per 100 000 (Benito-León et al. 2004; Driver et al. 
2009). A meta-analysis of eight high-quality incidence studies estimated an age-standardized PD 
incidence of 14 per 100 000 in developed countries (Hirtz et al. 2007); this figure rose to 160 per 
100 000 when the analysis was restricted to studies of elderly patients (Hirtz et al. 2007). 
As with PD prevalence, PD incidence rates are very low under the age of 40 and rise sharply after the 
age of 60, attesting to the importance of age as a PD risk factor (Van Den Eeden et al. 2003). A 
similar drop in PD incidence figures are reported for the old age groups (Morens et al. 1996; Bower et 
al. 1999); however, there is some debate over whether this decline is real or due to underdiagnosis 
(Driver et al. 2009).  
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Comparison of PD incidence across different countries is hampered by differences in study 
methodology in the various publications (e.g. reporting on crude incidence v. population-adjusted 
incidence). Most European studies report overall incidence estimates between 9 and 22 per 100 000 
(Taba and Asser 2003; Linder et al. 2010), whereas the corresponding estimates for Asian populations 
range from 1.5 to 17 per 100 000 (Wang et al. 1991; Morioka et al. 2002). Only a single study report 
on PD incidence in Africa, estimating the incidence in North-East Libya at 4.5 per 100 000 (Ashok et 
al. 1986). Few epidemiological studies consider incidence differences among ethnic populations 
within the same study group. In a study of a multi-ethnic Californian population, PD incidence was 
highest in Hispanic individuals, followed by non-Hispanic White, Asian and Black individuals (Van 
Den Eeden et al. 2003). Given the scarcity of incidence data for non-White populations, conclusive 
ethnic differences in PD incidence are a matter of debate.   
 
1.3 NEUROPATHOLOGY OF PD 
The primary neuropathological hallmark of PD is the loss of neuromelanin-containing dopaminergic 
neurons in the substantia nigra pars compacta (SNpc), which forms an integral part of the basal 
ganglia motor circuit. The neuronal loss characteristic of PD is illustrated in Figure 1.1. Such 
degeneration of neurons of the nigrostriatal pathway depletes the basal ganglia of dopamine, resulting 
in the distinguishing motor features of PD (Hornykiewicz 2008). Neuronal loss in the SNpc is most 
pronounced in the ventrolateral tier of neurons, which project to the striatum. Accompanying this loss 
is an increase in microglial activation and astrocytosis and a decrease in neuromelanin pigmentation 
in the affected area (Teismann and Schulz 2004). The extent of neuron loss in the SNpc has been 
shown to correlate well with the severity of many of the motor features of PD (Vingerhoets et al. 
1997). It is estimated that, by the time of the first appearance of motor symptoms, approximately 40-
60% of dopaminergic neurons of the SNpc have been lost, leading to an 60-80% reduction in 
nigrostriatal dopamine (Fearnley and Lees 1991; Halliday et al. 1996). Extrapolation of such findings 
suggests a preclinical phase of PD with progressively worsening SNpc degeneration of about 5 years 
(Greffard et al. 2006).  
While the biggest emphasis is consistently placed on degeneration of the nigrostriatal pathway, it 
should be noted that PD-associated degeneration is not restricted to the SNpc.  Dopaminergic and 
nondopaminergic neuronal loss can be found in the locus ceruleus, dorsal nuclei of the vagus, raphe 
nuclei, nucleus ambiguus, nucleus basalis of Meynert and several other areas of the brainstem (Braak 
and Braak 2000). The recognition of this extranigral pathology in PD is important for the proper 
management of the non-motor symptoms of PD, which usually do not respond well to treatment with 
the dopamine precursor levodopa or dopamine agonists (Chaudhuri and Odin 2010).   
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Figure 1.1 Neuropathology of Parkinson’s disease. A, brain regions and neuronal pathways 
affected by PD. The principal affected pathway is the dopaminergic neurons of the nigrostriatal 
pathway (red arrows) whose cell bodies are located in the substantia nigra pars compacta (SNpc).  
These neurons project to the basal ganglia and synapse at the striatum (both the caudate nucleus and 
the putamen). Degeneration of the nigrostriatal pathway in PD leads to a dopamine deficit resulting in 
dysregulation of the basal ganglia. B, depigmentation (loss of neuromelanin) in PD-affected SNpc due 
to the loss of dopaminergic neurons. Illustrated are transverse sections through the superior colliculus 
of an unaffected individual (top) and a PD patient (bottom). C, histology of unaffected SNpc showing 
many pigmented neurons. D, histology of PD-affected SNpc showing severe loss of pigmented cells. 
E, immunohistochemical labeling of Lewy bodies (LBs) in a PD-affected SNpc. Immunostaining with 
an α-synuclein antibody reveals dark-staining intraneuronal inclusions. (Figures adapted from 
http://neuropathology-web.org). Abbreviations: LB, Lewy body; PD, Parkinson’s disease; SNpc, 
substantia nigra pars compacta.    
 
 
In addition to the loss of dopaminergic neurons, a defining hallmark of PD is the presence of 
intraneuronal inclusions, or Lewy bodies (LBs), in the surviving neurons of affected brain regions. 
LBs are spherical, eosinophilic, cytoplasmic aggregates which consist of a heterogeneous mixture of 
over a hundred various proteins (Wakabayashi et al. 2013). The main component of LBs is aggregated 
α-synuclein protein; α-synuclein antibodies are routinely used for the immunohistochemical detection 
of LB pathology during post-mortem diagnosis (Figure 1.1E). Considerations of the distribution of LB 
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pathology has led Braak et al. (2003) to propose that LB formation and neurodegeneration is not 
random but spreads along interconnected brain regions in a regular pattern as PD progresses. This six-
stage pathological process begins at induction sites with degeneration of the olfactory bulb and the 
lowest parts of the brainstem, spreads rostrally up the brainstem to the raphe nuclei and locus ceruleus 
and progresses to encompass the SNpc. Later stages of disease involve LB pathology in the 
paralimbic regions and thalamus, spreading to the prefontal motor cortex and finally the entire 
neocortex at the terminal stages. Several studies have confirmed the validity of the Braak staging 
system, although it remains a subject of much debate and roughly 15% of PD patients do not conform 
to the proposed pattern (Kalaitzakis et al. 2008; Parkkinen et al. 2008). It has been suggested that 
many of the non-motor features of PD are related to the earlier Braak stages (Langston 2006).  
 
1.4 CLINICAL FEATURES OF PD 
PD is classically characterized by four cardinal motor features: bradykinesia, tremor at rest, rigidity 
and postural and gait impairment. However, each of these symptoms are not always present in every 
patient diagnosed with PD, as PD symptoms vary considerably with the diverse profiles and lifestyles 
of patients (Jankovic 2008). Motor features have traditionally defined the disorder, possibly because 
they are visually recognizable to even untrained observers. Nonetheless, various non-motor symptoms 
are frequently present in PD patients, including autonomic dysfunction, cognitive and psychiatric 
disturbances, sensory abnormalities and sleep disorders. Recent years have seen an increased interest 
in the non-motor features of PD not only because their presence aid in PD diagnostic purposes, but 
also because of the severe reduction in quality of life that these features bring about in PD patients, 
often necessitating specialized care (Lim et al. 2009; Gallagher et al. 2010).  
 
1.4.1 Motor symptoms 
1.4.1.1 Bradykinesia 
Bradykinesia, or slowness of movement, is the most characteristic and disabling symptom of PD, and 
encompasses problems in planning, initiating and executing movement. It is characterized by the 
progressive loss of speed or amplitude during the execution of a motor action. Bradykinesia initially 
presents as difficulties with fine motor tasks, such as handwriting or tying up shoelaces, as well as 
slow movement and reaction times (Berardelli et al. 2001). Other manifestations of bradykinesia 
include loss of spontaneous movements, reduced arm swinging while walking, loss of facial 
expression (hypomimia) and decreased blinking, speech impairment and drooling resulting from 
swallowing difficulties (Bagheri et al. 1999).  
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1.4.1.2 Rigidity 
Rigidity manifests as increased muscle tone resulting in stiffness and resistance to movement in joints. 
Passive movement of the limbs often results in ratchet-like movements, especially when related to an 
underlying tremor. This rigidity is present throughout the range of movement, and is increased by 
voluntary movements of the contralateral limb (Rodriguez-Oroz et al. 2009). Rigidity is often 
associated with pain, especially of the neck and shoulders; a painful shoulder is a frequent first 
presenting motor symptom of PD, although this often goes undiagnosed (Stamey et al. 2008)   
 
1.4.1.3 Resting tremor 
Tremor at rest is the most recognizable feature of PD, and is the first symptom in approximately 70% 
of PD patients (Hughes et al. 1993). Resting tremor is the rhythmic and involuntary movement of a 
body part that is not associated with any voluntary activity. The hands are most commonly affected, 
but tremor can also affect the lips, chin, legs and trunk; hand tremors are often described as “pill-
rolling”, involving a supination-pronation movement (Deuschl et al. 2000). Resting tremor is usually 
asymmetric at onset and worsens under stress or heightened emotion. Characteristically, resting 
tremor ceases with voluntary action and during sleep. 
 
1.4.1.4 Postural and gait impairment 
Patients with PD usually adopt a stooped posture with neck and trunk flexion due to the loss of 
postural reflexes (Jankovic 2008). The characteristic gait of PD patients is slow with short shuffling 
steps; turning around requires multiple small steps. Parkinsonian gait can also involve gait freezing, a 
sudden gait impediment where patients feel as if their feet are “glued to the floor” (Giladi et al. 1997). 
Postural instability refers to the gradual development of impaired balance, and usually only presents 
late in disease progress. Postural instability and gait abnormalities are the most common causes of 
falls among PD patients and significantly contribute to the risk of hip fractures (Williams et al. 2006).  
 
1.4.2 Non-motor symptoms 
1.4.2.1 Autonomic dysfunction 
Autonomic dysfunction is a common non-motor feature of PD and encompasses orthostatic 
hypotension, urinary dysfunction, erectile dysfunction and constipation. Orthostatic hypotension is 
reported in approximately 35% of PD patients and presents as dizziness, nausea, drowsiness and loss 
of consciousness (Low 2008). As such, orthostatic hypotension significantly increases the risk of falls 
(Matinolli et al. 2009). Urinary dysfunction, in the form of urge incontinence, urinary urgency or high 
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frequency of urination, was found to affect between 50% and 70% of PD patients (Martinez-Martin et 
al. 2007). The same study found that erectile dysfunction affects 42% of patients. Constipation is a 
very common non-motor feature of PD, with a reported prevalence ranging from 40% to 80% of 
patients (Jost 1997; Khoo et al. 2013). Interestingly, constipation predates onset of the first noticeable 
motor symptoms of PD in about half of PD patients, whereas other signs of dysautonomia such as 
orthostatic hypertension and urinary dysfunction are late features of PD (Pellicano et al. 2007). 
 
1.4.2.2 Cognitive and psychiatric disturbances 
Neuropsychiatric abnormalities are common and disabling non-motor features of PD. Cognitive 
decline is a near universal feature of PD, and results in impairment of problem-solving, planning and 
learning abilities (Barone et al. 2011). The prevalence of dementia has been estimated at 30% 
(Aarsland et al. 2005), with PD patients being at a six-fold increased risk of dementia (Aarsland et al. 
2001). Other psychiatric disturbances such as depression, anxiety, apathy, obsessive-compulsive 
behavior and psychosis are also commonly seen in PD patients (Bernal-Pacheco et al. 2012). 
Psychosis, usually in the form of paranoid delusions and hallucinations, has a reported prevalence as 
high as 50% in PD patients (Fénelon 2008) and is a significant factor leading to the need for full-time 
care in a nursing home (Aarsland et al. 2000). Depression affects around 35-50% of PD patients and 
can be present years before the manifestation of motor symptoms (Lieberman 2006).  
 
1.4.2.3 Sensory abnormalities 
Sensory symptoms, including olfactory dysfunction and unexplained painful sensations, are 
frequently present in patients diagnosed with PD. Painful sensations, manifesting as tingling, burning, 
neuralgia or diffuse pain are experienced by approximately 50% of PD patients (Tinazzi et al. 2006). 
A prominent sensory symptom of PD is loss of smell, or hyposmia, which affects up to 90% of PD 
patients (Ponsen et al. 2004) and has been associated with degeneration of the olfactory bulb (Pearce 
et al. 1995). Hyposmia is often present at diagnosis of PD and does not appear to progress over the 
course of disease. Idiopathic hyposmia is correlated with an increased risk of developing PD and may 
therefore be an early preclinical sign of PD (Ross et al. 2008a). 
 
1.4.2.4 Sleep disorders 
Sleep disturbances, such as excessive daytime sleepiness, frequent awakenings, sleep attacks and 
insomnia, were previously ascribed to anti-parkinsonian medications (Ondo et al. 2001), but are now 
recognized as integral features of the disease (Maass and Reichmann 2013). Particularly common is 
rapid eye movement (REM) sleep behavioral disorder (RBD), which is present in approximately 40% 
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of PD patients (Schenck and Mahowald 2002). This disorder is characterized by the loss of motor 
inhibition during REM sleep, leading to the often violent acting-out of dreams which frequently 
results in injury. The occurrence of RBD often predates the onset of motor symptoms by up to a 
decade, and RBD is a significant risk factor for the development of PD (Iranzo et al. 2006). RBD, 
along with hyposmia, constipation and depression, are some of the earliest symptoms of 
neurodegeneration in PD, and are considered to be prodromal non-motor symptoms of a pre-
parkinsonian state (Pellicano et al. 2007).  
 
1.5 DIAGNOSIS OF PD 
Proper diagnosis of PD is important for patient counseling and treatment, and is essential for clinical 
research. A definitive PD diagnosis requires the histological confirmation of LB pathology in the 
substantia nigra, which can only be done post-mortem (Gibb and Lees 1988a).  
Although patient diagnosis can be informed by radiological imaging, including 18F-dopa positron 
emission tomography (PET), diagnosis is most often based on clinical criteria. Diagnostic criteria 
have been developed by the UK Parkinson’s Disease Society Brain Bank which is routinely used for 
the accurate and objective diagnosis of PD; the use of these criteria typically delivers a diagnostic 
accuracy of around 90% (Hughes et al. 2001). A diagnosis of PD is made based on the presence of 
bradykinesia and at least one other motor symptom in the patient, and the absence of symptoms or 
history indicative of an alternative diagnosis (Appendix I).  
 
1.6 PROGNOSIS OF PD 
Life expectancy is significantly reduced in PD patients, with reported mortality ratios of 1.3-2.5 in 
comparison to age-matched controls, regardless of the duration of the disease (Herlofson et al. 2004; 
Driver et al. 2008). The duration from disease onset to death typically ranges from 7-14 years; 
however, this varies widely between patients. There is little evidence that levodopa treatment of PD 
decreases disease mortality (Macleod et al. 2014). Increased mortality of PD patients has been 
associated with an older age at onset, the male sex, and the presence of cognitive decline and 
dementia (de Lau et al. 2014). In contrast to the general population, the leading cause of death of PD 
patients is pneumonia (Beyer et al. 2001) 
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1.7 TREATMENT OF PD 
PD is an incurable and progressive disorder. Nonetheless, various avenues are available for the 
alleviation and management of PD symptoms. Such symptomatic treatment can substantially improve 
functional capacity and quality of life of patients diagnosed with PD.   
 
1.7.1 Pharmacological treatment of PD 
1.7.1.1 Levodopa 
The major pharmacological approach to PD treatment is dopamine replacement therapy, of which 
levodopa remains the most widely used and efficacious treatment (Schapira et al. 2009). Orally 
administered levodopa (L-DOPA; L-3,4-dihydroxyphenylalanine) crosses the blood-brain barrier and 
is metabolized to dopamine in the central nervous system (CNS) by DOPA-decarboxylase. Levodopa 
may also be metabolized in the peripheral nervous system resulting in side effects such as nausea, 
stiffness and dyskinesia (involuntary movements). Hence, levodopa is commonly administered in 
combination with a peripheral DOPA-decarboxylase inhibitor, such as carbidopa or benserazide, to 
prevent metabolism of levodopa outside of the CNS. While levodopa treatment results in marked and 
sustained benefits for PD patients for several years, many patients eventually develop dyskinesias, 
dystonia and debilitating fluctuations in treatment response. Such levodopa-induced effects are more 
frequent with early age of disease onset, prolonged levodopa treatment and higher doses of levodopa 
(Ku and Glass 2010).  
 
1.7.1.2 Dopamine agonists 
Dopamine agonists mimic the effect of levodopa by binding to dopamine receptors in the basal 
ganglia. They are the preferred first-line medication for younger patients, who are at a higher risk of 
levodopa-associated motor complications. However, dopamine agonists are more commonly 
associated with adverse effects such as nausea, dizziness, hallucinations and impulse control 
disorders, which may necessitate a change of treatment strategy (Antonini et al. 2009).  
 
1.7.1.3 MAO-B inhibitors 
Monoamine oxidase-type B (MAO-B) inhibitors such as selegiline or rasagiline increase the 
availability of dopamine in the striatum by limiting dopamine breakdown at the synaptic cleft. They 
offer milder therapeutic effects than levodopa or dopamine agonists, but they are typically better 
tolerated (Riederer and Laux 2011). MAO-B inhibitors used in conjunction with levodopa may reduce 
levodopa-associated motor fluctuations (Rascol et al. 2005; Olanow et al. 2009). Ultimately, the 
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choice of which pharmacological agent to prescribe for PD treatment depends largely on the 
characteristics and needs of the patient, as well as the preferences of the clinician, as each class of 
medication has its strengths and weaknesses.   
 
1.7.2 Deep brain stimulation  
While dopamine replacement therapy can be greatly effective at managing the symptoms of PD at the 
earlier stages of treatment, patient response to such medication almost invariably becomes less 
effective and predictable over time (Schapira et al. 2009). Patients who are responsive to levodopa but 
experience debilitating motor fluctuations or dyskinesias may be surgically treated with deep brain 
stimulation (DBS) (Okun 2012). This technique involves the placement of one or more electrodes in 
the brain which target specific basal ganglial nuclei, most commonly the subthalamic nucleus or the 
globus pallidus. The electrodes are connected to an insulated lead which passes through a burr hole in 
the skull and subcutaneously connects to an impulse generator implanted in the anterior chest wall. 
This delivers electrical stimuli to the brain in order to modulate neural activity in the basal ganglia. 
The effects of DBS can mitigate parkinsonian symptoms, especially tremor, and reduce the adverse 
effects of levodopa therapy. PD patients that undergo DBS may experience sustained clinical 
improvement for over ten years (Castrioto et al. 2011). However, DBS is very costly and has several 
adverse effects, including risk of infection, intracranial hemorrhage, seizures and a wide array of 
neuropsychiatric effects (Parsons et al. 2006).  
 
1.8 PD RISK FACTORS 
The great majority (~90%) of PD cases are sporadic and idiopathic, as they have no identifiable cause.  
Substantial progress has been made over the last two decades in the discovery of several causative 
monogenic mutations that induce familial PD; however, only a small percentage (~10%) of patients 
with sporadic PD has known genetic underpinnings. It is hoped that, ultimately, the genetic or non-
genetic factors that either cause or increase the risk of developing PD will be identified for the 
majority of sporadic PD cases.   
 
1.8.1 Intrinsic risk factors 
1.8.1.1 Age 
Age is the most significant risk factor for PD. As discussed in Section 1.2, the disorder is rare before 
the age of 50 years, after which both the prevalence and incidence of PD increase sharply with 
increasing age. Rare cases of juvenile PD (onset before the age of 20 years) have been reported, with 
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a clinical presentation similar to sporadic PD. Early onset PD (EOPD), with disease onset before the 
age of 50 years, increases the probability that genetic causes are involved (Schrag and Schott 2006).  
While the association of aging with increasing PD incidence might seem self-evident, the underlying 
mechanism by which aging promotes the development of PD remains unclear. In fact, other 
neurodegenerative disorders such as Huntington’s disease and amyotrophic lateral sclerosis (ALS) 
have earlier ages at onset than PD. It is assumed that some intrinsic age-dependent factors, or the 
accumulation of age-related damage, predispose older individuals to develop PD (Reeve et al. 2014).  
 
1.8.1.2 Gender 
The incidence of PD is higher in men than in women, as a meta-analysis of seven incidence studies 
reports an increased relative risk (RR) of 1.49 for men (Wooten et al. 2004). A similar meta-analysis 
of a separate set of studies reports a male to female ratio of 1.46 (Taylor et al. 2007). However, Taylor 
et al. found that this ratio is inconsistent across different study groups, with higher male-female ratios 
being reported in older study populations as well as a weaker association with gender in Asian 
populations (Taylor et al. 2007).  The reasons for this male preponderance are not known, but it may 
be related to different environmental and occupational exposures associated with the “male lifestyle”, 
the neuroprotective effects of estrogen in women (Inestrosa et al. 1998) or recessive susceptibility 
genes on the X chromosome.  
 
1.8.2 Environmental risk factors 
Many reports have implicated environmental factors in the development of PD. It was discovered in 
1983 that the accidental exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a by-
product of illicit heroin production, leads to a levodopa-responsive parkinsonian disorder with 
symptoms largely indistinguishable from PD (Langston et al. 1983). MPTP induces parkinsonism 
when its active metabolite MPP+ is transported into neurons by the dopamine transporter and inhibits 
the mitochondrial electron transport chain (ETC), which ultimately leads to degeneration of 
dopaminergic neurons. This discovery was heralded as proof of principle that exposure to 
environmental toxins may cause PD, or at least increase the risk of developing PD.   
The identification of environmental risk factors for PD is mostly based on epidemiological 
approaches; such studies are prone to several kinds of bias. As such, the multitude of studies of the 
association of various environmental factors with risk of PD are often equivocal and inconclusive (de 
Lau and Breteler 2006; Kieburtz and Wunderle 2013).  
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1.8.2.1 Cigarette smoking  
Many epidemiological studies have demonstrated a reduced risk for developing PD among cigarette 
smokers. A large meta-analysis of 48 studies encompassing 20 countries found a pooled RR of 0.6 for 
smokers compared to non-smokers (Hernán et al. 2002). In addition, most of these studies showed a 
dosage effect of smoking on PD risk, as people who have been smoking for a longer total period of 
time have an even lower risk of developing PD. Several possible mechanisms for the neuroprotective 
effects of smoking have been suggested; it is thought that nicotine may stimulate dopamine release, 
act as an antioxidant, or modulate MAO-B activity in the brain (Quik et al. 2012). On the other hand, 
several non-causal explanations have been proposed for the observed protective relationship between 
smoking and PD. Such explanations include the possibility that the increased mortality of smokers 
lowers their age-related risk of PD, or that early loss of smell and other sensory abnormalities of 
subclinical PD reduce the likelihood of smoking.  
 
1.8.2.2 Caffeine  
Similarly to cigarette smoking, caffeine intake decreases the risk of developing PD.  A meta-analysis 
of thirteen studies found a significantly lowered RR of 0.7 for coffee drinkers (Hernán et al. 2002). 
The protective agent in coffee is thought to be caffeine, as no association had been found for other 
coffee components and risk of PD while non-coffee sources of caffeine did demonstrate such an effect 
(Ross et al. 2000). While both men and women coffee drinkers experience a decreased risk of PD, this 
decrease is less pronounced in women (Palacios et al. 2012); the protective effect of caffeine appears 
to be attenuated by the use of estrogen replacement in postmenopausal women (Ascherio et al. 2003).  
Caffeine binds antagonistically to adenosine A2 receptors, which may protect against dopaminergic 
degeneration. In fact, caffeine administration improves motor deficits in a mouse model of PD (Xu et 
al. 2010). 
 
1.8.2.3 Pesticides and herbicides 
The discovery of the PD-inducing effect of MPTP, described above, spurred extensive research into 
the possible epidemiological effects of exposure to pesticides and other environmental toxins. While 
such studies consistently found a positive association between pesticide exposure and PD 
development, the association was only statistically significant in about half of these studies (Lai et al. 
2002). A recent meta-analysis of retrospective case-control studies calculated a pooled odds ratio 
(OR) of 1.5 for lifetime pesticide exposure, although a significant degree of heterogeneity was seen 
between studies (Allen and Levy 2013). In particular, the herbicide paraquat and insecticide rotenone 
are frequently associated with an increased risk of developing PD (Kamel et al. 2007; Tanner et al. 
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2011). Paraquat and rotenone, like MPTP, are potent mitochondrial ETC inhibitors, and cause 
dopaminergic neurodegeneration in animal models (Betarbet et al. 2000). However, current 
epidemiological evidence is not sufficient to unequivocally establish a causal link between exposure 
to specific pesticides and increased risk for PD.  
 
1.8.3 Genetic risk factors 
Until 1997, the involvement of genes and genetic risk factors in the etiology of PD was contentious; 
indeed, PD used to be considered a classical “nongenetic” disorder (Lincoln et al. 2003). Large cross-
sectional twin studies consistently found a lack of disease concordance in monozygotic twins, which 
argued against heritability (Piccini et al. 1999; Tanner et al. 1999; Wirdefeldt et al. 2004). Even 
though 10-30% of PD patients report a first-degree relative also affected by PD (Sveinbjörnsdottir et 
al. 2000; Rocca et al. 2004), the observed familial aggregation of this disorder was usually attributed 
to shared environmental exposures.   
Nevertheless, the last two decades has seen the successful application of genetic linkage analysis, 
genetic association studies and genomic sequencing to pedigrees of PD-multi-affected families. Such 
approaches have identified the genetic underpinnings of several familial forms of PD. To date, a total 
of six genes (SNCA, LRRK2, VPS35, parkin, PINK1 and DJ-1) have been robustly confirmed to 
harbor causal mutations for monogenic parkinsonism clinically similar to PD, with autosomal 
dominant (AD) or autosomal recessive (AR) modes of inheritance. Another gene (EIF4G1) has been 
associated with AD-PD, but its status as an authentic PD gene is currently unconfirmed. A further 
seven genes (ATP13A2, PLA2G6, FBXO7, DNAJC6, SYNJ1, SCA2 and SCA3) have been associated 
with atypical parkinsonism, demonstrating one or more non-PD features in addition to parkinsonism. 
The genes implicated in monogenic PD or parkinsonism are summarized in Table 1.1. Several genetic 
variants have also been identified as strong risk factors for PD. The genes, mutations and 
polymorphisms implicated in PD will be briefly discussed. 
 
1.8.3.1 Autosomal dominant PD 
1.8.3.1.1 α-Synuclein (SNCA) 
Genetic studies of PD first began with the identification of a pathogenic missense mutation in the 
SNCA gene (OMIM 163890), causing AD-PD (Polymeropoulos et al. 1997). Patients with SNCA 
mutations typically present with EOPD with a good response to levodopa treatment in the initial 
stages of disease; however, progression of the disease is rapid with a high prevalence of 
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Table 1.1 Genes implicated in monogenic PD or parkinsonism 
Gene Map locus Inheritance Phenotype Pathology Mutations Reference(s) 
SNCA 4q21-22 AD EOPD Diffuse LBs 
5 point mutations, whole gene 
duplications/triplications 
Polymeropoulos et al. (1997) 
LRRK2 12q12 AD Classical PD 
Pleomorphic, mostly 
typical LBs 
7 pathogenic mutations from 
~70 missense variants 
Paisán-Ruiz et al. (2004); 
Zimprich et al. (2004) 
VPS35 16q11 AD Classical PD Unknown 1 missense mutation 
Zimprich et al. (2011); 
Vilariño-Güell et al. (2011) 
EIF4G1 3q27 AD Classical PD Unknown 2 missense mutations Chartier-Harlin et al. (2011) 
Parkin 6q25-27 AR EOPD 
Nigral degeneration, 
mostly without LBs 
~170 point mutations, exonic 
rearrangements 
Kitada et al. (1998) 
PINK1 1p35-36 AR EOPD 
Typical LBs (one 
case only) 
~50 point mutations, rare large 
deletions 
Valente et al. (2004) 
DJ-1 1p36 AR EOPD Unknown 
~15 point mutations, large 
deletions 
Bonifati et al. (2003) 
ATP13A2 1p36 AR 
Juvenile onset, 
atypical parkinsonism 
Ceroid lipofuscinosis 
(one case only) 
5 point mutations Ramirez et al. (2006) 
PLA2G6 22q13 AR 
Juvenile onset, 
atypical parkinsonism 
Typical LBs 2 missense mutations Paisán-Ruiz et al. (2009) 
FBXO7 22q12-13 AR 
Juvenile onset, 
atypical parkinsonism 
Unknown 3 point mutations 
Shojaee et al. (2008);  
Di Fonzo et al. (2009) 
DNAJC6 1p31 AR 
Juvenile onset, 
atypical parkinsonism 
Unknown 
1 nonsense mutation, 1 large 
deletion 
Edvardson et al. (2012); 
Köroğlu et al. (2013) 
SYNJ1 21q22 AR 
Juvenile onset, 
atypical parkinsonism 
Unknown  1 missense mutation 
Krebs et al. (2013);  
Quadri et al. (2013) 
SCA2 12q24 AD Atypical parkinsonism Unknown CAG repeat expansion Gwinn-Hardy et al. (2000) 
SCA3 14q32 AD Atypical parkinsonism Nigral degeneration CAG repeat expansion Gwinn-Hardy et al. (2001) 
Abbreviations: AD, autosomal dominant; AR, autosomal recessive; ATP13A2, ATPase type 13A2; DJ-1, Daisuke-Junko 1; EIF4G1, eukaryotic translation initiation factor 
4 gamma 1; EOPD, early-onset Parkinson’s disease; FBXO7, F-box only 7; LBs, Lewy bodies; LRRK2, leucine-rich repeat kinase 2; p, short chromosomal arm; PD, 
Parkinson’s disease; PINK1, phosphatase and tensin homolog (PTEN)-induced kinase 1; PLA2G6, phospholipase A2 group VI; q, long chromosomal arm; SCA2, 
spinocerebellar ataxia type 2; SCA3, spinocerebellar ataxia type 3; SNCA, α-synuclein; SYNJ1, synaptojanin 1; VPS35, vacuolar protein sorting 35. 
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dementia and severe autonomic dysfunction. Atypical features such as cortical myoclonus may also 
be present.  Neuropathologically, SNCA-induced PD results in prominent and extensive LB pathology 
of the substantia nigra, hypothalamus and cerebral cortex, often incorporating limbic and glial 
pathology (Gwinn-Hardy et al. 2000). 
Mutations in SNCA are rare. To date, only five different SNCA point mutations as well as whole gene 
duplications and triplications have been described (Bonifati 2014). SNCA duplications have been 
reported in approximately 1% of families with AD-inherited PD (Ibáñez et al. 2009); whereas 
triplications and point mutations are exceedingly rare and have only been found in a handful of 
families worldwide. Point mutations include the A53T, A30P and E46K missense mutations, and two 
novel missense mutations, H50Q and G51D, have only recently been described (Appel-Cresswell et 
al. 2013; Lesage et al. 2013). Point mutations in SNCA are highly penetrant, whereas a reduced 
penetrance for whole gene duplications of 30-40% has been described for some families (Nishioka et 
al. 2006). SNCA duplications have also been found in sporadic PD cases (Ahn et al. 2008). 
Interestingly, a dosage effect is seen for such gene amplifications, as each additional SNCA copy leads 
to an earlier onset, faster disease progression and a more severe phenotype (Fuchs et al. 2007; Ross et 
al. 2008b). 
SNCA encodes the 140-amino acid (aa) cytosolic protein α-synuclein. This protein is abundantly 
expressed in the brain and forms a major component of LBs in PD neuropathology (Spillantini et al. 
1997). It is thought that α-synuclein plays a role in synaptic plasticity and synaptic vesicular 
trafficking (Lundblad et al. 2012; Scott and Roy 2012). While this protein is predominantly natively 
unfolded, its amino (N)-terminal region adopts an amphipathic, α-helical structure when associated 
with lipid membranes (Ulmer et al. 2005). The identified SNCA missense mutations, all of which 
cluster within the N-terminal region of α-synuclein, reduces its lipid affinity and promotes the 
formation of stable, β-sheet-rich toxic oligomers, protofibrils and fibrils (Bertoncini et al. 2005). 
Hence, it is thought that elevated or mutated α-synuclein contributes to disease via a toxic gain of 
function, whereas LBs may represent a cell-protective mechanism to sequester toxic α-synuclein 
aggregates (Olanow et al. 2004).   
 
1.8.3.1.2 Leucine-rich repeat kinase 2 (LRRK2) 
Mutations in the LRRK2 gene (OMIM 609007) have been associated with both AD familial PD and 
apparently sporadic PD and, to date, constitute the most common genetic cause of PD (Paisán-Ruiz et 
al. 2004; Trinh and Farrer 2013). LRRK2 mutation carriers present with parkinsonism that is largely 
clinically indistinguishable from idiopathic, late onset PD, with homozygous carriers presenting with 
a similar clinical phenotype to heterozygous carriers (Aasly et al. 2005; Lesage et al. 2005). The 
associated range of disease onset age is broad and includes patients with early and late onset. The 
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majority of autopsied PD patients with LRRK2 mutations demonstrate typical LB pathology, but pure 
dopaminergic degeneration without LBs, and degeneration with neurofibrillary tangles, have also 
been described (Wider et al. 2010). 
Seven disease-causing LRRK2 missense mutations (N1437H, R1441H, R1441C, R1441G, Y1699C, 
G2019S, I2020T) have been found to date, whereas the pathogenicity of other sequence variants in 
this gene are currently unclear (Bonifati 2014). LRRK2 mutations are found in approximately 10% of 
families with AD-PD. By far the most common and best studied is the G2019S mutation, occurring in 
approximately 1% of sporadic European cases, 20% of Ashkenazi Jewish patients and up to 40% of 
patients from North African Arab-Berber descent  (Lesage et al. 2006; Healy et al. 2008; Thaler et al. 
2009). The high frequencies of G2019S seen in apparently sporadic PD cases can be attributed to the 
age-related and ethnic-specific incomplete penetrance of this mutation. The penetrance can be as low 
as 30% at the age of 60 years, increasing to 75% penetrance at 80 years, while varying significantly 
between different population groups (Healy et al. 2008). 
It is still unclear how mutations in LRRK2 contribute to PD. The LRRK2 protein is a large, 2527-aa 
cytosolic protein with GTPase and kinase domains and multiple protein-protein interaction domains. 
It has been implicated in cellular signaling cascades, membrane trafficking, autophagy and 
mitochondrial function (Lewis and Alessi 2012). Mutations in the GTPase domain (R1441C, R441G, 
R441H) disrupt GTPase activity, whereas mutations in the kinase domain (G2019S, I2020T) increase 
the kinase activity of LRRK2 (West et al. 2005; Lewis et al. 2007). Hence, it is thought that mutated 
LRRK2 can promote cellular dysfunction via a disruption or exaggeration of normal function, or a 
gain of abnormal function (Dächsel et al. 2010).   
 
1.8.3.1.3 Vacuolar protein sorting 35 (VPS35) 
In 2011, two groups independently reported the same D620N mutation in the VPS35 gene (OMIM 
601501) as a novel cause of AD-PD (Vilariño-Güell et al. 2011; Zimprich et al. 2011). Of note, this 
was the first PD gene to be identified using a next-generation sequencing (NGS)-based exome 
sequencing approach. Patients with mutated VPS35 present with typical PD, albeit with a slightly 
earlier onset age, with a good response to levodopa therapy. The associated neuropathology of 
VPS35-linked PD remains unknown.  
The D620N mutation was originally found to segregate with disease in families of Swiss and Austrian 
origin, respectively, and has now been described in several additional large families of various 
ethnicities (Ando et al. 2012; Lesage et al. 2012a; Sharma et al. 2012). These studies have reported a 
prevalence for this rare mutation of approximately 0.5-1% in AD-PD cases. It has also been described 
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in sporadic cases, suggesting a reduced penetrance for this mutation. Despite intensive screening, 
additional pathogenic mutations in the VPS35 gene have not been found to date.  
VPS35 is a subunit of the retromer cargo-recognition complex, which is involved in the cellular 
recycling of membrane proteins.  It is thought to play a role in the sorting of acid hydrolases to 
lysosomes, retrograde transport between endosomes and the trans-Golgi network, developmental Wnt 
signaling, apoptosis and mitophagy (Chen et al. 2010a; Harterink et al. 2011; McGough and Cullen 
2011). While it is currently unclear how the D620N mutation affects the function of the retromer 
complex or how this contributes to PD, future research on VPS35 in the brain is likely to provide 
valuable insights. 
      
1.8.3.1.4 Eukaryotic translation initiation factor 4 gamma 1 (EIF4G1)  
The EIF4G1 gene (OMIM 600495) has recently been implicated as an AD PD-inducing gene, as the 
R1205H missense mutation has found to segregate within a large French family (Chartier-Harlin et al. 
2011). Further genetic screens identified this mutation, as well the A502V mutation, in a few 
additional families. However, subsequent studies failed to replicate these results convincingly, and the 
two mutations have been found in several unaffected control individuals (Lesage et al. 2012b; Schulte 
et al. 2012; Nishioka et al. 2014). Therefore, the status of EIF4G1 as a PD gene is currently 
contentious and further clarifying studies are warranted.    
 
1.8.3.2 Autosomal recessive PD 
1.8.3.2.1 Parkin 
Parkin (OMIM 602544) was the second PD-causing gene to be identified, and the first gene known to 
cause AR-PD (Kitada et al. 1998). Mutations in parkin are the most common cause EOPD, reported to 
account for up to 50% of familial EOPD cases and 15% of sporadic cases (Lücking et al. 2000). Some 
patients with parkin mutations have a disease onset even in childhood (juvenile PD). In addition to an 
early onset, parkin-induced PD is clinically characterized by a slow disease progression and an 
excellent and prolonged response to levodopa. Prominent dystonia and hyperreflexia are frequently 
observed, whereas cognitive decline and severe autonomic dysfunction are very rare non-motor 
features.  
The neuropathology of parkin-associated cases was initially thought to lack LBs, but recent reports 
have described α-synuclein positive LB pathology in a minority of cases (Pramstaller et al. 2005; 
Miyakawa et al. 2013). In contrast to idiopathic PD, neurodegeneration is largely confined to the 
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substantia nigra and locus ceruleus, which suggests that the pathology of parkin-induced PD does not 
conform to the Braak staging of PD (Ahlskog 2009; Doherty et al. 2013).  
A large number and wide spectrum of parkin mutations have been described, including point 
mutations, small deletions and whole exon rearrangements. As parkin is the focus of the present 
study, the molecular genetics of this gene will be discussed in more detail in Section 1.12.   
The parkin protein functions as an E3 ubiquitin ligase, conjugating ubiquitin to various substrate 
proteins (Shimura et al. 2000). Ubiquitination of such parkin substrates may result in the ubiquitin 
proteasome system (UPS)-mediated degradation of the protein, or alteration of substrate protein 
activity, function, translocation or signaling (Kahle and Haass 2004). As such, parkin is involved in 
many diverse cellular pathways, including protein degradation, mitochondrial health, cellular 
signaling, stress responses, tumor suppression and innate immunity. Pathogenic parkin mutations 
abolish or reduce its ubiquitin ligase activity, supporting a loss-of-function disease mechanism (Dauer 
and Przedborski 2003). The loss of parkin function might result in the accumulation/dysregulation of 
non-ubiquitinated parkin substrates, thereby contributing to cellular stress and neurodegeneration 
(McNaught and Olanow 2003). A detailed review of the parkin protein and the cellular pathways it 
has been implicated in will follow in Sections 1.14-1.16.    
 
1.8.3.2.2 Phosphatase and tensin homolog (PTEN)-induced kinase 1 (PINK1) 
Mutations in PINK1 (OMIM 602544) are associated with AR familial EOPD (Valente 2004). The 
frequency of PINK1 mutations varies considerably across different ethnic groups, and it is estimated 
to account for 1-8% familial EOPD cases (Bonifati et al. 2005; Klein et al. 2005; Kilarski et al. 2012). 
The clinical phenotype of PINK1-induced PD appears to be similar to parkin-PD, although psychiatric 
symptoms may be more prevalent among patients with PINK1 mutations. To date, only one autopsy 
of a patient with PINK1 mutations has been reported; this patient demonstrated nigral degeneration 
with LB-positive pathology comparable to idiopathic PD (Samaranch et al. 2010).       
Over 50 missense mutations, nonsense mutations, frameshifts and, rarely, large deletions have been 
described for PINK1 (Kawajiri et al. 2011). Point mutations are near equally distributed across the 
eight exons. While only approximately 25% of the described PINK1 mutations are nonsense 
mutations, more than 40% of patients carry a mutation that is truncating. Rare whole exon deletions in 
PINK1 have been described in a few families worldwide (Li et al. 2005; Cazeneuve et al. 2009).  
PINK1 mutations are also a rare cause of sporadic EOPD (Tan et al. 2006). 
PINK1 is a 581-aa cytosolic protein kinase that can be localized to the mitochondria. While the 
function of this protein is not fully understood, it has been implicated in mitochondrial homeostasis 
and mitophagy (Koh and Chung 2012). The majority of reported PINK1 mutations are loss-of-
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function mutations which disrupt its kinase domain; this supports the importance of PINK kinase 
activity in the pathogenesis of PD.   
 
1.8.3.2.3 Daisuke-Junko-1 (DJ-1) 
The third gene found to cause AR familial EOPD is the DJ-1 gene (OMIM 602533) (Bonifati et al. 
2003). Mutations in DJ-1 are rare and only account for approximately 1% of familial EOPD cases 
(Pankratz et al. 2006). While the clinical phenotype of DJ-1 mutation carriers has only been studied in 
a limited number of cases, it appears to be clinically indistinguishable from PINK1. The pathology of 
patients with DJ-1 mutations remains unknown, as no autopsies of cases with DJ-1 mutations have 
been reported yet.  
About ten different DJ-1 point mutations and large exonic deletions have been described (Tan and 
Skipper 2007). The best studied point mutation in DJ-1 is L166P, which destabilizes the DJ-1 protein 
resulting in its rapid proteasomal degradation (Miller et al. 2003).  
DJ-1 is a potent cellular sensor of oxidative stress. It is highly expressed in the brain where it adopts a 
dimeric structure (Macedo et al. 2003). In the presence of oxidative stress, DJ-1 is translocated to the 
mitochondrial membrane (Zhang et al. 2005). Although the precise cellular function of this protein is 
unknown, it has been implicated in neuroprotection against oxidative stress, mitochondrial 
dysfunction and dopamine toxicity (Wang et al. 2012a; Lev et al. 2013). Mutated DJ-1 protein is 
typically misfolded, unstable and rapidly degraded, suggesting that DJ-1 mutations contribute to PD 
by depleting the cellular levels of this protein (Malgieri and Eliezer 2008).    
 
1.8.3.3 Atypical parkinsonism 
1.8.3.3.1 ATPase type 13A2 (ATP13A2) 
Mutations in the ATP13A2 gene (OMIM 610513) cause an AR atypical parkinsonism termed Kufor-
Rakeb syndrome (Ramirez et al. 2006). This syndrome is clinically characterized by juvenile-onset, 
levodopa-responsive parkinsonism with rapid disease progression, pyramidal signs, dementia and 
supranuclear gaze palsy. While the pathology of ATP13A2 remains unknown, magnetic resonance 
imaging (MRI) of patients with ATP13A2 mutations suggest accumulation of metals in the brain 
(Santoro et al. 2011).  
Mutations in ATP13A2 are exceedingly rare and, to date, eleven different pathogenic mutations have 
been described in only a handful of families (Crosiers et al. 2011). Intriguingly, ATP13A2 mRNA is 
highly expressed in the substantia nigra of patients with classical late-onset PD (Ramirez et al. 2006). 
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The gene encodes a large transmembrane lysosomal protein of the P-type ATPase family. While the 
exact function of this protein is unclear, it is thought to be involved with the transport of metal cations 
from the cytosol into the lysosome.  
However, a recent study found that a mutation in ATP13A2 caused pathologically-confirmed neuronal 
ceroid-lipofuscinosis (Bras et al. 2012). Similar pathology was reported in a canine model of mutated 
ATP13A2 (Farias et al. 2011). This would suggest that ATP13A2-linked parkinsonism is a disorder 
distinct from atypical PD and cast doubt on the status of ATP13A2 as a de facto PD gene; however, 
additional studies are warranted.  
 
1.8.3.3.2 Phospholipase A2, group VI (PLA2G6) 
Mutations in the PLA2G6 (OMIM 603604) were initially described as the cause of infantile 
neuroaxonal dystrophy and idiopathic neurodegeneration with brain iron accumulation, a severe 
neurodegenerative disorder that bears no resemblance to PD (Morgan et al. 2006). However, PLA2G6 
mutations were later found in families presenting with adult-onset, levodopa-responsive parkinsonism 
with prominent dystonia and pyramidal signs (Paisán-Ruiz et al. 2009; Sina et al. 2009). Other 
pathogenic mutations in PLA2G6 were also found in additional families with a similar atypical PD 
phenotype (Paisán-Ruiz et al. 2010). 
MRI of patients with PLA2G6 mutations demonstrate broad neurodegeneration but generally no 
abnormal iron deposition, which is a defining feature of infantile onset cases of PLA2G6 mutations 
(Paisán-Ruiz et al. 2009; Sina et al. 2009). While evidence of the pathology of PLA2G6 is very 
limited, patients with PLA2G6 mutations demonstrate widespread α-synuclein-positive LB pathology 
in the substantia nigra and the cortex, suggesting a possible mechanistic link with typical PD (Gregory 
et al. 2008; Paisán-Ruiz et al. 2010).  Nevertheless, the role of PLA2G6 in PD remains controversial.  
 
1.8.3.3.3 F-box only protein 7 (FBXO7) 
FBXO7 (OMIM 605648) is implicated in a recessive form of early-onset parkinsonism with pyramidal 
features. Mutations in FBXO7 were initially identified in an Iranian kindred; pathogenic mutations 
were later found in several other unrelated families with a similar clinical phenotype (Shojaee et al. 
2008; Di Fonzo et al. 2009).  
Whereas the neuropathology of FBXO7 mutations is unknown, the FBXO7 protein is a known 
component of LBs of patients with typical PD (Zhao et al. 2013). This protein is implicated in the 
UPS and localizes to the nucleus. Patients with mutations in FBXO7 demonstrate a dramatic depletion 
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of FBXO7 (Zhao et al. 2011b). This suggests that the protein has neuroprotective properties, but the 
extent to which FBXO7 is involved in typical PD is unclear.  
 
1.8.3.3.4 Auxilin (DNAJC6) and synaptojanin 1 (SYNJ1)  
Two newly-identified PD-related genes, DNAJC6 (OMIM 608375) and SYNJ1 (OMIM 604297) have 
recently been discovered as novel causes of AR juvenile parkinsonism. An exome sequencing 
approach combined with genome-wide heterozygosity mapping identified mutations in DNAJC6 in a 
Palestinian family (Edvardson et al. 2012). These findings were later confirmed in a Turkish family 
(Köroğlu et al. 2013). With regards to SYNJ1, the same pathogenic mutation was independently 
reported to cause early-onset parkinsonism in families of Iranian and Italian ancestry, respectively 
(Krebs et al. 2013; Quadri et al. 2013).  
DNAJ1 encodes neuronally-expressed auxilin, and SYNJ1 encodes synaptojanin 1. Both these proteins 
play important and related roles in the recovery and recycling of synaptic vesicles (Montesinos et al. 
2005). This is of significant interest as other PD genes, including SNCA, LRRK2, VPS35 and parkin, 
have been implicated in synaptic vesicle dynamics. Further genetic and functional studies of DNAJ1 
and SYNJ1 and their relation to PD are warranted.  
 
1.8.3.3.5 Spinocerebellar ataxia type 2 (SCA2) and spinocerebellar ataxia type 3 (SCA3) 
Mutations in the SCA2 gene (OMIM 183090) cause an inherited ataxia syndrome with extrapyramidal 
symptoms, including levodopa-responsive parkinsonism (Gwinn-Hardy et al. 2000), whereas SCA3 
(OMIM 109150) mutations result in Machado-Joseph disease with negligible ataxia and parkinsonism 
accompanied by peripheral neuropathy, dystonia and spasticity (Gwinn-Hardy et al. 2001). Mutations 
in both SCA2 and SCA3 are due to CAG trinucleotide repeat expansions in their respective coding 
regions. SCA2 mutations are particularly common in some Asian populations where it accounts for 
approximately 5% of familial parkinsonism (Lu et al. 2004).   
While the physiological function of the SCA2 gene product ataxin-2 is currently unclear, ataxin-3 is a 
well-characterized de-ubiquitinating enzyme acting within the UPS (Burnett et al. 2003). 
Interestingly, ataxin-3 is known to interact with parkin, where ataxin-3-mediated de-ubiquitination 
regulates parkin activity (Durcan et al. 2011). Furthermore, mutant but not wild-type ataxin-3 
promotes the autophagic degradation of parkin (Durcan and Fon 2011). 
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1.8.3.4 Genetic susceptibility factors  
Despite the considerable progress made in the identification of genes responsible for monogenic PD 
and parkinsonism described above, mutations in the known PD genes account for only 5%-10% of PD 
cases. Monogenic models of PD are therefore inadequate to explain common, typical PD, which may 
result from complex gene-gene and/or gene-environment interactions. This stimulated the search for 
genetic susceptibility factors that alters the risk for, instead of causing, PD.  
 
1.8.3.4.1 SNCA 
Much of the earlier work on the identification of susceptibility variants was done using a candidate 
gene approach, which found an association between alleles at the REP1 dinucleotide repeat length 
polymorphism in the SNCA promoter region and sporadic PD (Krüger et al. 1999). Several follow-up 
studies were performed to verify this association, which delivered equivocal results. Nevertheless, a 
large collaborative meta-analysis provided a clear association between the REP1 susceptibility allele 
and a 1.4 fold increased risk of PD (Maraganore et al. 2006). Functional studies suggest that the REP1 
risk allele is associated with an increased expression of SNCA in a transgenic mouse model (Cronin et 
al. 2009).  Other polymorphisms in SNCA besides the REP1 polymorphism have also been implicated 
as susceptibility variants for sporadic PD, particularly at the 3’ end of the gene, but further studies are 
needed to confirm their relevance (Mueller et al. 2005; Mizuta et al. 2006a; Myhre et al. 2008) 
     
1.8.3.4.2 LRRK2 
The G2385R variant in LRRK2 was initially described as a pathogenic mutation in a Taiwanese family 
with PD (Mata et al. 2005).  However, subsequent studies found that this variant is a relatively 
common polymorphism in the Asian population, where it is strongly associated with the risk of PD 
(Di Fonzo et al. 2006; Tan et al. 2007). This finding was confirmed by several studies as well as a 
large meta-analysis, which associated the G2385R allele with a two-fold increased risk of PD in the 
Chinese and Japanese populations (Tan 2007). A similar magnitude of risk effect has been reported 
for another LRRK2 variant, R1628P, also in Asian populations (Ross et al. 2008c). However, this risk 
variant has does not have as much supportive evidence as G2385R (Ross et al. 2011).   
 
1.8.3.4.3 Microtubule-associated protein tau (MAPT) 
Common variability in MAPT (OMIM 157140) has been associated with several neurodegenerative 
diseases of which the pathological hallmark is the deposition of tau protein in neurofibrillary tangles. 
Rare pathogenic mutations in MAPT cause frontotemporal dementia with parkinsonism linked to 
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chromosome 17 (FTDP-17), whereas common MAPT variants have been robustly associated with an 
increased risk of progressive supranuclear palsy (PSP), Alzheimer’s disease and, more recently, PD 
(Spillantini and Goedert 2013). Two common MAPT haplotypes, H1 and H2, are present in European 
populations. The H1 haplotype has been associated with an increased risk of developing PD, with an 
OR of approximately 1.3 (Skipper et al. 2004; Fung et al. 2006; Zabetian et al. 2007). The elevated 
risk promoted by the H1 haplotype can be attributed to an increased MAPT expression (Myers et al. 
2007; Tobin et al. 2008). It is not clear how tau is involved in PD, as tau-positive neurofibrillary 
tangles are rare in PD cases. Nevertheless, the genetic association between MAPT variability and PD 
risk has been robustly confirmed in several studies.    
 
1.8.3.4.4 Glucocerebrosidase (GBA) 
Mutations in the GBA gene (OMIM 606463) cause AR Gaucher’s disease, a lysosomal storage 
disorder. Initial reports found that patients with Gaucher’s disease may present with PD more 
frequently than expected (Neudorfer et al. 1996; Tayebi et al. 2003). This keen observation led to the 
discovery that single heterozygous GBA mutations increases the risk of PD approximately seven-fold 
in the Ashkenazi Jewish population (Aharon-Peretz et al. 2004). This finding has been generalized to 
the worldwide PD population in a large meta-analysis which confirmed that single GBA mutations 
increase the risk of PD five-fold; GBA mutations were present in 15% of Ashkenazi Jewish PD 
patients, 3% of non-Ashkenazi Jewish patients, compared to 3% and <1% in unaffected controls, 
respectively (Sidransky et al. 2009).  
The clinical phenotype of PD associated with a GBA risk allele is similar to sporadic PD, except for a 
slightly younger age at onset and a greater rate of cognitive disturbances, with typical LB pathology 
being present at autopsy. While it is not fully understood how GBA mutations increases the risk of 
PD, it is thought to relate to abnormal lysosomal function (Swan and Saunders-Pullman 2013). 
 
1.8.3.4.5 Genome-wide association studies  
A large number of genome-wide association studies (GWAS) have now been performed in order to 
identify low-penetrance risk alleles that are undetectable through conventional linkage approaches. 
These GWAS have independently verified common variants in SNCA, LRRK2 and MAPT as risk 
factors for PD, in addition to the candidate gene approaches described above (Pankratz et al. 2009a; 
Satake et al. 2009; Simón-Sánchez et al. 2009; Edwards et al. 2010). The largest and best-powered 
GWAS, which included over 12 000 cases and 21 000 controls, provided evidence of association for 
sixteen independent loci (MAPT, SNCA, LRRK2, HLA-DRB5, BST1, GAK, PARK16, FGF20, 
ACMSD, STK39, MCCC1/LAMP3, SYT11, CCDC62/HIP1R, STX1B, STBD1 and GPNMB) 
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(International Parkinson’s Disease Genomics Consortium (IPDGC) and Wellcome Trust Case Control 
Consortium 2 (WTCCC2) 2011). Alleles at each of these loci represent only minor risk or protective 
factors, conferring 1.1 to 1.4 fold increases in risk and 0.97 to 0.7 decreases in risk, respectively. 
When viewing all sixteen risk variants collectively, individuals with the highest burden of risk alleles 
are at a three-fold increased risk of developing PD in comparison to individuals with the lowest 
burden of risk alleles. However, it is important to note that the biological relevance of most of the 
associated variants is unknown, and functional studies will be needed to assess GWAS-identified loci 
as bona fide susceptibility factors.   
 
1.9 PATHWAYS TO NEURODEGENERATION 
It is evident from the above-discussed literature that PD has a complex etiology with various 
contributing genetic and non-genetic factors. The identification of genes that induce familial PD has 
greatly advanced our understanding of the underlying molecular pathology of PD, whereby neuronal 
homeostasis is vulnerable to different genetic, cellular and environmental factors that independently 
or concurrently cause cell death over time (Sulzer 2007). Such factors appear to converge on common 
pathways to neurodegeneration, such as the accumulation of misfolded proteins, impairment of 
protein degradation pathways, and mitochondrial dysfunction (Figure 1.2). 
 
 
 
 
 
 
 
 
 
Figure 1.2 Pathways to neurodegeneration. An intersecting network of pathways, each of which are 
vulnerable to cellular stress from genetic susceptibility, environmental exposures or age-accumulated 
damage, independently or concomitantly impair neuronal homeostasis and contribute to 
neurodegeneration. Figure adapted from Valente et al. (2012). Abbreviations: UPS, ubiquitin 
proteasome system.  
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1.9.1 α-Synuclein accumulation 
α-Synuclein has long been viewed as a key player in the pathology of PD. Not only was SNCA the 
first conclusive demonstration of a genetic defect leading to PD, but misfolded and aggregated α-
synuclein protein is the main constituent of LB inclusions. LBs, the main pathognomonic feature of 
PD, are present in the brain tissue of both rare SNCA mutation carriers and common sporadic PD 
cases. Furthermore, GWAS consistently report SNCA variants as common risk factors for PD (Simón-
Sánchez et al. 2009; Edwards et al. 2010); α-synuclein may therefore provide a unifying link between 
familial and sporadic PD. 
It is generally accepted that enhanced α-synuclein protein levels, beyond a certain threshold, 
contribute to neurodegeneration, as familial SNCA duplications and triplications demonstrate a dose-
dependent relationship of α-synuclein load with PD phenotype (Fuchs et al. 2007; Ross et al. 2008b). 
In fact, transgenic delivery of α-synuclein to the SNpc is sufficient to induce PD-like dopaminergic 
neuronal degeneration and inclusion formation in primates (Eslamboli et al. 2007). Accumulating α-
synuclein levels promote its misfolding and subsequent oligomerization, aggregation and fibrillization 
(Giasson et al. 1999; Wood et al. 1999; Masliah et al. 2000). α-Synuclein oligomerization is also 
promoted by PD-causing SNCA missense mutations (Conway et al. 2000). The pathological 
aggregation propensity of α-synuclein is furthermore increased by various post-translational 
modifications, including nitrosylation and hyper-phosphorylation, as well as by dopamine adducts, 
which may contribute to the selective vulnerability of dopaminergic neurons in PD (Venda et al. 
2010).  
Misfolded and aggregated α-synuclein may have various cytotoxic effects. For example, it was found 
that the overexpression of α-synuclein in animal models induced mitochondrial defects (Song et al. 
2004; Martin et al. 2006), and that α-synuclein oligomers and aggregates disrupt the UPS (Snyder et 
al. 2003; Lindersson et al. 2004). Moreover, α-synuclein oligomers interact with the PD-associated 
protein GBA to disrupt lysosomal function (Mazzulli et al. 2011). Aggregated α-synuclein impairs 
microtubule-based subcellular transport, leading to synaptic dysfunction (Sheng and Cai 2012). 
Hence, α-synuclein accumulation and aggregation may disrupt neuronal homeostasis beyond the cell’s 
ability to recover, thereby inducing apoptotic cell death.  
Interestingly, accumulating evidence suggest that α-synuclein may spread from cell to cell, where the 
transfer of misfolded oligomers and aggregates from affected to unaffected neighboring cells induce 
the toxic conversion of natively-folded proteins. Such an aggregate nucleation or seeding event results 
in the misfolding and recruitment of endogenous α-synuclein that presumably would not have 
misfolded in the absence of such a protein seed. This process is akin to the templated misfolding of 
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prion proteins, and has been called the “prion hypothesis” of aggregation propagation, which may be a 
common feature of many neurodegenerative diseases (Jucker and Walker 2013).  
Several studies have reported the successful in vitro seeding of soluble α-synuclein after the 
internalization of recombinant α-synuclein in cell cultures, resulting in LB-like intracellular inclusions 
(Danzer et al. 2009; Desplats et al. 2009; Luk et al. 2009; Volpicelli-Daley et al. 2011). α-Synuclein 
aggregates have also been seen to propagate between co-cultured cells (Hansen et al. 2011). Perhaps 
the most striking examples of in vivo transfer and seeding of α-synuclein are reports of autopsies 
performed on PD patients who had received striatal grafts of fetal neuronal tissue 11-16 years earlier. 
Remarkably, LB pathology was found not only in the brains of the PD patients, but also in the 
implanted grafts (Kordower et al. 2008; Li et al. 2008, 2010). Such α-synuclein transfer was also seen 
in mouse models, where the intracerebral injection of brain extracts affected by LB pathology into 
young, unaffected transgenic mice resulted in the formation of α-synuclein aggregates and 
neurodegeneration (Luk et al. 2012; Mougenot et al. 2012). Significantly, intracerebral injection of 
mice with pure recombinant α-synuclein fibrils had the same effect as inoculation with brain 
homogenates of aged mice. Indeed, a dose-dependent effect was seen between the amount of 
recombinant α-synuclein and the acceleration of pathology. Synthetic α-synuclein fibrils are therefore 
sufficient to both induce LB pathology and to propagate disease in vivo.  
In a nutshell, the propagation and cell-to-cell transfer of α-synuclein aggregates provides a molecular 
pathway whereby PD pathology spreads within the nervous system from a highly localized initiating 
event to more distal brain regions, following a cascade of protein dysregulation and cellular stress. 
 
1.9.2 Defective protein clearance pathways 
The counterpart toxic mechanism to pathological protein accumulation is defective protein 
degradation. Two important cellular pathways are responsible for the degradation and clearance of 
excess, misfolded or damaged proteins within the cell: the UPS and autophagy-lysosomal pathway 
(ALP). These two pathways mediate proper protein quality control in order to maintain cellular 
homeostasis; impairment of these pathways is implicated in neurodegeneration. 
Early indications of the involvement of the UPS in PD came from the discovery that proteins in LBs 
are highly ubiquitinated (Kuzuhara et al. 1988; Lennox et al. 1989), and that LBs are composed of 
numerous UPS components, including proteasomal subunits, ubiquitinating and de-ubiquitinating 
enzymes and proteasome activators (Lowe et al. 1990; Kwak et al. 1991; Ii et al. 1997). Furthermore, 
the PD-causing gene parkin was found to be an E3 ubiquitin ligase, a component of the UPS (Shimura 
et al. 2000). Biochemical analyses of post-mortem brain tissue revealed reduced proteasomal activity 
in the SNpc of PD patients in comparison to age-matched controls (McNaught and Jenner 2001; 
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McNaught et al. 2003). Such results are similar to gene expression studies of PD brains, which found 
significantly downregulated expression of several proteasomal subunit genes in the SNpc (Grünblatt 
et al. 2004; Bukhatwa et al. 2010).  
Studies using in vitro and in vivo models also support the involvement of the UPS in PD. These 
studies demonstrated that exposure to the parkinsonism-inducing toxin MPTP resulted in a marked 
decrease in proteasomal activity (Fornai et al. 2005; Zeng et al. 2006; Caneda-Ferrón et al. 2008). 
Treatment with proteasomal inhibitors induced reproducible nigral degeneration in rodent models 
(Vernon et al. 2010; Xie et al. 2010). Finally, transgenic mice expressing a conditional deletion of a 
proteasomal regulatory subunit in dopaminergic cells demonstrated severe proteasomal deficits in the 
SNpc, as well as progressive neurodegeneration and LB-like inclusion formation, underscoring the 
importance of the UPS in PD (Bedford et al. 2008). 
The other major protein clearance pathway, the ALP, has also been implicated in PD. Early post-
mortem studies saw accumulation of autophagic vacuoles in the SNpc of PD patients (Anglade et al. 
1997), whereas more recent studies found altered levels of autophagy-related proteins in PD brains 
(Alvarez-Erviti et al. 2010; Li et al. 2011a; Tanji et al. 2011). Important genetic evidence in support of 
the involvement of the ALP in PD are mutations in the PD susceptibility gene GBA, encoding a 
lysosomal enzyme, and parkinsonism-inducing mutations in ATP13A2, a lysosomal transmembrane 
protein. Furthermore, parkin and PINK1 are part of the signaling pathway that controls mitophagy, a 
specialized autophagic pathway that eliminates damaged mitochondria.  
Impairment of the UPS and ALP may contribute to cellular dysfunction. For example, UPS 
dysfunction may result in proteolytic stress due to the accumulation and aggregation of excess and 
misfolded proteins in the cytosol. α-Synuclein in particular has been shown to accumulate and 
aggregate in cells treated with proteasomal inhibitors (Rideout et al. 2001; Rideout and Stefanis 
2002). Similarly, treatment with autophagy inhibitors promoted the toxic oligomerization of α-
synuclein (Klucken et al. 2012), whereas lysosomal dysfunction increased cell-to-cell transfer of α-
synuclein aggregates (Alvarez-Erviti et al. 2011). Many studies have demonstrated impairment of 
both the UPS and ALP by mutant or excessive normal α-synuclein (Petrucelli et al. 2002; Snyder et 
al. 2003; Cuervo et al. 2004). The reciprocal interaction between α-synuclein and protein clearance 
pathways posits an interesting vicious cycle, whereby increasing accumulation of α-synuclein impairs 
UPS and ALP function, which further exacerbates α-synuclein accumulation.  
 
1.9.3 Mitochondrial dysfunction and oxidative stress 
The important role of mitochondrial dysfunction in the pathogenesis of PD is evident from 
observations that exposure to mitochondrial complex I inhibitors, such as MPTP and rotenone, 
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induces parkinsonism (Langston et al. 1983). Furthermore, there are many reports of mitochondrial 
complex I deficits in PD patients, along with high burdens of somatic mitochondrial DNA (mtDNA) 
mutations in SNpc neurons (Schapira et al. 1989; Janetzky et al. 1994; Bender et al. 2006a). The 
mitochondrial involvement in PD is also strongly supported by genetic evidence, as the AR familial 
PD genes parkin, PINK1 and DJ-1 are known to be involved in the maintenance of mitochondrial 
health. Whereas parkin and PINK1 act in concert to promote the autophagic clearance of damaged 
mitochondria (Clark et al. 2006; Exner et al. 2007), DJ-1 is involved in mitochondrial protection 
against reactive oxygen species (ROS) (Canet-Avilés et al. 2004). 
Mitochondrial dysfunction mainly manifests as deficits in ATP production and elevated oxidative 
stress in the form of mitochondria-generated ROS. Such increased ROS production can instigate 
oxidative mtDNA damage, protein oxidation and lipid peroxidation, resulting in further damage of 
cellular organelles and triggering a vicious cycle of mitochondrial dysfunction and oxidative stress 
(Henchcliffe and Beal 2008). Furthermore, the impairment of cellular clearance pathways such as 
mitophagy may result in the deleterious accumulation of oxidatively damaged mitochondria. As 
physiological ROS also plays a part in intracellular signaling, heightened ROS generation may 
moreover disrupt important signaling cascades (Turrens 2003).   
Besides the key function of mitochondria in energy metabolism, mitochondria are also involved in 
Ca2+ homeostasis, cellular signaling, apoptosis and the inflammatory response (Newmeyer and 
Ferguson-Miller 2003). It is likely that these processes are also involved in neurodegeneration to 
various extents, although it is not currently clear whether these mitochondria-associated pathways are 
a cause or consequence of canonical mitochondrial dysfunction. 
While recent years has seen a lot of progress in understanding mitochondrial biology and the many 
cellular functions mitochondria are involved in, it is still unclear why mitochondria play such a 
pivotal role in neurodegeneration and PD (Exner et al. 2012; Corti and Brice 2013). The selective 
vulnerability of SNpc dopaminergic neurons to mitochondrial dysfunction might be due to the 
extremely long, unmyelinated, highly branched axons, multitude of synapses and low mitochondrial 
mass of these neurons (Liang et al. 2007; Matsuda et al. 2009; Bolam and Pissadaki 2012). 
Interestingly, common features between SNpc neurons and non-dopaminergic neurons that also 
undergo degeneration in PD include highly dense axonal arborization, pacemaker activity, high 
bioenergetic demands, elevated oxidative stress and heightened Ca2+ buffering stress (Sulzer and 
Surmeier 2013). It can be speculated that such characteristics collectively make certain neuronal 
populations particularly vulnerable to mitochondrial dysfunction, proteolytic stress, and a loss of 
cellular homeostasis.  
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1.10 THERAPEUTIC IMPLICATIONS OF VITAMIN K2 
The investigation of cellular and molecular pathways that contribute to neurodegeneration in PD has 
opened up new avenues for potential therapeutic approaches. Such neuroprotective approaches might 
prevent or treat neurodegeneration by targeting possible pathological processes such as α-synuclein 
accumulation, impairment of the UPS or ALP, or mitochondrial dysfunction. Potential 
neuroprotective agents would be a welcome addition to currently-available treatment options, based 
on levodopa-replacement strategies, which only provides symptomatic treatment for PD patients 
without addressing the underlying neuropathology. 
As mitochondrial dysfunction is implicated in both sporadic and familial PD, mitochondria are 
attractive targets for potential neuroprotective agents, and several such strategies are currently under 
investigation. Such compounds aimed at enhancing mitochondrial function include coenzyme Q10, a 
mitochondrial ETC enhancer and antioxidant, and creatine, a compound that elevates cellular ATP 
generation (Bender et al. 2006b; Storch et al. 2007; Salama et al. 2013). A particularly interesting 
potential therapeutic compound is vitamin K2, which has emerging roles in brain function and health 
(Beulens et al. 2013). As this dissertation will be investigating vitamin K2 as a potential PD 
therapeutic modality, relevant information and exciting new findings on vitamin K2 will be discussed. 
Vitamin K2 (menaquinone) is a generic term for a number of structurally related compounds that are 
characterized by a methylated naphthoquinone ring and an aliphatic side chain of varying numbers of 
isoprene residues (Shearer and Newman 2008). The best studied and most common form of vitamin 
K2 in the body is menaquinone-4 (MK-4) (Beulens et al. 2013). Whereas most vitamin K2 homologs 
are synthesized by intestinal bacterial flora, MK-4 is of note for being metabolized from dietary 
vitamin K1 (phylloquinone) in tissues such as the brain, pancreas and kidney (Okano et al. 2008). This 
in situ synthesis of MK-4 is catalyzed by the recently-discovered UbiA prenyltransferase domain 
containing protein 1 (UBIAD1) enzyme (Nakagawa et al. 2010). Unless otherwise stated, all mentions 
of vitamin K2 in this dissertation will refer to the MK-4 form of vitamin K2. 
Vitamin K2 has a well-established function in blood coagulation, via its essential role as a cofactor for 
γ-glutamyl carboxylase. This cofactor activity is required for the posttranslational modification and 
activation of numerous proteins, including most blood-clotting factors and proteins involved in bone 
metabolism (Vermeer 1990). Vitamin K2 has more recently been implicated in several other, γ-
glutamyl carboxylase-independent functions; these functions do not appear to extend to non-MK-4 
forms of Vitamin K2. For example, vitamin K2 was found to be involved in the transcriptional 
regulation of the steroid and xenobiotic nuclear receptor (SXR) (Azuma et al. 2009) and in the 
activation of protein kinase A (PKA) signaling (Ichikawa et al. 2007). Vitamin K2 has been shown to 
inhibit vascular calcification (Saito et al. 2007; Beulens et al. 2009) and to reduce the risk of coronary 
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heart disease (Geleijnse et al. 2004). Furthermore, vitamin K2 treatment elevated testosterone 
production in rats in a dose-dependent manner, implicating K2 in steroidogenesis (Ito et al. 2011). 
Several studies have suggested that K2 has anti-tumor properties. Treatment with vitamin K2 reduced 
proliferation and induced apoptosis in myeloid leukemia cell lines (Yaguchi et al. 1997), gastric 
cancer cell lines (Tokita et al. 2006) and colorectal cancer cell lines (Ogawa et al. 2007). These effects 
are also seen in a therapeutic context, as vitamin K2 supplementation has been reported to suppress the 
development of hepatocellular carcinoma in at-risk patients (Habu et al. 2004), and to reduce the 
recurrence of hepatocellular carcinoma after resection (Mizuta et al. 2006b). While the mechanism of 
these anti-cancer properties is not fully understood, it has been suggested that vitamin K2 reduces cell 
proliferation via inhibition of the transcription factor NF-κB, which suppresses the expression of the 
cell-cycle protein cyclin D1 (Ozaki et al. 2007). Moreover, vitamin K2 was shown to induce 
autophagy and apoptosis simultaneously in leukemia cells, via an unknown mechanism (Yokoyama et 
al. 2008). These findings suggest that vitamin K2 may be a promising anti-cancer compound.   
An unexpected and stimulating finding, and of particular relevance to PD, is the demonstration that 
vitamin K2 can act as an electron carrier in the mitochondrial ETC. Vos et al. (2012) used a genetic 
approach to identify the Drosophila homolog of mammalian UBIAD1, the gene responsible for 
vitamin K2 synthesis, as a genetic modifier of PINK1. Heterozygosity for UBIAD1 mutations strongly 
enhanced the mitochondrial defects seen in PINK1 mutant flies, such as reduced ATP production and 
loss of mitochondrial membrane potential, and these defects could be rescued by overexpressing 
UBIAD1. Overexpression of UBIAD1 could similarly rescue the mitochondrial phenotype of parkin 
mutant flies. Interestingly, supplementing the diet of PINK1 and parkin mutant flies with vitamin K2 
improved ETC efficiency and alleviated the mitochondrial defects of these mutants in a dose-
dependent manner. Intriguingly, vitamin K2 is a known electron carrier in bacterial membranes 
(Haddock and Jones 1977). Vos et al. (2012) convincingly demonstrated that vitamin K2 can also 
facilitate electron transport in the mitochondrial ETC in eukaryotic cells, and suggested that this novel 
function of vitamin K2 drives the phenotypic rescue seen in PINK1 and parkin mutant Drosophila. 
While the rescue effect of vitamin K2 on mitochondrial dysfunction has to date only been 
demonstrated in Drosophila, it would be interesting to see whether such pro-mitochondrial effects are 
also seen in human cell models with PINK1 and parkin mutations. As such, vitamin K2 may be a 
promising therapeutic compound in the treatment of PD.    
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PART TWO: PARKIN 
 
Indubitably, the identification of genes and genetic factors that contribute to PD development has 
greatly improved our understanding of the molecular etiology underlying this disease, as exemplified 
by the multitude of studies discussed above. While many important questions remain unanswered, 
such studies often illuminate new avenues of research that may provide valuable insights into PD 
pathology. Particularly interesting amongst the known PD genes is parkin, as parkin mutations are the 
most common cause of familial EOPD (Lücking et al. 2000). Furthermore, parkin is noteworthy for 
been implicated in a wide array of cytoprotective pathways and processes, which often converge to 
promote proper cellular function and health.  
This dissertation aims to further current knowledge on the role of parkin in PD. For that reason, a 
review of the established literature on parkin will follow.  
 
1.11 GENETIC STRUCTURE OF PARKIN 
The parkin gene (OMIM 602544; alternative symbols PARK2, PRKN) was first identified by Kitada 
et al. (1998), who used positional cloning to find the pathogenic locus of AR juvenile PD in a 
consanguineous Japanese family. This landmark publication mapped parkin to chromosomal position 
6q25.2-q27 and described the gene as spanning more than 500 kilobases (kb). A further study 
determined that parkin consists of twelve exons and spans a genomic region of 1380 kb, which makes 
parkin one of the largest genes in the human genome (Asakawa et al. 2001). The considerable size of 
parkin is due to the large parkin intronic regions; the largest intron, intron 1, spans 284 kb alone.  
Parkin lies in a head-to-head orientation with the parkin co-regulated gene (PACRG) (OMIM 
608427) on the opposite DNA strand (Asakawa et al. 2001; West et al. 2003). These two genes share 
a common 5’ flanking promoter region spanning 198 basepairs (bp). The 5’ promoter region has no 
apparent TATA or CAAT box elements, but it does contain transcription factor SP1-binding sites, an 
AP4-binding site, a MYC-binding site and CG- and CpG-rich regions, which allow for the regulation 
of parkin and PACRG (West et al. 2003).         
Interestingly, parkin is one of eight genes that lie within the fragile chromosome site FRA6E, one of 
the most active common fragile sites in the human genome (Cesari et al. 2003). This location of the 
parkin gene, in combination with its very large introns, makes parkin particularly prone to instability 
and deletions. The location of parkin within FRA6E suggests that it may be a candidate tumor 
suppressor gene (Cesari et al. 2003); this interesting association of parkin with cancer will be further 
discussed in Section 1.16.5.  
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1.12 MOLECULAR GENETICS OF PARKIN 
1.12.1 Pathogenic mutations 
Mutations in parkin are the most frequent known cause of EOPD. Initial reports identified parkin 
mutations in approximately 50% of patients of European descent with familial cases of EOPD, as well 
as 15% of sporadic EOPD cases (Lücking et al. 2000; Periquet 2003). Mutations in parkin were also 
reported to be common in EOPD patients from various other ethnic backgrounds (Hedrich et al. 
2004). Later, more comprehensive studies reported frequencies of parkin mutations in EOPD patients 
ranging from 1% to 10% across various populations (Kann et al. 2002; Choi et al. 2008; Sironi et al. 
2008; Mellick et al. 2009; Koziorowski et al. 2010). The frequency of parkin mutations decreases 
significantly with increasing age at onset of disease. This is exemplified by a study of 100 unrelated 
sporadic EOPD patients, which found parkin mutations in 77% of patients with PD onset before the 
age of 20 years, 26% of those between 20 and 30 years and only 3% of patients with onset between 30 
and 45 years (Lücking et al. 2000). Parkin mutations are rare in cases with onset later than 50 years of 
age (Klein et al. 2003). It can therefore be said that the frequency of parkin mutations is a function of 
onset age: the earlier the onset, the higher the frequency.  
Over 170 different mutations in parkin have been reported to date, including missense mutations, 
nonsense mutations, splice site mutations, small insertions/deletions (indels) and large whole exon 
deletions, duplications and triplications, across various ethnic groups (Nuytemans et al. 2010; Corti et 
al. 2011). A comprehensive list of the parkin mutations reported in the literature can be found in the 
PD Mutation Database (PDmutDB, http://www.molgen.ua.ac.be/PDmutDB). The exonic locations of 
a subset of the reported mutations are illustrated in Figure 1.3.  
Approximately 50% of pathogenic parkin mutations are exonic rearrangements which cannot be 
detected by sequencing approaches alone (Hedrich et al. 2001). This speaks to the importance of 
performing exon dosage analysis in addition to exon sequencing when screening for mutations in 
parkin. Rare parkin deletions that extend into the 5’ region of PACRG have also been reported 
(Lesage et al. 2007). The clinical phenotype of patients harboring such composite parkin-PACRG 
deletions is indistinguishable from the typical parkin-associated phenotype.   
Haplotype analyses have been performed in order to determine the origin of certain commonly found 
parkin mutations (Periquet et al. 2001; Hedrich et al. 2004). In general, whole exon rearrangements 
are thought to represent independent and recurrent events, whereas missense mutations, found in 
families of different geographic areas, may result from a common founder. 
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Figure 1.3 Schematic representations of the positions of the various pathogenic sequence 
mutations and copy number variations in parkin. A, the positions of pathogenic nonsense, 
missense, frameshift and splice site mutations in the parkin CDS and parkin protein domains. Only 
mutations reported in the homozygous or compound heterozygous state are shown. Numbers above 
the protein schematic indicate the amino acid boundaries of each domain. B, the positions of exonic 
rearrangements, including deletions, duplications and triplications, in the parkin CDS. A deletion 
affecting both parkin and PACRG is also shown. Figure adapted from Corti et al. (2011). 
Abbreviations: bp, basepairs; CDS, coding sequence; del, deletion; ex, exon; fs, frameshift; IBR, in-
between RING; IVS, intervening sequence; RING, really interesting new gene; PACRG, parkin co-
regulated gene; UBL, ubiquitin-like.    
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 Missense mutations 
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In accordance with the recessive inheritance of parkin, both alleles of parkin need to harbor mutations 
in order to cause disease. These biallelic mutations may be in either homozygous or compound 
heterozygous states. Most of the exon dosage mutations, indels and nonsense mutations are loss-of-
function mutations, as they result in significant structural disruption of the protein coding sequence 
(CDS) or premature termination of the transcript. On the other hand, the many missense mutations in 
parkin rely on evidence from functional studies with regards to their pathogenicity.  
 
1.12.2 The role of heterozygous variants 
In some PD patients, only a single heterozygous parkin mutation is present. It has been suggested that 
such heterozygous mutations may act as risk factors for the development of late onset typical PD; 
however, this view is quite controversial. Interest in heterozygous mutation carriers was fuelled by 
early observations of multi-affected families carrying parkin mutations. In such families, EOPD 
patients harbored homozygous or compound heterozygous parkin mutations, whereas some of their 
relatives who developed later-onset PD had single heterozygous parkin mutations (Farrer et al. 2001; 
Foroud et al. 2003). Furthermore, heterozygous parkin mutations identified in PD patients were not 
found in unaffected controls (Hedrich et al. 2002; Schlitter et al. 2006; Sun et al. 2006).   
These observations were criticized for the significant confounding effects of ascertainment bias. 
Moreover, the abovementioned studies only screened control subjects for the variants found in the PD 
patients, and may therefore have missed heterozygous variants present in controls but not patients. 
Later studies reported similar rates of heterozygous mutations among unaffected controls as PD 
patients (Kay et al. 2007). A comprehensive screen for parkin mutations in 1700 control subjects 
found exonic rearrangements in 1% of unaffected controls and heterozygous missense variants in 3% 
of controls (Kay et al. 2010). Interestingly, all of the exonic rearrangements identified in controls 
were found in exons 1-4, and no such rearrangements were seen in exons 5-12 which encode for 
functionally critical domains. Kay et al. (2010) found that heterozygous parkin mutations were not 
associated with an increased risk of PD. Single parkin mutations may therefore be incidental in PD 
patients and unrelated to disease; however, further large-scale studies are necessary. On the other 
hand, it is interesting to note that functional neuroimaging studies, such as 18F-dopa PET imaging, 
have reported presynaptic dysfunction of striatal neurons in asymptomatic heterozygous parkin 
mutation carriers (Scherfler et al. 2004; Pavese and Brooks 2009; Guo et al. 2011). This would add 
support to a role of heterozygous parkin mutations as susceptibility factors for PD. It is hoped that 
future studies can resolve this contentious issue conclusively.        
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1.13 PARKIN EXPRESSION AND LOCALIZATION 
1.13.1 Parkin transcript expression  
Parkin is expressed as a 4,5 kb transcript comprising of a 1395 bp open reading frame (ORF) (Kitada 
et al. 1998). This transcript is expressed in most human tissues with a particularly high expression in 
the heart, skeletal muscle and brain, including the substantia nigra (Figure 1.4).    
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Expression profile of the parkin gene. Northern blot analysis of parkin gene expression 
in various human tissues. Gene expression in various regions of the adult human brain is shown in the 
two rightmost panels. Figure adapted from Kitada et al. (1998). Abbreviations: kb, kilobases.    
 
 
 
Several alternatively spliced isoforms of parkin have been described. For example, isoforms lacking 
exon 4 or exon 5 are expressed in the brain (Kitada et al. 1998; Sunada et al. 1998; Tan et al. 2005). 
The pathogenic relevance of such splice variants is unclear; the ratio of exon 4 splice isoform to full-
length parkin is higher in sporadic PD patients in comparison to unaffected controls (Tan et al. 2005). 
Differential expression of parkin isoforms in various tissues have been described, which may reflect 
regulation of tissue-specific parkin activity. For example, a parkin splice variant lacking exons 3-5 is 
the most abundant parkin transcript in peripheral lymphocytes, whereas full-length parkin is the 
predominant transcript in the brain (Sunada et al. 1998).  
 
1.13.2 Parkin subcellular localization  
Various approaches have been employed to study the subcellular localization of parkin, the 465-aa, 52 
kDa protein product of the parkin gene. When considering fractionation studies, both endogenous and 
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overexpressed tagged parkin is found mainly in the cytosol, although parkin also co-fractionates with 
the outer mitochondrial membrane (OMM), Golgi apparatus, synaptic vesicles and postsynaptic 
membranes (Shimura et al. 1999; Kubo et al. 2001; Fallon et al. 2002; Darios et al. 2003).  
Ultrastructural investigation of overexpressed parkin in adult mouse brain tissue demonstrated that 
parkin associated with the OMM, the endoplasmic reticulum (ER), cytoplasmic vesicles, the outer 
nuclear membrane and the nuclear matrix (Stichel et al. 2000). 
 
Other studies used immunocytochemistry to investigate endogenous parkin localization in various 
cultured cell lines. Such approaches corroborated the mainly cytosolic presence of parkin and also 
found that it co-localizes with actin filaments and the cytoskeleton, the ER, plasma membrane, 
cytoplasmic vesicles, Golgi apparatus (Huynh et al. 2000; Zarate-Lagunes et al. 2001). Furthermore, 
several studies reported the association of endogenous parkin with the mitochondria and OMM under 
native conditions (Kuroda et al. 2006; Rothfuss et al. 2009). This is in contrast to other studies which 
found that parkin is recruited from the cytosol to the OMM only upon chemically-induced 
mitochondrial depolarization (Narendra et al. 2008; Matsuda et al. 2010; Rakovic et al. 2010). 
Nonetheless, the latter studies should not been interpreted as proof of absence of parkin in 
mitochondria under native conditions, as they merely demonstrated the substantial increase in the 
mitochondrial fraction of parkin protein under stress conditions. 
Subcellular localization studies using overexpressed, tagged proteins should be interpreted with 
caution as they are susceptible to artefacts. For example, the transgenic overexpression of parkin 
greatly increases its relative proportion of mitochondrial-bound protein (Narendra et al. 2010a). This 
speaks to the value of using endogenous protein for in vivo studies of parkin localization and function. 
  
1.14 PARKIN IS AN E3 UBIQUITIN LIGASE  
Early studies of parkin demonstrated that the protein has ubiquitin ligase enzymatic activity, and 
hence identified parkin as an E3 ubiquitin ligase (Imai et al. 2000; Shimura et al. 2000; Zhang et al. 
2000). This implicated parkin as a member of the UPS, the major cellular pathway for the degradation 
of soluble intracellular proteins. As an oversimplification, it can be said that the UPS consists of two 
major steps: the ubiquitination of E3-bound protein substrates (Section 1.14.1) followed by the 
proteasome-dependent degradation of ubiquitinated substrates (Section 1.16.2.1). It is E3 enzymes, 
such as parkin, that confer the substrate specificity of the UPS. Parkin-mediated ubiquitination is also 
involved in proteasome-independent processes such as protein trafficking, mitophagy, cell signaling 
and apoptosis.   
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1.14.1 Ubiquitination 
The process of ubiquitin conjugation requires the concerted, sequential action of three enzymes: an E1 
activating enzyme, an E2 conjugating enzyme and an E3 ubiquitin ligase (Hershko and Ciechanover 
1998). In brief, an ubiquitin monomer is activated by an E1 enzyme in an ATP-dependent manner, 
which results in the conjugation of the now adenylated C-terminal glycine (Gly76) of ubiquitin to a 
cysteine residue of E1 via a high-energy thiolester bond. Activated ubiquitin is then transferred from 
E1 to an active-site cysteine residue of an E2 enzyme, forming a similar thiolester linkage. The E1 
enzyme dissociates, and E2 interacts with a substrate-bound E3 enzyme. This results in the transfer of 
adenylated ubiquitin to the ε-amino group of an internal lysine residue of the substrate protein, 
conjugating ubiquitin to the substrate via an isopeptide bond.  
The above-described process results in the conjugation of a single ubiquitin monomer to a substrate 
protein, termed mono-ubiquitination. Mono-ubiquitination of substrates is involved with the 
regulation of endocytosis, histone modification and protein sorting (Osley et al. 2006; Clague et al. 
2012). However, as ubiquitin itself contains seven lysine residues, chains of ubiquitin molecules can 
be formed by the conjugation of the C-terminal glycine of an activated ubiquitin to a lysine residue of 
another ubiquitin, termed poly-ubiquitination. Such poly-ubiquitination, resulting in a chain of at least 
four monomers, is required for protein degradation. The best studied poly-ubiquitin chain is K48 
(conjugation of ubiquitin to lysine 48 of substrate ubiquitin), which targets proteins for degradation 
via the proteasome (Chau et al. 1989; Thrower et al. 2000). K63 poly-ubiquitin chains are involved in 
various proteasome-independent functions such as signal transduction, DNA repair, apoptosis and 
autophagy (Chan and Hill 2001; Chen and Sun 2009). Hence, the fate of an ubiquitinated protein is 
dependent on both the mode of ubiquitination (mono- or poly-ubiquitination) and the type of chain 
linkage. However, the wealth of recent studies suggest that cellular ubiquitin signaling, whether 
degradative or non-degradative, is significantly more complicated than previously appreciated 
(Komander and Rape 2012; Kravtsova-Ivantsiv and Ciechanover 2012).       
Early studies of parkin demonstrated that it associates with the UbcH7 and UbcH8 E2 enzymes to 
mediate K48 poly-ubiquitination, thereby targeting substrates for proteasome-dependent degradation 
(Kahle and Haass 2004; Rankin et al. 2011) (Section 1.16.2.1). Consistent with parkin’s involvement 
in the UPS, parkin’s UBL domain can directly associate with several subunits of the proteasome: 
Rpn1, Rpn10, Rpt5, Rpt6 of the 19S regulatory particle and the α4 subunit of the 20S core particle 
(Sakata et al. 2003; Tsai et al. 2003; Dächsel et al. 2005). Hence, parkin is able to mediate the 
translocation of its substrates to the proteasome and so promote their degradation. 
Surprisingly, parkin is also capable of mediating proteasome-independent ubiquitination of protein 
substrates such as mono-ubiquitination (Fallon et al. 2006; Hampe et al. 2006; Joch et al. 2007) and 
K63 poly-ubiquitination (Doss-Pepe et al. 2005; Lim 2005) via interactions with the E2 complex 
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UbcH13/Uev1a. Parkin furthermore self-regulates its ubiquitin ligase activity via auto-ubiquitination 
(Chaugule et al. 2011). Parkin is therefore a multifunctional ubiquitin ligase (Lim et al. 2006).  
 
1.14.2 The structure of parkin protein 
Until recently, all E3 ubiquitin ligases were divided into three structural classes: RING (Really 
Interesting New Gene) ligases, U-Box ligases and HECT (Homologous to E6 C-Terminus) ligases. 
These differed with respect to the mechanism of ubiquitin transfer to substrates. RING and U-Box 
ligases do not possess catalytic activity, but act as scaffolds to facilitate the direct transfer of ubiquitin 
from E2 to the substrate, whereas HECT ligases accept activated ubiquitin from E2 and subsequently 
catalyze the enzymatic transfer of ubiquitin to the substrate. Parkin belongs to the RING Between 
RING (RBR) set of E3 ligases, originally thought to be a subclass of RING E3s (Eisenhaber et al. 
2007). However, recent studies demonstrated that RBR ligases function like RING/HECT hybrids: 
they associate with E2 via a Zn2+-binding RING domain (like RING E3s), but transfer ubiquitin 
directly to substrates via a catalytic cysteine residue (like HECT E3s) (Wenzel et al. 2011). RBR 
ubiquitin ligases such as parkin consist of three consecutive domains: RING1, in between RING 
(IBR) and RING2. Parkin also contains an ubiquitin-like (UBL) domain at its N-terminal end. 
Recently, a third RING domain unique to parkin was identified N-terminally of RING1 and named 
RING0 (Hristova et al. 2009).  
Remarkably, the natively folded structure of parkin was only elucidated as recently as 2013, when 
four groups independently published the crystal structure of the parkin’s characteristic RBR domains 
(Riley et al. 2013; Spratt et al. 2013; Trempe et al. 2013; Wauer and Komander 2013); one of the 
groups also reported the structure of full-length parkin at a lower resolution (Trempe et al. 2013). 
Despite the different crystallization approaches used, the reported parkin structures are highly similar 
and very insightful (Figure 1.5). 
The studies found that the C-terminal RING1, IBR and RING2 domains are not an isolated structural 
unit, but are intertwined with the UBL and RING0 domains to form a compact structure that is folded 
back onto itself, reminiscent of a coiled snake (Dove and Klevit 2013). Interestingly, two regions that 
are critical for parkin’s ligase activity, the catalytic site in RING2 and the E2 binding site in RING1, 
are occluded. This validates other studies which suggested an inactive, auto-inhibited state for native 
parkin (Chaugule et al. 2011; Chew et al. 2011).  Parkin’s auto-inhibition is due to the hydrophobic 
interfacing of RING0 with RING2, which buries the catalytically vital cysteine residue (Cys431) in 
RING2, and the binding of the newly-discovered repressor element of parkin (REP) to RING1, which 
obstructs the E2 docking site in RING1.     
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Parkin’s crystal structure also confirmed that RING0, RING1, IBR and RING2 each bind two Zn2+-
ions as previously predicted (Hristova et al. 2009); however, the topologies of the folded RING 
domains differed significantly (Dove and Klevit 2013). RING1 is the only bona fide RING domain, as 
it adopts a canonical structure and coordinates its Zn2+-ions in a cross-brace pattern. In opposition to 
RING1, RING2 and IBR adopt similar folding topologies with Zn2+-binding cysteine residues 
arranged sequentially. RING0 coordinates Zn2+ in a hairpin structure, assuming a characteristic fold 
that has been previously called the unique parkin (UP) domain (Hampe et al. 2006).   
 
 
  
  
 
 
 
 
 
 
Figure 1.5 Schematic representation of parkin protein structure. A, the domain architecture of 
parkin. Numbers above the protein schematic indicate the amino acid boundaries of each domain. B, 
representation of the crystal structure of parkin. Parkin forms a compact structure with multiple 
domain interfaces; each domain is colored according to the diagram in A. Parkin is natively inactive 
and auto-inhibited, as two critical sites are inaccessible. The catalytic site in RING2 is obstructed by 
RING0, and the E2 binding site in RING1 is occluded by REP. Adapted from Winklhofer (2014). 
Abbreviations: IBR, in-between RING; RING, really interesting new gene; REP, repression element 
of parkin; UBL, ubiquitin-like.    
 
As stated, the enzymatic active site of parkin is located in RING2 and centered on the Cys431 residue. 
Several authors noted the close proximity of His433 and Glu444 to Cys431, which may form a 
catalytic triad whereby the pKa of Cys431 is lowered and the residue rendered highly reactive (Riley 
et al. 2013; Spratt et al. 2013). It is perhaps this high reactivity which necessitates the auto-inhibition 
of parkin activity.      
A 
B 
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However, several important questions remain unanswered. It is still unclear how posttranslational 
modifications and/or binding of interacting proteins switch parkin from an inactive to an active state, 
or how structurally dynamic the protein is. Indeed, the active sites of E2s and parkin’s Cys431 are 
separated by a distance of approximately 50Å; parkin therefore needs to undergo significant 
conformational rearrangements to permit ubiquitin transfer. The recent advances in the understanding 
of parkin’s structure will greatly inform further research into its regulation and function.  
   
1.14.3 Pathogenic mutations affect parkin’s ubiquitin ligase activity   
The structure of soluble, natively folded parkin (Section 1.14.2) provides valuable insights into how 
pathogenic parkin mutations may result in parkin dysfunction. As such, parkin mutations can 
conceivably impact on parkin function in four major ways: affecting parkin stability and solubility; 
decreasing parkin ligase activity; affecting protein-protein interactions with E2s, adaptor proteins, 
regulatory proteins or substrates, and increasing parkin ligase activity.  Mutations that disrupt Zn2+-
binding or other important structural residues may destabilize the tertiary structure of parkin, which 
would result in the loss of functional parkin. Such destabilized protein may also form aggregates, with 
potentially cytotoxic results. Parkin’s ligase activity can be abrogated by pathogenic mutations in its 
catalytic site (e.g. C431F) or E2 binding site (e.g. T240R). Mutations that disrupt parkin substrate 
recognition or binding would also result in a decrease in parkin ligase activity; however, it is still 
unclear how or through which domain parkin binds its substrates. Lastly, mutations that abolish 
parkin auto-inhibition would result in an increase of ligase activity. This may be mediated by 
pathogenic mutations at the interfaces of RING0 and RING2 (e.g. T183A) or REP and RING1 (e.g. 
A398T) (Riley et al. 2013; Spratt et al. 2013; Trempe et al. 2013; Wauer and Komander 2013). 
Spratt et al. (2013) noted that regulatory auto-ubiquitination of parkin occurs only in cis, not in trans, 
providing an interesting molecular explanation for the recessive nature of parkin mutations. If a 
heterozygous mutation destabilizes or inactivates the protein, only the mutant protein loses its 
function without affecting the wild-type copy. On the other hand, a heterozygous mutation that 
disrupts parkin auto-inhibition and subsequently increases its ligase activity, produces a mutant 
protein that auto-ubiquitinates itself in cis without affecting the wild-type copy. This would result in 
the selective degradation of the mutant protein, leaving the unaffected copy intact. Therefore, either 
homozygous or compound heterozygous mutations are necessary for the complete loss of parkin 
function.    
The complexity and interconnectedness of parkin’s structure make accurate predictions of a particular 
mutation’s effect difficult. This can be appreciated when considering that pathogenic mutations have 
been described in all five domains, rather than clustering in its catalytic domain; hence, mutations in 
any part of parkin can disrupt multiple intertwined domains on several levels.   
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1.15 PARKIN INTERACTORS 
Numerous proteins have been observed to interact with parkin to date, which are listed in Table 1.2. 
Such protein-protein interactions have been detected via established biochemical approaches, 
including yeast two-hybrid (Y2H), co-immunoprecipitation (co-IP) and affinity purification followed 
by mass spectrometry analysis (AP-MS). Interestingly, there are now several examples of previously-
identified parkin interactors that cannot be reconciled with the recent elucidation of parkin structure. 
For example, many studies originally reported the interaction of UbcH8 (an E2 ubiquitin-conjugating 
enzyme) with parkin’s RING2 domain (Imai et al. 2000; Zhang et al. 2000; Olzmann et al. 2007); 
recent findings that RING2 is not a canonical RING domain and lacks the conserved residues required 
for E2 recruitment cast significant doubt on such an interaction (Spratt et al. 2013).  
The identified parkin interactors can be grouped in five non-exclusive categories (Table 1.2): proteins 
that interact with parkin as part of the ubiquitination machinery, parkin substrates which are 
ubiquitinated by parkin, parkin interactors without current evidence of ubiquitination, interactors 
which translocate parkin to various cellular organelles or events, and interactors which regulate parkin 
ligase activity either via direct association or by chemical modifications. Many of the identified parkin 
interactors will be discussed in subsequent sections in relation to the cellular functions of parkin.  
 
Table 1.2 Reported protein-protein interactions with parkin 
Interactor 
Official 
symbol* 
Detection 
method(s) 
Reference(s) 
Components of ubiquitination machinery 
CASK CASK Co-IP Fallon et al. (2002) 
Cullin-1 CUL1 Co-IP Staropoli et al. (2003) 
Ubc7 UBE2G1 Co-IP Imai et al. (2000); Shimura et al. (2000) 
UbcH5c UBE2D3 Co-IP Joch et al. (2007); Shin et al. (2011) 
UbcH6 UBE2E1 Co-IP Shin et al. (2011) 
UbcH7 UBE2L3 Co-IP Imai et al. (2000); Wenzel et al. (2011) 
UbcH13 UBE2N Co-IP Doss-Pepe et al. (2005); Olzmann et al. (2007) 
Ubiquitin UBC Co-IP Shimura et al. (2000); Zhang et al. (2000) 
Uev1a UBE2V1 Co-IP Doss-Pepe et al. (2005) 
Interactors which are ubiquitinated 
Aβ APP 
Co-IP;            
co-localization 
Rosen et al. (2010); Lonskaya et al. (2013) 
Ataxin-2 ATXN2 Co-IP Huynh et al. (2007) 
Bax BAX Co-IP Johnson et al. (2012) 
β-Catenin CTNNB1 AP-MS Rawal et al. (2009) 
CISD1 CISD1 AP-MS Okatsu et al. (2012) 
Cyclin E CCNE1 Co-IP Staropoli et al. (2003) 
DAT SLC6A3 Co-IP Jiang et al. (2004) 
DMT1 SLC11A2 Co-IP Roth et al. (2010) 
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Interactor 
Official 
symbol* 
Detection 
method(s) 
Reference(s) 
Drp1 DNM1L Co-IP Wang et al. (2011a) 
Eps15 EPS15 Co-IP Fallon et al. (2006) 
ERRα ESRRA Co-IP Ren et al. (2011) 
ERRβ ESRRB Co-IP Ren et al. (2011) 
ERRγ ESRRG Co-IP Ren et al. (2011) 
FAF-1 HFAF1 Co-IP Sul et al. (2013) 
FBP1 FBP1 Co-IP Ko et al. (Ko 2006); 
Fbw7β FBXW7B Co-IP Staropoli  et al. (2003); Ekholm-Reed et al. (2013) 
GBA GBA Co-IP Ron et al. (2010) 
Hexokinase 1 HK1 Co-IP; AP-MS Okatsu et al.  (2012); Sarraf et al. (2013) 
IKKγ IKBKG Co-IP Henn et al. (Henn et al. 2007) 
LIM kinase 1 LIMK1 Co-IP Lim et al. (2007) 
Miro RHOT1 Co-IP Wang et al. (2011b) 
Mitofusin 1 MFN1 Co-IP; AP-MS Glauser et al. (2011); Sun et al. (2012) 
p38 AIMP2 Co-IP Corti et al. (2003); Ko et al. (2005) 
Pael-R GPR37 Y2H; Co-IP Imai et al. (2000) 
PARIS ZNF746 Co-IP Shin et al. (2011) 
Parkin PARK2 Co-IP Shimura et al. (2000); Chaugule et al. (2011) 
PDCD2 PDCD2 Co-IP Fukae et al. (2009) 
Phospholipase c-γ1 PLCG1 Co-IP Dehvari et al. (2009) 
PICK1 PICK1 Co-IP Joch et al.  (2007) 
RanBP2 RANBP2 Co-IP Um et al. (Um et al. 2006) 
Septin 4 ARTS Co-IP Choi et al. (2003); Kemeny et al. (2012) 
Septin 5 SEPT5 Y2H; Co-IP Zhang et al. (2000) 
SIM2 SIM2 Co-IP Okui et al. (2005) 
αSp22 SNCA Co-IP Choi et al. (2001); Shimura et al (2001); 
Synaptotagmin XI SYT11 Y2H; Co-IP Huynh et al. (2003) 
Synphilin-1 SNCAIP Y2H; Co-IP Chung et al. (2001); Bandopadhyay et al. (2005) 
TOMM70A TOMM70A 
Co-IP; AP-MS; 
FRET 
Okatsu et al. (2012); Bertolin et al. (2013) 
TRAF2 TRAF2 Co-IP Henn et al. (2007); Chung et al. (2013) 
α-Tubulin TUBA Co-IP Ren et al. (2003) 
β-Tubulin TUBB1 Co-IP Ren et al. (2003) 
γ-Tubulin TUBG1 Co-IP Zhao et al. (2003) 
VDAC1 VDAC1 Co-IP; AP-MS Okatsu et al. (2012); Sun et al. (2012) 
Interactors which are not ubiquitinated 
Actin ACTA1 AP-MS Kim and Son (2000) 
Ambra1 AMBRA1 Co-IP; AP-MS Van Humbeeck et al. (2011) 
Arrestin-1 ARRB1 Co-IP Ahmed et al. (2011) 
Bcl-2 BCL2 Co-IP Chen et al.(2010b) 
CHIP STUB1 Co-IP; AP-MS Imai et al. (2002) 
DJ-1 PARK7 Co-IP Moore et al. (2005); Xiong et al. (2009) 
HHARI ARIH1 Co-IP Parelkar et al. (2012) 
Hsc70 HSPA8 Co-IP Imai et al. (2002); Imai et al. (2003) 
HSJ1a DNAJB2A Co-IP Imai et al. (2002) 
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Interactor 
Official 
symbol* 
Detection 
method(s) 
Reference(s) 
Hsp70 HSPA4 Co-IP; AP-MS Imai et al. (2002); Tsai et al. (2003) 
Hsp90 HSPA1 Co-IP Imai et al. (2003) 
Mitofusin 2 MFN2 Co-IP; AP-MS Glauser et al. (2011); Sun et al. (2012) 
Mortalin HSPA9 Co-IP Yang et al.  (2011) 
NME2 NME2 AP-MS Okatsu et al. (2012) 
p62 SQSTM1 Co-localization Narendra et al. (2010b) 
PACRG PACRG Co-IP Imai et al. (2003) 
PCNA PCNA Co-IP Kao et al. (2009) 
PIK3C3 PIK3C3 Co-IP Choubey et al. (2014) 
PS-α4 PSMA4 Y2H; Co-IP Dächsel et al. (2005) 
Rpn1 PSMD2 Co-IP Um et al. (2010) 
Rpn10 PSMD4 Co-IP Sakata et al. (2003); Uchiki et al. (2009) 
Rpt5 PSMC3 Co-IP Um et al. (2010) 
Rpt6 PSMC5 Co-IP Tsai et al (2003); Um et al. (2010) 
Tau MAPT Co-IP Petrucelli et al. (2004) 
TDP-43 TARDBP Co-IP Hebron et al. (2013) 
TOMM40 TOMM40 FRET Bertolin et al. (2013) 
VDAC2 VDAC2 AP-MS Okatsu et al. (2012); Sun et al. (2012) 
VDAC3 VDAC3 AP-MS Okatsu et al. (2012); Sun et al. (2012) 
Interactors which mediate parkin translocation 
AF-6 MLLT4 Co-IP Haskin et al. (2013) 
Beclin 1 BECN1 Co-IP Choubey et al. (2014) 
HDAC6 HDAC6 Co-IP; AP-MS Jiang et al. (2008); Hebron et al. (2013) 
Klokin 1 CHPF Y2H; Co-IP Kuroda et al. (2012) 
Interactors which regulate parkin activity 
14-3-3η YWHAH Co-IP Sato et al. (2006) 
Ataxin-3 ATXN3 Co-IP Durcan et al. (2011); Bai et al. (2013) 
BAG5 BAG5 Co-IP Kalia et al. (2004) 
C-Abl ABL1 Co-IP Ko et al. (2010); Imam et al. (2011) 
Casein kinase-1 CSNK1A1 Co-IP Yamamoto et al. (2005) 
Cdk5 CDK5 Co-IP Avraham et al. (2007) 
HtrA2 HTRA2 Co-IP Park et al. (2009) 
LRRK2 LRRK2 Co-IP Smith et al. (2005) 
NAC1 NACC1 Co-IP Korutla et al. (2014) 
NEDD8 NEDD8 Co-IP; AP-MS Choo et al. (2012); Um et al. (2012) 
Nrdp1 RNF41 Y2H; Co-IP Zhong et al. (2004) 
p32 C1QBP Co-IP Li et al. (2011c) 
PINK1 PINK1 Co-IP Sha et al (2009); Shiba et al. (2009); 
Protein Kinase A PKA Co-IP Yamamoto et al. (2005) 
Protein kinase C DYT10 Co-IP Yamamoto et al. (2005) 
SUMO-1 SUMO1 Co-IP Um & Chung (2006) 
*Refers to the HGNC approved gene symbol. Adapted from the BioGRID database (http://thebiogrid.org). 
Abbreviations: AP-MS, affinity purification mass spectrometry; Co-IP, co-immunoprecipitation; FRET, Förster 
resonance energy transfer; Y2H, yeast two-hybrid. 
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1.16 CELLULAR FUNCTIONS OF PARKIN 
A wide array of neuroprotective functions of parkin has been described. Such neuroprotection is 
aimed against numerous sources of cellular stress that may result in cell death, including proteotoxic 
stress, mitochondrial stress, excitotoxicity and pro-apoptotic stimulation (Corti et al. 2011; Rankin et 
al. 2011; Exner et al. 2012). In fact, several studies have reported that parkin is transcriptionally 
upregulated during periods of cell stress.  The neuroprotective functions of parkin can be broadly 
grouped into three mechanisms: maintaining proper protein degradation, promoting mitochondrial 
function and health, and modulating proteasome-independent ubiquitin signaling in pro- and anti-
apoptotic pathways. Parkin has also been implicated in non-neuronal functions, such as tumor 
suppression and innate immunity, which will be briefly discussed. 
 
1.16.2 Parkin and protein degradation 
Early studies of parkin demonstrated that it can associate with the UbcH7 and UbcH8 E2 enzymes to 
mediate K48 poly-ubiquitination, thereby targeting substrates for proteasome-dependent degradation 
(Kahle and Haass 2004; Rankin et al. 2011). Loss of function of parkin may therefore result in the 
deleterious accumulation of such substrates, potentially contributing to neurotoxicity. While many 
parkin substrates have been identified to date (Table 1.2), there is little evidence that most of these 
substrates accumulate in the absence of functional parkin or that parkin modulates their levels in a 
proteasome-dependent manner in vivo (Periquet et al. 2005; Davison et al. 2009; Dawson and Dawson 
2010). However, a handful of authentic parkin UPS substrates (cyclin E, AIMP2, FBP-1 and PARIS) 
demonstrate pathological relevance (Corti et al. 2003; Ko 2005, 2006; Shin et al. 2011); these 
interactions will be discussed in Section 1.16.2.2.  
 
1.16.2.1 The proteasomal degradation pathway 
Parkin plays important roles in protein quality control and turnover via the UPS. Therefore, the 
process whereby ubiquitinated substrates are degraded will be briefly discussed. Degradation of 
sufficiently poly-ubiquitinated substrates is mediated by a large multimeric protein complex called the 
26S proteasome (Bedford et al. 2010). This structure consists of a 20S core particle which can be 
capped at one or both ends by the 19S regulatory particle. The 20S core particle is a hollow, barrel-
shaped structure composed of 28 subunits organized into four heptameric rings. Whereas the two 
outer rings, comprised of seven α-subunits, enable docking of the 19S regulatory particles to the core 
particle, the two inner rings of seven β-subunits have potent proteolytic activities. The β1, β2 and β5 
subunits of the 20S core possess peptidylglutamyl-like activity, trypsin-like activity and 
chymotrypsin-like activity, respectively.  
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Access to the 20S core particle is tightly regulated by the 19S regulatory particle, which recognizes, 
de-biquitinates and unfolds poly-ubiquitinated substrates through the concerted action of various 
ubiquitin-binding, de-ubiquitinating and ATPase-like subunits (Bedford et al. 2010). The unfolded, 
untagged protein is subsequently threaded through the catalytic core of the proteasome, where it is 
promptly degraded.  
 
1.16.2.2 Parkin targets substrates for degradation 
Several studies demonstrated that parkin regulates the steady-state levels of many (but not all) of its 
protein substrates via the UPS; the accumulation of such substrates may contribute to cytotoxicity and 
dopaminergic neurodegeneration. Parkin is able to act as a component of a multiprotein SCF (Skp1, 
Cullin-1, Roc1 and F-box protein)-like ubiquitin ligase complex via interactions with cullin-1 and 
fbw7β (Staropoli et al. 2003). As part of such a complex, parkin targets and promotes the degradation 
of the apoptosis-regulator cyclin E. Parkin deficiency in primary neurons potentiates the accumulation 
of cyclin E and resulting apoptosis in primary neurons experiencing kainite-induced excitotoxicity, 
whereas overexpressed parkin attenuated cyclin E accumulation in such a model of neuronal stress.   
Transgenic mice that overexpress the authentic parkin substrate aminoacyl-tRNA synthase complex-
interacting multifunctional protein-2 (AIMP2)/p38 present with age-dependent dopaminergic 
neuronal loss and accompanying motor features (Lee et al. 2013). Such accumulation of AIMP2 
mediated cell death via a nuclear interaction between AIMP2 and poly(ADP-ribose)-polymerase-1 
(PARP1), which resulted in the activation of PARP1 and accumulation of poly(ADP-ribose) 
molecules. Interestingly, the subsequent neurodegeneration was restricted to the ventral midbrain of 
such transgenic mice.         
The accumulation of the parkin-interacting substrate (PARIS, ZNF746) is regulated by parkin  in a 
neuronal cell model: overexpression of parkin results in reduced expression of PARIS, whereas 
downregulation of parkin expression results in PARIS upregulation (Shin et al. 2011). PARIS is a 
specific and key transcriptional repressor of peroxisome proliferator-activated receptor γ coactivator 
1α (PGC-1α), an important mediator of mitochondrial biogenesis (St-Pierre et al. 2006; Ventura-
Clapier et al. 2008). PARIS accumulation in a parkin deficient mouse model resulted in the selective 
degeneration of dopaminergic neurons (Shin et al. 2011).  
During periods of oxidative stress, parkin ubiquitinates and mediates the degradation of F-box protein 
fbw7β (Ekholm-Reed et al. 2013). Fbw7β regulates the degradation of the mitochondrial pro-survival 
factor myeloid cell leukemia-1 (Mcl-1); hence, parkin indirectly promotes neuronal survival by 
maintaining Mcl-1 levels. Mcl-1 is downregulated when parkin is knocked down in primary neuronal 
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cell cultures, resulting in an acute sensitivity to oxidative stress. Pathogenic mutations in parkin may 
therefore result in dopaminergic cell death via unregulated Fbw7β-targeted degradation of Mcl-1.  
Another study found that parkin mediates the degradation of the pro-apoptotic Fas-associated factor 1 
(FAF1) in a neuronal cell line, where pathogenic parkin mutations resulted in the accumulation of 
FAF1 (Sul et al. 2013). Furthermore, FAF1 accumulated selectively in the substantia nigra of a 
MPTP-induced mouse model of PD, and the subsequent dopaminergic degeneration is attenuated in 
transgenic mice with diminished levels of FAF1.   
 
1.16.3 Parkin and mitochondrial health 
Compelling evidence of the mitochondrial involvement of parkin were obtained from Drosophila 
models of parkin deficiency. Such flies demonstrated prominent mitochondrial dysfunction, muscle 
degeneration and dopaminergic degeneration (Greene et al. 2003; Cha et al. 2005; Whitworth et al. 
2005). Flies overexpressing mutated parkin showed similar neural degeneration and mitochondrial 
impairment as flies lacking in parkin (Wang et al. 2007). Interestingly, the abnormalities seen in 
parkin knockout flies closely resembled that of PINK1 knockout Drosophila models; furthermore, 
parkin overexpression rescued the pathological effects of PINK1 deficiency, but not vice versa (Clark 
et al. 2006; Park et al. 2006; Yang et al. 2006). These interesting observations spurred the discovery 
of a common PINK-parkin pathway acting upon mitochondria (Poole et al. 2008).  
Narendra et al. (2008) found that carbonyl cyanide 3-chlorophenylhydrazone (CCCP)-induced 
mitochondrial depolarization of HeLa cells induced the recruitment of parkin at the OMM, where 
parkin promoted the sequestration and autophagic degradation of damaged mitochondria (mitophagy). 
Moreover, the mitochondrial translocation of parkin was found to be depended on PINK1, which 
accumulates at the OMM upon mitochondrial depolarization (Narendra et al. 2010a; Matsuda et al. 
2010).In addition to recruiting parkin to the OMM, PINK1 is also involved in the activation of parkin-
mediated mitophagy by phosphorylating parkin at Ser65 within parkin’s UBL domain (Kondapalli et 
al. 2012; Shiba-Fukushima et al. 2012). The PINK1-mediated parkin recruitment is aided and 
regulated by several recently identified components, including translocase of outer membrane (TOM) 
member 7 (TOMM7) and hexokinase 2 (HK2) (Hasson et al. 2013; McCoy et al. 2014). At the OMM, 
activated parkin ubiquitinates mitofusins 1 and 2 (Mfn1 and Mfn2), voltage-dependent anion-selective 
channel protein 1 (VDAC1), CDGSH iron-sulfur domain-containing protein 1 (CISD1), hexokinase 1 
(HK1) as well as members of the TOM complex (Gegg et al. 2010; Geisler et al. 2010; Yoshii et al. 
2011; Okatsu et al. 2012). However, parkin likely ubiquitinates a wide variety of currently unknown 
proteins on the OMM in response to mitochondrial damage (Sarraf et al. 2013). The widespread 
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ubiquitination of OMM proteins results in the recruitment of the autophagy machinery and the 
autophagic clearance of damaged mitochondria, promoting cell survival (Chan et al. 2011b).  
While the discovery of the important role of parkin in mitophagy in chemically-stressed cell models is 
very insightful, it is not clear to what extent impairment of this function is responsible for in vivo 
dopaminergic neuronal degeneration in cases of pathogenically mutated parkin. It was recently 
reported that the rate of mitochondrial protein turnover is reduced in parkin mutant Drosophila, 
supporting the role of parkin in mitophagy under normal physiological conditions (Vincow et al. 
2013). The role of parkin-induced mitophagy in mouse models has yet to be demonstrated.  
Parkin, together with PINK1, has also recently been implicated in a selective vesicular pathway for 
mitochondrial quality control (McLelland et al. 2014). This subtler pathway, distinct from canonical 
mitophagy, involves the selective sorting and transport of oxidized and damaged mitochondrial 
proteins in mitochondria-derived vesicles (MDVs), which then bypass autophagosomes and are 
delivered directly to lysosomes for degradation. McLelland et al. (2014) found that wild-type, but not 
mutant, parkin co-localized with MDVs in response to mild oxidative stress, and stimulated the 
formation of MDVs in an ubiquitin-dependent manner. It is thought that this vesicular pathway 
provides a mechanism for routine mitochondrial quality control, whereas mitophagy may be reserved 
for more severe mitochondrial damage.    
While the numerous recent studies of parkin’s role in mitophagy have garnered much attention, parkin 
is also implicated in other pathways promoting mitochondrial health. For example, parkin has been 
shown to promote mitochondrial biogenesis.  Parkin associated with the mitochondrial transcription 
factor TFAM, enhancing TFAM-mediated transcription activity; conversely, parkin deficiency 
significantly decreased the level of mitochondrial-encoded mRNA (Kuroda et al. 2006a). Parkin was 
also found to directly bind mtDNA and to preserve mtDNA integrity in response to elevated ROS 
levels  (Rothfuss et al. 2009). Moreover, parkin promotes mitochondrial biogenesis via its UPS-
dependent regulation of the PARIS-PGC-1α pathway (Section 1.16.2.2).  
Parkin is also involved in the regulation of mitochondrial fission and fusion, continuous processes that 
orchestrate a dynamic cellular network of mitochondria. These processes fine-tune the mitochondrial 
network in response to changes in cellular conditions, in order to promote proper mitochondrial 
function and health (Westermann 2010). The core machinery of mitochondrial fusion is composed of 
Mfn1, Mfn2 and optic atrophy protein 1 (OPA1), whereas fission is driven by dynamin-related protein 
1 (Drp1). Parkin, together with PINK1, is thought to regulate mitochondrial fusion and fission via 
ubiquitination of Mfn1, Mfn2 and Drp1 in a common PINK1-parkin pathway (Gegg et al. 2010; Poole 
et al. 2010; Glauser et al. 2011; Wang et al. 2011a). Indeed, Drp1-dependent mitochondrial 
fragmentation is commonly reported in cell- and animal models of parkin deficiency (Deng et al. 
2008; Lutz et al. 2009; Yu et al. 2011).  Hence, parkin plays important roles in the promotion and 
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coordination of many aspects of mitochondrial health, including degradation of damaged 
mitochondria, mitochondrial biogenesis and mitochondrial dynamics. Dysregulation of the careful 
balance between these processes may significantly compromise mitochondrial health and contribute to 
neurodegeneration (Exner et al. 2012). 
 
1.16.4 Parkin and cell death pathways 
Various neuroprotective effects of parkin have been described that relate to apoptotic signaling. 
Parkin is involved in the regulation of the mitochondrial release of cytochrome c; there is an inverse 
relationship between cellular parkin levels and cytochrome c release and apoptosis (Darios et al. 2003; 
Berger et al. 2009). Parkin also physically interacts with the promoter region of p53 and 
downregulates its transcription, which reduces caspase-3 activation (da Costa et al. 2009). 
Interestingly, this anti-apoptotic effect of parkin is not dependent on its ligase activity. In contrast, 
parkin ligase activity is required for its transcriptional attenuation of MAO-A and MAO-B (Jiang et al. 
2006). MAO is a substantial source of ROS in dopaminergic neurons; parkin therefore indirectly 
reduces the generation of ROS.  
Parkin associates with and stabilizes microtubules, where it protects neurons against microtubule-
depolymerizing toxins by diminishing the activation of mitogen-activated protein kinases (MAPK) 
such as extracellular signal-related kinase (ERK), c-Jun N-terminal kinase (JNK) and p38 (Ren et al. 
2009). The regulation of JNK activity by parkin was also seen in parkin Drosophila models (Cha et al. 
2005). Parkin suppression of JNK and p38 activity was found to protect against tyrosinase-mediated 
neurotoxicity (Hasegawa et al. 2008). Furthermore, JNK signaling induces cyclooxygenase 2, a 
necessary step for neurodegeneration in a MPTP-induced mouse model of PD; suppression of this 
pathway may be another avenue for parkin-mediated neuroprotection (Hunot et al. 2004). 
Parkin suppresses the trafficking of epidermal growth factor (EGF) receptor (EGFR) by ubiquitinating 
the adaptor protein Eps15 (Fallon et al. 2006). As ubiquitination of Eps15 interferes with its ability to 
bind and internalize EGFR, the absence of parkin resulted in accelerated EGFR degradation and 
reduced EGFR signaling via the phosphoinositide 3-kinase (PI(3)K)/Akt signaling cascade. Parkin 
therefore promotes PI(3)K/Akt pro-survival signaling (Fallon et al. 2006). In fact, transgenic delivery 
of constitutively active Akt protected against neurodegeneration in a drug-induced mouse model of 
PD (Ries et al. 2006). Parkin was also found to mediate neuroprotection via the activation of the IκB 
kinase/NF-κB pathway (Henn et al. 2007). Moreover, parkin was observed to ubiquitinate Bax in a 
way that abrogated the mitochondrial translocation of Bax and thus suppressed Bax’s pro-apoptotic 
effects (Johnson et al. 2012). This effect was mediated by cytosolic parkin without the translocation of 
parkin to mitochondria under pro-apoptotic conditions, illustrating that the neuroprotective and 
mitochondrial functions of parkin are mediated through different mechanisms. 
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1.16.5 Parkin and cancer 
As stated previously, the parkin genomic structure spans a large region of FRA6E, one of the most 
active common chromosome fragile sites in the human genome (Cesari et al. 2003). Such fragile sites 
are susceptible to chromosomal breaks and rearrangements and are implicated in oncogenesis. In fact, 
parkin copy number mutations are frequently reported in breast cancer (Shah et al. 2012), renal 
carcinoma (Toma et al. 2008), esophageal carcinoma (Gu et al. 2010), glioma (Yin et al. 2009), non-
small cell lung cancer (Iwakawa et al. 2012), cervical cancer (Mehdi et al. 2011) and gastric cancer 
(Deng et al. 2012). Such genetic observations are supported by functional studies of parkin as a tumor 
suppressor; for example, heterozygous deletion of parkin accelerated the development of intestinal 
adenoma in transgenic mice expressing mutant APC, a regulator of Wnt signaling (Poulogiannis et al. 
2010), whereas parkin knockout mice demonstrated enhanced hepatocyte proliferation and 
development of hepatic tumors (Fujiwara et al. 2008)   
The mechanism of the tumor suppressor activity of parkin is not fully understood. As stated in Section 
1.16.2.2, cyclin E is a substrate for parkin ubiquitination and subsequent proteasomal degradation. It 
is interesting to speculate that dysregulation of this important cell cycle regulator may contribute to 
oncogenesis, and several studies have found increased cyclin E levels in parkin-null cancer cell lines 
(Ikeuchi et al. 2009; Tay et al. 2010; Yeo et al. 2012). Parkin deficiency may also promote cancer via 
metabolic changes resulting from parkin-linked mitochondrial dysfunction. Tumor cells often 
demonstrate the Warburg effect, whereby the cells switch from mitochondrial energy production to 
anaerobic glycolysis, coupled with an increased glucose uptake and utilization (Van der Heiden et al. 
2009). Parkin, a p53 target gene, mediates the role of the tumor suppressor p53 in glucose metabolism 
and the Warburg effect (Zhang et al. 2011); in fact, parkin deficiency was found to promote glycolysis 
and reduced mitochondrial respiration in human lung cancer cells, leading to the Warburg effect 
(Zhang et al. 2011). 
 
1.16.6 Parkin and innate immune defense  
Whereas parkin plays an important and much-studied role in mediating mitophagy (Section 1.16.3), a 
recent report implicated parkin in an additional autophagic pathway: the clearance of intracellular 
pathogens via the process of xenophagy (Manzanillo et al. 2013). This interesting finding supports 
genomic association studies which show that parkin polymorphisms, resulting in decreased parkin 
expression, are associated with increased susceptibility to intracellular bacterial pathogens such as 
Mycobacterium leprae and Salmonella typhi (Mira et al. 2004; Ali et al. 2006). Manzanillo et al. 
(2013) demonstrated that parkin is required for the ubiquitin-mediated xenophagy of Mycobacterium 
tuberculosis in macrophages, where parkin ubiquitinates an unknown membrane protein on 
phagosomal vesicles containing ingested M. tuberculosis, thereby targeting the phagosome for 
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lysosomal degradation. Interestingly, it was found that both mouse and Drosophila models of parkin 
deficiency demonstrate increased susceptibility to various intracellular bacterial pathogens, suggesting 
that parkin may play an evolutionarily conserved role in eukaryotic innate immune responses 
(Manzanillo et al. 2013).   
 
1.17 THE PRESENT STUDY 
It is evident from the above-discussed literature that PD has a complex etiology with various 
contributing genetic and non-genetic factors. The identification of genes that induce familial PD has 
greatly advanced our understanding of PD pathogenesis; however, much of the etiology and 
pathobiology of the disease remain unclear. It is hoped that further investigation of PD-associated 
proteins, and the molecular pathways they form part of, would lead to new insight and direction in PD 
research.  
This dissertation focusses specifically on the role of parkin, and the study is divided into three parts. 
The first part comprises a molecular genetic screen for parkin mutations in South African PD 
patients. While the genetic basis of PD has been extensively characterized in North American, 
European and Asian populations, very little is known of the molecular etiology of PD in sub-Saharan 
Africa (Blanckenberg et al. 2013). Investigation of the genetic contribution to PD in South African 
patients may be particularly insightful given the unique genetic heritage of the Black African, 
Afrikaner and mixed ancestry sub-populations of South Africa. As both parkin point mutations and 
exonic rearrangements are reported to be common causes of EOPD, the present study aimed to assess 
the contribution of parkin mutations to PD in South African populations by determining the frequency 
of both point mutations and exon rearrangements in all 12 parkin exons in a group of unrelated South 
African patients diagnosed with PD. A better understanding of the molecular genetics of parkin in a 
South African context may assist in risk stratification, diagnosis and counseling of South African PD 
patients.   
The second part of the study entails an identification and investigation of novel parkin-interacting 
proteins. Although many substrates of parkin’s E3 ligase activity have been identified in the literature, 
it is anticipated that novel, pathologically-relevant parkin substrates remain to be discovered. The 
benefit of identifying parkin substrates is well illustrated by the recognition of PARIS, AIMP2, 
Fbw7β and other proteins as authentic, pathologically-relevant parkin substrates, as described in 
preceding sections. The current study aimed to identify novel parkin-interacting proteins by using the 
RBR region of parkin as bait in a yeast two-hybrid (Y2H) library screen. This functionally important 
RBR region contains substrate binding sites for a variety of known parkin substrates, including 
PARIS, AIMP2 and Fbw7β; it is therefore appropriate for use in a Y2H library screen for novel 
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interactors. As the identified parkin interactions may constitute UPS-mediated regulation and 
degradation of a parkin substrate, it is hypothesized that the absence of functional parkin would result 
in an accumulation of such substrates, eventually leading to cellular toxicity.  
The third part of this dissertation involves the functional effects of parkin deficiency in a cell model 
and a pilot study of the possible rescue effect of vitamin K2 treatment. Initially, it was aimed to 
employ RNA interference (RNAi) to create a parkin knockdown neuronal cell model, in order to 
determine the effect of the absence of parkin on each parkin interactor’s level of expression. 
Subsequently, dermal fibroblasts obtained from patients with parkin-null mutations were used as a 
parkin deficient cell model. The effect of the absence of parkin on various cellular parameters such as 
cell viability and proliferation, mitochondrial respiration rate, mitochondrial membrane potential and 
mitochondrial network integrity was determined. It was then investigated whether the treatment with 
the recently identified potential therapeutic agent vitamin K2 would ameliorate the effect of absence of 
parkin on such cellular parameters. While it was previously demonstrated that the treatment of parkin-
knockout Drosophila with vitamin K2 rescued the mitochondrial defects seen in this fly model 
(section 1.9.4), it would be worthwhile to investigate whether similar effects would be seen in a 
human neuronal cell model. Such evidence would add weight to the potential use of vitamin K2 as a 
therapeutic agent for PD patients with parkin mutations.  
To summarize, the present study had the following objectives: 
1. Determine the frequencies of both parkin missense mutations and exonic rearrangements in a 
group of 229 unrelated South African patients diagnosed with PD, by means of high 
resolution melt (HRM) analysis and multiplex ligation-dependent probe amplification 
(MLPA) analysis, and verification by DNA sequencing.   
2. Identify potentially novel interactors of the RBR region of parkin using a Y2H approach. 
3. Verify selected putative parkin interactors by means of in vivo 3D co-localization and co-
immunoprecipitation assays. 
4. Assess whether the protein expression levels of the verified parkin interactors are increased in 
a cellular model of parkin deficiency. 
5. Investigate the effect of parkin deficiency on various cellular parameters by means of cell 
growth and viability assays, mitochondrial respiration assays, mitochondrial membrane 
potential assays and mitochondrial network morphology analyses. 
6. Evaluate the effect of treatment with vitamin K2 on aforementioned cellular parameters. 
Hence, results generated by this study would stimulate further discussion about parkin and parkin-
interacting proteins, as well as their potential relevance in cellular stress, neurodegeneration and PD. 
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CHAPTER TWO: MATERIALS AND METHODS 
 
PART ONE: MOLECULAR ANALYSIS OF PARKIN  
 
The first part of this dissertation entails a molecular genetic investigation of the parkin gene in the 
context of PD in South African patients. As such, the genetic contribution of parkin mutations to PD 
pathology was assessed by determining the frequency of mutations in all 12 exons of parkin in a 
group of South African patients diagnosed with PD (Section 2.2). Point mutations and small 
insertions/deletions were detected by performing HRM analysis (Section 2.6) and automated DNA 
sequencing (Section 2.7), whereas whole exon rearrangements were identified by MLPA analysis 
(Section 2.8). Furthermore, reverse-transcription PCR (RT-PCR) was performed on lymphocytes of 
selected study participants (Section 2.5.5). Relevant and detailed information regarding the materials 
and methods used in this part of the study follows below.  
 
2.1 ETHICAL CONSIDERATIONS 
This study gained ethical approval from the Health Research Ethics Committee of Stellenbosch 
University, Cape Town, South Africa (Protocol number 2002/C059). Ethical approval was renewed 
annually during the course of this study. Written informed consent was obtained from all participants. 
 
2.2 STUDY PARTICIPANTS AND BLOOD COLLECTION 
The study group consisted of 229 unrelated PD patients, who were recruited from the Movement 
Disorders clinic at Tygerberg Hospital (Cape Town, South Africa) and the Parkinson’s Association of 
South Africa. All patients recruited at Tygerberg Hospital underwent a standardized examination by a 
movement disorder specialist and were diagnosed with PD based on the UK Parkinson’s Disease 
Society Brain Bank diagnostic criteria (Gibb and Lees 1988b). The majority of recruited patients 
demonstrated early disease onset (age at onset (AAO) <=50 years) and/or positive family history of 
PD. AAO and family history were determined via a questionnaire filled out by a trained research 
nurse, where a positive family history was defined as the self-reported presence of PD in a first- or 
second-degree relative. Patients with late onset PD (AAO > 60 years) were included in the study as 
parkin mutations had been found in both early and late onset PD patients (Sun et al. 2006). 
Over 100 ethnically-matched control samples were recruited from healthy, unrelated individuals of 
each relevant ethnic group; these control individuals had not been examined for PD symptoms by a 
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neurologist. No information regarding the ages of the control individuals was available as control 
samples were de-identified. While the 229 PD patients recruited for the genetic study were unrelated, 
patients that were found to harbor pathogenic parkin mutations following the genetic screen (Section 
3.1.2) were subjected to a thorough family work-up by a research nurse. This included the 
procurement of blood samples from consenting family members, who were then screened for presence 
of the relevant parkin mutation(s). The genetic results of these family members of the 229 unrelated 
probands were not included in the analysis of parkin mutation frequency. 
Blood samples were collected from each study participant by a trained phlebotomist using two 10ml 
Vacutainer® ethylene-diamine-tetra-acetic acid (EDTA) tubes (Becton Dickinson, Franklin Lakes, 
New Jersey, USA) for DNA extraction (Section 2.3). For selected study participants, blood samples 
were collected in two 2.5ml volumes in PAXgene™ Blood RNA tubes (PreAnalytiX, Hombrechtikon, 
Switzerland) for RNA extraction (Section 2.4).  
 
2.3 DNA EXTRACTION FROM BLOOD 
DNA was extracted from whole blood samples using a modification of the method described by 
Corfield et al. (1993). All DNA blood extractions were performed by Mrs. Ina le Roux.  
Briefly, each EDTA-blood sample was transferred to a 50ml polypropylene tube and the sample 
brought to a final volume of 45ml with cold (4°C) cell lysis buffer (Appendix II). Samples were 
incubated on ice for 10min followed by centrifugation at 2800rpm for 10min at 10°C on an Eppendorf 
model 5810R centrifuge (Eppendorf, Hamburg, Germany), and the supernatant discarded. Pellets 
were resuspended in 20ml cell lysis buffer and the incubation and centrifugation steps repeated. The 
supernatant was discarded and volumes of 900µl Na-EDTA solution (Appendix II), 100µl of 10% 
SDS and 100µl proteinase K (Roche, Basel, Switzerland) added to the pellets, which were fully 
resuspended and incubated at 37°C overnight (16h).  
Following the overnight incubation, volumes of 2ml ddH2O, 500µl of 3M Na-Ac (Appendix II) and 
2.5ml phenol-chloroform (Appendix II) were added to each tube. Tubes were incubated at 4˚C for 
10min with shaking on an Orbit 300 shaker (Labnet, Edison, New Jersey, USA). The mixtures were 
transferred to separate 10ml glass tubes and centrifuged at 8000rpm for 12 min at 10°C in a Sorvall™ 
RC5B Plus centrifuge (Thermo Fisher Scientific, Waltham, Massachusetts, USA). Each aqueous 
phase was transferred to fresh glass tubes.  A volume of 2.5ml chloroform-octanol (Appendix II) was 
added to each tube and the tubes centrifuged at 8000rpm for 10 min at 10°C in a Sorvall™ RC5B Plus 
centrifuge. Supernatants were then transferred to 15ml polypropylene tubes and a total of 5ml of ice-
cold (-20°C) 96% ethanol added to facilitate DNA precipitation. The precipitate was transferred to a 
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1.5ml microcentrifuge tube containing 1ml of 70% ethanol. Samples were pelleted by centrifugation 
at 15 000rpm for 3min at room temperature in a Labnet Prism™ microcentrifuge (Labnet, Edison, 
New Jersey, USA). The supernatants were discarded and the 70% ethanol wash repeated. After 
centrifugation, pellets were air-dried at room temperature for approximately 30min.  
Pellets were resuspended in the following manner: A volume of 200µl of 1X TE buffer (Appendix II) 
was added to each tube which were then incubated at 37°C overnight (16h) followed by further 
incubation at 4°C on a model HS100 rotating wheel (Labnet, Edison, New Jersey, USA) for three 
days. Subsequently, DNA concentration and purity was determined using a NanoDrop® ND-1000 
spectrophotometer (Thermo Scientific, Waltham, Massachusetts, USA) and NanoDrop1000® 
software version 3.7.1 (Thermo Scientific, Waltham, Massachusetts, USA). Purified DNA samples 
were stored at -20°C until use. 
   
2.4 BLOOD RNA EXTRACTION AND cDNA CONVERSION 
Total RNA was extracted from whole blood samples collected in PAXgene™ Blood RNA tubes. 
RNA extraction was performed by using a PAXgene™ Blood RNA kit (PreAnalytiX, 
Hombrechtikon, Switzerland) according to manufacturer’s instructions. Isolated RNA concentration 
and quality was subsequently measured with an Experion™ StdSens Analysis kit (Bio-Rad, Hercules, 
California, USA) on an Experion™ automated electrophoresis station (Bio-Rad, Hercules, California, 
USA). Only RNA samples with a RNA quality indicator (RQI) value above 8.0 (out of 10) were used 
in subsequent applications.  
Following RNA isolation, the purified RNA was converted to complementary DNA (cDNA) by using 
a Quantitect® Reverse Transcription Kit (Qiagen, Hilden, Germany) as per manufacturer’s 
instructions. cDNA concentration was determined using a NanoDrop® ND-1000 spectrophotometer 
and NanoDrop1000® software version 3.7.1. The cDNA samples were then stored at -20°C until use. 
 
2.5 POLYMERASE CHAIN REACTION (PCR) 
2.5.1 Oligonucleotide primer design and synthesis 
Oligonucleotide primers were designed using published sequence data obtained from the Ensembl 
Genome Browser database (http://www.ensembl.org) or the NCBI GenBank database 
(http://www.ncbi.nlm.nih.gov). Primers were designed using Primer3 software version 4.0.0 
(http://primer3.ut.ee) (Koressaar and Remm 2007) and were subsequently tested for primer-primer 
complementarity, self-complementarity and melting temperature compatibility using IDT 
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OligoAnalyzer® software version 3.1 (http://eu.idtdna.com/analyzer/Applications/OligoAnalyzer). 
Primer sequences were also submitted to the Basic Local Alignment Search Tool (BLAST) 
(http://www.ncbi.nlm.nih.gov/BLAST) in order to verify the specificity of the primer binding sites. 
All primers were synthesized using standard phosphoramidite chemistry at Integrated DNA 
Technologies (IDT, Coralville, Iowa, USA).  
 
2.5.2 Primers for parkin exon screening 
Primers were designed for the amplification of all twelve parkin exons. Primer design was based on 
parkin genomic DNA (gDNA) sequence data obtained from the NCBI GenBank database (accession 
number NT_007422). These primers were designed to amplify whole exonic sequences by annealing 
to sites in flanking intronic regions; these primer sequences are shown in Table 2.1. 
 
2.5.3 Primers for reverse-transcription PCR (RT-PCR) 
Primers were designed for the amplification of a 555bp fragment of the parkin CDS. These primers 
were designed to recognize cDNA sequences flanking parkin exons 3-4, which facilitated exon 
dosage analysis of exons 3-4 by means of RT-PCR (Section 2.5.5). Primer design was based on 
parkin cDNA sequence data obtained from the Ensembl Genome Browser database (Ensembl ID 
ENST00000366898). The primer sequences for the amplification of the parkin CDS fragment for RT-
PCR are shown in Table 2.2. 
 
2.5.4 PCR amplification  
PCR amplification of all twelve parkin exons was performed in all 229 patients.  This was done in 
order to screen for parkin sequence variants by means of HRM analysis (Section 2.6). In addition, 
PCR amplification was also performed as part of two-step RT-PCR analysis of selected study 
participants (Section 2.5.5).  
In brief, PCR was performed in 25µl reactions in a 2720 Thermal Cycler (Applied Biosystems, 
Forster City, California, USA), with each reaction mixture containing 10ng template DNA, 20pmol of 
each primer (Tables 2.1 and 2.2), 1.5mM MgCl2, 75µM dNTPs (Promega, Madison, Wisconsin, 
USA), 1X NH4 reaction buffer (Bioline, London, UK) and 0.5 U BIOTAQ DNA polymerase (Bioline, 
London, UK). A total of 5% formamide was used for selected reactions (Table 2.1). PCR cycling 
conditions were as follows: an initial denaturation step at 94oC for 5min, 35 cycles consisting of 
denaturation at 94oC for 30sec, annealing at Ta for 30sec and extension at 72oC for 45sec, and a final 
extension at 72oC for 7min. 
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Table 2.1 Primer sequences for parkin exon screening  
parkin exon Primer Sequence (5’-3’) Ta (˚C) Additive 
1 
PARK2 1 F GAACTACGACTCCCAGCAG 
55 Formamide 
PARK2 1 R CCCGTCATTGACAGTTGG 
2 
PARK2 2 F CACCATTTAAGGGCTTCGAG 
55 Formamide 
PARK2 2 R TCAGGCATGAATGTCAGATTG 
3 
PARK2 3 F TCTCGCATTTCATGTTTGACA 
55 n/a 
PARK2 3 R GCAGACTGCACTAAACAAACA 
4 
PARK2 4 F GCTTTTAAAGAGTTTCTTGTC 
55 n/a 
PARK2 4 R TTTCTTTTCAAAGACGGGTGA 
5 
PARK2 5 F GGAAACATGTCTTAAGGAGT 
55 n/a 
PARK2 5 R TTCCTGGCAAACAGTGAAGA 
6 
PARK2 6 F CCAAAGAGATTGTTTACTGTG 
55 n/a 
PARK2 6 R GGGGGAGTGATGCTATTTTT 
7 
PARK2 7 F CCTCCAGGATTACAGAAATTG 
55 n/a 
PARK2 7 R GTTCTTCTGTTCTTCATTAGC 
8 
PARK2 8 F GGCAACACTGGCAGTTGATA 
55 n/a 
PARK2 8 R GGGGAGCCCAAACTGTCT 
9 
PARK2 9 F TCCCATGCACTGTAGCTCCT 
55 n/a 
PARK2 9 R   CCAGCCCATGTGCAAAAGC 
10 
PARK2 10 F CCAGCCAGAGGAATGAATAT 
53 n/a 
PARK2 10 R GGAACTCTCCATGACCTCCA 
11 
PARK2 11 F CCGACGTACAGGGAACATAAA 
55 n/a 
PARK2 11 R GGCACGTACAGGGAACATAAA 
12 
PARK2 12 F TCTAGGCTAGCGTGCTGGTT 
55 Formamide 
PARK2 12 R GCGTGTGTGTGTGTGTTTGA 
Abbreviations: 3’, three-prime end; 5’, five-prime end; A, adenine; C, cytosine; F, forward primer; G, guanine; 
n/a, not applicable; PARK2, parkin gene; R, reverse primer; T, thymine; Ta, annealing temperature. 
 
 
Table 2.2 Primer sequences for RT-PCR 
Gene Primer Sequence (5’-3’) Ta (˚C) 
parkin (CDS) 
PARK2 2i F GGAGCTGAGGAATGACTGGA 
60 
PARK 5i R ATCATCCCAGCAAGATGGAC 
Abbreviations: 3’, three-prime end; 5’, five-prime end; A, adenine; C, cytosine; CDS, coding sequence; F, 
forward primer; G, guanine; PARK2, parkin gene; R, reverse primer; T, thymine; Ta, annealing temperature. 
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2.5.5 RT-PCR and analysis 
RT-PCR was performed on cDNA obtained from lymphocytes of selected study participants found to 
harbor exonic rearrangements following MLPA analysis (Sections 2.4, 2.8 and 3.1.2). This was done 
in order to confirm the presence and determine the phase of the detected exonic rearrangements. 
Amplification was done as described in Section 2.5.4, using 1µl of synthesized cDNA as template and 
primers listed in Table 2.2. An aliquot of the PCR products were subsequently resolved on a 1% 
agarose gel (Section 2.10.1). In addition, PCR products were purified and subjected to automated 
DNA sequencing and sequence analysis (Section 2.7) in order to verify mutation status.   
 
2.6 HIGH-RESOLUTION MELT (HRM) ANALYSIS  
Amplified DNA fragments were screened for variants using HRM analysis. This approach 
quantitatively assessed the melting behavior of double stranded DNA (dsDNA) fragments. As melting 
behavior of dsDNA fragments is highly dependent on sequence length and content, altered melting 
behavior can be used as a proxy for DNA sequence changes (Reed et al. 2007).     
Prior to HRM analysis, all twelve parkin exons were PCR amplified (Section 2.5.4) with the inclusion 
of 2µM of SYTO® 9 green fluorescent intercalating nucleic acid dye (Life Technologies, Carlsbad, 
California, USA) in PCR reaction mixtures. PCR setup employed an Eppendorf epMotion™ 5070 
automated pipetting system (Eppendorf, Hamburg, Germany) for liquid handling. HRM of PCR 
products was performed on a Rotor-Gene 6000 analyzer (Corbett Life Sciences, Mortlake, Australia) 
and Rotor-Gene 6000 software version 1.7.65 (Corbett Life Sciences, Mortlake, Australia). Melting 
profiles were acquired from 75oC to 95oC with a temperature ramp rate of 0.1˚C/sec. The denaturation 
profiles were subsequently normalized and compared to wild type control samples using the Rotor-
Gene 6000 software. Samples demonstrating altered heat denaturation profiles following HRM 
analysis were subjected to automated DNA sequencing and analysis (Section 2.7). 
 
2.7 AUTOMATED DNA SEQUENCING AND ANALYSIS 
Automated DNA sequencing of PCR fragments was performed in order to characterize DNA 
sequence variants identified by HRM analysis (Section 2.6) and to verify the presence of exonic 
rearrangements identified by RT-PCR (Section 2.5.5). Selected PCR products were subjected to post-
PCR clean-up in preparation of DNA sequencing. This was performed as follows: A total 0.5U each 
of Exonuclease I (Exo I) (Promega, Madison, Wisconsin, USA) and shrimp alkaline phosphatase 
(SAP) (Thermo Fisher Scientific, Waltham, Massachusetts, USA) was added to 8μl of PCR product in 
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a 200µl PCR tube. The mixture was incubated at 37˚C for 15min followed by heat-inactivation at 
85˚C for 15min. Cleaned-up PCR products were stored at 4˚C until use.    
Automated DNA sequencing of purified PCR products was performed at the Core Sequencing Unit of 
the Central Analytical Facility (CAF) of Stellenbosch University, Stellenbosch, South Africa using a 
BigDye® Terminator version 3.01 Cycle Sequencing kit (Applied Biosystems, Forster City, 
California, USA) on an ABI Prism™ 3100 automated sequencer (Applied Biosystems, Forster City, 
California, USA). Primers used in these sequencing reactions are listed in Tables 2.1 and 2.2. 
DNA sequencing electropherograms obtained from automated DNA sequencing were analyzed using 
Bioedit Sequence Alignment Editor Software version 7.0.5 (Ibis Bioscience, Carlsbad, California, 
USA) (Hall 1999). PCR fragments were compared to DNA sequences deposited in the Ensembl 
Genome Browser database (http://www.ensembl.org) and the NCBI GenBank database 
(http://www.ncbi.nlm.nih.gov). All sequence variants were characterized according to established 
nomenclature (den Dunnen and Antonarakis 2000). Possible consequences of coding non-
synonymous variants on parkin protein function were bioinformatically predicted with PolyPhen-2 
software version 2.2.2 (http://genetics.bwh.harvard.edu/pph2) (Adzhubei et al. 2010) and 
MutationTaster software version 2.0 (http://www.mutationtaster.org) (Schwarz et al. 2010). 
 
2.8 MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION (MLPA) ANALYSIS 
Exon rearrangements, resulting in exon dosage mutations, were detected by multiplex ligation-
dependent probe amplification (MLPA) analysis. These assays were done by Dr. Rowena Keyser. 
  
MLPA assays were performed using the P051 and the P052 Salsa® MLPA Parkinson probe sets 
(MRC Holland, Amsterdam, The Netherlands). Both kits included probes for all twelve parkin exons; 
true positive results needed to be detected in both kits. MLPA was performed using 150ng of gDNA 
according to manufacturer’s instructions. MPLA products were analyzed on an ABI 3130x1 Genetic 
Analyzer (Applied Biosystems, Forster City, California, USA) using GeneScan™-500 LIZ® size 
standards (Applied Biosystems, Forster City, California, USA), with MLPA peaks visualized using 
GeneMapper® software version 3.7 (Applied Biosystems, Forster City, California, USA). Thereafter, 
peak height and area values were exported to a Microsoft Excel template. Data normalization and 
dosage calculations were performed according to manufacturer’s instructions (MRC Holland, 
Amsterdam, The Netherlands). Dosage ratio values of 0.7-1.3 were considered to be normal 
(indicating the absence of exon rearrangements); values of 0.3-0.6 were indicative of heterozygous 
deletions, 1.4-1.6 of heterozygous duplications and a dosage ratio value ≥1.7 of triplications. 
Homozygous deletions were detected by the absence of a peak (dosage ratio value = 0.0).   
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PART TWO: PARKIN INTERACTORS 
  
This second part of the dissertation deals with the identification, verification and investigation of 
parkin-interacting proteins. This entailed the identification of putative parkin interactors using Y2H 
methodology (Section 2.19), verification of selected putative interactions using in vivo 3D co-
localization (Section 2.22) and co-immunoprecipitation (Section 2.24), as well the establishment of 
two cell models of parkin deficiency, a RNAi-mediated parkin knockdown neuronal model and a 
parkin-null primary fibroblast model, in order to study the effect of the lack of parkin on each 
interacting protein (Section 2.25). 
 
2.9 POLYMERASE CHAIN REACTION (PCR) 
2.9.1 Primers for generation of yeast two-hybrid (Y2H) construct 
Oligonucleotide primers were designed for the specific amplification of the cDNA fragment encoding 
the C-terminal region of parkin (aa 223-465). Primer design was based on parkin cDNA sequence 
data obtained from the Ensembl Genome Browser database (Ensembl ID ENST00000366898). The 
primers incorporated restriction enzyme (RE) recognition sites at their respective 5’ ends, which 
allowed for subsequent subcloning of PCR amplified inserts into the pGBKT7 vector (Section  2.13). 
The use of these RE sites was dependent on their presence in the multiple cloning site (MCS) of the 
pGBKT7 vector (appendix V) and their absence in the parkin insert sequence. In addition, primers 
incorporated universal “seat” sequences 5’ to their respective RE sites to facilitate proper RE binding 
and digestion (Section 2.12). Primer design and synthesis is described in Section 2.5.1. The primer 
sequences for the amplification of the parkin insert for the generation of Y2H constructs are shown in 
Table 2.3. 
 
 
Table 2.3 Oligonucleotide primer sequences for generation of Y2H construct 
Primer Sequence (5’-3’) Ta (˚C) 
PARK2 RBR F ACTGCAGAA CATATG TCAGTAGCTTTGCACCTGATCG 
57 
PARK2 FL R ACTGCAGAA GAATTC CTACACGTCGAACCAGTGG…… 
Sequences in black font represent gene-specific primer sequences that anneal to cDNA template during PCR 
amplification. Sequences in colored font represent sequences for cloning. Blue, universal enzyme seat; pink, 
NdeI recognition site; green, EcoRI recognition site. Abbreviations: 3’, three-prime end; 5’, five-prime end; A, 
adenine; C, cytosine; F, forward primer; FL, full length; G, guanine; PARK2, parkin gene; R, reverse primer; 
RBR, RING1-between RINGS-RING2; T, thymine; Ta, annealing temperature; Y2H, yeast two hybrid. 
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2.9.2 Primers for Y2H insert screening 
Vector-specific oligonucleotide primers were designed for the amplification of vector inserts from the 
MCS of the Y2H vectors pGBKT7 (BD Biosciences, Clontech, Paulo Alto, California, USA) and 
pGADT7 (BD Biosciences, Clontech, Paulo Alto, California, USA). This was necessary for the DNA 
sequence identification of insert fragments by means of automated DNA sequencing and sequence 
analysis (Section 2.11). The vector sequences used in the design of the primers were obtained from 
the Clontech MATCHMAKER™ vector handbook (http://www.clontech.com). The sequences of 
these primers are shown in Table 2.4. 
 
Table 2.4 Primer sequences for Y2H construct insert screening 
Vector Primer Sequence (5’-3’) Ta (˚C) 
pGBKT7 
pGBKT7 F TCATCGGAAGAGAGTAG 
45 
pGBKT7 R TCACTTTAAAATTTGTATACA 
pGADT7 
pGADT7 outer F CGATGATGAAGATACCCCACCAAA 
57 
pGADT7 outer R TCAAGTGAAGTTGACAGCTAGCAC 
pGADT7 inner F TAATACGACTCACTATAGGGCGAGC 
59 
pGADT7 inner R CGACGTCTACTTAGCATCTATGACTTT 
Abbreviations: 3’, three-prime end; 5’, five-prime end; A, adenine; C, cytosine; F, forward primer; G, guanine; 
R, reverse primer; T, thymine; Ta, annealing temperature; Y2H, yeast two hybrid. 
 
 
 
2.9.3 Primers for construct integrity verification 
Constructs used in establishing a Y2H bait culture (Section 2.19.2) were first subjected to automated 
DNA sequencing and DNA sequence analysis (Section 2.11). This was done in order to verify the 
integrity of the vector inserts. Primers used for these purposes are listed in Table 2.5.  
 
Table 2.5 Primer sequences for construct integrity verification 
Vector Primer Sequence (5’-3’) 
pGBKT7-parkin                  
(C-terminal region) 
pGBKT7 F TCATCGGAAGAGAGTAG 
pGBKT7 R TCACTTTAAAATTTGTATACA 
Abbreviations: 3’, three-prime end; 5’, five-prime end; A, adenine; C, cytosine; C-terminal, carboxy-terminal; F, 
forward primer; G, guanine; R, reverse primer; T, thymine.  
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2.9.4 PCR amplification for generation of Y2H construct  
PCR was used to amplify the C-terminal-encoding region of the parkin CDS from a fetal human brain 
cDNA library. Subsequently the cDNA fragment was cloned into the pGBKT7 Y2H vector (Section 
2.13). 
For amplification of this cDNA fragment, 50ng of a fetal human brain library (BD Bioscience, 
Clontech, Palo Alto, California, USA) was used as template in a 25μl reaction containing 20pmol of 
each primer (Table 2.3), 1.5mM MgCl2, 75µM dNTPs (Promega, Madison, Wisconsin, USA), 1X 
NH4 reaction buffer (Bioline, London, UK) and 0.5U BIOTAQ® DNA polymerase (Bioline, London, 
UK). 
Amplification was performed in a ABI 2720 Thermal Cycler (Applied Biosystems Inc., Foster City, 
California, USA) under the following thermal cycling conditions: an initial denaturing step at 94˚C for 
5min followed by 35 cycles consisting of denaturation at 94˚C for 45sec, annealing at Ta for 45sec 
and elongation at 72˚C for 1min. Cycling was followed by a final extension step at 72˚C for 10min. 
PCR amplification products were subsequently electrophoresed on a 1% agarose gel for verification 
(Section 2.10.1) 
 
2.9.5 Bacterial colony PCR 
Bacterial colony PCR was employed to rapidly identify transformed bacterial colonies containing 
recombinant pGBKT7 with a correctly ligated parkin-CDS insert. This was necessary as the Y2H 
constructs do not allow for blue-white colony screening.  
A small quantity of a single bacterial colony was picked from an agar plate and used a DNA template 
in the PCR amplification.  The same primers used for the generation of the Y2H construct (Table 2.3) 
were utilized for bacterial colony PCR, which followed identical PCR conditions and cycling 
parameters as described above (Section 2.9.4). PCR amplification products were subsequently 
electrophoresed on a 1% agarose gel for verification (Section 2.10.1). Successful bacterial colony 
PCR amplification using primers listed in Table 2.3 indicated correct ligation of the parkin-CDS 
insert into pGBKT7. 
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2.10 GEL ELECTROPHORESIS 
2.10.1 Agarose gel electrophoresis 
Agarose gel electrophoresis was performed in order to visualize successful PCR amplification 
(Section 2.9.4) and to confirm successful plasmid isolation (Section 2.17.2). Electrophoresis was 
performed as follows: a 1-2% agarose gel, depending on the size of the DNA fragment, containing 
1μg/ml ethidium bromide was cast and submerged in 1X sodium tetraborate (SB) buffer (Appendix 
II). A total of 8μl of each PCR product was individually mixed with 2μl bromophenol blue loading 
dye (Appendix II) and loaded into separate wells. A 100bp molecular size marker (Promega, Madison, 
Wisconsin, USA) was co-electrophoresed with the DNA fragments in order to facilitate fragment size 
estimation. Electrophoresis followed at 240V for approximately 20min in 1X SB buffer. 
Subsequently, the samples were visualized and photographed in a SynGene UV gel documentation 
system (Synoptics Ltd., Cambridge, UK) using GeneTools software version 3.0.6 (Synoptics Ltd., 
Cambridge, UK). 
Agarose gel electrophoresis was also employed to separate RE digested PCR fragments (Section 2.12) 
in order to excise the RE digested fragments for subsequent purification (Section 2.17.1). For these 
applications, a total of 24μl digested product was mixed with 6μl bromophenol blue loading dye 
resolved in a similar manner as described above. Samples were visualized by means of a long-wave 
3UV transilluminator (UVP, Upland, California, USA) and the appropriate band was excised from the 
gel using a sterile scalpel blade. The excised band was subsequently purified using a Wizard® SV Gel 
and PCR clean-up kit (Promega, Madison, Wisconsin, USA) (Section 2.17.1).   
 
2.10.2 Sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was used for the size-dependent separation of 
proteins either obtained from a whole cell extract (Section 2.23.1) or from immunoprecipitation (IP) 
or co-immunoprecipitation (co-IP) reactions (Section 2.24). SDS-PAGE was performed in 
100x80x1mm 12% polyacrylamide gels containing 0.1% SDS (Appendix II) for selected applications. 
Alternatively, 4-15% Mini-Protean® TGX™ precast gels (Bio-Rad, Hercules, California, USA) were 
used. Samples to be resolved were mixed with an appropriate volume of 2X or 5X SDS loading buffer 
(Appendix II) and incubated at 95˚C for 10min. The samples were then centrifuged at 15 000rpm for 
1min in a Labnet Prism™ microcentrifuge (Labnet, Edison, New Jersey, USA). Subsequently, 
samples were loading into separate gel wells and electrophoresed in 1X SDS running buffer 
(Appendix II) at 100V for 1.5 - 2h. When 4-15% Mini-Protean® TGX™ precast gels were used, 
electrophoresis followed at 150V for 45min. A total of 7μl of Spectra™ Broad Range Multicolor 
protein ladder (Thermo Scientific, Waltham, Massachusetts, USA) was co-electrophoresed with the 
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samples. Protein samples were then transferred to a polyvinylidene difluoride (PVDF) membrane 
(Section 2.10.3) for downstream western blotting (Section. 2.23).   
 
2.10.3 Transfer of proteins from SDS polyacrylamide gels to PVDF membrane 
Proteins separated by SDS-PAGE were electrophoretically transferred to a PVDF membrane, to be 
used during western blotting (Section 2.23). This was done using the iBlot™ Dry Blotting System 
(Life Technologies, Carlsbad, California, USA) along with iBlot™ PVDF Gel Transfer Stacks (Life 
Technologies, Carlsbad, California, USA), according to manufacturer’s instructions.  
Alternatively, proteins were transferred to a PVDF membrane following a wet transfer approach: 
After SDS-PAGE was completed, the gels were retrieved and briefly rinsed in ddH2O by shaking for 
5min on an Stuart® orbital shaker SSL1 (Bibby Scientific Ltd., Stone, Staffordshire, UK) at room 
temperature. The gel was then immersed in ice-cold transfer buffer (Appendix II) and left shaking for 
an additional 20min. During this time, a PDVF membrane (GE Healthcare Ltd., Little Chalfont, 
Buckinghamshire, UK) was prepared by activating the membrane in absolute methanol for 15sec 
followed by rinsing with ddH2O for 5min. The membrane was then also soaked in ice-cold transfer 
buffer for 20min, along with six equal-sized Whatman papers and two sponges per membrane. A 
transfer stack was then assembled consisting of a sponge and three Whatman papers on either side of 
the stack, with the gel (on the anode side) and the activated membrane (on the cathode side) in the 
middle. The transfer stack was placed in a tank filled with transfer buffer and containing an ice pack, 
and electrophoresed at 100V for 1h with constant stirring. The stack was disassembled and the 
membrane briefly rinsed in ddH2O prior to further use (Section 2.23.4). 
 
2.11 AUTOMATED DNA SEQUENCING AND ANALYSIS 
Automated DNA sequencing of construct inserts was performed in order to identify the insert 
sequence or to verify the insert sequence integrity. This was done at the Core Sequencing Unit of 
CAF at Stellenbosch University, Stellenbosch, South Africa using a BigDye® Terminator version 
3.01 Cycle Sequencing kit on an ABI Prism™ 3100 automated sequencer. Vector-specific primers 
(Tables 2.4 and 2.5) were used for these sequencing reactions.       
DNA sequencing electropherograms obtained from automated DNA sequencing were analyzed using 
Bioedit Sequence Alignment Editor Software version 7.0.5. The generated Y2H construct (Section 
2.13) was analyzed to confirm insert integrity; this was done to verify that the correct reading frame 
of the vector, as well as the correct CDS of the insert, were maintained during cloning. Insert 
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sequences were compared to cDNA sequences deposited in the Ensembl Genome Browser database 
(http://www.ensembl.org).  
DNA sequences of Y2H prey construct inserts were entered into BLAST and compared to cDNA and 
messenger RNA (mRNA) sequences in GENBANK using a BLASTn query 
(http://www.ncbi.nlm.nih.gov/BLAST) in order to identify the prey insert. Moreover, each insert 
DNA sequence was translated in the correct reading frame using DNAMAN™ Software version 4.1 
(Lynnon Biosoft, Pointe-Claire, Canada), after which the corresponding protein sequences were 
analyzed using a BLASTp query (http://www.ncbi.nlm.nih.gov/BLAST). A list of the protein 
products of the prey insert was compiled, after which publicly available databases such as ExPASy 
http://www.expasy.org), GeneCards (http://www.genecards.org) and the Human Protein Atlas 
(http://www.proteinatlas.org) were used to obtain relevant information regarding the function and 
subcellular expression of the proteins.          
 
2.12 RESTRICTION ENZYME DIGESTION  
In order to facilitate cloning of the DNA fragment encoding the C-terminal region of parkin into the 
pGBKT7 Y2H shuttle vector,  the PCR amplified fragment harbored restriction enzyme (RE) 
recognition sites on either end (Section 2.9.1; Table 2.3). The PCR fragments as well as the vector 
were separately double-digested with two RE’s: NdeI and EcoRI.  
Double digestion was performed as follows: a first digestion RE (NdeI) cocktail of final volume 20μl 
was prepared containing either 5μl purified vector (Section 2.17.2) or 15μl purified insert fragments 
(Section 2.17.1), 2U NdeI and 1X RE buffer supplied by the manufacturer (Fermentas, Burlington, 
Canada). The cocktail was incubated for 3h at 37˚C in a Scientific 9000 Series incubator (United 
Scientific, Cape Town, South Africa) followed by heat-inactivation for 15min at 65˚C. Digested 
products were then purified using the Wizard SV® Gel and PCR clean-up system (Section 2.17.1) and 
eluted in a volume of 30μl ddH2O. Thereafter, a second RE digestion (EcoRI) cocktail of final volume 
20μl was prepared containing 16μl purified NdeI-digested fragments, 2U EcoRI and 1X RE buffer 
(Fermentas, Burlington, Canada). The cocktail was incubated for 3h at 37˚C in a Scientific 9000 
Series incubator (United Scientific, Cape Town, South Africa) followed by heat-inactivation for 
15min at 65˚C. Digested products were then purified using the Wizard SV® Gel and PCR clean-up 
system (Section 2.17.1) and eluted in a volume of 50μl ddH2O. Double-digested vector and insert 
fragment were subsequently used in the generation of Y2H constructs (Section 2.13). 
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2.13 GENERATION OF Y2H CONSTRUCT 
The C-terminal region of parkin was cloned into the pGBKT7 shuttle vector in order to generate the 
Y2H bait construct. Both the PCR fragments (Section 2.9.4) and the pGBKT7 Y2H bait vector 
(Appendix V) were first double-digested with appropriate RE’s (Section 2.12) in order to facilitate 
cloning of the insert sequence in the correct orientation.  
The digested and purified vector was then subjected to calf intestinal alkaline phosphatase (CIP) 
treatment to dephosphorylate 5’ ends of the linearized vector, which prevented self-ligation of the 
vector. This was not done to digested PCR fragments. CIP treatment was performed as follows: a 
cocktail of volume 50 µl was prepared containing 30μl double-digested and purified vector, 2U CIP 
and 1X CIP buffer supplied by the manufacturer (Promega, Madison, Wisconsin, USA). The cocktail 
was incubated for 30min at 37˚C in a Scientific 9000 Series incubator (United Scientific, Cape Town, 
South Africa) after which an additional 2U SIP was added to the cocktail. This was followed by 
further incubation for 30min at 37˚C and heat-inactivation for 20min at 65˚C. The vector was then 
purified using the Wizard SV® Gel and PCR clean-up system (Section 2.17.1.). 
Thereafter, DNA ligation of double-digested PCR fragments and linearized vector was performed in 
order to generate the pGBKT7-parkin Y2H bait construct.  Briefly, 1μl of CIP-treated vector was 
added to 1μl, 3μl or 5μl digested PCR fragments (Section 2.12). This was added to a cocktail of final 
volume 10μl additionally consisting of 5U T4 DNA ligase and 1X T4 DNA ligase buffer (Promega, 
Madison, Wisconsin, USA). The cocktail was incubated at 4˚C overnight (16h), after which 5μl of the 
ligation reaction was used in a bacterial plasmid transformation (Section 2.16.1).  
Following retrieval of the generated construct by means of bacterial colony PCR (Section 2.9.5) and 
bacterial plasmid purification (Section 2.17.2), the construct was subjected to DNA sequencing and 
analysis to verify insert integrity (Sections 2.11). Only constructs in which the correct reading frame 
and insert CDS were maintained during cloning were used to transform the S. cerevisiae strain AH109 
(Section 2.16.2).  
 
2.14 BACTERIAL AND YEAST STRAINS 
2.14.1 Bacterial strains 
Escherichia coli (E. coli) strain DH5α (Appendix IV) was transformed in order to facilitate selection, 
amplification and purification of constructs. Transformed bacterial colonies were selected for their 
ability to grown on Luria-Bertani (LB) agar plates (Appendix II) containing the appropriate selection 
antibiotic. For selection of pGBKT7 constructs, kanamycin (5μg/ml) was used, while ampicillin 
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(25μg/ml) was used to select for pGADT7 constructs. Bacterial colony PCR was performed to 
identify colonies containing recombinant constructs (Section 2.9.5).    
 
2.14.2 Yeast strains 
The pGBKT7-parkin Y2H bait construct was transformed into Saccharomyces cerevisiae (S. 
cerevisiae) strain AH109 (Appendix IV). S. cerevisiae strain Y187 (Appendix IV) was pre-
transformed with pGADT7 Y2H prey constructs by the manufacturer (BD Biosciences, Clontech, 
Palo Alto, California, USA). Both yeast strains AH109 and Y187 lack the nutritional genes ADE2, 
HIS3, LEU2 and TRP1 and are therefore unable to growth in synthetic defined (SD) media deficient in 
adenine (-Ade), histidine (-His), leucine (-Leu) and tryptophan (-Trp) (Appendix II). AH109 
transformed with the pGKBT7 construct was selected based on the ability to grow in SD-Trp media, 
while Y187 transformed with pGADT7 constructs were selected on the ability to grow in SD-Leu 
media.       
 
2.15 GENERATION OF BACTERIAL COMPETENT CELLS 
In order to generate transformation-competent bacterial cells, the following procedure was performed: 
A 50μl aliquot of an E. coli DH5α frozen (-80˚C) glycerol stock was used to inoculate 10ml of 
antibiotic-free LB media (Appendix II). The culture was then incubated overnight (16h) at 37˚C while 
shaking at 200rpm in a YIH DER model LM-530 shaking incubator (Scilab Technology Co. Ltd., 
Taipei, Taiwan).  
The following day, 1ml of the culture was used to inoculate 200ml antibiotic-free LB media in a 2L 
Erlenmeyer flask, which was incubated for 16-24h at room temperature while shaking at 70rpm on a 
Stuart® orbital shaker SSL1 (Bibby Scientific Ltd., Stone, Staffordshire, UK), until the culture 
reached mid-logarithmic (log) phase (OD600nm= 0.4-0.6). The culture was then transferred to four 
50ml polypropylene tubes and centrifuged at 3000rpm for 15min at 4˚C in a Beckman model TJ-6 
centrifuge (Beckman Coulter, Pasadena, California, USA). The supernatant was discarded and the 
pellets resuspended in 4ml of ice-cold CAP buffer (Appendix II). This suspension was aliquoted in 
200μl volumes into 2ml microcentrifuge tubes, which were left at 4˚C overnight before being 
transferred to -80˚C for long-term storage.     
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2.16 TRANSFORMATION OF PLASMIDS INTO BACTERIAL AND YEAST CELLS 
2.16.1 Bacterial plasmid transformation 
In preparation of a bacterial plasmid transformation, frozen (-80˚C) microcentrifuge tubes containing 
200μl aliquots of competent E. coli DH5α cells (Section 2.15) were thawed on ice for approximately 
30min. To this, 1μl of purified plasmid (Section 2.17.1) or 5μl ligation reaction (Section 2.13) was 
added and the tubes incubated on ice for a further 20min. The tubes were subsequently immersed in a 
Lasec 102 circulating water bath (Lasec Laboratory and Scientific Co. Ltd. Pty, Cape Town, South 
Africa) at 42˚C for 45sec. Tubes were removed from the water bath and left at room temperature for 
2min. Thereafter, 1ml of antibiotic free LB media (Appendix II) was added to each tube and the 
cultures incubated at 37˚C for 1h while shaking at 200rpm in a YIH DER model LM-530 shaking 
incubator.  
A total of 200μl of the culture was plated on LB agar plates containing the appropriate selection 
antibody (Appendix II). The remaining culture was centrifuged at 15 000rpm for 1min in a Labnet 
Prism™ microcentrifuge (Labnet, Edison, New Jersey, USA). The supernatant was discarded and the 
pellet resuspended in 200μl LB media, after which the concentrated culture was plated on LB agar 
plates containing the appropriate selection antibody. All plates were incubated, inverted, overnight 
(16h) at 37˚C in a model 239 CO2 stationary incubator (Forma Scientific, Marietta, Ohio, USA). The 
following day, colonies were picked for bacterial plasmid purification (Section 2.17.2) or colony PCR 
(Section 2.9.5).    
 
2.16.2 Yeast plasmid transformation 
S. cerevisiae strains to be transformed were streaked from frozen (-80˚C) glycerol stocks onto yeast 
peptone dextrose adenine (YPDA) agar plates (Appendix II), which were then incubated at 30˚C for 
3-4 days in a Sanyo MIR262 stationary ventilated incubator (Sanyo Electric, Moriguchi, Osaka, 
Japan).  
Several large yeast colonies were picked with a sterile inoculation loop and suspended in 1ml ddH2O 
in a 2ml microcentrifuge tube. The cells were centrifuged for 30sec at 15 000rpm in an Eppendorf 
model 5417C centrifuge and the supernatant discarded. The pellet was resuspended in 1ml of 100mM 
lithium acetate (LiAc) (Appendix II) and the suspension incubated at 30˚C for 5min in a Sanyo 
MIR262 stationary ventilated incubator. The cells were subsequently repelleted via centrifugation at 
15 000rpm for 30sec in an Eppendorf model 5417C centrifuge and the supernatant discarded. The 
following reagents were added to the pellet in quick succession: 240μl of 50% polyethylene glycol 
(PEG), 36μl of 1M LiAc (Appendix II), 25μl of 2mg/ml heat-denatured and snap-cooled herring 
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sperm DNA (Promega, Madison, Wisconsin, USA), 10-20μl purified plasmid and ddH2O to a final 
volume of 350μl. The sample was then thoroughly mixed by vortexing for at least 1min on a Snijders 
model 34524 press-to-mix vortex (Snijders Scientific, Tilburg, the Netherlands). After the pellet was 
fully resuspended, the sample was incubated at 42˚C for 25min in a Lasec 102 circulating water bath.  
After incubation, the sample was centrifuged at 15 000rpm for 30sec in an Eppendorf model 5417C 
centrifuge and the supernatant discarded. The pellet was resuspended in 200μl ddH2O and the 
suspension plated on appropriate agar selection plates (Appendix II). All plates were inverted and 
incubated at 30˚C in a Sanyo MIR262 stationary ventilated incubator for 3-4 days.  
 
2.17 DNA ISOLATION AND PURIFICATION  
2.17.1 DNA purification from agarose gels  
In order to purify yeast plasmid preparations (Section 2.17.3), PCR amplified DNA products (Section 
2.9.4) and RE digestion products (Section 2.12) a Wizard® SV Gel and PCR Clean-up Kit (Promega, 
Madison, Wisconsin, USA) was used according to manufacturer’s instructions. Purified product was 
used for bacterial plasmid transformation (Section 2.16.1) or cloning experiments (Sections 2.12 and 
2.13), or stored at 4˚C.  
 
2.17.2 Bacterial plasmid purification  
Bacterial plasmid purification was performed to obtain DNA constructs for subsequent yeast 
transformation (Section 2.16.2) and automated DNA sequencing and analysis (Section 2.11). A single 
transformed bacterial colony was picked from appropriate selection plates and used to inoculate 10ml 
of LB media containing the appropriate selection antibody (Appendix II) in a 50ml polypropylene 
tube. The tube was incubated overnight (16h) at 37˚C while shaking at 200rpm in a YIH DER model 
LM-530 shaking incubator. 
The culture was then centrifuged at 3000rpm for 10min a Beckman model TJ-6 centrifuge. The 
supernatant was discarded and plasmid DNA extracted using a TOpure™ Plasmid Miniprep Kit 
(Gene Technologies, Hong Kong, China) according to manufacturer’s instructions. Subsequently, 
DNA concentration and purity was determined using a NanoDrop® ND-1000 spectrophotometer and 
NanoDrop1000® software version 3.7.1. Additionally, an aliquot of the purified construct was 
electrophoresed on a 1% agarose gel (Section 2.10.1) to visually verify plasmid integrity. 
 
 
Stellenbosch University  https://scholar.sun.ac.za
75 
 
2.17.3 Yeast plasmid extraction  
Y2H constructs were extracted from diploid yeast colonies to be used in bacterial plasmid 
transformations (Section 2.16.1). A yeast colony was picked with a sterile inoculation loop and used 
to inoculate 1ml of SD media containing the appropriate dropout supplement (BD Biosciences, 
Clontech, Palo Alto, California, USA), which was thereafter incubated overnight (16h) at 30˚C while 
shaking at 150rpm in a Labnet 311DS shaking incubator (Labnet, Edison, New Jersey, USA).  
The following morning, 4ml of YPDA media (Appendix II) was added to the culture, which was then 
incubated for an additional 4h at 30˚C with shaking at 150rpm. The culture was subsequently 
centrifuged at 3000rpm for 5min in a Beckman model TJ-6 centrifuge and the supernatant discarded 
by decanting. The pellet was resuspended in residual supernatant and transferred to a 2ml 
microcentrifuge tube. To this, 200μl of yeast lysis buffer (Appendix II), 200μl of 
phenol:chloroform:isoamyl alcohol 25:24:1 (PCI) (Sigma Aldrich, St. Louis, Missouri, USA) and 
300mg sterile 450μm-600μm glass beads (Sigma Aldrich, St. Louis, Missouri, USA) were added. 
Yeast cells were then triturated by uninterrupted vortexing for 2.5min on a Snijders model 34524 
press-to-mix vortex and centrifuged at 15 000rpm for 10min in an Eppendorf model 5417C centrifuge 
(Eppendorf, Hamburg, Germany) to facilitate phase separation. The upper aqueous phase was 
transferred to a sterile microcentrifuge tube and the plasmids purified as described in Section 2.17.1.  
 
2.18 ASSESSMENT OF Y2H CONSTRUCTS  
2.18.1 Phenotypic assessment of yeast strains 
S. cerevisiae strains AH109 and Y187 were phenotypically assessed prior to being transformed with 
Y2H constructs (Section 2.16.2), in order to verify purity and viability of the strain. This was 
accomplished by streaking selected colonies grown on YPDA plates on selective plates lacking 
specific essential amino acids, i.e. SD-Trp, SD-Leu, SD-His, SD-Ade and SD-Ura agar plates (Appendix II). 
All plates were then inverted and incubated at 30˚C in a Sanyo MIR262 stationary ventilated 
incubator for 3-4 days. Only untransformed colonies that were unable to grow on SD-Trp, SD-Leu, SD-His 
and SD-Ade plates but did grow on SD-Ura plates were used in subsequent yeast transformations 
(Section 2.16.2). 
An additional phenotypic assessment was done on transformed AH109 harboring the pGBKT7-parkin 
Y2H bait construct, in order to test for autonomous activation of Y2H reporter genes by the bait 
construct and to ensure that transformation did not alter the strain phenotype improperly. Only 
transformed AH109 colonies that were unable to grow on SD-Leu, SD-His and SD-Ade plates but did 
grow on SD-Trp and SD-Ura plates were used in subsequent Y2H analysis (Section 2.19).        
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2.18.2 Yeast transformation toxicity test 
An evaluation of yeast transformation toxicity was performed prior to Y2H analysis to determine 
whether the Y2H bait construct detrimentally affected the growth of S. cerevisiae strain AH109. To 
this end, a growth curve of AH109 transformed with the pGBKT7-parkin bait construct was generated 
and compared to a growth curve of AH109 transformed with non-recombinant pGBKT7. The two 
growth curves were set up in tandem under similar experimental conditions.  
The two transformed strains were each inoculated in 1ml of SD-Trp media in 50ml polypropylene tubes 
and growth to stationary phase for 24h at 30˚C while shaking at 200rpm in a Labnet 311DS shaking 
incubator. A 1:10 dilution in SD-Trp media was made of both cultures, which were incubated for a 
further 24h at 30˚C while shaking at 200rpm in a Labnet 311DS shaking incubator. During this 
incubation period, 1ml aliquots of the cultures were taken and the OD600nm measurements recorded at 
time points 0h, 2h, 4h, 6h, 8, and 24h. Linearized growth curves were established by charting the log 
of these measurements against time and the gradients of the two graphs, recombinant and non-
recombinant transformed AH109, were compared. Significant differences in growth of the two 
transformed strains would preclude the use of the pGBKT7-parkin bait construct in Y2H analysis 
(Section 2.19). 
 
2.18.3 Establishment of yeast mating efficiency 
Small scale yeast matings were performed to evaluate the effect of the Y2H bait construct on S. 
cerevisiae strain AH109 mating efficiency. This was done by mating AH109, transformed with the 
pGBKT7-parkin bait construct, with the prey host strain Y187 transformed with non-recombinant 
pGADT7. A positive control mating was also performed between AH109 transformed with control 
construct pGBKT7-53 (containing murine p53) (BD Biosciences, Clontech, Palo Alto, California, 
USA) and Y187 transformed with non-recombinant pGADT7.  
The various strains were plated on appropriate selection plates (AH109 transformed with pGBKT7-
parkin; pGBKT7-53 = SD-Trp plates; Y187 transformed with pGADT7 = SD-Leu plates). All plates 
were inverted and incubated at 30˚C in a Sanyo MIR262 stationary ventilated incubator for 3-4 days. 
Singles colonies of both AH109 strains were separately picked and combined with Y187 colonies in 
1ml YPDA media in a 2ml microcentrifuge tube, which were incubated overnight (16h) at 30˚C in a 
Labnet 311DS shaking incubator, shaking at 200rpm. After this incubation period, serial dilutions 
(1:10, 1:100, 1:1000 and 1:10 000) of the mating culture were plated onto SD-Leu, SD-Leu and SD-Leu-Trp 
plates and incubated inverted for 3-4 days at 30˚C in a Sanyo MIR262 stationary ventilated incubator. 
The colonies on each plate were counted and the yeast mating efficiency calculated (Appendix III). 
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2.19 YEAST TWO-HYBRID (Y2H) ANALYSIS 
Y2H analysis was employed in the present study to identify physical interactions between two 
proteins. This methodology exploits the two functional domains of the S. cerevisiae galactose 
metabolism transcription factor GAL4, namely the GAL4 DNA binding domain (DNA-BD) and the 
GAL4 activation domain (AD). Whereas both domains are necessary for proper activation of the 
galactose metabolism gene GAL promoter, the modular nature of GAL4 allows for the two domains to 
function in proximity to each other without direct binding. Hence, the GAL4 DNA-BD and AD can 
be separately expressed from engineered constructs as fusion proteins and still activate the GAL 
promoter provided that the two domains indirectly reconstitute the GAL4 transcription factor (Keegan 
et al. 1986).  
In Y2H, the protein fused to the DNA-BD is referred to as the bait protein (the C-terminal region of 
parkin in the present study) while the protein fused to the AD is referred to as the prey protein 
(members of a library of brain-expressed proteins in the present study). Co-transformation of bait- and 
prey-expressing Y2H constructs into yeast strains allows for possible physical interactions between 
bait and prey proteins to be evaluated: if binding takes place between the bait and prey fusion 
proteins, the GAL4 DNA-BD and AD is brought into sufficient proximity for the successful activation 
of the GAL promoter. Positive bait-prey interactions are then detected by transcription of downstream 
reporter genes. If no binding takes place between the bait and prey proteins, the reporter genes are not 
expressed; interaction detection is therefore based on observable changes in the yeast phenotype. 
Three reporter genes are utilized in the present study: the HIS3 and ADE2 nutritional reporter genes 
and the MEL1 colorimetric reporter gene.  
 
2.19.1 Adult human brain cDNA library  
A Clontech MATCHMAKER™ adult human brain cDNA library, consisting of brain-expressed 
cDNA sequences cloned into the pGADT7 Y2H prey vector (Appendix V), was pre-transformed into 
S. cerevisiae strain Y187 by the manufacturer (BD Biosciences, Clontech, Palo Alto, USA) and used 
in a Y2H library screen. This library was constructed from mRNA isolated from normal, whole brains 
of eight male Caucasian individuals of ages 43-66 years. Cause of death of all eight individuals was 
sudden death.  The cDNA was normalized prior to library construction to reduce the copy number of 
highly abundant CDNAs. The cDNA library inserts ranged in size from 700bp to 3kb, with an average 
insert size of 1.56kb. 
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2.19.2 Establishment of the bait culture 
Four separate colonies of S. cerevisiae strain Y187 transformed with pGBKT7-parkin (Section 2.16.2) 
were picked using a sterile inoculation loop and used to inoculate four 200ml Erlenmeyer flasks each 
containing 50ml of SD-Trp media, which were incubated overnight (16h) at 30˚C while shaking at 
200rpm in a Labnet 311DS shaking incubator. The cultures were then transferred to four 50ml 
polypropylene tubes, centrifuged at 3000rpm for 10min in a Beckman model TJ-6 centrifuge and the 
supernatant discarded by decanting. The pellets were resuspended in residual supernatant and pooled 
to provide a final bait culture titer greater than 1 x 1010, as confirmed by a hemocytometric cell count 
(Appendix III).  
 
2.19.3 Library mating 
In preparation of library mating, a 1ml aliquot of a frozen (-80˚C) pre-transformed Clontech 
MATCHMAKER™ adult human brain cDNA library (Section 2.19.1) was thawed at room 
temperature and, after brief mixing, a 10μl aliquot was set aside to establish a library titer (Section 
2.19.4). 
The bait (Section 2.19.2) and library cultures were combined in a 2L Erlenmeyer flask containing 
45ml of 2X YPDA media (Appendix II), which was incubated overnight (16h) at 30˚C with gentle 
shaking at 50rpm in a YIH DER model LM510R shaking incubator (Scilab Technology Co. Ltd., 
Taipei, Taiwan).  
The mating culture was then transferred to a 50ml polypropylene tube, centrifuged at 3000rpm for 
10min in a Beckman model TJ-6 centrifuge and the supernatant discarded. The 2L Erlenmeyer flask 
was rinsed with 40ml of 2X YPDA media which was subsequently used to resuspend the pelleted 
culture. The mating culture was repelleted by centrifugation at 3000rpm for 10min in a Beckman 
model TJ-6 centrifuge and the supernatant discarded. This rinsing and centrifuging process was 
repeated once more, with the final pellet resuspended in 10ml of 0.5X YPDA (Appendix II). A 10μl 
aliquot of the mating culture was set aside for a control mating experiment (Section 2.19.5). 
The total remaining volume of the mating culture was then plated on multiple (approximately 60) 
triple dropout (TDO) (SD-Leu-Trp-His) plates (Appendix II) with a volume of 200μl used on each plate. 
All plates were inverted and incubated at 30˚C in a Sanyo MIR262 stationary ventilated incubator for 
3 weeks. 
(Harper et al. 1993; James et al. 1996) 
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2.19.4 Establishment of library titer 
A 10μl aliquot of the adult brain cDNA library culture (Section 2.19.3) was serially diluted (1:10, 
1:100, 1:1000 and 1:10 000), plated onto SD-Leu, SD-Leu and SD-Leu-Trp plates and incubated inverted for 
3-4 days at 30˚C in a Sanyo MIR262 stationary ventilated incubator. The colonies on each plate were 
counted and the library titer calculated (Appendix III). 
 
2.19.5 Control mating 
A 10μl aliquot of the library mating culture (Section 2.19.3) was serially diluted (1:10, 1:100, 1:1000 
and 1:10 000) and plated onto SD-Leu, SD-Leu and SD-Leu-Trp plates. All plates were incubated inverted 
for 3-4 days at 30˚C in a Sanyo MIR262 stationary ventilated incubator. The colonies on each plate 
were counted and used to calculate the yeast mating efficiency as well as the number of diploid clones 
screened (Appendix III). 
 
2.19.6 Selection and screening for reporter gene activation 
2.19.6.1 Selection for nutritional reporter gene activation 
Diploid yeast colonies resulting from the library mating were grown on TDO (SD-Leu-Trp-His) plates for 
three weeks (Section 2.19.3). The plates were monitored every four days and full-grown 
(diameter>2mm) colonies, capable of activating the HIS3 nutritional reporter gene, were re-streaked 
onto TDO and quadruple dropout (QDO) (SD-Leu-Trp-His-Ade) plates (Appendix II), which were incubated 
inverted at 30˚C in a Sanyo MIR262 stationary ventilated incubator for 5 days. Successful colony 
formation on QDO plates indicated the additional activation of the ADE2 nutritional reporter gene.  
Streaked colonies on TDO and QDO plates were phenotypically assessed for colony growth and 
color. Colony growth was visually categorized as very good (+++), good (++), weak (+) or no growth 
(-). Furthermore, only white (healthy) colonies were considered for further analysis, whereas red 
(dying or dead) colonies were excluded. Colonies growing on QDO plates were then transferred onto 
QDO plates containing 5-bromo-4-chloro-3-indolyl α-D-galactopyranoside (X-α-gal) (Section 
2.19.6.2).  
 
2.19.6.2 Screening for colorimetric reporter gene activation  
In order to test for activation of the MEL1 colorimetric reporter gene, in addition to activation of HIS3 
and ADE2 nutritional reporter genes, diploid colonies were transferred from QDO plates to QDO 
plates containing the chromogenic substrate X-α-gal.  
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QDO-X-α-gal plates were prepared by evenly spreading 200μl of a 5mg/ml X-α-gal solution 
(Appendix II) (Sigma Aldrich, St. Louis, Missouri, USA) onto fresh QDO plates. Colonies grown on 
QDO plates (Section 2.19.6.1) were replicated onto Hybond N+ nylon membranes (GE Healthcare 
Ltd., Little Chalfont, Buckinghamshire, UK) which were placed colony-side up onto QDO-X-α-gal 
plates. The plates were incubated at 30˚C in a Sanyo MIR262 stationary ventilated incubator for 24h. 
Activation of the MEL1 reporter gene was subsequently evaluated by blue-white screening. 
 
2.19.7 Prey plasmid isolation and purification from diploid yeast colonies 
Diploid yeast colonies that were able to activate all three reporter genes, i.e. strong growth on QDO 
plates that turned blue on QDO-X-α-gal plates (Section 2.19.6), harbored bait and prey constructs 
expressing putatively interacting fusion peptides. Hence, the pGADT7 prey constructs were retrieved 
for prey insert identification (Section 2.11) and interaction specificity tests (Section 2.19.8). 
Yeast constructs were extracted as described in Section 2.17.3 and subsequently transformed into 
competent E. coli DH5α cells (Section 2.16.1), which were plated on LB plates supplemented with 
ampicillin (25μg/ml). This allowed for selection of colonies harboring pGADT7. All plates were 
incubated inverted overnight (16h) at 37˚C in a model 239 CO2 stationary incubator. The following 
day, colonies were picked for bacterial plasmid purification (Section 2.17.2).  
 
2.19.8 Interaction specificity test 
Direct Y2H tests were performed to determine whether the interactions seen in diploid yeast colonies 
(Section 2.19.6) were specific to the pGBKT7-parkin bait construct. Rescued prey constructs (Section 
2.19.7) were each retransformed into S. cerevisiae strain Y187 (Section 2.16.2). Transformed Y187 
colonies were individually mated with S. cerevisiae strain AH109 colonies transformed with one of 
four heterologous bait constructs: pGBKT7-parkin, non-recombinant pGBKT7, pGBKT7-53 and 
pGBKT-TTN (encoding the 11-repeat superdomain of human cardiac-expressed titin, a kind gift from 
Ms. Carol Todd).  
Mating was performed by individually mixing Y187 prey-expressing colonies with each of the 
AH109 heterologous bait-expressing colonies on YPDA plates. The plates were then inverted and 
incubated overnight (16h) at 30˚C in a Sanyo MIR262 stationary ventilated incubator. The following 
morning, colonies were streaked onto TDO and QDO plates, which were incubated at 30˚C in a Sanyo 
MIR262 stationary ventilated incubator for 2 weeks. Colony growth and appearance was then 
evaluated for each mating pair. Only healthy (white) prey colonies that were able to grow on QDO 
plates when mated to pGBKT7-parkin bait colonies, but did not grow on QDO plates when mated to 
non-recombinant pGBKT7, pGBKT7-53 and pGBKT7-TTN bait colonies, were considered to 
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demonstrate specific bait-prey interactions. Prey constructs resulting in such interaction-specific 
colonies were considered to be putatively true parkin interactors, and the relevant pGADT7 prey 
constructs were subjected to automated DNA sequencing and analysis (Sections 2.9.3 and 2.11) to 
identify the parkin-interacting preys. These putative interactions, identified in a Y2H experimental 
setting, were further investigated in human cell lines in order to better approximate biologically-
relevant cellular conditions (Section 2.20).  
 
2.20 HUMAN CELL LINES 
2.20.1 The SH-SY5Y cell line 
Human derived neuroblastoma SH-SY5Y cell line was purchased from the European Collection of 
Cell Cultures (ECACC, Porton Down, Salisbury, UK). The originator cell line SK-N-SH was isolated 
from a bone marrow biopsy of a four-year old female with neuroblastoma, from which the derived 
cell line SH-SY5 was subcloned. The cell line was subcloned for a third time to produce the SH-
SY5Y cell line (Biedler et al. 1978). SH-SY5Y cells are routinely used as ex vivo models of mature 
dopaminergic neurons, as SH-SY5Y cells exhibit dopamine-β-hydroxylase activity and express 
several dopaminergic markers (Ciccarone et al. 1989). 
In the present study, SH-SY5Y cells were used for co-localization (Section 2.22), western blot 
(Section 2.23) and co-IP (Section 2.24) experiments. In addition, SH-SY5Y cells were transfected 
with small interfering RNA (siRNA) for use in RNA-interference (RNAi) experiments (Section 2.25). 
 
2.20.2 Primary dermal fibroblast cell lines 
Primary cells lines derived from individuals with disease are a useful tool to study disease-related 
cellular phenotypes. In particular, PD patient-derived dermal fibroblasts are widely used as cellular 
models of PD. The use of such explant cell lines is advantageous as it creates a model system with the 
predefined mutations and age-accumulated cellular damage of patients, while being minimally 
invasive to donor individuals (Auburger et al. 2012). 
In the present study, primary dermal fibroblasts were obtained from three patients diagnosed with PD, 
hereafter referred to as patient 1 (P1), patient 2 (P2) and patient 3 (P3). All three patients harbored 
homozygous parkin-null mutations, which were identified as part of this study using MLPA analysis 
and confirmed with cDNA sequencing (Sections 2.5.5 and 2.7; Section 3.1.1). Three wild-type (WT) 
age- and gender-matched control individuals were also used in the present study: WT2, WT3 and 
WT4 (WT1, a male individual recruited for a previous study, was not included in the present study). 
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The three controls had no history of neurological disease, and were confirmed to be wild-type in 
regards to the parkin gene by means of DNA sequencing (Section 2.7). Relevant genotypic and 
phenotypic details of the three PD patients and three controls are summarized in Table 2.6. 
Dermal fibroblasts were obtained from P1, P2, P3 and WT2 by means of skin punch biopsies (Section 
2.21.1), whereas WT3 and WT4 fibroblast cell lines were purchased from Sciencell Laboratories 
(Sciencell, San Diego, California, USA).       
      
2.21 CULTURING OF CELL LINES 
2.21.1 Isolation of dermal fibroblasts from skin punch biopsies 
Primary dermal fibroblast cell lines were established by isolating dermal fibroblasts from skin punch 
biopsies from three PD patients with homozygous parkin-null mutations and one control individual. 
Skin punch biopsies were performed by a trained clinician at Tygerberg Hospital (Cape Town, South 
Africa), after which dermal fibroblast cell lines were established by Unistel Medical Laboratories 
(Pty) Ltd. (Cape Town, South Africa).  
A 2mm x 2mm skin punch biopsy was taken from the inner upper arm and suspended in fibroblast 
culture media (Appendix II) in a 15ml polypropylene tube for transportation purposes. In a sterile 
tissue culture environment, a volume of 300μl per 1ml culture media of collagenase (Sigma Aldrich, 
St. Louis, Missouri, USA) was added to the suspended biopsy. The suspension was incubated for 1h 
at 37˚C, with manual agitation at regular intervals, after which the suspension was centrifuged at 
1200rpm for 10min in a Sorval® GLC-6 general laboratory centrifuge (Separations, Johannesburg, 
Table 2.6 Genotypic and phenotypic characteristics of the five dermal fibroblast donors  
Identifier Parkin mutation Gender Ethnicity 
AAO 
(years) 
AAR* 
(years) 
PD duration 
(years) 
PD patients 
P1 Deletion exon 3-4 hom Female MA 27 39 12 
P2 Deletion exon 4 hom Female AC 27 54 27 
P3 Deletion exon 4 hom Female AC 27 52 25 
   Controls 
WT2 n/a Female AC n/a 62 n/a 
WT3 n/a Female C n/a 56 n/a 
WT4 n/a Female Unknown n/a 44 n/a 
*Refers to the age of the donor at the time of skin punch biopsy. Abbreviations: AAO, age at onset; AAR, age at 
recruitment; AC, Afrikaner Caucasian; C; Caucasian; hom, homozygous; MA, Mixed ancestry; n/a, not 
applicable; P, patient; PD, Parkinson’s disease; WT, wild-type. 
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South Africa). The supernatant was discarded and the pellet resuspended in 5ml fibroblast isolation 
media (Appendix II), and the suspension transferred to a CellBind® T25 tissue culture flask (Corning 
Inc., Corning, New York, USA). Incubation followed at 37˚C in in a Farma thermosteri-cycle 5% CO2 
humidified incubator (Farma International, Miami, Florida, USA).    
After four days of incubation, the culture media was decanted and 5ml fresh fibroblast isolation media 
added. The tissue culture flask was regularly checked for the formation of nest-like fibroblastic 
colonies. After confluency of approximately 70-80% was reached, the cells were subcultured as 
described below (Section 2.21.3).  
 
2.21.2 Culture of cells from frozen stocks 
Frozen (-196˚C, in liquid N2) cell stocks were rapidly thawed by submerging the vial in a 37˚C water 
bath (Memmert, Schwabach, Germany). Immediately upon thawing, the exterior of the vial was 
sterilized with 70% ethanol and the toxic cryoprotectant, dimethyl sulfoxide (DMSO), was removed 
in the following manner: A total of 1ml of the appropriate pre-warmed culture media (Appendix II) 
was directly added to the thawed cell stock and the suspension transferred to a 12ml Greiner tube 
(Greiner Bio-one, Frickenhausen, Germany). An additional 5ml culture media was added to the 
suspension, after which it was centrifuged at 1000rpm for 2min in a Sorval® GLC-6 general 
laboratory centrifuge. The supernatant was discarded and the pellet resuspended in 5ml culture media, 
and the suspension transferred to a CellBind® T25 tissue culture flask. The flask was gently swirled 
to distribute cells evenly over the growth surface. Incubation followed at 37˚C in in a Farma 
thermosteri-cycle 5% CO2 humidified incubator.    
 
2.21.3 Subculturing of cells 
Cell cultures were growth in a Farma thermosteri-cycle 5% CO2 humidified incubator until a 
confluency of approximately 70-80% was reached (3-5 days for SH-SY5Y cells, 7-10 days for dermal 
fibroblasts). Cells were then subcultured: The growth media was removed from the adherent cells and 
the cell monolayer gently rinsed with 3ml sterile phosphate-buffered saline (PBS) (Lonza, Basel, 
Switzerland). A volume of 3ml trypsin (0.5g/L) (Lonza, Basel, Switzerland) was added to the cells, 
which was incubated at room temperature for 5min to facilitate detachment of cells from the growth 
surface. Subsequently 3ml of culture media was added to the cell suspension and mixed by gentle 
pipetting. The suspension was transferred to a 12ml Greiner tube and centrifuged at 1000rpm for 2min 
in a Sorval® GLC-6 general laboratory centrifuge. The supernatant was discarded and the pellet 
resuspended in 4ml culture media. This suspension was transferred either to four T25 CellStar® tissue 
culture flasks (Greiner Bio-one, Frickenhausen, Germany) each containing 5ml complete growth 
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media, or to a T75 or T175 CellStar® tissue culture flask (Greiner Bio-one, Frickenhausen, Germany) 
containing final volumes of 15ml or 25ml complete growth media, respectively.     
 
2.21.4 Seeding cells onto coverslips 
Cells to be labeled for in vivo co-localization analyses (Section 2.22) were grown on glass coverslips. 
This was done by placing sterile glass coverslips in CellStar® six well tissue culture plates (Greiner 
Bio-one, Frickenhausen, Germany) containing 3ml culture media (Appendix II) in each well. An 
aliquot of a cell suspension to be subcultured (Section 2.21.3) was used to perform a hemocytometric 
cell count (Appendix III). Thereafter, a volume of cell suspension containing approximately 50 000 
cells was seeded per well in a drop-wise manner. Plates were incubated in a Farma thermosteri-cycle 
5% CO2 humidified incubator until a confluency of 60-70% was reached (1-2 days). 
 
2.22 IN VIVO CO-LOCALIZATION 
2.22.1 Fluorophores 
Three-dimensional (3D) in vivo co-localization of putatively interacting proteins was performed in 
order to evaluate such interactions of endogenously-expressed proteins in a cellular environment. All 
co-localization experiments were done with SH-SY5Y cells grown on glass coverslips, where 
endogenous proteins were immunocytochemically labeled with fluorophore-conjugated secondary 
antibodies. This procedure is described below (Section 2.22.2), and information regarding the relevant 
fluorophores is detailed in Table 2.7.      
 
Table 2.7 Excitation and emission spectra of fluorophores for co-localization experiments 
Fluorophore Excitation (nm) Emission (nm) Visible color 
Alexa488 494 517 Green 
Cy3 550 570 Red 
Abbreviations: Alexa488, Alexa Fluor® 488; Cy3, cyanine 3; nm, nanometer. 
 
2.22.2 Immunocytochemistry 
SH-SY5Y cells were grown on glass coverslips in a CellStar® six well tissue culture plate until a 
confluency of 60-70% was reached (Section 2.21.4). Thereafter, the growth media was removed and 
the wells briefly rinsed with PBS. A total of 3ml of 4% paraformaldehyde (Appendix II) was added to 
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each well and the cells fixed at room temperature for 10min. Alternatively, cells to be stained with the 
γ-actin antibody were fixed with 3ml of ice-cold (-20˚C) absolute methanol at -20˚C for 10min. Each 
well was washed in PBS for 10min three times, with fresh PBS used for each wash. Coverslips were 
carefully removed from the six well plate and placed in a light-proof humidified chamber, after which 
the coverslips were blocked by incubation with 300μl of 1% bovine serum albumin (BSA)-PBS 
containing 0.1% Triton® X-100 (Sigma Aldrich, St. Louis, Missouri, USA) for 1h at room 
temperature. Cells fixed in absolute methanol were blocked in 1% BSA-PBS without Triton® X-100. 
Subsequently, 150μl of 1% BSA-PBS containing the relevant primary antibody/antibodies (Table 2.8) 
was added to each coverslip. The humidified chamber was sealed and incubated overnight (16h) at 
4˚C.  
 
Table 2.8 Antibody pairs and optimized dilution ratios for co-localization experiments 
Antigen Primary Ab Manufacturer 
Primary Ab 
Dilution Ratio 
Secondary Ab 
Secondary Ab 
Dilution Ratio 
Parkin 
Anti-parkin pAb 
Abcam  
(ab15954) 
1:50 DaR-Cy3 1:500 
Anti-parkin mAb 
Cell Signaling 
(Park8) 
1:100 
DaM-
Alexa488 
1:500 
SEPT5 Anti-sept5 pAb 
Abcam 
(ab109294) 
1:250 DaR-Cy3 1:500 
SEPT9 Anti-MSF mAb 
Abcam 
(ab38314) 
1:100 DaR-Cy3 1:500 
14-3-3η Anti-14-3-3η pAb 
Cell Signaling 
(#9640) 
1:50 DaR-Cy3 1:500 
γ-Actin Anti-γ-actin mAb 
Abcam      
(2A3) 
1:1500 
DaM-
Alexa488 
1:500 
ATPAF1 
Anti-ATPAF1 
pAb 
Abcam  
(AB107202) 
1:500 DaR-Cy3 1:500 
Manufacturer details: Abcam (Abcam, Cambridge, UK); Cell Signaling (Cell Signaling Technology, 
Cambridge, UK); Promega (Promega, Madison, Wisconsin, USA). Abbreviations: Ab, antibody; Alexa488, 
Alexa Fluor® 488; Cy3, cyanine 3; DaM, donkey anti-mouse; DaR, donkey anti-rabbit; mAb, monoclonal 
antibody; pAb, polyclonal antibody. 
 
 
The following morning, the coverslips were washed in PBS for 10min three times. The coverslips 
were then incubated in the dark with 200ul of PBS containing the relevant secondary 
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antibody/antibodies (Table 2.8) for 90min at room temperature. After a series of three PBS washes, 
the coverslips were incubated with 200ul of a 1:5000 dilution Hoechst H-33342 nucleic acid stain 
(Sigma Aldrich, St. Louis, Missouri, USA) in PBS for 10min at room temperature in the dark. The 
coverslips were rinsed a final time with PBS for 10min, after which the coverslips were mounted on 
clean microscope slides with a 15μl aliquot of Mowiol mounting media (Appendix II). Slides were 
left in the dark overnight at room temperature and then stored at 4˚C until viewing (Section 2.22.3).  
For each co-localization experiment, a set of immunocytochemical slides were prepared as described 
above, which included a secondary antibody negative control, a single-stained control for each of the 
two proteins under investigation and a double-stained experiment slide. The negative control was 
incubated with 1% BSA-PBS without any primary antibodies and both secondary antibodies for the 
primary and secondary antibody incubation steps, respectively. Similarly, single-stained controls were 
incubated with one primary antibody and one secondary antibody and double-stained experiments 
were incubated with both primary antibodies and both secondary antibodies. All slides were stained 
with Hoechst H-33342 nucleic acid stain for image orientation purposes. 
 
2.22.3 Confocal microscopy and analysis   
Fixed and stained cells were viewed at the Cell Imaging Unit of CAF at Stellenbosch University, 
Stellenbosch, South Africa. A Carl Zeiss LSM780 confocal microscope system (Carl Zeiss, 
Oberkochen, Germany) was employed to this end.  
This system is equipped with a 488nm argon multiline laser, a 561nm red diode-pumped solid state 
laser and a 633 HeNe laser for excitation of the Alexa488 fluorophore, Cy3 fluorophore and Hoechst 
H-33342 nucleic acid stain, respectively. Fluorescence emission was detected using a 32-channel 
GaAsP PMT detector with quantum efficiency of 45%, a significant improvement on the 25% 
efficiency typically achieved by classic PMT detectors.  Images were acquired an Alpha Plan-
Apochromat 100X/1.4 DIC M27 oil-immersion objective and ZEN 2011 imaging software (Carl 
Zeiss, Oberkochen, Germany).            
Images were acquired of each of the secondary antibody negative control, single-stained controls and 
double-stained co-localization experiments in triplicate, where two to three cells were imaged per 
replicate. The inclusion of a negative control facilitated correcting for background fluorescent 
staining, whereas single-stained controls provided fluorescent signal parameters for setting relevant 
co-localization thresholds. Importantly, image acquisition settings were kept constant for each set of 
experiment and controls. All images were acquired with Z-stacking, which facilitated signal 
acquisition and resolution in all three dimensions. This was done by acquiring images in multiple 
focal planes; Z-stacks consisted of 21 images taken at 0.25μm intervals in the optical plane. Hence, 
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each three-dimensional Z-stacked image was 58.02µm in length, 85.02µm in width and 5.25μm in 
depth. Images were evaluated for signal co-localization using co-localization scatter plots as well as 
visual images of co-localized pixels in each Z-stack plane, as generated by the ZEN 2011 imaging 
software.  
 
2.23 WESTERN BLOTTING 
2.23.1 Mammalian cell lysis 
Cultured SH-SY5Y cells were lysed for subsequent use in western blot, co-IP and RNAi experiments 
(Sections 2.23, 2.24, 2.25.4). Similarly, cultured fibroblasts were lysed for western blot experiments 
(Sections 2.25.4). 
Cell lysis was achieved in the following manner: Growth media was removed and the cell monolayer 
rinsed with PBS, after which an appropriate amount of pre-heated (37˚C) trypsin was added to the 
tissue culture vessel (T25, T75, T175 CellStar® tissue culture flasks or CellStar® six well tissue 
culture plates). The vessel was incubated at room temperature for 5-10min, after which cells were 
further dislodged with a cell scraper. The cell suspension was transferred to a 50ml polypropylene 
tube containing 10ml growth media. In the case of cells cultured in CellStar® six well tissue culture 
plates, similarly treated cells from separate wells were pooled in 50ml polypropylene tubes. The 
suspension was centrifuged at 3000rpm for 3min at 4˚C in an Eppendorf model 5810R centrifuge 
(Eppendorf, Hamburg, Germany) and the supernatant discarded. The pellet was resuspended in 1ml of 
PBS after which the suspension was transferred to a sterile 2ml microcentrifuge tube and repelleted by 
centrifugation at 5000rpm for 1min in a Labnet Prism™ microcentrifuge. The supernatant was 
discarded and the pellet resuspended in 50-300μl ice-cold passive lysis buffer (Appendix II), 
depending on pellet size. Cells were incubated on ice for 30min. Centrifugation at 15 000rpm for 
15min at 4˚C in a UEC 13 microcentrifuge (UniEquip, Munich, Germany) followed, after which the 
supernatant was transferred to a sterile 1.5ml microcentrifuge tube.  
All cell lysates were either used immediately for downstream applications or stored at -80˚C for future 
use. Prior to use, the protein concentration of the whole cell extract was determined via a Bradford 
assay (2.23.2). 
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2.23.2 Bradford protein concentration determination 
Accurate measurements of cell lysate protein concentration were obtained by means of a Bradford 
assay prior to the use of the lysates in western blot, co-IP and RNAi experiments (Sections 2.23, 2.24, 
2.25).  
To generate a standard curve of protein concentrations, 10μl of a dilution range of BSA in PBS 
ranging from 0-1000μg/μl were loaded in duplicate into a luminometer 96 well plate. A volume of 1μl 
of each sample to be assayed was also loaded in duplicate. A total of 200μl Bradford protein reagent 
(Appendix II) was added to each well, and the protein concentration measured via absorbance at 
595nm in a Synergy HT luminometer (BioTek Instruments Inc., Winooski, Vermont, USA) using 
KC4™ software version 3.4 (BioTek Instruments Inc., Winooski, Vermont, USA).     
 
2.23.3 Western blot preparation  
Western blots were performed in order to visualize proteins of interest either in whole cell lysates 
(Section 2.25.4) or pulled down as part of co-IP experiments (Section 2.24). Western blotting 
conditions, including the ratios of primary and secondary antibodies used to immunoblot proteins of 
interest, were first optimized. Optimal western blotting conditions are summarized in Table 2.9.    
Cell lysates to be used were subjected to a Bradford assay to determine protein concentration (Section 
2.23.2). Lysates were resolved using SDS-PAGE (Section 2.10.2) with a total of 50-100μg of protein 
loaded per well. Subsequently the resolved proteins were transferred to a PVDF membrane (Section 
2.10.3). 
 
2.23.4 Membrane blocking 
The PVDF membrane, containing the resolved and transferred proteins, was blocked in order to 
prevent non-specific binding of antibodies to the membrane. This was achieved by submerging the 
membrane in blocking buffer consisting of either 5% fat free powder milk in tris-buffered saline with 
0.1% Tween-20 (TBST) (Appendix II) or 3% BSA in TBST, depending on the protein on interest 
(Table 2.9). The membranes was incubated in blocking buffer for 1h at room temperate while shaking 
on a Stuart® SSL1 orbital shaker. 
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Table 2.9 Optimized western blot conditions   
Antigen 
Membrane 
Blocking  
Primary Ab  Manufacturer 
Primary   
Ab Dilution 
Ratio 
Primary Ab 
Diluent 
Secondary 
Ab 
Secondary 
Ab Dilution 
Ratio 
Secondary 
Ab Diluent 
Expected 
Size (kDa) 
Parkin 
5% milk-
TBST 
Anti-parkin pAb 
Abcam  
(ab15954) 
1:500 
0.5% milk-
TBST 
DaR 1:4000 
5% milk-
TBST 
52 
SEPT5 
5% milk-
TBST 
Anti-sept5 pAb 
Abcam 
(ab109294) 
1:1000 
5% milk-
TBST 
DaR 1:6000 
5% milk-
TBST 
43 
SEPT9 
5% milk-
TBST 
Anti-MSF mAb 
Abcam 
(ab38314) 
1:750 
5% milk-
TBST 
DaR 1:6000 
5% milk-
TBST 
65 
14-3-3η 
5% BSA-
TBST 
Anti-14-3-3η 
pAb 
Cell Signaling 
(#9640) 
1:2000 TBST DaR 1:4000 TBST 28 
γ-Actin 
5% milk-
TBST 
Anti-γ-actin 
mAb 
Abcam       
(2A3) 
1:20 000 
5% milk-
TBST 
DaM 1:40 000 
5% milk-
TBST 
42 
ATPAF1 
5% BSA-
TBST 
Anti-ATPAF1 
pAb 
Abcam  
(AB107202) 
1:500 TBST DaR 1:4000 TBST 36 
GAPDH 
5% milk-
TBST 
Anti-GAPDH 
mAb 
Santa Cruz  
(FL-335) 
1:2500 
5% milk-
TBST 
DaR 1:8000 
5% milk-
TBST 
36 
Manufacturer details: Abcam (Abcam, Cambridge, UK); Cell Signaling (Cell Signaling Technology, Cambridge, UK); Promega (Promega, Madison, Wisconsin, USA), 
Santa Cruz (Santa Cruz Biotechnology, Dallas, Texas, USA). Abbreviations: Ab, antibody; BSA, bovine serum albumin; DaM, donkey anti-mouse; DaR, donkey anti-
rabbit; kDa, kiloDalton; mAb, monoclonal antibody; pAb, polyclonal antibody; TBST, tris-buffered saline with 0.1% Tween-20. 
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2.23.5 Addition of primary antibody 
After the membrane was blocked (Section 2.23.4), it was washed in TBST for 5min on a Stuart® 
SSL1 orbital shaker. A volume of 2-5ml of the appropriate primary antibody dilution (1:500-1:20 
000) was prepared with the relevant antibody diluent (TBST, 0.5% milk in TBST or 5% milk in 
TBST) as listed in Table 2.9. The blocked membrane was immersed in the primary antibody solution 
in a plastic sleeve, which was then sealed and incubated overnight (16h) at 4˚C with shaking on an 
Orbit 300 shaker (Labnet, Edison, New Jersey, USA). 
The following morning, the membrane was vigorously rinsed twice in TBST, followed by a 15 min 
wash in TBST and then three 5min TBST washes. TBST was discarded and fresh TBST added after 
each wash step.  
 
2.23.6 Addition of secondary antibody 
After the membrane has been adequately washed of excess primary antibody (Section 2.23.5), the 
membrane was incubated with a relevant HRP-conjugated secondary antibody (Santa Cruz 
Biotechnology, Dallas, Texas, USA): A volume of 5ml of the appropriate secondary antibody dilution 
(1:4000-1:40 000) was prepared with the relevant antibody diluent (TBST or 5% milk in TBST) as 
summarized in Table 2.9. The membrane was immersed in the secondary antibody solution in a 
plastic sleeve, which was then sealed and incubated for 1h at room temperature with shaking on a 
Stuart® SSL1 orbital shaker. 
Following incubation, the membrane was vigorously rinsed twice in TBST, followed by a 15min 
wash in TBST and then three 5min TBST washes. TBST was discarded and fresh TBST added after 
each wash step.  
 
2.23.7 Chemiluminescent visualization of membrane-bound proteins 
Chemiluminescent detection of the protein of interest followed thorough removal of excess secondary 
antibody from the membrane (Section 2.23.6). In a darkroom, a 1:1 mixture of the two substrate 
components (SuperSignal® West Pico Stable Peroxide solution and the SuperSignal® West Pico 
Luminol/Enhancer solution) of a SuperSignal® West Pico Chemiluminescent Substrate kit (Thermo 
Scientific, Waltham, Massachusetts, USA) was prepared. This was added to the membrane which was 
incubated in the chemiluminescent substrate for 5min at room temperate. The membrane was then 
transferred to an autoradiography cassette and excess substrate removed by gently blotting with paper 
towels, after which the membrane was covered with a transparent plastic sheath. CL-Xposure™ 
autoradiography film (Thermo Scientific, Waltham, Massachusetts, USA) was placed in the cassette 
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and exposed for an appropriate amount of time (10sec-16h), depending to the strength of the 
chemiluminescent signal. The exposed film was developed in a Hyperprocessor™ automatic 
autoradiography film processor (GE Healthcare Ltd., Little Chalfont, Buckinghamshire, UK). 
 
2.23.8 Stripping of membranes 
For applications in which more than one protein of interest needed to be detected in the same lysate 
on a single membrane, such as the protein expression experiments (Section 2.25.4), either cutting or 
stripping of the membrane was employed. If the difference in expected sizes of the proteins to be 
detected was sufficiently large, the membrane was cut in two at the position halfway between the 
expected proteins, and each membrane section incubated with the appropriate primary antibody 
simultaneously (Section 2.23.5). Otherwise, the membrane was stripped and reprobed for each protein 
of interest sequentially, as described below. 
Following the chemiluminescent visualization of the membrane (Section 2.23.7), the membrane was 
rinsed twice in TBST for 10min per rinse. It was then incubated in 10-20ml of stripping buffer 
(Appendix II) for 15min at room temperature with shaking on a Stuart® SSL1 orbital shaker, after 
which the stripping buffer was discarded and the membrane incubated in fresh stripping buffer for a 
further 15min at room temperature with shaking. Following incubation, the membrane was vigorously 
rinsed twice in TBST, followed by a 15min wash in TBST and then three 5min TBST washes. TBST 
was discarded and fresh TBST added after each wash step. The membrane was subsequently blocked 
(Section 2.23.4) and incubated with the appropriate primary antibody (Section 2.23.5).   
 
2.24 CO-IMMUNOPRECIPITATION 
Co-immunoprecipitation (co-IP) of endogenous proteins was performed as follows: Whole cell 
extracts were prepared (Section 2.23.1) and the protein concentration determined (Section 2.23.2). A 
total of 200-1000μg protein was then transferred to a 1.5μl microcentrifuge tube and the volume 
equalized to 200μl with fresh passive lysis buffer (Appendix II). A volume of 20μl Protein G agarose 
bead slurry (KPL, Gaithersburg, Massachusetts, USA) was added to the sample, which was incubated 
on a model HS100 rotating wheel (Labnet, Edison, New Jersey, USA) for 40min at 4˚C to pre-clear 
the lysates. Samples were centrifuged at 7000rpm for 1min at 4˚C in UEC 13 microcentrifuge and the 
supernatant transferred to a clean 1.5μl microcentrifuge tube. A total of 2μg of primary antibody 
directed against the protein to be immunoprecipitated was added to the lysate, which was incubated 
overnight (16h) at 4˚C on model HS100 rotating wheel.  
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The next morning, 60μl of Protein G agarose bead slurry was added to the lysate followed by further 
incubation on a model HS100 rotating wheel at 4˚C for 1h. Beads were collected by centrifugation at 
7000rpm for 30sec at 4˚C in a UEC 13 microcentrifuge, and the supernatant carefully transferred to a 
clean 1.5μl microcentrifuge tube for western blot analysis (Section 2.23).  The beads were then gently 
washed a total of four times in ice-cold passive lysis buffer, recollecting the beads via centrifugation 
after each wash. Finally, 30μl of 2X SDS loading dye (Appendix II) was added to the beads and the 
mixture boiled at 95˚C for 10min. Subsequently the sample was centrifuged at 15000rpm for 5min in 
a Labnet Prism™ microcentrifuge and the supernatant loaded onto a SDS-PAGE gel (Section 2.10.2) 
for use in western blot analysis (Section 2.23).   
 
2.25 CREATION AND ANALYSIS OF PARKIN-DEFICIENT CELL MODELS  
2.25.1 RNA-interference-mediated parkin knockdown 
RNA-interference (RNAi) using siRNA was performed to bring about the targeted knockdown of 
parkin expression in cultured SH-SY5Y cells. This was done to evaluate the functional consequences 
of suppressed/absent parkin expression (Sections 2.25.4). 
Four non-validated human siRNAs were purchased (Qiagen, Hilden, Germany); siRNA sequence 
information is listed in Table 2.10. Each siRNA was optimized and assessed for parkin knockdown 
efficiency and only siRNAs demonstrating sufficient parkin knockdown were used in subsequent 
experiments.  
 
Table 2.10 siRNA sequences for parkin knockdown 
siRNA name Strand siRNA sequence (5’-3’) 
Hs_PARK2_2 
Sense GUUUGUUCACGACCCUCAATT 
Antisense UUGAGGGUCGUGAACAAACTG 
Hs_PARK2_8 
Sense CCAUCUAUAUAAAUCGCAUTT 
Antisense AUGCGAUUUAUAUAGAUGGAA 
Hs_PARK2_9 
Sense GAGGAAAGUCACCUGCGAATT 
Antisense UUCGCAGGUGACUUUCCUCTG 
Hs_PARK2_10 
Sense GGCUCCACUGUAAAUUUAATT 
Antisense UUAAAUUUACAGUGGAGCCAA 
Abbreviations: 3’, three-prime end; 5’, five-prime end; A, adenine; C, cytosine; G, guanine; Hs, Homo sapiens; 
PARK2, parkin gene; siRNA, small interfering RNA; T, thymine. 
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SY-SY5Y cells were cultured as described (Section 2.21). An aliquot of a cell suspension to be 
subcultured (Section 2.21.3) was used to perform a hemocytometric cell count (Appendix III). 
Thereafter, a volume of cell suspension containing approximately 200 000 cells was seeded per well 
in a CellStar® six well tissue culture plate in a drop-wise manner. The plate was incubated in a Farma 
thermosteri-cycle 5% CO2 humidified incubator until a confluency of 70-80% was reached (16h).  
The following day, the culture media in each well was removed and replaced by 2.3ml of fresh 
complete culture media (Appendix II). For each transfection, a total of 0.6µl of 20µM siRNA stock 
was diluted in 98.2µl serum-free media (Appendix II) in a 200µl PCR tube, to which 12µl of 
HiPerFect transfection reagent (Qiagen, Hilden, Germany) was added. The tubes were incubated at 
room temperature for 10min to allow for siRNA complex formation. The transfection mixture was 
subsequently added to the cells in a drop-wise manner, resulting in a final concentration of 5nM 
siRNA per well. Plates were gently rocked to distribute the transfection mixture evenly over the cell 
monolayer and then incubated in a Farma thermosteri-cycle 5% CO2 humidified incubator for 48h.  
Concurrent to targeted siRNA transfections, cells were also transfected with a non-silencing control 
(NSC) siRNA (Qiagen, Hilden, Germany) as well as subjected to a mock transfection, i.e. a 
transfection mixture containing no siRNAs. The efficiency of siRNA-mediated parkin knockdown 
was subsequently evaluated on a mRNA level (Section 2.25.3) as well as a protein level (2.25.4).   
 
2.25.2 Total RNA extraction and cDNA conversion 
Total RNA was extracted from siRNA-transfected SH-SY5Y cells (Section 2.25.1). RNA extraction 
was performed by using a RNeasy Plus Mini Kit (Qiagen, Hilden, Germany) as per manufacturer’s 
instructions. Isolated RNA concentration and quality was subsequently measured with an Experion™ 
StdSens Analysis kit on an Experion™ automated electrophoresis station. Only RNA samples with a 
RQI value above 8.0 were used for subsequent analyses.  
Following RNA isolation, the purified RNA was converted to cDNA by using a Quantitect® Reverse 
Transcription Kit as per manufacturer’s instructions. cDNA concentration was determined using a 
NanoDrop® ND-1000 spectrophotometer and NanoDrop1000® software version 3.7.1. The cDNA 
samples were then stored at -20°C until use. 
 
2.25.3 Two-step quantitative reverse-transcription PCR (q-RT-PCR)  
Real-time quantitation of cDNA obtained from siRNA-transfected SH-SY5Y cells (Section 2.25.1) 
was done using four IDT PrimeTime® Std qPCR assays targeting parkin as well as GAPDH 
(glyceraldehyde-3-phosphate dehydrogenase), B2M (β-2 microglobulin) and RPL13A (ribosomal 
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protein L13a) housekeeping genes (Integrated DNA Technologies, Coralville, Iowa, USA). Briefly, 
100ng of cDNA was used as template in a 5µl reaction containing 1X Primetime® Std qPCR assay 
and 1X QuantiFast™ Multiplex PCR master mix (Qiagen, Hilden, Germany). All quantitation 
reactions were set up in triplicate and included cDNA-free negative control reactions. Reaction setup 
employed an Eppendorf epMotion™ 5070 automated pipetting system (Eppendorf, Hamburg, 
Germany) for liquid handling.  
Q-RT-PCR was performed on an ABI 7900HT Fast Real-Time PCR System (Applied Biosystems 
Inc., Foster City, California, USA) using SDS software version 2.3 (Applied Biosystems Inc., Foster 
City, California, USA) under the following cycling conditions: an initial denaturation step at 95oC for 
10min followed by 40 cycles consisting of denaturation at 95oC for 15sec and annealing/extension at 
60°C for 45sec. 
Relative parkin mRNA expression was quantified with reference to the three housekeeping genes 
using normalization factor calculations based on the geometric mean of multiple housekeeping genes, 
as described by Vandesompele et al. (2002). 
 
2.25.4 Protein expression analysis 
In order to verify successful parkin knockdown on a protein level, siRNAs that demonstrated 
sufficient parkin mRNA knockdown following q-RT-PCR analysis (Section 2.25.3) were used to 
transfect SH-SY5Y cells as described in Section 2.25.2. Whole cell extracts were then prepared of the 
transfected cells and the protein concentrations determined (Sections 2.23.1 and 2.23.2). Equal 
quantities of parkin siRNA-treated and NSC-treated cell lysates were used for western blotting with 
an anti-parkin antibody (Section 2.23). Following the autoradiographical recording of membrane-
bound parkin (Section 2.23.7), the membrane was stripped of antibodies and reprobed with an anti-
GAPDH antibody (Section 2.23.8). Visualization of GAPDH content of each lysate served as a 
loading control to verify equal loading of all lysates.  
The band intensities of parkin and GAPDH bands on the obtained autoradiograph film were 
quantified using ImageJ Software version 1.47 (http://imagej.nih.gov/ij) (Schneider et al. 2012), and 
the band intensities of parkin in siRNA and NSC-transfected cell lysate lanes were normalized to the 
corresponding band intensities of GAPDH in the same lanes. Relative parkin expression in siRNA-
treated cells was quantified in reference to normalized parkin expression in NSC-transfected cells. A 
total of three replicate knockdown experiments were independently performed to evaluate the 
reliability of siRNA-mediated parkin knockdown. All differences in protein expression were 
statistically assessed by means of mixed-effects linear modeling, as described in Section 2.30. 
Stellenbosch University  https://scholar.sun.ac.za
95 
 
Membranes containing lysates in which successful parkin knockdown was verified were stripped and 
reprobed for each of the parkin-interacting proteins (Section 2.23.8), in order to assess the effect of 
the lack of parkin on the protein expression of each parkin interactor. The band intensity of each 
parkin-interacting protein was normalized to GAPDH and the relative expression of each protein was 
quantified in parkin-siRNA-treated cells in reference to their expression in NSC-transfected cells, as 
described above.   
The effect of the lack of parkin on the protein expression of each parkin interactor was also evaluated 
in parkin-null dermal fibroblasts (Section 2.20.2). Equal quantities of whole cell lysates of the patient-
derived parkin-null fibroblast cell lines and wild-type control fibroblast cell lines were used for 
western blotting (Section 2.23). A single membrane was probed for each parkin-interacting protein, 
whereas probing for GAPDH served as a loading control. The relative expression levels of each 
protein of interest in parkin-null fibroblasts were quantified and assessed as described above.  
 
PART THREE: PARKIN DEFICIENCY AND VITAMIN K2 
 
In the third and final part of this dissertation, parkin-null primary fibroblasts were used to assess the 
effect of parkin deficiency on several informative parameters of cellular health. This third part 
furthermore entails an evaluation of the effect of the potential PD therapeutic agent vitamin K2 on 
such cellular parameters in parkin-deficient fibroblasts. It has been reported that vitamin K2 
supplementation alleviated mitochondrial defects in PINK1 and parkin mutant Drosophila (Vos et al. 
2012); the present study therefore investigated mitochondrial health in particular. To this end, four 
parameters of cellular function and health were assayed: cell viability after cytotoxic insult (Section 
2.26), mitochondrial respiration (Section 2.27), mitochondrial membrane potential (Section 2.28) and 
the integrity of mitochondrial networks (Section 2.29). 
 
2.26 CELL VIABILITY AND CELL GROWTH ASSAYS 
Dermal fibroblast cell viability was assessed by means of colorimetric thiazolyl blue tetrazolium 
bromide (MTT) assays. MTT, a water-soluble yellow tetrazole, is reduced to insoluble purple 
formazan by NAD(P)H-dependent oxidoreductases in living cells. Formazan aggregates can then be 
dissolved by the addition of an appropriate solubilization buffer, and the resulting color change can be 
measured via spectrophotometry. As the formation of formazan is dependent on cellular metabolic 
rates, MTT assays can be used as sensitive gauges of viable cell number (Berridge et al 2005). MTT 
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assays are also valuable in the assessment of the cytotoxicity of various compounds (Meerloo et al. 
2011).     
The CyQUANT® assay, on the other hand, is based on the measurement of cellular DNA content via 
fluorescent dye binding. As cellular DNA content is tightly regulated, CyQUANT® assays can be 
used as indirect measurements of cell number. The extent of cell proliferation can then be gauged by 
the comparison of cell counts of cells treated with various compounds to untreated cells (Jones et al. 
2001). As cell proliferation is considered to be one of the most sensitive indicators of overall cellular 
health (Abraham et al. 2008), CyQUANT® assays were performed alongside MTT assays in this 
study as two parallel measurements of viable cell number. These assays were used to investigate the 
effect of treatment with vitamin K2 on cell viability and growth in parkin-null and wild-type 
fibroblasts, in the absence and the presence of cellular stress.   
 
2.26.1 Optimization of vitamin K2 concentration 
In the present study, a MTT assay was initially performed to evaluate potential cytotoxic effects of the 
vitamin K2 analogue menaquinone 4 (MK-4) on wild-type fibroblasts, in order to determine the 
optimal MK-4 concentration for subsequent experiments. Briefly, an aliquot of a cell suspension of 
WT2 fibroblasts to be subcultured (Section 2.21.3) was used to perform a hemocytometric cell count 
(Appendix III). Thereafter, a volume of cell suspension containing approximately 5000 cells was 
seeded per well in a Corning® Costar® 96-well flat-bottom tissue culture plate (Corning Inc., 
Corning, New York, USA). The plate was incubated at 37ºC in a Farma thermosteri-cycle 5% CO2 
humidified incubator overnight (16h). 
The following morning, the culture media was removed and replaced with a dilution series of MK-4 
in 200µl fresh culture media, with MK-4 concentrations ranging from 0-100µM MK-4 (Sigma 
Aldrich, St. Louis, Missouri, USA) (Appendix II). Each concentration was added to the wells in 
quadruplicate. The plate was returned to the Farma thermosteri-cycle 5% CO2 humidified incubator 
and incubated for a further 24h. The next day, a MTT assay was performed as described in Section 
2.26.3. 
 
2.26.2 Preparation of fibroblasts for MTT and CyQUANT® assays 
MTT and CyQUANT® assays were also employed to assess cell viability and proliferation of patient 
and wild-type fibroblasts after cytotoxic insult; this was performed with and without vitamin K2 co-
treatment. Fibroblasts were seeded into 96-well plates at a density of 5000 cells per well as described 
above (Section 2.26.1), with two 96-well plates being prepared in parallel for MTT and CyQUANT® 
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assays, respectively. The following morning, the culture media was removed and a volume of 200µl 
of each of four treatment solutions was added to appropriate wells. The four treatment solutions were: 
0.1% (v/v) ethanol in culture media (for untreated cells; the addition of ethanol serves as a vehicle 
control), 40µM MK-4 solution in culture media (Appendix II), 10µM carbonyl cyanide m-
chlorophenylhydrazone (CCCP) solution in culture media (Appendix II), and culture media 
containing both 40µM MK-4 and 10µM CCCP. Each treatment solution was added to the wells in 
quadruplicate. Incubation followed for 24h at 37ºC in a Farma thermosteri-cycle 5% CO2 humidified 
incubator. In the present study, 10µM CCCP was used to induce cellular stress, as a similar 
concentration is routinely used in the literature to produce mitochondrial impairment and bring about 
parkin-selective mitophagy of damaged mitochondria (Narendra et al. 2008; Matsuda et al. 2010).   
After the fibroblasts had been appropriately treated, the two 96-well plates were separately used for 
MTT and CyQUANT® assays, respectively (Sections 2.26.3 and 2.26.4). Each assay was performed 
in triplicate as three separate experimental runs.  
 
2.26.3 MTT assay 
MTT assays were performed as follows: The culture media was removed and the wells gently rinsed 
once with 200µl pre-warmed sterile PBS. A 1:10 dilution of MTT stock solution (Sigma Aldrich, St. 
Louis, Missouri, USA) (Appendix II) was made in pre-warmed PBS, which was added to the wells in 
volumes of 100µl. The plate was covered in aluminum foil and incubated at 37ºC in a Farma 
thermosteri-cycle 5% CO2 humidified incubator for 4h. Subsequently, the MTT solution was carefully 
aspirated and a volume of 100µl acidified isopropanol (Appendix II) added to each well. Formazan 
aggregates were dissolved by trituration followed by incubation at 37ºC with shaking for 10min in a 
Hybaid Midi Dual 14 incubator (United Scientific, Cape Town, South Africa). The resulting 
coloration was measured via absorbance at 570nm in a Synergy HT luminometer using KC4™ 
software version 3.4. Background absorbance was simultaneously measured at 650nm and subtracted 
from absorbance at 570nm. Statistical significance was measured as described in Section 2.30. 
 
2.26.4 CyQUANT® assay 
CyQUANT® assays were performed using a CyQUANT® NF Cell Proliferation Assay Kit (Life 
Technologies, Carlsbad, California, USA), according to manufacturer’s instructions. Briefly, the 
culture media was removed from the cells in a 96-well plate, and the wells gently rinsed once with 
200µl pre-warmed sterile PBS. A volume of 100μl of 1X dye binding solution was added to each 
well. The plate was then incubated in the dark at 37ºC in a Farma thermosteri-cycle 5% CO2 
humidified incubator for 1h. The subsequent fluorescence intensity was measured in a Synergy HT 
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luminometer using KC4™ software version 3.4, with excitation at 480nm and emission detection at 
530nm. Statistical analysis was performed as described in Section 2.30. 
 
2.27 MITOCHONDRIAL RESPIRATION ANALYSIS 
Measurements of mitochondrial respiration are strong indicators of the functional capacity of 
mitochondria, and of overall cellular health.  While classical respirometric methods largely rely on the 
use of Clark oxygen electrodes, these approaches are not conductive to the simultaneous measurement 
of several samples, and require large quantities of cells. The Seahorse Extracellular Flux Analyzer 
overcomes these challenges by using a plate-based approach and fluorescence detectors to accurately 
measure cellular oxygen consumption (Ferrick et al. 2008). Furthermore, the Seahorse Analyzer 
allows for the sequential addition of pharmacological inhibitors to probe the function of individual 
components of the mitochondrial respiratory chain in a single experiment. This can then be expressed 
as various parameters of mitochondrial function, such as basal respiration, ATP coupling efficiency 
and spare respiratory capacity, which can be insightful gauges of mitochondrial health (Brand and 
Nicholls 2011). 
   
The present study used a Seahorse Analyzer, located in the Mito Laboratory of North West 
University, Potchefstroom, South Africa, to investigate mitochondrial respiratory control in parkin-
null and wild-type fibroblasts. Furthermore, the effect of vitamin K2 treatment on mitochondrial 
respiration was determined. All mitochondrial respiration assays were kindly performed by Dr. 
Chrisna Swart. 
 
2.27.1 Seahorse Analyzer assay 
Mitochondrial respiration assays were done using a Seahorse XF96 Cell Mito Stress Test Kit 
(Seahorse Biosciences, North Ballerica, Massachusetts, USA), in accordance with manufacturer’s 
instructions. Briefly, fibroblasts were seeded at a density of 22 000 cells per well in a 96-well 
Seahorse assay plate: cells that were to be treated with vitamin K2 were seeded into 80μl of 40µM 
MK-4 solution in culture media (Appendix II), whereas cells that were not treated with vitamin K2 
were seeded into 80μl of 0.1% (v/v) ethanol in culture media. The plate was then incubated at 37˚C 
with 5% CO2 for 24h.  
The following day, a Seahorse XF96 Extracellular Flux Analyzer (Seahorse Biosciences, North 
Ballerica, Massachusetts, USA) and XFe Wave software (Seahorse Biosciences, North Ballerica, 
Massachusetts, USA) was used to measure the oxygen consumption rate (OCR) of each well. A 
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period of 1h before the measurements were initiated, the culture media in each well was replaced with 
150μl of Seahorse assay media supplemented with 1mM pyruvate, and the plate was incubated for 1h 
at 37˚C without CO2. Then, a series of successive OCR measurements were performed, which 
consisted of three basal OCR measurements, three OCR measurements after the automated injection 
of 1μM oligomycin into each well, three OCR measurements after the injection of 1μM carbonyl 
cyanide p-trifluoromethoxyphenyl hydrazone (FCCP), and three final OCR measurements after the 
dual injection of 1μM rotenone and 1 μM antimycin A. Oligomycin was used to inhibit the 
mitochondrial F1F0-ATP synthase; FCCP is a protonphore used to depolarize the inner mitochondrial 
membrane, and rotenone and antimycin A were used to inhibit complex I and complex III, 
respectively. All four of these reagents were included in the Seahorse XF96 Kit, and the working 
concentrations of all four were optimized to identify their minimum effective concentration. 
Experimental treatments were performed on six wells of each plate as technical replicates. After all 
twelve OCR measurements were taken, the plate was saved and the relative DNA content in each well 
was measured using a CyQUANT® assay (Section 2.26.4). 
   
2.27.2 Analysis of mitochondrial respiratory control 
The Seahorse assays (Section 2.27.1) were analyzed using XFe Wave software, according to 
manufacturer’s instructions. All OCR measurements were normalized to cell number as determined 
by a CyQUANT® assay. These normalized OCR measurements were used to calculate various 
mitochondrial parameters: The minimum OCR after rotenone and antimycin A injection was 
interpreted as the OCR due to non-mitochondrial respiration, and this rate was subtracted from all 
other responses in order to isolate mitochondrial OCR. The basal mitochondrial OCR was defined as 
the third measurement under basal conditions (the last measurement prior to oligomycin injection, 
after non-mitochondrial OCR subtraction). The oligomycin response, indicative of the OCR due to the 
proton leak across the inner mitochondrial membrane, was defined as the minimum OCR after 
oligomycin injection. The decline in OCR after oligomycin injection is indicative of the OCR due to 
ATP synthesis, and the ratio of this decline to the basal OCR was expressed as the ATP coupling 
efficiency. The FCCP response was defined as the maximum OCR after FCCP injection, and the ratio 
of this response to the basal OCR was used to calculate the spare respiratory capacity. These 
parameters, as well as the overall OCR measurements, were statistically analyzed as described in 
Section 2.30.  
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2.28 MITOCHONDRIAL MEMBRANE POTENTIAL ANALYSIS 
Maintenance of the mitochondrial membrane potential (Δψm) is essential for the proper functioning 
and health of cells, particularly for cells with high energetic demands, and measurements of Δψm can 
be used as an indicator of the energization state and health of cellular mitochondria. In the present 
study, Δψm was assessed with the tetraethyl benzimidazolyl carbocyanine iodide (JC-1) cationic dye 
and flow cytometric methods. JC-1 exhibits potential-dependent accumulation in mitochondria, 
resulting in a fluorescence emission shift from 525nm (green) to 590nm (red). Therefore, loss of Δψm 
is detectable by the decrease in the red:green florescence emission ratio (Reers et al. 1995).  
 
2.28.1 Preparation and staining of fibroblasts with JC-1 
Differences in Δψm were assessed in patient and wild-type fibroblasts with and without vitamin K2 
treatment. This was done as follows: Fibroblasts cells were cultured in T25 CellStar® tissue culture 
flasks until a confluency of 70-80% was reached. Two additional wild-type fibroblast flasks were 
cultured for subsequent use as positive and unstained controls, respectively. The culture media was 
discarded and a volume of 5ml of 40µM MK-4 solution in culture media (Appendix II) was added to 
cells that were to be treated with vitamin K2. Alternatively, cells that were not treated with vitamin K2 
were incubated in 0.1% (v/v) ethanol in culture media. The flasks were left to incubate for 24h at 37ºC 
in a Farma thermosteri-cycle 5% CO2 humidified incubator. 
Thereafter, the culture media was removed and the cell monolayer stained with 3ml pre-warmed 
0.5μg/ml JC-1 solution (Life Technologies, Carlsbad, California, USA) (Appendix II); 3ml clean 
culture media was added to the unstained control. The positive control flask was co-treated with 
CCCP at a final concentration of 50μM. CCCP is a potent electron transport chain uncoupler; in the 
present study CCCP was used to artificially induce the loss of Δψm. The cell monolayers were stained 
in the dark for 1h at 37ºC in a Farma thermosteri-cycle 5% CO2 humidified incubator. Afterwards, the 
staining solution was removed and the stained cells briefly rinsed with pre-warmed sterile PBS. The 
cells were detached by trypsin treatment (Section 2.21.3) and each cell suspension transferred to a 
12ml Greiner tube and centrifuged at 1000rpm for 2min in a Sorval® GLC-6 general laboratory 
centrifuge. The supernatants were discarded and the pellets resuspended in 1ml of pre-warmed PBS to 
give an approximate final concentration of 200 000-300 000 cells/ml.  
 
2.28.2 Flow cytometry and analysis 
JC-1 dye equilibration was allowed for 10min at room temperature, after which the stained cell 
suspensions were immediately analyzed at the Flow Cytometry Unit of CAF at Stellenbosch 
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University, Cape Town, South Africa. A BD FACSCalibur flow cytometer (Becton Dickinson, 
Franklin Lakes, New Jersey, USA) and BD CellQuest PRO software (Becton Dickinson, Franklin 
Lakes, New Jersey, USA) was employed to this end. The JC-1 fluorophore was excited with a 488nm 
argon-ion laser after which red and green emission were separately detected in the FL1 and FL2 
channels, respectively, using standard PMT detectors. Debris and aggregates were gated out by 
establishing a population of interest based on forward scatter/side scatter (FSC/SSC) properties. 
Compensation between FL1 and FL2 was carefully adjusted in reference to the CCCP-treated positive 
control sample, according to the manufacturer’s instructions. A total of 10 000 events were collected 
per sample per run, and each fibroblast culture was assessed by means of JC-1 staining and flow 
cytometry in three separate experiments. Statistical differences were assessed as described in Section 
2.30. 
 
2.29 MITOCHONDRIAL NETWORK ANALYSIS  
Despite the classic depiction of mitochondria as rod-like, individual organelles, mitochondria are in 
fact engaged in a complex cellular network that constantly fuses and divides. The morphology of this 
mitochondrial network is carefully maintained by the dual processes of mitochondrial fission and 
fusion, which act to regulate mitochondrial integrity and function (Detmer and Chan 2007). 
Dysregulation of such mitochondrial dynamics, perceivable as mitochondrial swelling and 
fragmentation of the mitochondrial network, can be used as an informative marker of cellular and 
mitochondrial dysfunction (Burbulla et al. 2010).  In the present study, the mitochondrial morphology 
of fibroblast cells was assessed by means of live-cell fluorescence microscopy, where the 
Mitotracker® Red CMXRos dye was used to visualize the mitochondrial network. 
 
2.29.1 Preparation of fibroblasts for live-cell microscopy 
Mitochondrial morphology was assessed in patient and wild-type fibroblasts with and without vitamin 
K2 treatment. This was done as follows: An aliquot of a cell suspension to be subcultured (Section 
2.21.3) was used to perform a hemocytometric cell count (Appendix III). Thereafter, a volume of cell 
suspension containing approximately 3000 cells was seeded per well in a Nunc® Lab-Tek® 8-well 
chamber slide (Thermo Scientific, Waltham, Massachusetts, USA). The chamber slide was incubated 
at 37ºC in a Farma thermosteri-cycle 5% CO2 humidified incubator overnight (16h). 
The following morning, the culture media was removed and a volume of 200μl of 40µM MK-4 
solution in culture media (Appendix II) was added to wells containing cells that were to be treated 
with vitamin K2. Alternatively, cells that were not treated with vitamin K2 were incubated in 0.1% 
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(v/v) ethanol in culture media. The chamber slide was returned to the Farma thermosteri-cycle 5% 
CO2 humidified incubator and incubated for a further 24h.  
 
2.29.2 Live-cell fluorescence microscopy and analysis 
Fluorescence image acquisition was performed at the Cell Imaging Unit of CAF at Stellenbosch 
University, Stellenbosch, South Africa. An Olympus IX-81 motorized inverted fluorescence 
microscope (Olympus Biosystems GmbH, Tokyo, Japan), equipped with a F-view-II cooled CCD 
camera (Soft Imaging Systems, Berlin, Germany), and Cell^R software (Olympus Biosystems GmbH, 
Tokyo, Japan) was employed to this end. 
Staining and imaging of the cultured cells was performed with each well of the chamber slide 
separately, in order to reduce photobleaching of the dye as well as dye-induced cytotoxicity. Briefly, 
the culture media was removed from the well to be stained, after which 100μl of a 100nM solution of 
Mitotracker® Red CMXRos (Life Technologies, Carlsbad, California, USA) in pre-warmed culture 
media was added to the well. The chamber slide was placed on the viewing deck of the Olympus IX-
81 microscope inside a live-cell environmental chamber, where it was incubated for 5min at 37ºC and 
5% CO2 before viewing. Fluorescence was excited through a 572nm excitation filter, and fluorescence 
emission collected at 599nm using a UBG triple-bypass emission filter cube and an Olympus Plan AP 
N 60X/1.42 oil-immersion objective. All images were acquired as Z-stacks, with 7-12 image frames 
per stack and increments of 0.26-0.3μm between frames. A total of six images were taken per sample 
per experimental run, after which the next sample was separately stained and imaged. Each sample 
was stained and imaged in quadruplicate.  
Following image acquisition, the images were deconvoluted using the Cell^R software in order to 
remove out-of-focus fluorescent signal. The Z-stack was then exported as a maximum intensity 
projection in TIFF file format for further processing and analysis. Clearly visible cells were 
individually analyzed using ImageJ Software version 1.47 (http://imagej.nih.gov/ij) with an average 
of 40 cells analyzed per sample across all experimental runs. Image analysis was performed as 
follows: Raw images were binarized by conversion to 8-bit image format and optimized by manual 
contrast adjustment to reduce non-specific fluorescent signal. The individual morphological 
characteristics of the mitochondria within a given cell, such as area, perimeter, and major and minor 
axes, were measured by the ImageJ software. These parameters were used to calculate and describe 
the morphological characteristics of the mitochondrial network of the cell, including the aspect ratio 
(ratio between the major and minor axes of the ellipse equivalent to the mitochondrion) and the form 
factor (defined as  
perimeter2
4π×area
 ). The aspect ratio is consistent with mitochondrial length, whereas form 
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factor is a quantification of the degree of branching of the mitochondrial network. Statistical analyses 
were performed as detailed below (Section 2.30). 
 
2.30 STATISTICAL ANALYSIS 
All statistical analyses were performed by Prof. Lize van der Merwe. The freely-available program R, 
a language and environment for graphics and statistical computing (http://www.r-project.org), and R 
packages nlme and effects were used for statistical modeling and graphics (Fox 2003; R Core Team 
2012; Pinheiro et al. 2014).  
General linear modeling was used for pairwise comparisons of outcomes between individual 
fibroblast cell lines. When grouped patient-derived and wild-type fibroblasts were compared, a 
mixed-effects linear model was used, with groups as fixed effects. Here, adjustments were made for 
the effect that the observations on a specific cell line will be correlated. Separate experimental runs 
were modeled as random effects. All effect sized, confidence intervals and p-values were derived 
from the results of the specific models. All results corresponding to a p-value of <0.05 were described 
as statistically significant. Results were not adjusted for multiple testing because it has been suggested 
that corrections, such as Bonferroni, are too conservative when several associations are tested in the 
same group of individuals (Perneger 1998). Results may therefore be considered hypothesis-
generating, where functional explanations of observed statistical differences may support the 
plausibility of such results.   
For analysis of the protein expression levels (Section 2.25.4), the relative densitometry measurements 
(for each fibroblast lysate) for a given protein of interest in a given experimental run, were adjusted 
for differences in relative densitometry of the loading control (GAPDH) in the corresponding lysates, 
for the particular experimental run. Differences in protein expression between individual fibroblast 
cell lines were assessed by means of a general linear model, whereas mixed-effects linear modelling 
was used to compare grouped patient vs. grouped wild-type control fibroblasts. Here, effect plots were 
generated for the interaction between protein level and group identity (whether patient or wild-type).  
All assessments of the effects of treatments, whether with CCCP (Section 2. 26) or with MK-4 
(Sections 2.26-2.29) required a statistical interaction term in the general linear models (for 
assessments within individual fibroblast cell lines) or in the mixed-effects linear models (for 
assessments within groups). Where appropriate, a 22 factorial design was used to model effects of 
treatment on various outcomes.  For analysis of mitochondrial network morphology (Section 2.29.2), 
all outcome distributions were transformed (taking the natural logarithm) in order to approach 
normality, as the untransformed distributions of form factor and aspect ratio were positively skewed. 
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CHAPTER THREE: RESULTS 
 
3.1 PARKIN MUTATION SCREENING 
Our research group has previously reported on a molecular analysis of parkin in 91 South African PD 
patients (Bardien et al. 2009), as well as exon dosage analysis of these patients (Keyser et al. 2009). 
The present study expands on that work by the screening of an additional 138 South African PD 
patients. The results reported here are on the combined total of 229 patients. 
 
3.1.1 Characteristics of the study group 
Relevant demographic and clinical data of the study group is summarized in Table 3.1. The mean 
AAO of the PD patients was 54.4 ± 12.1 years, ranging from 17-80 years. The majority (132/229; 
57.6%) of the study participants either had EOPD (defined as an AAO <=50 years) or a positive 
family history of PD. The study group was ethnically heterogeneous, consisting of 71.2% (163/229) 
Caucasian, 19.7% (45/229) Mixed ancestry, 7.4% (17/229) Black and 1.7% (4/229) Indian patients. 
Amongst the Caucasian patients, 41.7% (68/163) were of Afrikaner descent, a uniquely South African 
population known to have undergone a genetic bottleneck during the 19th century (Le Saux et al. 
2002). The Mixed ancestry ethnic group refers to a uniquely admixed population with genetic 
contributions from indigenous African, European, Malagasy, Indian and South-East Asian populations 
(Patterson et al. 2009). The Black patient group consisted of Xhosa-speaking individuals from the 
South African Nguni ethnic group; indigenous Sub-Saharan African populations, such as the Nguni, 
exhibit complex evolutionary histories and remarkable degrees of genetic diversity (Tishkoff et al. 
2009). The South African Indian subpopulation is mostly descended from indentured workers brought 
to South Africa in the 19th century.  
Table 3.1 Demographic and clinical characteristics of 229 South African PD patients 
  Total N = 229 
 AAO, mean ± SD, (range) 54.4 ± 12.1 years (17-80 years) 
 AAO<=50 82 (35.8%) 
 Family history of PD 81 (35.4%) 
 AAO <= 50 years and/or family history of PD 132 (57.6%) 
 Males 145 (63.3%) 
 Families with consanguinity 2 
 Ethnicity  
                 Caucasian 163 (71.2%) 
                 Mixed ancestry 45 (19.7%) 
                 Black 17 (7.4%) 
                 Indian 4 (1.7%) 
Abbreviations: AAO, age at onset; N, sample size; PD, Parkinson's disease; SD, standard deviation.  
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3.1.2 Parkin variants identified in South African PD patients 
The study participants were screened for mutations in parkin, using HRM to detect point mutations 
and small insertions/deletions (Section 2.6) and MLPA to detect exonic rearrangements (Section 2.8). 
In total, this study identified seven patients with homozygous or compound heterozygous mutations in 
parkin in the 229 South African PD patients (Figure 3.1, Table 3.2).  
 
 
 
 
 
 
 
 
 
Figure 3.1 Schematic representation of parkin, with locations of mutations and sequence 
variants identified in this study indicated. The top figure represents the parkin protein sequence, 
with functional domains as indicated. The bottom figure represents the parkin coding sequence, where 
exon rearrangements are indicated by red lines representing their locations and sizes. Abbreviations: 
Del, deletion; dup, duplication; ex, exon; IBR, in-between RING; UBL, ubiquitin-like; UP, unique 
parkin.   
 
The patient labeled ID 1 (henceforth referred to as patient 1), a Black male with an AAO of 45 years, 
was found to harbor compound heterozygous mutations: a duplication of exon 2 and a deletion of 
exon 9. The same mutations were found in an affected female sibling; both siblings had an early AAO 
(<50 years) and presented with typical tremor predominant PD. The exon dosage mutations were 
detected by MLPA analysis; however, the presence of these mutations was not confirmed via RT-PCR 
analysis on the proband’s lymphocytes as the patient was lost to follow-up. Interestingly, patient 1, 
along with patient 107, is one of only three cases of parkin mutations in Black Sub-Saharan African 
patients reported to date, with the third being a Zambian PD patient  (Yonova-Doing et al. 2012; 
Blanckenberg et al. 2013).  
Stellenbosch University  https://scholar.sun.ac.za
107 
 
Table 3.2 Putative and established mutations identified in parkin in 229 South African PD patients 
Patient 
ID  
Ethnicity 
AAO 
(years) 
Family 
History 
Mutation status 
In 
controls  
Protein 
domain 
PolyPhen-2 
prediction 
MutationTaster 
prediction 
Study* 
Compound heterozygous/ homozygous mutations 
1 Black 45 Yes 
Duplication exon 2 het                         
+ Deletion exon 9 het 
ND                     
ND 
UBL              
IBR 
 
 
 Keyser et al. 2009 
16 Caucasian 27 Yes Deletion exon 4 hom ND RING0  
 
 
Bardien et al. 2009 
23 Mixed ancestry 27 No Deletion exon 3-4 hom ND RING0  
 
 
Bardien et al. 2009 
105 Caucasian 25 Yes 
P113fsX163 het 
+ Deletion exon 3 het 
ND                 
ND 
RING0             
RING0 
  Present study 
107 Black 56 No 
G430D (GGC > GAC) het 
(rs191486604)                                      
+ Deletion exon 4 het 
0/106 RING2 Probably damaging 
 
Disease causing 
 
Present study 
ND RING0 
108 Caucasian 27 No 
G430D (GGC > GAC) het                    
+ Deletion exon 4 het 
0/106           
ND 
RING2        
RING0 
Probably damaging 
 
Disease causing 
 
Present study 
121 Caucasian 48 Yes 
Duplication exon 2-6 het                        
+ Duplication exon 5 het 
ND 
UBL; RING0       
RING0 
  Present study 
Heterozygous variants 
11 Caucasian 37 No 
R402C (CGT > TGT) het 
(rs55830907) 
0/100 REP Probably damaging Polymorphism Bardien et al. 2009 
21 Caucasian 42 No 
E310D (GAG > GAC) het 
(rs72480423) 
0/110 IBR Benign Disease causing Bardien et al. 2009 
31 Caucasian 56 No Duplication exon 2 het ND UBL  
 
 
 Keyser et al. 2009 
61 Caucasian 55 Yes 
H200Q (CAC > CAG) het 
(rs72480421) 
0/106 RING0  Possibly damaging Polymorphism Bardien et al. 2009 
91 Mixed ancestry 50 No Duplication exon 2-3 het ND UBL; RING0 
 
 
 Keyser et al. 2009 
126 Mixed ancestry 49 Yes Deletion exon 4 het ND RING0  
 
 
 Present study 
133 Caucasian 54 No 
P437L (CCG > CTG) het           
(rs56092260) 
0/110 RING2 Probably damaging Disease causing Present study 
217 Mixed ancestry 61 No Deletion exon 3-4 het ND RING0   
 
 
Present study 
*Mutation status was reported in various publications: Bardien et al. (2009), Keyser et al. (2009) and the present study (Haylett et al. 2012). Abbreviations: AA0, age at onset; 
het, heterozygote; hom, homozygote; IBR, in between RING domain; ND, not determined; PD, Parkinson's disease; RING, RING-finger motif; UBL, ubiquitin-like domain.  
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A homozygous exon 4 deletion was found in patient 16, a Caucasian female with an early AAO of 27 
years. Her affected sibling has the same homozygous exon 4 deletion. Both the proband and her 
sibling presented with typical PD features as well as dystonia. RNA was obtained from the patient and 
her sibling and RT-PCR used to confirm the presence of these mutations; this is illustrated in Figure 
3.2A and B. Furthermore, dermal fibroblasts were obtained from this patient and her affected sibling 
by means of a skin biopsy (Section 2.21.1) for subsequent studies. The results emanating from such 
functional studies will be described later in this dissertation.   
Patient 23 also has an early AAO (27 years), but was not aware of any family history of PD. The 
homozygous exon 3-4 deletion of patient 23 was confirmed by RT-PCR and sequencing analysis 
(Figure 3.2C). The patient presented with mild dyskinesia, tremor and dystonia of her left leg, and 
responded well to levodopa therapy. Dermal fibroblasts were obtained from this patient for use in 
functional studies of the homozygous parkin exon 3-4 deletion.  
 
A                                                             Deletion of exon 4 
 
   
 
 
B                                 Deletion of exon 4   
 
 
 
 
C                                            Deletion of exons 3-4         
 
 
 
 
Figure 3.2 DNA sequence analysis of RT-PCR products which verify the presence of deletions in 
parkin. Positions of the deletions are indicated. A, patient 16 with homozygous whole exon 4 
deletions. B, the affected sibling of patient 16, also with homozygous whole exon 4 deletions. C, 
patient 23 with homozygous whole exon 3-4 deletions. 
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In one patient (patient 105) a heterozygous 40bp deletion in parkin exon 3 resulting in a frameshift 
mutation (P113fsX163; c.337_376del) was found. The patient’s other allele was found to harbor a 
heterozygous deletion of exon 3, which was confirmed with RT-PCR and sequencing analysis. This 
patient presented with gradual onset of dystonia in the legs, followed by onset of mild features of PD 
nine years later at the age of 25 years. This individual has Irish ancestry on both his maternal and 
paternal side, which is consistent with previous reports of this 40bp parkin exon 3 deletion (Lincoln et 
al. 2003). 
Interestingly, two unrelated patients (patient 107 and 108), of different ethnic backgrounds (Black and 
Caucasian, respectively) each harbored identical compound heterozygote mutations; a heterozygous 
G430D and a whole exon 4 deletion. DNA samples from family members of the patients could not be 
obtained, which precluded haplotype analysis to determine the relatedness of the patients. The two 
patients, patient 107 and 108, have an AAO of 56 and 27 years, respectively. Both patients presented 
with typical tremor predominant PD; prominent left arm dystonia was seen in patient 107. The finding 
of parkin mutations in a patient with an AAO > 50 years justifies the inclusion of patients with older 
AAO’s in our setting. 
Patient 121 was found to harbor a compound heterozygous mutation consisting of an exon 2-6 
duplication on one allele and an exon 5 duplication on the other allele. This female Caucasian patient 
reported family history of PD and has an AAO of 48. The patient presented with typical features of 
PD, with good levodopa responsiveness and occasional hypotension.  
In addition to these seven PD patients with homozygous or compound heterozygous parkin mutations, 
heterozygous missense variants (H200Q, E310D, R402C, P437L), and various exonic deletions and 
duplications were found in a further eight patients but currently the pathogenicity of these single 
heterozygous variants are unclear (Table 3.2). In cases where only a single parkin mutation was 
detected, all twelve parkin exons were subjected to direct sequencing (Section 2.7) in order to verify 
the absence of a second mutation. All of the point mutations were detected only in the patients under 
study, being absent in over 100 control chromosomes. It should however be noted that heterozygosity 
for a deletion or duplication encompassing more than one exon could in fact be due to compound 
heterozygosity for two different exon rearrangements acting in trans. This may be the case for patient 
91 (involving exons 2 and 3) and patient 217 (exons 3 and 4). Further clarifying studies could be 
performed on these individuals in order to determine the phase of the exon rearrangements; this could 
not be done in the present study as neither RNA from the patient nor DNA from family members were 
available for RT-PCR or haplotype analysis, respectively.   
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3.1.3 Parkin polymorphisms identified in South African PD patients 
In addition to mutations, numerous polymorphisms were detected in parkin (Table 3.3). Sequence 
variants were designated as polymorphisms if the variant was located in a non-coding region, resulted 
in a silent substitution (P37P, C238C, L261L, A397A and R402R), had been previously described as a 
polymorphism (A82E) or if the variant was observed in ≥1% of ethnically-matched control 
chromosomes (Q34R, S167N, M192L, R334C, V380L and D394N). All of the polymorphisms 
detected in our study had been previously described. Interestingly, the S167N and M192L 
polymorphisms had been previously described as pathogenic variants (Satoh and Kuroda 1999; 
Hedrich et al. 2002); however, the high frequencies of these sequence variants found in control 
chromosomes from South African individuals (7.9% and 6.7%, respectively; Table 3.3) make it 
unlikely that they are of pathogenic relevance.  
 
Table 3.3 Polymorphisms identified in the parkin gene in 229 South African PD patients 
Sequence variant Ethnicity of patient(s) with variant 
Frequency in controls* 
(%) 
5'UTR -258T > G Caucasian, Mixed ancestry and Black 
14.0 (Caucasian)            
18.0 (Mixed ancestry) 
5'UTR -227A > G Caucasian and Mixed ancestry ND 
5'UTR -89C > T Caucasian ND 
IVS1 +42C > T Mixed ancestry ND 
Q34R (CAG > CGG) Mixed ancestry 3.2 
P37P (CCG > CCA) Mixed ancestry and Black ND 
IVS2 +10C > T Mixed ancestry 0 
IVS2 +20delC Mixed ancestry 4.8 
IVS2 +25T > C Mixed ancestry and Black ND 
IVS2 +35G > A Caucasian and Mixed ancestry ND 
IVS2 +62G > A Mixed ancestry ND 
IVS3 -20T > C Caucasian ND 
A82E  (CGA > GAA) Caucasian 0 
S167N (AGC > AAC) Caucasian and Mixed ancestry 7.9 
M192L (ATG > CTG) Mixed ancestry 6.7 
C238C (TGC > TGT) Black ND 
L261L (TTA > TTG) Black ND 
IVS7 -68C > G Caucasian ND 
IVS7 -35G > A Caucasian and Black ND 
IVS8 +43A > G Mixed ancestry and Black ND 
IVS8 +48C > T Caucasian and Black ND 
IVS8 -21_-17del Mixed ancestry ND 
R334C (CGC > TGC) Mixed ancestry and Indian 2.0 (Mixed ancestry) 
V380L (GTA > CTA) Caucasian, Mixed ancestry and Black 27.2 (Caucasian) 
D394N (GAT > AAT) Caucasian, Mixed ancestry, Black and Indian 6.0 (Caucasian) 
A397A (GCC > GCT) Mixed ancestry ND 
R402R (CGT > CGC) Mixed ancestry and Black ND 
3'UTR *16G > A Mixed ancestry ND 
3'UTR *94A > G Caucasian ND 
3'UTR *103C > T Black ND 
*Frequency was only determined for exonic, non-synonymous variants. Abbreviations: del, deletion; IVS, 
intervening sequence; ND, not determined. 
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Possible heterozygous whole exon 5 deletions of parkin had been detected in two patients; however, 
this putative deletion was only detected by the P051 MLPA probe set and not by the P052 set. Further 
investigation revealed that the two patients with ostensible whole exon 5 deletions were in fact 
heterozygous for the M192L polymorphism.  The presence of this polymorphism disrupts the binding 
site of a probe in the P051 MLPA kit, resulting in a false positive result (Figure 3.3). This exemplifies 
the benefit of using two different MLPA kits to reduce the risk of false positives, and only exon 
dosage mutations in parkin that were independently detected by both MLPA kits were considered as 
true positive results. 
 
A        Probe ligation           Amplification 
   
…TAAGGTTTGGCCTACTCACCACTT… 
560     TAATTCCAAACCGGATGAGTGGTGAATGCCAATCCCCACACTGCCCTGGGACT 612 
187 -L--I--P--N--R--M--S--G--E--C--Q--S--P--H--C--P--G--T- 205 
 
 
 
B                                                        No probe ligation  No amplification 
  
…TAAGGTTTGGCCTACTCACCACTT… 
560     TAATTCCAAACCGGCTGAGTGGTGAATGCCAATCCCCACACTGCCCTGGGACT 612 
187 -L--I--P--N--R--L--S--G--E--C--Q--S--P--H--C--P--G--T- 205 
 
Figure 3.3 The M192L parkin polymorphism disrupts the binding site of a P051 MLPA probe. 
The partial parkin CDS and the encoded amino acid sequence are listed in black font. The position of 
the c.574A>C; M192L polymorphism is illustrated in red font. Partial sequences of the two halves of 
the 366bp P051 MLPA probe (probe 02177-L24889) are indicated in blue and pink. A, parkin 
sequence harboring the major allele (A) of the M192L polymorphism. The two halves of the MLPA 
oligonucleotide probe anneal adjacent DNA sequences. This allows for oligonucleotide probe ligation, 
MPLA primer binding and successful amplification, which would indicate the presence of exon 5. B, 
parkin sequence harboring the minor allele (C) of the M192L polymorphism. The pink half of the 
MLPA probe does not properly anneal at the ligation site (black box); hence, no oligonucleotide probe 
ligation or amplification takes place. This would falsely indicate the absence of exon 5. 
 
3.2 IDENTIFICATION AND VERIFICATION OF PARKIN INTERACTORS 
In order to further current knowledge on the role of parkin in health and disease, a focus of the present 
study was to use a Y2H approach to identify novel parkin-interacting proteins (Section 3.2.1). Such 
putative interactors were verified under biologically-relevant conditions using two in vivo approaches: 
3D co-localization and co-IP (Section 3.2.3). The effect of the lack of parkin on each interacting 
protein was also evaluated in cellular models of parkin deficiency (Section 3.2.4)   
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3.2.1 Parkin Y2H analysis 
3.2.1.1 Generation of parkin Y2H bait construct  
The pGBKT7-parkin Y2H bait construct was successfully cloned as described in Section 2.13. The 
construct was subjected to DNA sequencing and sequence analysis, which confirmed that both the 
correct reading frame and insert sequence integrity had been retained throughout the cloning process.  
 
3.2.1.2 Phenotypic assessment of yeast strains 
The pGBKT7-parkin Y2H bait construct was used to transform S. cerevisiae strain AH109. This 
transformed strain, as well as untransformed AH109 and Y187 host strains, was assessed for their 
ability to grow on various nutritionally-deficient selection plates. Untransformed AH109 and Y187 
were able to grow on SD-Ura plates, but did not grow on SD-Trp, SD-Leu, SD-His and SD-Ade plates. This 
confirmed the viability and purity of the untransformed strains. AH109 transformed with pGBKT7-
parkin was able to grow on SD-Ura and SD-Trp plates, but did not grow on SD-Leu, SD-His and SD-Ade 
plates, which confirmed that the phenotype of AH109 was retained following transformation. 
Additionally, this verified that the HIS3 and ADE2 reporter genes were not autonomously activated by 
expression of the bait protein. Phenotypic assessment of yeast strains is summarized in Table 3.4.  
 
Table 3.4 Phenotypic assessment of S. cerevisiae strains 
Nutritional selection 
plate 
AH109 Y187 
AH109 transformed 
with pGBKT7-parkin 
SD-Ura ++ ++ ++ 
SD-Trp - - ++ 
SD-Leu - - - 
SD-His - - - 
SD-Ade - - - 
Abbreviations: ++, growth; -, no growth; -Ade, lacking adenine; -His, lacking histidine; -Leu, lacking leucine; 
-Trp, lacking tryptophan; -Ura, lacking uracil; SD, synthetic defined. 
 
 
3.2.1.3 Yeast transformation toxicity test 
Prior to Y2H analysis, a toxicity test was performed to determine whether the Y2H bait construct 
detrimentally affected the growth of S. cerevisiae strain AH109 (Section 2.18.2). To this end, a 
growth curve of AH109 transformed with the pGBKT7-parkin bait construct was generated and 
compared to a growth curve of AH109 transformed with non-recombinant pGBKT7 (Figure 3.4). It 
was determined that the bait construct had no significant effect of the growth of AH109, as evidenced 
by the similar gradients of the pGBKT7-parkin growth curve (gradient = 0.0241) and the non-
recombinant pGBKT7 growth curve (gradient = 0.0256).   
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Figure 3.4 Linearized growth curves of S. cerevisiae strain AH109 transformed with pGBKT7-
parkin and non-recombinant pGBKT7. Similar growth rates of AH109 transformed with pGBKT7-
parkin and non-recombinant pGBKT7 demonstrated that pGBKT7-parkin did not adversely affect the 
growth of AH109. Abbreviations: Log, logarithm; nm, nanometer; OD, optical density.  
 
 
3.2.1.4 Mating efficiency determination 
Prior to Y2H analysis, S. cerevisiae strain AH109 transformed with pGBKT7-parkin bait construct 
was mated with Y187 transformed with non-recombinant pGADT7 (Section 2.18.3). An additional 
assessment of AH109 transformed with pGBKT7-53 and mated with Y187 transformed with non-
recombinant pGADT7 served as a positive control mating. It was concluded that the bait construct did 
not adversely affect the mating efficiency of AH109 (Table 3.5). During Y2H analysis a further small-
scale mating assessment was performed. AH109 transformed with pGBKT7-parkin bait construct was 
mated with Y187 transformed with the pGADT7-cDNA library (Section 2.19.5). This delivered an 
actual Y2H mating efficiency of 11.6%, which is well above the minimum mating efficiency of 2% 
recommended by the MATCHMAKER™ Y2H system manufacturer (Clontech, Palo Alto, California, 
USA).   
 
Table 3.5 Effect of Y2H bait construct on S. cerevisiae AH109 mating efficiency  
Mating pairs Mating efficiency (%) 
pGBKT7-parkin::AH109 X pGADT7::Y187  17.9 
pGBKT7-53::AH109 X pGADT7::Y187 10.1 
pGBKT7-parkin::AH109 X pGADT7-cDNA library::Y187 11.6 
Abbreviations: Y2H, yeast two-hybrid. 
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3.2.1.5 Parkin Y2H adult brain cDNA library screen 
The Y2H bait culture, S. cerevisiae strain AH109 transformed with pGBKT7-parkin bait construct, 
passed all of the abovementioned quality control assessments (Sections 3.2.1.1-3.2.1.4). The bait 
culture was therefore deemed adequate for use in a Y2H library screen. This was performed by mating 
the bait culture with the Y2H prey culture, S. cerevisiae strain Y187 transformed with the pGADT7-
cDNA library (Section 2.19.3). It is estimated that approximately 1.8 x 107 cDNA clones were 
screened in this Y2H analysis (Section 2.19.5). 
Diploid yeast colonies were assessed for their ability to activate the Y2H reporter genes (Section 
2.19.6). A total of 505 diploid yeast colonies formed on TDO plates, indicating successful activation 
of the HIS3 nutritional reporter gene by 505 clones. Such colonies were numbered, individually 
picked and plated onto QDO plates. These high-stringency media plates required activation of both 
HIS3 and ADE2 nutritional reporter genes for colony formation. A total of 245 clones formed colonies 
on QDO plates. These clones were selected for X-α-gal assays to evaluate their ability to activate the 
MEL1 colorimetric reporter gene. Clones were subsequently classified into 107 primary clones and 
138 secondary clones according to their color intensity in the X-α-gal assay as well as their robustness 
of growth on QDO plates. A representative subset of scored clones is listed in Table 3.6 to illustrate 
the assessment of HIS3, ADE2 and MEL1 reporter genes activation.  A complete list of scored clones 
is available in Appendix VI. 
 
Table 3.6 Representative subset of clones illustrating scoring of HIS3, ADE2 and MEL1 reporter 
genes activation 
Clone ID 
Growth on TDO    
(HIS3 activation) 
Growth on QDO   
(ADE2 activation) 
X-α-gal assay                    
(MEL1 activation) 
1 ++++ +++ Pale blue 
2 +++ + No blue 
3 +++ - - 
4 ++++ ++++ Pale blue 
5 ++++ ++++ Dark blue 
6 ++++ +++ Pale blue 
7 +++ - - 
8 ++++ ++++ Medium blue 
9 ++ ++ Medium blue 
10 ++++ - - 
11 +++ ++ Pale blue 
12 +++ - - 
13 + - - 
14 ++++ +++ Dark blue 
15 ++ - - 
16 + - - 
Clones in blue font were designated as primary clones. Abbreviations: ++++, excellent growth; +++ fair 
growth; ++ weak growth; +, very weak growth; -, no growth; QDO, quadruple dropout (SD media lacking 
tryptophan, leucine, histidine and adenine); TDO, triple dropout (SD media lacking tryptophan, leucine and 
histidine); X-α-gal, 5-bromo-4-chloro-3-indolyl α-D-galactopyranoside. 
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The 107 primary clones were investigated for the specificity of their interactions with the pGBKT7-
parkin bait construct (Section 2.20.8). Only clones that were able to grow colonies on TDO plates 
when mated to pGBKT7-parkin, but had no or negligent colony growth when mated to either of three 
heterologous bait constructs, were considered to demonstrate specific bait-prey interactions. An 
example of such a TDO plate is shown in Figure 3.5. A representative subset of evaluated primary 
clones indicating their interaction specificity is listed in Table 3.7. A complete list of evaluated clones 
is tabulated in Appendix VII. Of the 107 primary clones subjected to interaction specificity testing, a 
total of 64 clones demonstrated interactions specific to the parkin bait.  
 
 
 
                                                   
 
Figure 3.5 Interaction specificity testing using heterologous bait mating. Shown above are diploid 
yeast colonies resulting from six clones individually mated with four heterologous bait constructs and 
grown on a QDO plate for 7 days. Only clones that formed colonies when mated to pGBKT7-parkin, 
but did not form colonies when mated to non-recombinant pGBKT7, pGBKT7-53 or pGBKT7-TTN 
were considered to demonstrate specific bait-prey interactions (clone 43 above). Abbreviations: QDO, 
quadruple dropout (SD media lacking tryptophan, leucine, histidine and adenine).   
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Table 3.7 Representative subset of clones scored for bait-prey interaction specificity  
Clone ID pGBKT7-parkin pGBKT7 pGBKT7-53 pGBKT7-TTN 
62 ++++ + + - 
64 ++++ + - + 
65 ++++ ++++ ++++ +++ 
66 ++++ + + + 
69 ++++ + + + 
71 ++++ ++++ +++ ++ 
75 ++++ ++++ + + 
90 ++++ +++ + + 
100 ++++ + + + 
101 ++++ - - + 
102 ++++ + - + 
104 ++++ + ++++ - 
113 ++++ + +++ + 
116 ++++ + ++++ - 
123 ++++ ++ +++ +++ 
140 ++++ + ++++ + 
141 ++++ + + - 
142 ++++ + + + 
147 ++++ + - - 
149 ++++ +++ - - 
150 ++++ - +++ + 
161 ++++ + + + 
162 ++++ + +++ + 
164 ++++ + + + 
165 ++++ + + + 
Clones in blue font were considered to demonstrate specific parkin-bait interactions. All colonies were scored 
after 7 days on QDO plates. Abbreviations: ++++, excellent growth; +++ fair growth; ++ weak growth; +, 
very weak growth; -, no growth; QDO, quadruple dropout (SD media lacking tryptophan, leucine, histidine 
and adenine). 
 
3.2.1.6 Identification of putative parkin-interacting clones 
Each of the 64 clones that demonstrated parkin-specific interactions were subjected to automated 
DNA sequencing. The insert sequence as well the in silico translated sequence were then compared to 
known cDNA and protein sequences using the BLASTn and BLASTp queries, respectively 
(http://www.ncbi.nlm.nih.gov/BLAST). This delivered 29 unique clones encoding in-frame proteins, 
16 duplicate clones (with identical insert sequences), and 19 clones with out-of-frame insert 
sequences (as dictated by the reading frame of the upstream GAL4-AD) that had no significant 
protein match when translated. The identities of the 64 investigated clones are listed in Table 3.8.  
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Table 3.8 Identification of putative parkin-interacting clones from the Y2H cDNA library screen 
  Genomic hit: BLASTn Protein hit: BLASTp   
Clone ID Identity Accession nr E-value        Accession nr E-value    
Cellular 
localization 
Domains 
23; 321 
H. sapiens exocyst complex 
component 4 (EXOC4) 
NM_021807.3 0.00         NP_068579.3 2E-95 Cytoplasm 
Sec8 exocyst 
complex component 
specific domain 
43; 101; 161; 
330; 377; 379 
H. sapiens pre-mRNA cleavage 
complex 2 protein (Pcf11) 
NM_015885.3 0.00 NP_056969.2 1E-85 Nucleus  CID domain 
66 H. sapiens dehydrodolichyl 
diphosphate synthase (DHDDS) 
NM_205861.2 6E-133 NP_995583.1 5E-41 
Plasma 
membrane 
Cis-isoprenyl 
diphosphate 
synthases 
142 H. sapiens caldesmon 1 
(CALD1) 
NM_033140.3 0.00 NP_149131.1 2E-21 
Plasma 
membrane; 
cytoskeleton  
Caldesmon 
147 H. sapiens fatty acid elongase 1 
(ELOVL1) 
NM_022821.2 1E-166 NP_073732.1 8E-13 Cytoplasm GNS1/SUR4 family 
165 H. sapiens coiled-coil domain 
containing 56 (CCDC56) 
NM_001040431.1 0.00 NP_001035521.1 1E-56 
Cytoplasm; 
mitochondria 
Coiled-coil-56  
superfamily 
166 H. sapiens myelin basic protein 
(MBP) 
NM_002385.2 0.00 NP_002376.1 2E-77 
Cytoplasm; 
centrosome 
Myelin MBP 
superfamily 
188; 435; 437; 
489; 494; 496 
H. sapiens serine/arginine-rich 
splicing factor 3 (SRSF3) 
NM_003017.4 0.00 NP_003008.1 6E-121 
Nucleus but 
not nucleoli 
RRM superfamily 
204 H. sapiens transketolase (TKT) NM_001064.3 0.00 NP_001055.1 3E-89 Cytoplasm 
TPP enzyme PYR 
superfamily; 
transketolase C-
terminal domain 
208 
H. sapiens protein-L-
isoaspartate (D-aspartate)  
O-methyltransferase (PCMT1) 
NM_005389.2 9E-59 NP_005380.2 5E-65 Cytoplasm 
AdoMet-MTase 
superfamily 
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  Genomic hit: BLASTn Protein hit: BLASTp   
Clone ID Identity Accession nr E-value Accession nr E-value 
Cellular 
localization 
Domains 
218 
H. sapiens non-POU domain 
containing, octamer-binding 
(NONO) 
NM_001145408.1 0.00 NP_001138880.1 4E-12 
Nucleus but 
not nucleoli 
NOPS_p54nrb 
superfamily; 
RRM1_p54nrb 
superfamily; 
RRM2_p54nrb 
superfamily 
 
223 
H. sapiens ArfGAP with 
RhoGAP domain, ankyrin repeat 
and PH domain 2 (ARAP2) 
NM_015230.2 0.00 NP_056045.2 1E-48 
Cytoplasm; 
cytoskeleton; 
focal 
adhesions 
RhoGAP domain;  
5 ankyrin and PH 
domain repeats; 
SAM domain of 
Arap1,2,3; 
 ArfGap superfamily; 
Ras association 
domain; 
 Sterile alpha motif 
225; 277; 333 
439 
H. sapiens transmembrane 
protein 222 (TMEM222) 
NM_032125.2 0.00 NP_115501.2 3E-112 Cytoplasm DUF778 superfamily 
242 
H. sapiens A kinase (PRKA) 
anchor protein (yotiao) 9 
(AKAP9) 
NM_005751.4 0.00 NP_005742.4 8E-55 
Golgi 
apparatus; 
vesicles; 
centrosome 
Centrosomal 
targeting domain;  
DUF515 
superfamily;  
Smc domain;  
SbcC domain 
252 
H. sapiens 
dehydrogenase/reductase (SDR 
family) member 7 (DHRS7) 
NM_016029.2 0.00 NP_057113.1 1E-71 
Nucleus but 
not nucleoli; 
cytoplasm 
NADB-Rossmann 
superfamily;  
DltE domain 
        
257 
H. sapiens ATP synthase 
mitochondrial F1 complex 
assembly factor 1 (ATPAF1) 
NM_022745.4 0.00 NP_073582.3 3E-87 
Cytoplasm; 
mitochondria 
ATP11 superfamily 
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  Genomic hit: BLASTn Protein hit: BLASTp   
Clone ID Identity Accession nr E-value Accession nr E-value 
Cellular 
localization 
Domains 
258; 443 
H. sapiens adaptor-related 
protein complex 3, sigma 1 
subunit (AP3S1) 
 
NM_001284.2 7E-173 NP_001275.1 
1.00E-
130 
Cytoplasm 
Clathrin adaptor S 
superfamily 
259 
H. sapiens calpain 3, (p94) 
(CAPN3) 
NM_000070.2 5E-40 NP_775111.1 1E-67 Cytoplasm 
EFh superfamily;  
EF-hand calcium 
binding motif; 
calpain-III 
superfamily 
274 
H. sapiens carboxypeptidase E 
(CPE) 
NM_001873.2 1E-101 NP_001864.1 9E-20 
Plasma 
membrane; 
cytoplasm; 
nucleus  
Peptidase M14-like 
superfamily 
276; 329 
H. sapiens small nuclear 
ribonucleoprotein polypeptide N 
(SNRPN) 
NM_003097.3 0.00 NP_073719.1 4E-75 Nucleus 
Sm protein B 
superfamily 
278 
H. sapiens guanine nucleotide 
binding protein beta polypeptide 
3 (GNB3) 
NM_002075.2 0.00 NP_002066.1 4E-60 
Plasma 
membrane; 
cytoplasm 
WD40 domain 
317 H. sapiens transformer 2 alpha 
homolog (Drosophila) (TRA2A) 
NM_013293.4 0.00 NP_037425.1 1E-88 
Nucleoli, 
vesicles 
RRM superfamily 
318 H. sapiens septin 9 (SEPT9) NM_001113491.1 0.00 NP_001106963.1 2E-105 
Cytoplasm; 
cytoskeleton 
MCLC superfamily; 
CDC/septin GTPase 
family 
319 
H. sapiens actin, gamma 1 
(ACTG1) 
 
NM_001614.3 0.00 NP_001605.1 6E-23 Cytoskeleton  Actin 
337 
H. sapiens phosphoglucomutase 
1 (PGM1) 
NM_002633.2 0.00 NP_002624.2 1E-50 
Cytoplasm;  
cytoskeleton  
phosphoglucomutase 
superfamily 
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  Genomic hit: BLASTn Protein hit: BLASTp   
Clone ID Identity Accession nr E-value Accession nr E-value 
Cellular 
localization 
Domains 
395 
H. sapiens tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation 
protein, eta polypeptide 
(YWHAH) 
NM_003405.3 0.00 NP_003396.1 8E-128 Cytoplasm 14-3-3 superfamily 
423 
H. sapiens nuclear receptor 
subfamily 1, group H, member 2 
(NR1H2) 
NM_007121.5 6E-39 NP_009052.3 5E-40 
Cytoplasm; 
nucleus 
NR-DBD 
superfamily 
432 
H. sapiens hepatocyte growth 
factor-regulated tyrosine kinase 
substrate (HGS) 
NM_004712.3 0.00 NP_004703.1 2E-67 
Cytoplasm; 
vesicles 
VHS-ENTH-ANTH 
superfamily; 
 ApoLp-III-like 
superfamily; 
Hrs-helical domain; 
FYVE domain  
483 
H. sapiens phosphoglycerate 
mutase 1 (PGAM1) 
NM_002629.2 0.00 NP_002620.1 2E-54 Cytoplasm Histidine phosphatase 
domain 
141 
PREDICTED: H. sapiens 
potassium voltage-gated 
channel, KQT-like subfamily, 
member 2 (KCNQ2) 
XM_006723791 0.00 
no significant 
similarity 
- - - 
198 
H. sapiens postmeiotic 
segregation increased 2 
pseudogene 4 (PMS2P4) 
NR_046297.1 0.00 
no significant 
similarity 
- - - 
48; 69; 100; 
164; 372 
H. sapiens chromosome 3 
genomic contig -      
ubiquitin carboxyl-terminal 
hydrolase 4 (UCHL4) 
NT_022517.18 0.00 
no significant 
similarity 
- - - 
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  Genomic hit: BLASTn Protein hit: BLASTp   
Clone ID Identity Accession nr E-value Accession nr E-value 
Cellular 
localization 
Domains 
62 
H. sapiens chromosome 20 
genomic contig - 
double-stranded RNA-binding 
protein Staufen (STAU) 
 
NT_011362.10 0.00 
no significant 
similarity 
- - - 
64 
H. sapiens chromosome 6 
genomic contig - calcipressin-2 
NT_007592.15 0.00 
no significant 
similarity 
- - - 
102, 8 H. sapiens chromosome 2 
genomic contig 
NW_001838860.1 0.00 
no significant 
similarity 
- - - 
174; 221 
H. sapiens chromosome 1 
genomic contig 
NT_167186.1 0.00 
no significant 
similarity 
- - - 
222 
H. sapiens chromosome 5 
genomic contig - 
BRCA1-A complex subunit 
(RAP80) 
NT_023133.13 0.00 
no significant 
similarity 
- - - 
14; 224 
H. sapiens chromosome 4 
genomic contig 
NW_001838915.1 0.00 
no significant 
similarity 
- - - 
436 
H. sapiens chromosome 16 
genomic contig - 
ADP-ribosylation factor-binding 
protein (GGA2) 
NT_010393.16 0.00 
no significant 
similarity 
- - - 
476 
H. sapiens chromosome 18 
genomic contig  
NT_010859.14 0.00 
no significant 
similarity 
- - - 
495 
H. sapiens chromosome 12 
genomic contig -  
TBC1 domain family member 
30 (TBC1D30) 
NT_029419.12 0.00 
no significant 
similarity 
- - - 
Abbreviations: BLASTn, Basic Local Alignment Search Tool nucleotide; BLASTp, Basic Local Alignment Search Tool protein; Y2H, yeast two-hybrid; all domain 
abbreviations can be found in the conserved domain database (http://www.ncbi.nlm.nih.gov/ccd). 
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3.2.2 Selection of putative parkin interactors  
Each of the 29 putative parkin interactors were investigated in publicly available databases such as 
ExPASy http://www.expasy.org), GeneCards (http://www.genecards.org) and the Human Protein 
Atlas (http://www.proteinatlas.org) in order to obtain relevant information regarding the function, 
tissue expression and subcellular expression of the proteins. Based on such information, four of the 
putative parkin interactors were prioritized for verification and further characterization: 14-3-3η, γ-
actin, ATPAF1 and SEPT9. The selection of these four putative interactors does not exclude the other 
25 as parkin-interacting candidates; however, due to time constraints, it was necessary to focus on 
interactors of plausible functional consequence. Each prioritized putative parkin interactor will be 
briefly discussed to highlight why they were selected for further analysis.     
 
3.2.2.1 14-3-3η 
The 14-3-3 eta (14-3-3η) protein, also referred to as tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, eta polypeptide (YWHAH), is a member of the 14-3-3 protein 
family which mediates signal transduction by binding to phosphoserine-containing proteins. The 14-
3-3 proteins are abundantly expressed in the brain, and are involved in the regulation of neuronal 
development and cell death (Takahashi 2003).  
This protein has been previously shown to interact with parkin (Sato et al. 2006); 14-3-3η acts as a 
negative regulator of parkin activity by reducing parkin substrate affinity. The identification of a 
known parkin interactor by the Y2H library screen in this study supports the validity of this approach. 
Investigating the interaction between 14-3-3η and parkin might deepen our understanding of the 
regulation of parkin, which might be of interest in PD research.    
 
3.2.2.2 ATP synthase mitochondrial F1 complex assembly factor 1 (ATPAF1) 
Very little is known about ATPAF1; it is thought to be a soluble mitochondrial-associated protein that 
is required for the correct assembly of the α and β subunits of the F1-ATP synthase (Wang and 
Ackerman 2000; Wang et al. 2001). This putative interactor was selected for further verification given 
parkin’s important role in mitochondrial health, and ATPAF1 being the only mitochondrial-associated 
protein identified in the Y2H screen. While the nature and consequence of the interaction of parkin 
with ATPAF1 is unclear, disruption of this interaction could conceivably influence mitochondrial 
energetics. This may of relevance to PD and neurodegeneration (Petrozzi et al. 2007).  
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3.2.2.3 γ-Actin 
The association between parkin and the cytoskeleton has been well established. Parkin associates with 
microtubules and promotes the ubiquitination and proteasomal degradation of α-tubulin and β-tubulin 
(Ren et al. 2003). It has also been demonstrated that parkin co-localizes with actin filaments in 
neuronal cells (Huynh et al 2000). Parkin is known to interact with LIM kinase-1, which 
phosphorylates cofilin, an actin depolymeration enzyme (Lim et al. 2007). It has also been shown that 
parkin overexpression reduces LIM kinase-1 induced actin filament accumulation, suggesting that 
parkin contributes to the regulation of actin accumulation. It would therefore be worthwhile to 
characterize this interaction of parkin and gamma-actin (γ-actin) further, particularly as the 
accumulation of actin has been associated with apoptosis and neurodegeneration (Gourlay and 
Ayscough 2005; Fulga et al. 2007).  
 
3.2.2.4 Septin 9 (SEPT9) 
Septins, including SEPT9, are GTPases that interact with the cytoskeleton and contribute to cellular 
processes such as cytokinesis, motility and cell polarity (Field and Kellogg 1999). Two members of 
the septin family, septins 2 (SEPT2) and 4 (SEPT4), were previously identified in neurofibrillary 
tangles and senile plaques in brains affected by Alzheimer’s disease (Kinoshita et al. 1998). This 
supports the involvement of septins in neurodegeneration. 
Parkin is known to interact with, ubiquitinate and promote the degradation of septin 5 (SEPT5; also 
known as CDCrel-1) (Zhang et al. 2000).  A similar study found a further functional interaction 
between parkin and septin 4 (Choi 2003). Both septins 4 and 5 accumulate in the brains of patients 
with EOPD (Choi 2003; Shehadeh et al. 2009), suggesting an important functional relationship 
between parkin and septin proteins.  
While SEPT9 has not been implicated in neurodegeneration to date, the putative parkin-SEPT9 
interaction warrants further study, given the demonstrated role of septin proteins as parkin interactors. 
In addition, the interaction between parkin and SEPT5 will be used as a positive control in subsequent 
analyses, as SEPT5 is known to accumulate within cells in the absence of parkin.   
 
3.2.3 Verification of four parkin interactors 
When identifying putative protein interactions using the Y2H system, it is pivotal to distinguish 
between true interactions and false positive results. Such false positive interactions might arise due to 
several factors: proteins observed to interact in yeast do so as fusion proteins and not as their native 
forms; observed interactions occur in the yeast nucleus, which does not necessarily imitate the 
Stellenbosch University  https://scholar.sun.ac.za
124 
 
subcellular localization of the proteins in neurons, or the observed interactions might be facilitated by 
the intracellular environment of the yeast cell (Serebriiskii et al. 2000; Guo et al. 2008). It is therefore 
important to perform experiments that verify the protein interactions in a setting that mimics the in 
vivo conditions as closely as possible.  
For this reason, two further, independent approaches were used to verify the four putative parkin 
interactions in a human SH-SY5Y neuroblastoma cell line: three-dimensional in vivo co-localization 
(Section 3.2.3.1) and co-IP (Section 3.2.3.2). In addition to the four identified parkin interactions, the 
previously-described interaction of parkin with SEPT5 (Zhang et al. 2000) will be used as a positive 
control in these experiments.   
 
3.2.3.1 In vivo co-localization of parkin and putative parkin interactors 
Immunocytochemistry followed by confocal microscopy imaging of stained SH-SY5Y cells were 
used to investigate the in vivo co-localization of endogenously-expressed parkin and each of the 
putative parkin interactors (Section 2.22). Furthermore, Z-stacking was employed in order to acquire 
and resolve fluorescent signals in all three dimensions, encompassing the entire volume of the imaged 
cell.  
The results of the co-localization analyses of each interacting pair are relayed in Figures 3.6 to 3.10. 
Each co-localization analysis was performed in triplicate (consisting of two to three imaged cells per 
replicate), of which one representative image of each interacting pair is shown in these figures. 
Illustrated in each figure is a single representative frame out of 25 frames collected in Z-stacks.  
Each of Figures 3.6 to 3.10 consists of three fluorescent images: fluorescence acquired in the green 
channel (Panel A of each figure) and fluorescence acquired in the red channel (Panel B), where the 
green and red fluorescence correspond to the localization of each of the two proteins under 
investigation, and an overlay of the fluorescence acquired in the green, red and blue channels (Panel 
C), where Hoechst H-33342 nuclear staining (blue fluorescence) was employed for orientation 
purposes. Panel D of each figure illustrates a software-generated image of the subcellular co-
localization of the protein pair, where yellow pixels indicate sites of co-localization. Co-localization is 
also diagrammatically represented as a scatter plot of the fluorescence acquired for each pixel (Panel 
E); green fluorescent intensity is plotted on the y-axis and red fluorescent intensity on the x-axis. 
Pixels with co-localizing green and red signals are represented in box 3 of the scatter plot (Panel E), 
where the threshold values for inclusion in box 3 were determined by the fluorescent intensity of 
single fluorophore-stained images of each protein of interest. Finally, each figure is accompanied by 
measures of the degree of co-localization as calculated by the imaging software (Panel F). The 
weighted co-localization coefficients of each color channel quantify the relative contribution of that 
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channel to the pixels of interest (ranging from 0 to 1.0); the overlap coefficient signifies the actual 
overlap of signals and represents the true degree of co-localization (ranging from 0 to 1.0), and the 
correlation R denotes the Pearson’s correlation coefficient of intensity distribution between the two 
color channels (ranging from -1.0 to 1.0) (Zinchuk et al. 2007; Dunn et al. 2011).  
 
Parkin and SEPT5 
As can be seen in Figure 3.6A, SEPT5 is highly expressed in nuclei as well as the cytosol of SH-
SY5Y cells. Parkin, on the other hand, is mainly localized to the cytosol, with little to no parkin 
staining observed in nuclei (Figure 3.6B). Parkin also demonstrates small punctuate staining behavior 
(e.g. upper left side of cell), which may represent the association of parkin with cellular organelles 
such as mitochondria (Narendra et al. 2008). Parkin and SEPT5 co-localize in the cytosol (Figure 
3.6D), with the co-localization being particularly prominent in the uppermost neuronal projection of 
  
   
 
 
 
 
  
 
 
 
 
Figure 3.6 Florescent imaging and co-localization analysis of parkin and SEPT5. SH-SY5Y cells 
were immunocytochemically stained with primary antibodies directed against parkin and SEPT5 as 
well as appropriate fluorophore-conjugated secondary antibodies. A, localization of SEPT5 stained 
with Alexa488 (green). B, localization of parkin stained with Cy3 (red). Parkin punctae are indicated 
by a white arrow. C, overlay of red, green and Hoechst nuclear (blue) fluorescent signals. D, Co-
localization of green and red signals. E, scatter plot of signal intensity in green and red channels, 
where pixels in box 3 represent co-localizing signals. F, quantitative measures of co-localization of 
parkin and SEPT5.  
Weighted co-localization 
coefficient (green) 
0.149 
Weighted co-localization 
coefficient (red) 
0.236 
Overlap coefficient 0.41 
Correlation R 0.04 
 
A                          SEPT5      B                 Parkin       C       Overlay 
 
 
 
 
 
D            Co-localization      E              F 
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the imaged cell. The successful co-localization of parkin and SEPT5 is further reflected in the overlap 
coefficient of 0.41 (Figure 3.6F). While low values for the weighted co-localization coefficients of 
parkin (0.236) and SEPT5 (0.149) and the correlation R (0.04) were obtained, this is consistent with a 
model of transiently-interacting proteins, where only a small fraction of parkin is expected to be 
interacting with SEPT5 (and only a small fraction of SEPT5 with parkin) at a given time point.    
 
Parkin and SEPT9 
SEPT9 is observed throughout the cytosol and the nuclei (Figure 3.7A). Interestingly, SEPT9 adopts a 
fibrillar structure in the perinuclear area, which may be related to its function (Surka et al. 2002). The 
successful co-localization of parkin and SEPT9 is visually represented in Figure 3.7D, where the two 
proteins co-localize in the cytosol of SH-SY5Y cells. This co-localization is mainly in the central (but 
not nuclear) parts of the cells.   
 
     
  
 
 
 
 
   
 
 
 
  
 
Figure 3.7 Florescent imaging and co-localization analysis of parkin and SEPT9. SH-SY5Y cells 
were immunocytochemically stained with primary antibodies directed against parkin and SEPT9 as 
well as appropriate fluorophore-conjugated secondary antibodies. A, localization of SEPT9 stained 
with Alexa488 (green). B, localization of parkin stained with Cy3 (red). C, overlay of red, green and 
Hoechst nuclear (blue) fluorescent signals. D, Co-localization of green and red signals. E, scatter plot 
of signal intensity in green and red channels, where pixels in box 3 represent co-localizing signals. F, 
quantitative measures of co-localization of parkin and SEPT9.  
Weighted co-localization 
coefficient (green) 
0.073 
Weighted co-localization 
coefficient (red) 
0.476 
Overlap coefficient 0.34 
Correlation R 0.03 
 
A                            SEPT9     B                   Parkin     C        Overlay 
 
 
 
 
 
D              Co-localization     E              F 
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Parkin and ATPAF1 
ATPAF1-positive staining was observed throughout the cytosol, as well as strong staining in the cell 
nuclei (Figure 3.8A). The regions of intense staining within nuclei are likely due to high expression of 
this protein within nucleoli. While cytosolic ATPAF1 is mostly dispersed in a diffuse fashion, some 
punctuate staining can be seen towards the left side of Figure 3.8A. Parkin “punctae” are clearly 
visible in the cytosol on these cells (Figure 3.8B). ATPAF1 and parkin co-localize somewhat 
irregularly in the cytosol (Figure 3.8D). No co-localization was found in the nuclei. Interestingly, 
some of the observed co-localization correspond to the aforementioned punctae (lower left area of 
Figure 3.8D), which may indicate the dual recruitment of these proteins to the same cellular locations.     
 
 
   
 
 
 
 
 
  
 
 
 
 
 
Figure 3.8 Florescent imaging and co-localization analysis of parkin and ATPAF1. SH-SY5Y 
cells were immunocytochemically stained with primary antibodies directed against parkin and 
ATPAF1 as well as appropriate fluorophore-conjugated secondary antibodies. Punctuate staining is 
indicated by white arrows. A, localization of ATPAF1 stained with Alexa488 (green). B, localization 
of parkin stained with Cy3 (red). C, overlay of red, green and Hoechst nuclear (blue) fluorescent 
signals. D, Co-localization of green and red signals. E, scatter plot of signal intensity in green and red 
channels, where pixels in box 3 represent co-localizing signals. F, quantitative measures of co-
localization of parkin and ATPAF1.  
 
Weighted co-localization 
coefficient (green) 
0.061 
Weighted co-localization 
coefficient (red) 
0.576 
Overlap coefficient 0.41 
Correlation R 0.22 
 
A                           ATPAF1   B                   Parkin    C       Overlay 
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Parkin and 14-3-3η 
The 14-3-3η protein is found in the cytosol, nuclei and nucleoli (Figure 3.9A). Some co-localization 
of parkin and 14-3-3η is seen in cytosol, but not the nuclei, of SH-SY5Y cells (Figure 3.9D). The co-
localization of these proteins is supported by the overlap coefficient of 0.41 (Figure 3.9F).    
 
   
 
 
 
 
 
  
 
 
 
 
 
Figure 3.9 Florescent imaging and co-localization analysis of parkin and 14-3-3η. SH-SY5Y cells 
were immunocytochemically stained with primary antibodies directed against parkin and 14-3-3η as 
well as appropriate fluorophore-conjugated secondary antibodies. A, localization of 14-3-3η stained 
with Alexa488 (green). B, localization of parkin stained with Cy3 (red). C, overlay of red, green and 
Hoechst nuclear (blue) fluorescent signals. D, Co-localization of green and red signals. E, scatter plot 
of signal intensity in green and red channels, where pixels in box 3 represent co-localizing signals. F, 
quantitative measures of co-localization of parkin and 14-3-3η.  
 
Parkin and cytoskeletal actin 
It should be noted that the anti-γ-actin antibody used in this study is also likely to recognize the β-
actin isoform (according to the manufacturer). This is due to the very high sequence similarity 
between these two cytoskeletal actin isoforms. Hence, it cannot be assumed that the results obtained 
here is specific to the γ-actin isoform only. This dissertation will therefore refer to cytoskeletal actin 
instead of γ-actin to reflect this distinction. In contrast with the other co-localization analyses, the 
cells that were stained for the co-localization analysis of parkin and γ-actin were fixed with methanol 
Weighted co-localization 
coefficient (green) 
0.037 
Weighted co-localization 
coefficient (red) 
0.453 
Overlap coefficient 0.41 
Correlation R 0.09 
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instead of paraformaldehyde (Section 2.22.2). This was done as methanol fixation is better suited to 
preserving cytoskeletal fine-structure than paraformaldehyde, and was therefore appropriate for the 
imaging of actin. Actin demonstrated strong staining along the cytoskeletal filaments and the plasma 
membrane (Figure 3.10B). Interestingly, methanol-fixed parkin showed strand-like staining behavior 
in the cytosol which was not as evident in paraformaldehyde-fixed cells (Figure 3.10A). The 
substantial co-localization of parkin and cytoskeletal actin along actin filaments in the cytosol and 
along the plasma membrane is shown in Figure 3.10D.    
 
                    
 
 
 
 
          F 
 
 
 
 
 
 
Figure 3.10 Florescent imaging and co-localization analysis of parkin and actin. SH-SY5Y cells 
were immunocytochemically stained with primary antibodies directed against parkin and γ-actin as 
well as appropriate fluorophore-conjugated secondary antibodies. A, localization of parkin stained 
with Alexa488 (green). B, localization of γ-actin (and β-actin) stained with Cy3 (red). C, overlay of 
red, green and Hoechst nuclear (blue) fluorescent signals. D, Co-localization of green and red signals. 
E, scatter plot of signal intensity in green and red channels, where pixels in box 3 represent co-
localizing signals. F, quantitative measures of co-localization of parkin and actin.  
 
In summary, all five of the putative parkin interactors (SEPT5, SEPT9, ATPAF1, 14-3-3η and 
cytoskeletal actin) that were investigated, co-localize with parkin to a sufficient degree; i.e. a 
significant fraction of each protein of interest was localized to the same subcellular localization as 
parkin. These co-localization analyses therefore support the plausibility of the putative protein 
interactions.  
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3.2.3.2 Co-IP of parkin and putative parkin interactors 
While in vivo co-localization analyses provided evidence for the physical proximity of parkin and the 
putative parkin interactors in SH-SY5Y cells, further verification was needed to demonstrate physical 
interaction of these proteins. Co-IPs of each protein pair were therefore performed, where each 
endogenous protein was immunoprecipitated out of SH-SY5Y whole cell lysate (along with any 
interacting proteins), after which western blotting was used to test for the presence of the interacting 
partner (Sections 2.22 and 2.23).   
Two control co-IPs were performed concurrent to each experiment: immunoprecipitation with an anti- 
hemagglutinin-tag (HA) antibody, and a protein G agarose control without any antibody. The use of 
these negative controls validated the specificity and authenticity of the obtained results.  
The results of the co-IP experiments are shown in Figure 3.11. All five of the investigated parkin 
interactors (SEPT5, SEPT9, ATPAF1, 14-3-3η and γ-actin) were co-immunoprecipitated with parkin 
(Figure 3.11, left column). Reciprocally, parkin was co-immunoprecipitated with each of the proteins 
of interest (Figure 3.11, right column). No protein bands were visible in either of the two control lanes 
(labeled HA and Prot. G), demonstrating that the observed co-IPs are not spurious but the result of 
true interactions between parkin and the investigated parkin interactors.    
Notably, in initial co-IP experiments involving parkin and SEPT9, it was found that, while parkin was 
present in a SEPT9 precipitate, the reciprocal co-IP of SEPT9 along with parkin could not be achieved 
(results not shown). This one-directional co-IP persisted during several repeat experiments. However, 
it was found that the use of a different anti-parkin antibody (Sigma-Aldrich, PRK8), which recognizes 
a different epitope on the parkin protein, did produce a successful co-IP of parkin and SEPT9 (Figure 
3.11B, left column). This discrepancy could possibly be due to the binding site of SEPT9 on the 
parkin protein: binding of these two proteins may obscure the epitope for one anti-parkin antibody 
(preventing immunoprecipitation) without affecting the epitope of another antibody.   
Initial co-IP of cytoskeletal actin along with parkin revealed binding of the anti-γ-actin antibody to 
proteins in both of the control lanes (results not shown). In order to overcome the non-specific binding 
of this antibody in this immunoprecipitation application, a different antibody raised against β-actin 
(Cell Signaling, #4970) was used to detect both β-actin and γ-actin isoforms in the parkin-
immunoprecipitated lysate. According to the manufacturer, the β-actin antibody is not specific to the 
β-actin isoform only, due to the high homology of these isoforms (similar as to the γ-actin antibody). 
Probing with this β-actin antibody produced a positive and specific co-IP result (Figure 3.11E, left 
column).  
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A 
IP: parkin                         IP: SEPT5 
WB: SEPT5                         WB: parkin 
 
B 
IP: parkin                         IP: SEPT9 
WB: SEPT9                         WB: parkin 
 
C 
IP: parkin                         IP: ATPAF1 
WB: ATPAF1                         WB: parkin 
 
D 
IP: parkin                         IP: 14-3-3η 
WB: 14-3-3η                         WB: parkin 
 
E 
IP: parkin                         IP: γ-actin 
WB: β-actin                         WB: parkin 
 
Figure 3.11 Co-IP of parkin and putative parkin interactors.  Endogenous proteins were 
immunoprecipitated out of SH-SY5Y cell lysates and tested for the presence of the putative interactor 
via western blot. Reciprocal co-IPs were performed for each protein pair. Numbers on the right-hand 
side of western blots denote protein sizes (in kDa) Extra bands in C were removed for cosmetic effect. 
A, co-IP of parkin and SEPT5. B, co-IP of parkin and SEPT9. C, co-IP of parkin and ATPAF1. D, co-
IP of parkin and 14-3-3η. E, co-IP of parkin and β/γ-actin. Abbreviations: co-IP, co-
immunoprecipitation; HA, hemagglutinin-tag antibody control; IP, immunoprecipitation; kDa, 
kiloDalton; Prot. G, protein G agarose control; WB, western blot; WCE, whole cell extract. 
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As stated, the antibodies used could not distinguish whether parkin interacts with the γ-isoform only 
or with both the β- and γ-actin isoforms, but this uncertainty was overlooked given the extremely high 
sequence similarity (99%) and near-complete functional overlap of the two cytoskeletal actin 
isoforms. In fact, while the insert sequence of the Y2H clone used to identify γ-actin as a parkin-
interacting protein (Section 3.2.1.6) had a higher nucleotide match with ACTG1 (100% identity) than 
with ACTB (92% identity), the in silico translated sequence had a 100% identity to both actin isoforms 
(Figure 3.12). This strongly suggests that parkin interacts with the protein region common to both 
isoforms.   
 
 β-Actin      MDDDIAALVVDNGSGMCKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEAQS 60 
 γ-Actin      MEEEIAALVIDNGSGMCKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEAQS 60 
 ORF          ----------------------------------------------MGQKDSYVGDEAQS 14 
                                                            ************** 
 
 β-Actin      KRGILTLKYPIEHGIVTNWDDMEKIWHHTFYNELRVAPEEHPVLLTEAPLNPKANREKMT 120 
 γ-Actin      KRGILTLKYPIEHGIVTNWDDMEKIWHHTFYNELRVAPEEHPVLLTEAPLNPKANREKMT 120 
 ORF          KRGILTLKYPIEHGIVTNWDDMEKIWHHTFYNELRVAPEEHPVLLTEAPLNPKANREKMT 74 
              ************************************************************ 
 
 β-Actin      QIMFETFNTPAMYVAIQAVLSLYASGRTTGIVMDSGDGVTHTVPIYEGYALPHAILRLDL 180 
 γ-Actin      QIMFETFNTPAMYVAIQAVLSLYASGRTTGIVMDSGDGVTHTVPIYEGYALPHAILRLDL 180 
 ORF          QIMFETFNTPAMYVAIQAVLSLYASGRTTGIVMDSGDGVTHTVPIYEGYALPHAILRLDL 134 
              ************************************************************ 
 
 β-Actin      AGRDLTDYLMKILTERGYSFTTTAEREIVRDIKEKLCYVALDFEQEMATAASSSSLEKSY 240 
 γ-Actin      AGRDLTDYLMKILTERGYSFTTTAEREIVRDIKEKLCYVALDFEQEMATAASSSSLEKSY 240 
 ORF          AGRDLTDYLMKILTERGYSFTTTAEREIVRDIKEKLCYVALDFEQEMATAASSSSLEKSY 194 
              ************************************************************ 
 
 β-Actin      ELPDGQVITIGNERFRCPEALFQPSFLGMESCGIHETTFNSIMKCDVDIRKDLYANTVLS 300 
 γ-Actin      ELPDGQVITIGNERFRCPEALFQPSFLGMESCGIHETTFNSIMKCDVDIRKDLYANTVLS 300 
 ORF          ELPDGQVITIGNERFRCPEALFQPSFLGMESCGIHETTFNSIMKCDVDIRKDLYANTVLS 254 
              ************************************************************ 
 
 β-Actin      GGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWISKQ 360 
 γ-Actin      GGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWISKQ 360 
 ORF          GGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWISKQ 314 
              ************************************************************ 
 
 β-Actin      EYDESGPSIVHRKCF 375 
 γ-Actin      EYDESGPSIVHRKCF 375 
 ORF          EYDESGPSIVHRKCF 329 
              *************** 
 
Figure 3.12 Protein alignment of translated ORF sequence of Y2H clone 319 with actin 
isoforms. Protein sequence of clone 319 had a 100% identity to both the β- and γ-actin isoforms. In 
silico alignment was performed with CLUSTAL O 1.2.1 (http://www.ebi.ac.uk/Tools/msa/clustalo). 
 
In summary, both in vivo co-localization and co-IP experiments demonstrated that the interaction of 
parkin with SEPT9, ATPAF1, 14-3-3η and cytoskeletal actin, originally identified in a Y2H library 
screen, are in fact true interactions. 
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3.2.4 Effect of parkin deficiency on protein levels of parkin interactors 
The functional consequence of the verified interactions of parkin with SEPT9, ATPAF1, 14-3-3η and 
actin were investigated in cellular models of parkin deficiency. Given parkin’s role in targeting many 
of its interactors for proteasomal degradation, the absence of functional parkin might result in the 
accumulation of such UPS-substrates. This loss-of-parkin-dependent accumulation has been 
demonstrated for many parkin substrates, including cyclin E (Staropoli et al. 2003), AIMP2 (Corti et 
al. 2003), PARIS (Shin et al. 2011) and FAF1 (Sul et al. 2013).  Hence, accumulation of a parkin 
interactor in the absence of parkin would support the role of such an interactor as an authentic 
substrate for parkin K48-linked ubiquitination and proteasomal degradation. The previously described 
accumulation of SEPT5 (Zhang et al. 2000) will be used as a positive control in these experiments.    
 
3.2.4.1 In an RNAi-mediated parkin knockdown model 
The present study aimed to create an RNAi-mediated cell model of parkin deficiency, by using siRNA 
transfection to bring about the targeted knockdown of parkin in cultured SH-SY5Y cells. Of the four 
siRNA molecules tested, only two (Hs_PARK2_8 and Hs_PARK2_10) demonstrated an effect on 
parkin mRNA expression as determined by q-RT-PCR. Transfection with either of these siRNA 
molecules (henceforth referred to as siRNA’s 8 and 10, respectively) decreased the expression of 
parkin mRNA by 50-55%, in comparison to cells transfected with a non-silencing control siRNA 
(Figure 3.13). This result was consistent across three separate experimental runs. 
 
 
 
 
 
 
 
Figure 3.13 q-RT-PCR analysis of parkin mRNA expression following siRNA transfection. SH-
SY5Y cells were treated with 5nM of siRNA’s 8, 10 or a non-silencing control for 48h. Parkin 
mRNA expression was normalized to the expression of GAPDH, B2M and RPL13A reference genes. 
Relative mRNA expression is shown as mean ± SD, N=3. Asterisks indicate significance (p<0.05) 
upon unpaired t-testing (8: p=0.0025; 10: p=0.0012). Abbreviations: 8, Hs_PARK2_8 siRNA; 10, 
Hs_PARK2_10 siRNA; N, experimental runs; NSC, non-silencing control; SD, standard deviation.  
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When validating siRNA molecules for RNAi experiments, it is important to determine gene 
knockdown efficiency on both a mRNA and a protein level, as the optimal experimental conditions 
for protein knockdown may differ from that of mRNA knockdown (Shan 2010). Therefore, both 
siRNA’s 8 and 10 were subjected to further knockdown efficiency validation via western blot.    
Initial western blot experiments of siRNA-treated SH-SY5Y cells showed that neither siRNA 
molecule had an observable effect on parkin protein expression (results not shown). Consequently, 
siRNA transfection conditions were modified by increasing siRNA concentration from 5nM to 50nM, 
as well as by increasing siRNA treatment time from 48h to 72h. The siRNA concentration was 
increased in effort to improve siRNA transfection efficiency, whereas a longer incubation period may 
be necessary for parkin protein already expressed at the time of transfection to be degraded. Initial 
experiments showed that transfection of siRNA’s 8 and 10 at these modified conditions resulted in 
90% and 75% parkin knockdown, respectively (Figure 3.14A). However, multiple repeat experiments 
using the same transfection conditions failed to replicate these results consistently. Repeat 
transfections resulted in either only one of the siRNA’s demonstrating sufficient knockdown of parkin 
(Figure 3.14B) or neither having a significant effect (Figure 3.14C).  
 
 
  
 
 
 
 
 
 
 
Figure 3.14 Parkin protein expression following siRNA transfection. SH-SY5Y cells were treated 
with 50nM of siRNA’s 8, 10 or a non-silencing control (NSC) for 72h. Parkin expression (top lanes, 
52 kDa) was normalized to GAPDH expression (bottom lanes, 36 kDa). Relative expression was 
calculated relative to NSC. Parkin knockdown efficiency of 8 and 10 was inconsistent across 
numerous experimental runs, with representative results illustrated here. A, successful knockdown by 
both siRNA’s. B, successful knockdown by only one siRNA. C, unsuccessful knockdown by both 
siRNA’s. Abbreviations: 8, Hs_PARK2_8 siRNA; 10, Hs_PARK2_10 siRNA; kDa, kiloDalton; 
NSC, non-silencing control.  
52 -  
36 -  
           8              10           NSC            8              10         NSC            8            10          NSC 
A                                                     B                                                   C 
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Due to the inconsistency in knockdown ability at the protein level, it could not be confidently 
assumed that parkin is sufficiently knocked down following transfections with either of the two tested 
siRNA molecules. It is pivotal in downstream experiments that successful parkin knockdown can be 
implicitly assumed, as many of these downstream applications do not allow for parkin knockdown to 
be directly confirmed. For that reason, it was decided to use an alternative approach to investigate the 
functional effects of parkin deficiency.  
 
3.2.4.2 In fibroblasts from patients with parkin mutations  
Primary fibroblasts obtained from patients with parkin mutations are commonly used as cellular 
models of parkin dysfunction (Auburger et al. 2012). In particular, the use of fibroblasts with 
homozygous parkin mutations that grossly destabilize or truncate the protein, such as whole exonic 
deletions, provide cell models without any functional parkin (Mortiboys et al. 2008; Grunewald et al. 
2010; Pacelli et al. 2011). Such parkin-null cell models are therefore valuable in the investigation of 
the functional effects of parkin deficiency, and will be employed in the present study as an alternative 
to RNAi-mediated parkin knockdown SH-SY5Y cells. While dermal fibroblasts may have several 
drawbacks in comparison to neuronal cells when studying neurodegeneration-related proteins, it is 
advantageous over RNAi-generated cell models in many regards. Of relevance to the current study, 
fibroblasts with predefined parkin mutations do not require repeated and transient genetic 
manipulation to bring about the loss of parkin. Parkin-mutant fibroblasts were therefore used as a 
robust and stable model of parkin deficiency.  
Fibroblasts were obtained from three South African PD patients with parkin-null mutations, as 
identified by parkin mutation screening in this dissertation (Section 3.1.2), and who consented to skin 
punch biopsies. This included patient 23 with a homozygous exon 3-4 deletion (henceforth referred to 
as P1), as well as the affected sibling of patient 16 and the proband (patient 16), both with 
homozygous exon 4 deletions, which will be referred to as P2 and P3, respectively. P2, which was not 
included as a proband in the initial parkin genetic screen, has been examined by a movement disorder 
specialist. Three wild-type parkin fibroblast cell lines, namely WT2, WT3 and WT4, were used as 
age- and gender-matched controls. These samples were not re-labeled for the purposes of this study in 
order to ensure consistency of sample labeling in experiments by other members of our research team. 
All three patients were initially available for the current study. However, due to extensive microbial 
contamination of P1’s fibroblasts, these cells had to be discarded and P1 was therefore not available 
for any of the functional studies in this dissertation.  
The functional effect of parkin deficiency on the protein expression levels of each of the four parkin 
interactors was investigated in patient-derived and wild-type fibroblasts. Here, western blots and 
densitometry was used to assay the relative expression of each parkin interactor (Figure 3.15A-D). 
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Figure 3.15 Protein expression levels of parkin interactors in patient-derived and control 
fibroblasts. Relative protein expression of (A) ATPAF1, (B) SEPT9, (C) γ-actin and (B) 14-3-3η  
was assayed with western blots in fibroblasts from patients with parkin mutations (P2 and P3) and 
wild-type controls (WT2, WT3, WT4). Expression of interactors (top lanes) was normalized to 
GAPDH expression (bottom lanes). Experiment was performed in triplicate (N=3) of which one 
representative western blot is shown for each interactor; all three replicate western blots can be found 
in Appendix VIII. Numbers on the side of western blots denote protein sizes (in kDa). Box-and-
whisker plots depict relative protein densitometric measurements for three experimental runs. 
Abbreviations: AU, arbitrary units; kDa, kiloDalton; P, patient; WT, wild-type. 
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Each interactor was immunoblotted in three separate experimental runs in whole cell lysates from 
each of P2, P3, WT2, WT3 and WT4 cells. New lysates were obtained from three successive passages 
of each cell line for every experimental run. Lysates were simultaneously blotted for GAPDH 
expression, which served as a loading control and allowed for normalization of protein expression 
across different samples. Relative protein expression of each parkin interactor was calculated across 
all three experimental runs, as illustrated in Figure 3.15. As some variation was seen in protein 
expression levels among the three wild-type fibroblasts, relative protein levels were not scaled or 
expressed as a percentage of a given control.  
For each parkin interactor, comparisons of grouped patient fibroblasts vs. grouped wild-type control 
fibroblasts were performed using mixed-effects linear modeling. Modeled effect sizes for each of the 
two groups are depicted in Figure 3.16. 
 
 
 
 
 
 
 
Figure 3.16 Mixed-effects linear modeling of protein expression levels in patients with parkin 
mutations and wild-type controls. Modeled effect sizes (differences between patients and controls) 
are shown with 95% confidence intervals (CI). Effect sizes with non-overlapping CI differ 
significantly (p<0.05) and are indicated by an asterisk. A, ATPAF1; B, SEPT9; C, γ-actin; D, 14-3-
3η. Abbreviations: AU, arbitrary units; CI, confidence intervals; P, patient; WT, wild-type. 
 
As can be seen in Figure 3.16A, ATPAF1 was found to strongly accumulate in patient-derived 
fibroblasts in comparison to wild-type controls (p=0.0004). Similarly, the protein expression levels of 
SEPT9 was marked higher in patients (p=0.0003; Figure 3.16). It should be noted that, for both 
proteins, little or no accumulation was seen in P2 (Figure 3.15). It is unclear why accumulation of 
ATPAF1 and SEPT9 was not seen in this one patient with parkin mutations. It should furthermore be 
noted that P2 and P3 are siblings, and the results obtained from this limited dataset should be 
interpreted with caution.  
In contrast to the accumulation of ATPAF1 and SEPT9 in patients, the protein expression of 
cytoskeletal actin (as probed by a γ-actin antibody) was similar in patient-derived and wild-type 
fibroblasts (p=0.8632, Figure 3.16C). Hence, parkin deficiency had no observable effect on the 
    ATPAF1         SEPT9                             γ-Actin             14-3-3η 
A           B        C                     D 
  *        * 
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steady-state protein level of actin. Similarly, the protein expression of 14-3-3η was comparable 
between patients and wild-type controls (p=0.5099; Figure 3.16D). 
Unfortunately, the previously described accumulation of SEPT5 (Zhang et al. 2000) could not be used 
as a positive control in these fibroblast models, as this protein is not expressed in fibroblasts to a 
detectable degree (Beites et al. 1999). Immunoblotting with an anti-SEPT5 antibody failed to detect 
this protein in fibroblast cell lysates (results not shown). 
In summary, it was found that the parkin-null fibroblasts had substantially higher protein levels of 
both ATPAF1 and SEPT9 than the wild-type fibroblasts. This is consistent with a model wherein 
ATPAF1 and SEPT9 are authentic parkin substrates, which accumulate in the absence of parkin. 
While a marked accumulation of these two proteins was found in P3, their expression levels were 
similar in P2 in comparison to wild-type fibroblasts. It is interesting to consider that some unknown 
compensatory pathway may be suppressing the accumulation of these parkin substrates in the P2 
fibroblast cell line. Importantly, actin and 14-3-3η did not accumulate in the parkin-null fibroblasts, 
which may suggest that the observed accumulation of ATPAF1 and SEPT9 is due to specific parkin-
substrate interactions with these proteins.      
 
3.3 FUNCTIONAL STUDIES IN A PARKIN-DEFICIENT CELLULAR MODEL 
As two of the parkin-interacting proteins (ATPAF1 and SEPT9) were shown to accumulate in patient-
derived fibroblasts, it was aimed to investigate the possible functional effects of such accumulation on 
cellular health. This protein accumulation may contribute to previously-described mitochondrial 
impairments in parkin-mutant fibroblasts (Mortiboys et al. 2008; Grunewald et al. 2010; Pacelli et al. 
2011). Therefore, a range of experiments were undertaken in order to assess various aspects of 
cellular and mitochondrial function in a parkin-deficient cellular model. These included cell growth 
and viability assays (Section 3.3.1), mitochondrial respiration analysis (Section 3.3.2), Δψm analysis 
(Section 2.3.3) and mitochondrial network analysis (Section 2.3.4). Unless stated otherwise, all results 
refer to comparisons of grouped patient-derived vs. grouped wild-type fibroblasts. Graphical 
depictions of results obtained for individual fibroblast cell lines can be found in Appendix IX.   
 
3.3.1 Cell growth and viability assays 
Two complementary assays, a CyQUANT® assay of cell growth and a MTT assay of cell viability, 
were performed to determine whether the overall states of cellular health differed between patient-
derived and wild-type fibroblasts (Section 2.26). These two assays were performed simultaneously in 
parallel plates, the results of which are shown in Figure 3.17.  
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Figure 3.17 Cell growth and viability in patient-derived and wild-type fibroblasts under basal 
and CCCP-stressed conditions. Left panels represent cell growth as assessed by a CyQUANT® 
assay, whereas right panels represent cell viability as assessed by a MTT assay. Box-and-whisker 
plots depict grouped patients (P) and wild-type (WT) measurements for three experimental runs. A, 
cell growth and viability under basal (untreated) conditions. B, cell growth and viability after 
treatment with 10μM CCCP for 24h. C, comparison of cell growth and viability under basal and 
stressed conditions. Abbreviations: AU, arbitrary units; P, patient; WT, wild-type. 
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It was found that cell growth was significantly higher in patient-derived fibroblasts than controls 
under basal conditions (p=0.0001; Figure 3.17A, left panel). In contrast, cell viability was similar in 
all fibroblasts cell lines under basal conditions (p=0.7843; Figure 3.17A, right panel).  
Cell growth and viability of the fibroblasts were also assessed under conditions of cellular stress, as 
any differences between patient-derived and wild-type cells may not be readily apparent under basal 
conditions. Here, the fibroblasts were treated with CCCP to induce mitochondrial impairment, and 
subsequent parkin recruitment to damaged mitochondria. It was found that both cell growth and cell 
viability were similar in all fibroblasts cell lines even after CCCP treatment (p=0.0922 and 0.7815, 
respectively; Figure 3.17B). However, a comparison of the effect of CCCP treatment within each 
fibroblast group (i.e. with and without cellular stress) demonstrated that the growth of patient-derived 
fibroblasts was significantly more suppressed by CCCP than the growth of wild-type fibroblasts 
(p=0.0013; Figure 3.17C, left panel). This is indicative of a heightened sensitivity to CCCP of patient-
derived fibroblasts in comparison to wild-type fibroblasts.  
In contrast, the cell viability was seemingly enhanced in all fibroblasts cell lines after treatment with 
the cytotoxic compound CCCP (p=0.0004; Figure 3.17C, right panel), but this effect was similar in 
patient-derived and wild-type fibroblasts (p=0.7226). This contradictory and perplexing result is best 
explained as an artefact of the MTT assay: it is possible that CCCP-treated cells reduce MTT to 
formazan at a greater rate than untreated cells not because they are more viable, but because CCCP 
artificially alters the rate of MTT reduction. Indeed, this high susceptibility to treatment-induced 
artefacts is a well-known limitation of the MTT assay (Berridge et al. 2005). The alternative scenario, 
i.e. increased cell viability in the presence of CCCP, contradicts the established cytotoxic properties of 
this mitochondrial depolarizing agent (Narendra et al. 2008).        
 
3.3.2 Mitochondrial respiration analysis 
Given the important role of parkin in maintaining mitochondrial health, it was decided to specifically 
compare parkin-mutant and wild-type fibroblasts in regards to various parameters of mitochondrial 
function. Therefore, rates of mitochondrial respiration were evaluated.  
Respiration analyses were performed using a Seahorse Extracellular Flux Analyzer (Section 2.27). 
This allowed for a series of measurements to be taken of the oxygen consumption rate (OCR) of each 
fibroblast population, where pharmacological inhibitors were sequentially added to the cells in order 
to probe the function of individual components of the mitochondrial respiratory chain. All OCR 
readings were normalized to cell number, as determined by a CyQUANT® assay. The overall 
respiratory responses of all patient-derived and wild-type fibroblasts are illustrated in Figure 3.18A, 
from which several important respiratory parameters can be assessed (Figure 3.18B). 
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Figure 3.18 Respiratory flux profile of patient-derived and wild-type fibroblasts. Respiratory flux 
was determined with a Seahorse Extracellular Flux Analyzer by twelve consecutive measurements of 
oxygen consumption rate (OCR). Addition of ATP synthase inhibitor oligomycin, ETC uncoupler 
FCCP and complex I and III inhibitors rotenone and antimycin A are indicated. A, respiratory flux 
profiles of patient-derived and wild-type fibroblasts. Results are expressed as mean ± SEM. B, a 
representative respiratory flux profile indicating various parameters of respiratory control. These 
include: OCR due to non-mitochondrial respiration (rotenone/antimycin A response); basal 
mitochondrial OCR (basal measurement – rotenone/antimycin A response); ATP-linked OCR (basal 
measurement – oligomycin response); OCR due to proton leak (oligomycin response - 
rotenone/antimycin A response); ATP coupling efficiency (basal mitochondrial OCR / ATP-linked 
OCR); maximum OCR (FCCP response - rotenone/antimycin A response) and spare respiratory 
capacity (maximum OCR / basal mitochondrial OCR). Abbreviations: AU, arbitrary units, OCR, 
oxygen consumption rate; P, patient; SEM, standard error of the mea7n; WT, wild-type.   
A           
B           
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A comparison of these parameters in grouped parkin-mutant and wild-type control fibroblasts is given 
in Figure 3.19. As can be seen in Figure 3.19A, patient-derived fibroblasts had a higher mitochondrial 
respiration than wild-type fibroblasts under basal conditions (p=0.0355). This mitochondrial 
respiration is composed of two components: the oxygen consumption devoted to ATP synthesis, and 
the oxygen consumption required to overcome the natural proton leak across the inner mitochondrial 
membrane. The addition of the ATP synthase inhibitor oligomycin allowed for these contributory 
components to be isolated. While patient-derived fibroblasts had higher ATP-linked respiration than 
wild-type fibroblasts (p=0.0481; Figure 3.19B), the difference in proton leak between patient-derived 
and wild-type fibroblasts was more pronounced (p=0.0273; Figure 3.19C). In fact, a comparison of 
the ATP-coupling efficiency demonstrated that the patient-derived fibroblasts had a trend towards a 
lower coupling efficiency (≈80% OCR that is ATP-linked vs. ≈87% OCR that is ATP-linked in wild-
type fibroblasts), but this trend did not reach statistical significance (p=0.0983; Figure 3.19D).  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 3.19 Parameters of respiratory control in patient-derived and wild-type fibroblasts. Box-
and-whisker plots depict grouped patients (P) and wild-type (WT) values. A, basal mitochondrial 
OCR. B, ATP-linked OCR. C, OCR due to proton leak. D, ATP coupling efficiency (percentage OCR 
due to ATP synthesis). E, maximum OCR. F, percentage spare respiratory capacity. Abbreviations: 
AU, arbitrary units; OCR, oxygen consumption rate; P, patient; WT, wild-type.   
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The addition of the ETC-accelerator FCCP allowed for an estimation of the maximum, uncontrolled 
OCR. FCCP is an ionophore which directly transports protons across the inner mitochondrial 
membrane instead of via the ATP synthase proton channel. Hence, addition of FCCP collapses the 
Δψm, leading to a rapid consumption of oxygen without the generation of ATP. The fold difference 
between this maximal uncontrolled OCR and basal OCR is indicative of the spare respiratory capacity 
of cells. The maintenance of some spare respiratory capacity is a major determinant of cellular health 
and survival, as it allows for increased ATP synthesis in times of high energetic demand (Nicholls 
2009). This spare capacity is determined by several factors, including the functional capacity of the 
ETC. It was found that the patient-derived cells had a markedly higher maximum respiratory rate than 
control fibroblasts (p=0.0081; Figure 3.19E), whereas spare respiratory capacity was comparable 
between these two groups (p=0.2947; Figure 3.19F). However, it is important to note that significant 
differences were observed in these parameters between the two patient-derived fibroblast cell lines 
(Figure 3.20). Comparisons of P2 and P3 reveal that P2 had significantly higher maximum respiration 
(p=0.0016) and spare respiratory capacity (p<0.0001) than P3, whereas P3 was similar to wild-type 
fibroblasts in these regards.     
 
 
 
 
 
 
 
Figure 3.20 Maximum respiration and spare respiratory capacity in individual fibroblasts cell 
lines. Marked differences in the maximum respiration and spare respiratory capacity were observed 
between the two patient-derived fibroblast cell lines (P2 and P3). Abbreviations: AU, arbitrary units; 
OCR, oxygen consumption rate; P, patient; WT, wild-type.   
 
3.3.3 Mitochondrial membrane potential (Δψm) analysis 
As Δψm is a central parameter of mitochondrial integrity, it was decided to assess Δψm in the parkin-
mutant and wild-type fibroblasts. The fibroblasts were stained with the JC-1 potentiometric dye, and 
the green and red fluorescent emissions of each cell population were simultaneously measured by 
means of flow cytometry (Section 2.28). A representative experimental run of WT2 fibroblasts, as 
well as CCCP-treated depolarized WT2 is shown in Figure 3.21.  
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                               Untreated WT2 
 
 
 
 
 
 
 
           CCCP-treated WT2 
 
 
 
 
 
 
 
 
Figure 3.21 Bivariate flow cytometry analysis of JC-1 fluorescent emission in fibroblasts. A-D, 
representative experimental results of untreated WT2 fibroblasts. E-H, representative experimental 
results of CCCP-treated depolarized WT2 fibroblasts. For each JC-stained cell sample, several 
informative plots were generated. A, E, forward scatter/side scatter (FSC/SSC) plots. Debris and 
aggregates were gated out, with only the events enclosed in the black ovals analyzed further. B, F, 
fluorescent intensity histograms for green fluorescence (top panels) and red fluorescence (bottom 
panels). Fluorescent thresholds, as determined by fluorescence of unstained control cells, are 
demarcated by black bars. C, G, bivariate fluorescence depicted as logarithmic scatter plots, with 
fluorescent thresholds demarcated by crossbars. D, H, mean above-threshold green and red 
fluorescent intensities. These value were used to calculate the ratio of green:red fluorescent emission. 
Abbreviations: +, above threshold; -, below threshold; FSC/SSC, forward scatter/side scatter; WT, 
wild-type.  
 
Mean fluorescence red+        29.60 
Mean fluorescence green+    28.80 
Ratio red:green  1.05 
Mean fluorescence red+        2.80 
Mean fluorescence green+   63.80 
Ratio red:green                0.05  
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Each fibroblasts sample was assayed over three separate experimental runs, with 10 000 events 
collected per run. Differences in Δψm were detected by dissimilarities in red:green florescent emission 
ratios. The obtained red:green florescent emission ratios of the patient-derived and wild-type 
fibroblasts are graphically illustrated in Figure 3.22. No significant differences in Δψm were observed 
for parkin-derived and wild-type fibroblasts (p=0.1533). 
 
  
 
 
 
 
 
 
 
Figure 3.22 Relative Δψm of untreated patient-derived and wild-type fibroblasts. Relative Δψm 
was determined by JC-1 red:green fluorescent emission ratios. Similar Δψm was seen for patient-
derived (P) and wild-type (WT) fibroblasts (p=0.3285). Abbreviations: Δψm, mitochondrial membrane 
potential; P, patient; WT, wild-type.  
 
3.3.4 Mitochondrial network analysis  
As parkin is known to be involved in the regulation of mitochondrial dynamics, various parameters of 
mitochondrial morphology were assessed in the parkin-mutant and wild-type fibroblasts. This was 
done by means of live-cell microscopy and image analysis (Section 2.29). Approximately 40 cells 
were analyzed of each fibroblasts cell line, and representative images of P2 and WT2 fibroblasts are 
shown in Figures 3.23A and B, respectively. Each image was assessed in regards to two 
morphological parameters: the form factor (degree of mitochondrial branching) and the aspect ratio 
(degree of mitochondrial elongation). It was found that the form factor of patient-derived fibroblasts is 
significantly lower than that of wild-type controls (p=0.0306; Figure 3.23C). No significant 
differences were observed between the aspect ratios of patient-derived and wild-type fibroblasts 
(p=0.1654; Figure 3.23D).     
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Figure 3.23 Mitochondrial network analysis of patient-derived and wild-type fibroblasts. 
Mitotracker Red and live-cell microscopy was used to visualize the mitochondrial network. A, B, 
representative images of patient and wild-type cells. All images were assessed in regards to the degree 
of mitochondrial branching (form factor) and degree of mitochondrial elongation (aspect ratio) The 
distribution of these parameters in grouped patient-derived and grouped wild-type fibroblasts are 
represented on logarithmic scale in box-and-whisker-plots, N=40. C, comparison of form factor, 
which was significantly lower in patient cells than wild-type cells (p=0.0306). D, comparison of 
aspect ratio, which was similar in patient and wild-type cells (p=0.1654). Abbreviations: AU, arbitrary 
units; N; cells analyzed; P, patient; WT, wild-type.  
 
 
B           WT 
A                P 
C 
 
 
 
 
  
D 
 
 
 
 
  
Stellenbosch University  https://scholar.sun.ac.za
147 
 
3.4 VITAMIN K2 AS A POTENTIAL THERAPEUTIC MODALITY 
It was recently reported that supplementing the diets of parkin-mutant Drosophila with vitamin K2 
alleviated the mitochondrial defects of these mutants in a dose-dependent manner (Vos et al. 2012). 
This exciting discovery may be of therapeutic value, as treatment with vitamin K2 may similarly 
alleviate mitochondrial impairments in parkin-mutant human cells. Therefore, it was decided to 
perform a pilot study to investigate whether vitamin K2 treatment can modulate the functional 
differences seen in parkin-null and wild-type fibroblasts.   
 
3.4.1 Optimization of vitamin K2 concentration 
In the study by Vos et al (2012), mutant flies were placed on molasses medium supplemented with 
1mM vitamin K2, in the form of MK-4. It can be difficult to directly translate these supplementation 
conditions to appropriate working concentrations of MK-4 in cell culture. Hence, it was initially 
attempted to determine the effect of a range of MK-4 concentrations on the cell viability of wild-type 
fibroblasts (Section 2.26.1). It was determined that treatment with MK-4 did not significantly affect 
the cell viability of fibroblasts in the tested concentration range (0-100μM) after 24h of treatment 
(Figure 3.24). 
 
 
  
 
 
 
 
 
Figure 3.24 Effect of varying MK-4 concentrations on cell viability. A concentration range (0-
100μM) MK-4 was added to WT2 fibroblasts for 24h, after which cell viability was assessed with a 
MTT assay. Untreated cells (0 μM MK-4) were supplemented with 0.1% ethanol as a vehicle control. 
All values are expressed as % viability in comparison to untreated cells (0 μM MK-4) ± SD, of four 
replicate readings. Abbreviations: MK-4, menaquinone 4 (vitamin K2); SD, standard deviation; WT, 
wild-type.  
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As no apparent cytotoxic effects of MK-4 treatment were observed even at the highest tested 
concentration (100μM), it was decided to consult the established literature on effective working 
concentrations for MK-4 treatment in cell culture. The majority of these studies were investigating the 
anti-cancer properties of MK-4, and reported that significant functional effects of MK-4 treatment can 
been seen at concentrations of 30-50μM after 24h (Otsuka et al. 2004; Cao et al. 2009; Yao et al. 
2012; da Silva et al. 2013). While MK-4 was similarly effective at concentrations higher than ≈40μM, 
the magnitude of the observed effects typically plateaued at higher concentrations. Furthermore, all 
concentrations higher than 10μM had pro-apoptotic effects when treated for longer than 48h (Cao et 
al. 2009). Hence, it was decided to use a MK-4 concentration of 40μM for 24h in this pilot study as an 
informed compromise between concentrations and incubation periods high enough to elicit effective 
cellular responses, but low enough to avoid non-specific effects and cytotoxicity.   
    
3.4.2 Vitamin K2 modulates cellular and mitochondrial parameters 
In order to assess vitamin K2 as a potential therapeutic compound, the parkin-mutant and wild-type 
fibroblasts were treated with MK-4. Various parameters of cellular and mitochondrial health were 
then evaluated by means of the same approaches discussed in Section 3.3, i.e. cell growth and 
viability assays, mitochondrial respiration analysis, Δψm analysis and mitochondrial network analysis. 
Where appropriate, the MK-4 treated cells were compared to “untreated” control cells, which were 
treated with a suitable vehicle control. All results demonstrate comparisons of treatment responses in 
grouped patient-derived vs. grouped wild-type fibroblasts. Graphical depictions of results obtained for 
individual fibroblast cell lines (before and after MK-4 treatment) can be found in Appendix IX.   
It was found that cell growth was higher in patient-derived fibroblasts treated with MK-4 than in 
treated wild-type fibroblasts (p=0.0006; Figure 3.25A, left panel). However, this is likely a reflection 
of the higher cell growth rates of patient cells already seen under basal conditions (Section 3.3.1). In 
contrast, cell viability was similar in patients and controls treated with MK-4 (p=0.915; Figure 3.25A, 
right panel). When cells were simultaneously treated with MK-4 and the cellular stressor CCCP, both 
cell growth and cell viability were comparable between patient-derived and wild-type fibroblasts 
(p=0.1036 and p=0.6933, respectively; Figure 3.25B).  
A comparison of the cellular responses to the different treatments employed in this study (untreated, 
CCCP, MK-4 and MK-4+CCCP) is shown in Figure 3.25C, where the results obtained for untreated 
and CCCP-treated fibroblasts were described in Section 3.3.1. It was found that overall response 
patterns to MK-4 treatment was very similar in patient-derived and wild-type fibroblasts when 
assessing cell growth (p=0.14; Figure 3.25C, top panel) and cell viability (p=0.4963; Figure 3.25C, 
bottom panel). Hence, 22 factorial modeling was used to analyze the global effects of MK-4 treatment  
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Figure 3.25 Cell growth and viability in patient-derived and wild-type fibroblasts after vitamin 
K2 treatment. Left panels represent cell growth as assessed by a CyQUANT® assay, whereas right 
panels represent cell viability as assessed by a MTT assay. Box-and-whisker plots depict grouped 
patients (P) and wild-type (WT) measurements for three experimental runs. A, cell growth and 
viability after treatment with 40μM MK-4 for 24h. B, cell growth and viability after co-treatment with 
40μM MK-4 and 10 μM CCCP for 24h. C, comparison of cell growth (top panel) and cell viability 
(bottom panel) of fibroblasts under various treatment conditions. Graphs depicting cell growth and 
viability of untreated and CCCP-treated fibroblasts can be found in Figure 3.17. Abbreviations: AU, 
arbitrary units; MK-4, menaquinone 4 (vitamin K2); P, patient; WT, wild-type. 
  Cell growth                                                        Cell viability 
A             + MK-4                                                       
B             + MK-4; + CCCP                                                      
C           
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(on combined patient and wild-type cells), adjusting for correlations inside individual cell lines and 
experimental runs. It was found that treatment with MK-4 had no observable effect on cell growth in 
comparison to untreated fibroblasts (p=0.1531) or when co-administered with CCCP and compared to 
CCCP-only treated fibroblasts (p=0.5253). In contrast, MK-4 treatment was found to lower the cell 
viability of all treated cells in comparison to untreated fibroblasts (p=0.0014). Interestingly, MK-4 
and CCCP co-treatment significantly increased measurements of cell viability in all fibroblasts 
(p=0.0001). Hence, MK-4 enhanced the previously mentioned MTT-artefact produced by CCCP 
treatment (Section 3.3.1); this artefact was not seen when MK-4 was used by itself. It is interesting to 
speculate that CCCP and MK-4 interact biochemically to artificially elevate the rate of MTT 
reduction, which does not occur in the absence of CCCP.   
Several interesting effects on mitochondrial respiration were observed when patient-derived and wild-
type fibroblasts were treated with MK-4, which are depicted in Figure 3.26.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.26 Parameters of respiratory control in patient-derived and wild-type fibroblasts after 
vitamin K2 treatment. Fibroblasts were either treated with a vehicle control (0.1% ethanol) or 40μM 
MK-4 for 24h. Box-and-whisker plots depict grouped patients (P) and wild-type (WT) values. A, 
basal mitochondrial OCR. B, ATP-linked OCR. C, OCR due to proton leak. D, ATP coupling 
efficiency (percentage OCR due to ATP synthesis). E, Maximal OCR. F, Percentage spare respiratory 
capacity. Abbreviations: AU, arbitrary units; MK-4, menaquinone 4 (vitamin K2); OCR, oxygen 
consumption rate; P, patient; WT, wild-type.    
D                       E                            F 
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It was found that fibroblasts treated with MK-4 had increased basal mitochondrial respiration in 
comparison to untreated cells (p=0.0459; Figure 3.26A). Similarly, treatment with MK-4 increased 
the ATP-linked respiration (p=0.0465; Figure 3.26B), the oxygen consumption due to proton leakage 
(p=0.025; Figure 3.26C) and the maximum respiration (p=0.0331; Figure 3.26E) of all fibroblasts cell 
lines. When correcting for differences in basal mitochondrial respiration, if was found that MK-4 
treatment did not significantly alter either the ATP coupling efficiency (p=0.0707; Figure 3.26D) or 
spare respiratory capacity (p=0.2495; Figure 3.26F).  
Comparisons of patient-derived and wild-type fibroblasts in their responses to MK-4 treatment 
demonstrated that the increase in proton leak was more pronounced in patient-derived cells 
(p=0.0082). Similarly, the increase in maximum respiration was stronger in patient-derived cells 
(p=0.0105). The effect of MK-4 treatment on basal and ATP-linked respiration was found to be 
comparable between patient-derived and wild-type fibroblasts.     
Potential effects on Δψm were similarly assessed after treatment with MK-4. As can be seen in Figure 
3.27, no significant differences were found in the effect of MK-4 treatment on Δψm between patient-
derived fibroblasts and wild-type fibroblasts. When all fibroblasts are viewed collectively, MK-4 
treatment did not significantly alter the Δψm in comparison to untreated fibroblasts (p=0.3285).   
 
 
 
 
 
 
 
 
Figure 3.27 Relative Δψm of patient-derived and wild-type fibroblasts after vitamin K2 
treatment. Fibroblasts were either treated with a vehicle control (0.1% ethanol) or 40μM MK-4 for 
24h. Relative Δψm was determined by JC-1 red:green fluorescent emission ratios. Similar Δψm was 
seen for treated and untreated patient-derived fibroblasts (p=0.3285), as well as for treat and untreated 
wild-type fibroblasts (p=0.3285). Abbreviations: Δψm, mitochondrial membrane potential; MK-4, 
menaquinone 4 (vitamin K2); P, patient; WT, wild-type.  
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Lastly, the mitochondrial networks of parkin-derived and wild-type fibroblasts were evaluated after 
treatment with MK-4. It was found that MK-4 treatment significantly increased the form factor of all 
fibroblast cell lines investigated (p<0.0001; Figure 3.28A). This effect on the form factor was 
observed in parkin-derived and wild-type fibroblasts; however, there was a non-significant statistical 
trend towards a more pronounced increase in the form factor in patients (p=0.0729). Moreover, the 
aspect ratio was increased in MK-4-treated cells (p<0.0001; Figure 3.28B); this was seen to a similar 
extent in parkin-derived and wild-type fibroblasts, irrespective of parkin mutation status (p=0.4091).  
  
 
 
 
 
 
 
 
Figure 3.28 Mitochondrial network analysis of patient-derived and wild-type fibroblasts after 
vitamin K2 treatment. Fibroblasts were either treated with a vehicle control (0.1% ethanol) or 40μM 
MK-4 for 24h. Mitotracker Red and live-cell microscopy was used to visualize the mitochondrial 
network. All images were assessed in regards to the degree of mitochondrial branching (form factor) 
and degree of mitochondrial elongation (aspect ratio) The distribution of these values are represented 
in box-and-whisker-plots, N=40. A, comparison of form factor. B, comparison of aspect ratio. 
Abbreviations: AU, arbitrary units; MK-4, menaquinone 4 (vitamin K2); N; cells analyzed; P, patient; 
WT, wild-type.  
 
In summary, treatment with vitamin K2 (in the form of MK-4) modulated several parameters of 
mitochondrial health in interesting and unexpected ways. These effects were mostly seen to a similar 
extent in parkin-derived and wild-type fibroblasts (increased basal and ATP-linked respiration; 
increased aspect ratio), with some effects being more pronounced in parkin-mutant fibroblasts 
(increased oxygen consumption due to proton leak; increased maximum respiration; increased form 
factor). These interesting observations suggest functional interactions of vitamin K2 with 
mitochondrial pathways, which should be investigated further in future studies.  
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CHAPTER FOUR: DISCUSSION 
 
The present study undertook an investigation of the parkin gene and its protein product on various 
levels. Initially, it was found that mutants in parkin are infrequent in PD in South African PD patients. 
It was therefore sought to identify additional candidate PD genes by screening for protein interactors 
of parkin using a Y2H approach. This yielded a number of putative parkin interactors, of which four 
(ATPAF1, SEPT9, 14-3-3η and actin) were prioritized for verification and further study. Interestingly, 
two novel parkin interactors were found to accumulate in a cellular model of parkin deficiency. 
Additional investigation of cellular and mitochondrial dysfunction in these patient-derived fibroblast 
models demonstrated interesting and unanticipated effects, including possible compensatory increases 
in mitochondrial respiration. Moreover, the parkin-deficient cell model was used to evaluate vitamin 
K2 as a potential therapeutic modality for PD.      
 
4.1 PARKIN MUTATION SCREENING 
The elucidation of genetic factors contributing to PD is of importance as such genetic factors may 
provide valuable insight into the etiology and molecular pathology of this disorder. However, while 
the molecular basis of PD has been extensively studied in numerous population groups over the last 
two decades, very little is known of the etiology of PD in Sub-Saharan African populations. In fact, a 
recent review of the available literature found only nine published studies on the genetics of PD in 
Sub-Saharan Africa (Blanckenberg et al. 2013). The majority (5/9) of these studies emanated from our 
research group focusing on South African PD patients, including results published from the present 
study (Haylett et al. 2012).  
The investigation of the genetic etiology of PD in South African patients is of particular interest, 
given the diverse and distinctive genetic heritage of the population groups in this country. Hence, the 
present study aimed to investigate the contribution of parkin mutations to South African PD patients. 
Our research group had previously reported on a comparable molecular analysis of parkin, which 
concluded that parkin mutations are not a major cause of PD in the South African population (Bardien 
et al. 2009). While the previous study is of note as being the first report on the molecular etiology of 
PD in South African patients, the conclusions of the preliminary study were limited by a small sample 
size of only 91 study participants, and the fact that the contribution of parkin exon deletions and 
insertions was not determined. Therefore, the present study expands upon previous findings from our 
research group by the screening of an additional 138 South African PD patients, as well as by the 
inclusion of MLPA analysis to detect exonic rearrangements.   
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Only seven patients with homozygous or compound heterozygous parkin mutations were found in the 
study group of 229 South African PD patients (Section 3.1). A further eight patients were 
heterozygous carriers of a single parkin missense variant or exonic rearrangement, but the pathogenic 
relevance of such heterozygous variants are currently unclear.    
The frequency of parkin mutations (3.1%; 7/229) in South African PD patients is low in comparison 
to previous reports of parkin mutation frequencies, with reported frequencies as high as 50% of 
EOPD patients with a family history of PD, as well as 15-20% of sporadic EOPD cases (Lücking et 
al. 2000; Periquet 2003; Hedrich et al. 2004). However, the reported parkin mutation frequencies vary 
significantly across different studies and study populations (Kann et al. 2002; Choi et al. 2008; Sironi 
et al. 2008; Mellick et al. 2009; Koziorowski et al. 2010). For example, homozygous or compound 
heterozygous parkin mutations were reported in as high as 25.4% of Mexican-mestizo EOPD patients 
(Camacho et al. 2012), whereas only 1.4% of EOPD patients from Queensland, Australia had parkin 
mutations (Mellick et al. 2009). It can be speculated that the parkin mutation frequency is dependent 
on the ethnicity on the study group, which is supported by the available literature (Djarmati et al. 
2004). The low frequency of parkin mutations found in this study may therefore reflect the unique 
genetic heritage of the Black African, Afrikaner and Mixed ancestry sub-populations of South Africa.     
The range of parkin mutation frequencies reported in the literature may be furthermore due to 
differences in study inclusion criteria. The present study also included PD patients with late onset PD, 
as parkin mutations had been previously reported in both early and late onset PD patients (Sun et al. 
2006). In fact, this study identified a compound heterozygous parkin mutation in a patient with an 
AAO of 56 years (patient 107), which suggests that the conventional cut-off AAO of 50 years for 
parkin mutation screening is not recommended for the South African population. When considering 
only the 82 patients with EOPD, six (7.3%; 6/82) had homozygous or compound heterozygous parkin 
mutations, with a further four patients (4.8%; 4/82) carrying single heterozygous parkin variants. The 
majority of the EOPD patients included in the study (92.7%) therefore did not have parkin mutations. 
Surprisingly, no parkin mutations were found in one patient with juvenile onset PD, with an AAO of 
17 years.   
All five of the parkin missense variants (H200Q, E310D, R402C, G430D, P437L) as well as the 
parkin deletion (P113fsX163) identified in this study had been previously reported in the literature; 
however, the H200Q variant have only been reported by our research group to date (Bardien et al. 
2009). While the pathogenic relevance of H200Q is unclear, this variant was found to be absent in 106 
control chromosomes, and it is located in the functionally important RING0 domain. Functional 
studies of other parkin variants in the RING0 domain, such as K161N and K211N, found that such 
variants result in defective parkin auto-ubiquitination and protein interaction (Sriram et al. 2005; 
Hampe et al. 2006). The pathogenicity of the E310D variant is similarly uncertain; E310D was absent 
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in 110 control chromosomes in the present study. This variant was also absent in 526 control 
chromosomes in a published study of American PD patients (Pankratz et al. 2009b).  
No functional studies of the R402C variant have been reported to date, and the pathogenicity of this 
variant remains equivocal. Functional studies of the P437L variant in RING2 reported that it markedly 
impairs parkin ubiquitination activity (Chen et al. 2010; Glauser et al. 2011); however, heterozygous 
P437L variants have been previously described in unaffected individuals and may therefore be a risk 
factor for, instead of a cause of, PD (Kay et al. 2007). On the other hand, the pathogenicity of the 
G430D mutation is well established in the literature. This mutation, affecting the catalytic site in 
RING2, has been shown to abrogate parkin ligase activity, impair its mitochondrial translocation, and 
reduce its neuroprotective capacity (Henn et al. 2007; Vives-Bauza et al. 2009; Koyano et al. 2013). 
Small deletions, such as P113fsX163, as well as the numerous exonic rearrangements reported in the 
present study, are likely to result in protein truncation due to the introduction of frameshifts; therefore, 
homozygous or compound heterozygous parkin mutations containing such deletions or insertions 
would result in the abolishment of parkin biological activity (Dawson and Dawson 2010).  
In the present study, G430D was the only parkin missense mutation found in a compound 
heterozygous state; no homozygous parkin missense mutations were detected. It is currently unclear 
whether the four missense variants found only in a heterozygous state (H200Q, E310D, E402C, 
P437L) contribute to PD, as they may represent rare non-pathogenic parkin polymorphisms (Kay et 
al. 2007).   
It can be concluded that parkin mutations are not a major cause of PD in South African patients. The 
229 South African PD patients screened in the present study for parkin mutations were concurrently 
screened by our research group for mutations in other PD genes, including SNCA, LRRK2, PINK1 and 
DJ-1, VPS35 and EIF4G1 (Keyser 2011; Blanckenberg et al. 2014; unpublished data). Overall, 
mutations in the known PD genes are rare in the South African PD population: of the 229 study 
participants, one (0.4%; 1/229) was found with a whole gene triplication of SNCA; six (2.6%; 6/229) 
with LRRK2 mutations (five with G2019S and one with R1441C); and one patient with a homozygous 
PINK1 mutation (Y258X) (Keyser 2011). When these results are combined with the results obtained 
in the present study, only fifteen (6.6%; 15/229) of the PD patients have mutations in a known PD 
gene. This is unexpected, given that the majority of the study participants had either EOPD or a 
known family history of PD. If only the 82 EOPD patients are considered, eight (9.8%; 8/82) have 
mutations in known EOPD genes (six patients with parkin mutations, one each with a SNCA 
triplication and PINK1 mutation). Therefore, a total of 90.2% of the patients with a disease onset 
younger than 50 years do not have mutations in any of the known EOPD genes.  
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4.2 PARKIN INTERACTORS 
In addition to a genetic investigation of parkin, the present study aimed to further current 
understanding of the cellular and physiological function of parkin. In this regard, a Y2H cDNA library 
screen was used to identify known and novel parkin-interacting proteins. It is speculated that such 
interactors may partake in the many cellular pathways parkin has been implicated in and, ultimately, 
the dysregulation or dysfunction of parkin interactors may contribute to neurodegeneration.  
It is estimated that the present study screened approximately 1.8 x 107 cDNA clones from an adult 
human brain cDNA library, using the RBR region of parkin as bait (Section 3.2.1). Of these, a total of 
64 clones were selected for their ability to successfully activate all three the Y2H reporter genes; such 
clones were considered to encode peptides that specifically interacted with the parkin bait protein 
under the Y2H experimental conditions.  
 
4.2.1 Putative parkin interactors excluded from the present study 
The clones were each bioinformatically analyzed in order to identify the in-frame cDNA clone and 
encoding peptide. Of the 64 clones, sixteen were discarded as duplicate clones, i.e. clones that 
encoded identical peptides. Such detection of duplicate bait-prey interactions was not unexpected, as 
each clone may be represented numerous times in the cDNA library, providing multiple opportunities 
for interactions with the parkin bait (Gietz 2006). A further nineteen clones had insert sequences that 
were not in-frame according to the reading frame dictated by the upstream GAL4-AD; therefore, 
when translated, these clones had no significant protein match in the NCBI database 
(http://www.ncbi.nlm.nih.gov). These nineteen out-of-frame clones were discarded as they encoded 
short, physiologically-irrelevant peptides. The high prevalence of such clones is a known and 
common limitation of cDNA libraries derived from oligo(dT)-primed cDNA, such as the Clontech 
MATCHMAKER™ cDNA library used in this study, where only one in six of all cDNA inserts are 
cloned in-frame with the GAL4-AD (Van Criekinge and Beyaert 1999). 
The 29 in-frame cDNA clones with significant protein matches were investigated in publicly available 
databases in order to obtain relevant information regarding the subcellular expression and proposed 
function of the proteins. Based on such information, four of the putative parkin interactors were 
prioritized for further study, and will be discussed in Section 4.2.2. The remaining 25 candidate 
parkin-interacting proteins were not prioritized due to several reasons, which will be briefly discussed. 
While parkin has been observed in many subcellular compartments, including the ER, cytoplasmic 
vesicles, mitochondria and the nucleus, endogenous parkin is predominantly localized to the cytosol 
(Section 1.13.2). Therefore, putative parkin interactors that are not likewise localized to the cytosol 
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were de-emphasized in the current study, as they are less likely to reflect physiologically-relevant 
interactions (Patil and Nakamura 2005). On the other hand, mitochondrial or mitochondrial-associated 
proteins were emphasized as being of particular interest, given parkin’s role in the maintenance of 
mitochondrial function and health (Section 1.16.3).    
Five of the 29 putative parkin interactors (representing sixteen of the 45 in-frame cDNA clones) are 
nuclear proteins. These proteins (PCF11, NONO, SNRPN, SRSF3 and TRA2A) were not prioritized 
for the present study as their cellular localization makes in less likely that they would interact with 
predominantly cytosolic parkin outside of the Y2H experimental environment. However, as limited 
parkin expression in the nucleus has been previously described (Shimura et al. 1999; Stichel et al. 
2000), and parkin has been shown to have some nuclear-specific functions (da Costa et al. 2009; 
Duplan et al. 2013), it cannot at present be ruled out that some of these nuclear proteins are, if fact, 
authentic parkin interactors. Interestingly, all five of these proteins are involved in pre-mRNA 
splicing and processing, although parkin does not have a known RNA processing-related function.  It 
is of note that the two putative interactors PCF11 and SRSF3 were repeatedly identified by six 
independent clones each, suggesting that their observed interaction with the parkin bait is less likely 
to be an artefact of the Y2H methodology (Parrish et al. 2006).     
One other protein was identified by multiple (more than two) independent clones in the Y2H screen, 
namely TMEM222. The recurrent detection of such a presumed parkin-TMEM222 interaction via 
Y2H analysis is suggestive of the validity of this interaction. However, the putative parkin interactor 
was discarded as this protein is uncharacterized at present, and its biological function remains 
unknown. The uncharacterized protein DHRS7 was similarly excluded from further study. 
Conversely, another protein that was discarded from the study for being uncharacterized at the time, 
has lately been reported to be of potential relevance in neurodegeneration. This protein, CCDC56, was 
only recently characterized as a mitochondrial transmembrane protein and essential factor in 
cytochrome c oxidase (mitochondrial complex IV) biogenesis (Clemente et al. 2013). Given that 
mitochondrial respiratory dysfunction is a known pathological feature of parkin deficiency (Section 
1.16.3), the identification of a putative interaction between parkin and CCDC56 may be of significant 
relevance to neurodegeneration, and future studies should aim to verify this protein interaction.   
The remaining seventeen putative parkin interactors were not prioritized for verification; their 
biological function(s) are of unclear relevance to the known functions of parkin. These include several 
proteins involved in intracellular signaling (ARAP2, AKAP9, CALD1, GNB3 and NR1H2), various 
metabolic pathways (DHDDS, ELOVL1, PCMT1, PGAM1, PGM1, and TKT), vesicular trafficking 
and sorting (AP3S1, EXOC4, and HGS), prohormone processing (CPE), astrocyte plasticity and 
motility (CAPN3), and maintenance of the myelin sheath (MBP). While the detection of these 
putative parkin interactors with unclear functional relationships may be due to false positive Y2H 
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results (Mahdavi and Lin 2007), it cannot be ruled out that they reflect true, physiologically-relevant 
interactions with parkin. It is interesting to speculate that these candidate parkin interactions may 
illuminate previously unknown pathways to neurodegeneration. For that reason, these interactions 
should be verified in future studies in order to gain a more comprehensive understanding of the role of 
parkin in the cell.  
 
4.2.2 Verified parkin interactors 
Four of the parkin-interacting proteins originally detected in a Y2H screen were demonstrated to be 
authentic parkin interactors. Furthermore, it was shown that two of these interactors (SEPT9 and 
ATPAF1) accumulate in the absence of parkin, whereas parkin does not affect the steady-state protein 
level of the other two interactors (14-3-3η and actin) (Section 3.2.4.2). It should however be noted 
that this protein accumulation was not observed in one of the two parkin-mutant cell models, and that 
these preliminary findings need to be interpreted with caution. The following section will discuss 
what is known about the function of these parkin-interacting proteins, as well as hypothesize as to the 
possible biological significance of such interactions.  
 
4.2.2.1 ATPAF1 
The current study demonstrated a physical interaction of parkin with the ATPAF1 protein. 
Furthermore, it was found that ATPAF1 accumulated in the absence of parkin. Very little is known 
about ATPAF1; a PubMed literature search (http://www.ncbi.nlm.nih.gov/pubmed) using the 
keyword “ATPAF1” delivered just six published articles, while a search for Atp11p, the yeast 
homolog of ATPAF1, returned just thirteen results. Nevertheless, the discovery of a functional 
interaction between parkin and an assembly factor for an essential mitochondrial protein complex 
makes this an interesting protein to investigate further.  
The mitochondrial F1F0-ATP synthase, also referred to as complex V, is located in the inner 
mitochondrial membrane.  This multi-protein assembly consists of two physically and functionally 
coupled sectors: a catalytic F1 enzyme complex and a membrane-imbedded F0 ring-like channel. The 
electrochemical gradient generated by the ETC drives proton translocation from the inter-membrane 
space to the matrix through the F0 channel. This is coupled to the rotation of F0, which in turn induces 
conformational changes in F1 that promotes the synthesis and release of ATP. This interesting 
mechanism has been well-studied (Boyer 1997; Senior et al. 2002).   
The biogenesis of the mitochondrial ATP synthase has received considerably less attention. It is 
generally accepted to be a sophisticated process involving the coordinated activity of a number of 
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assembly factors, which drives the translocation, oligomerization and assembly of individual ATP 
synthase subunits to constitute functional ATP synthases (Ackerman and Tzagoloff 2005). The F1 
complex is comprised of five types of nuclear-encoded oligomeric subunits (α, β, γ, δ and ε), where 
the catalytic activity of F1 is conveyed by the important hexameric assembly of three α- and three β-
subunits (α3:β3). Biogenesis of F1 requires two assembly factors: ATPAF1, which binds selectively to 
unassembled β-subunits of F1, and ATPAF2, which associates with unassembled α-subunits (Wang 
and Ackerman 2000; Wang et al. 2001; Ackerman 2002). These two proteins act as substrate-specific 
molecular chaperones to stabilize unassembled α- and β-subunits by shielding their hydrophobic 
surfaces. This prevents the aggregation of α- and β-subunits prior to their assembly into a functional 
α3:β3 F1 complex (Sheluho and Ackerman 2001). Binding of α- and β-subunits to their assembly 
factors is then appropriately relieved by the γ-subunit of the nascent F1 complex (Ludlam et al. 2009). 
Separate assembly pathways are present for the assembly of the F0-ATP synthase channel, as well as 
for the dimerization and oligomerization of fully assembled F1F0-ATP synthase complexes 
(Jonckheere et al. 2012). This mechanism of assembly factor-dependent biogenesis of mitochondrial 
ATP synthase is conserved in all eukaryotic lineages (Pícková et al. 2005). 
Further studies found that the absence of either ATPAF1 or ATPAF2 not only resulted in their failure 
to assemble the F1-ATP synthase complex, but lead to the accumulation of both α- and β-subunits 
within large aggregates in the mitochondrial matrix (Lefebvre-Legendre et al. 2005). This suggests 
that proper α3:β3 assembly is dependent on a balanced protein stoichiometry. While the functional 
effect of the opposite scenario, i.e. an overabundance of ATPAF1 over ATPAF2 or vice versa, has not 
been investigated, it could be speculated that this may also affect the proper assembly of the F1-ATP 
synthase complex in some way.  
A quantitative analysis of ATPAF1 and ATPAF2 mRNA expression revealed that these genes are 
expressed at very low levels in various tissues (Pı́cková et al. 2003). While this study did not 
investigate the protein expression of either ATPAF1 or ATPAF2, it is noteworthy that very low 
protein levels of ATPAF1 was seen in both SH-SY5Y cells (Section 3.2.3.2; Figure 3.11C) and wild-
type fibroblasts (Section 3.2.4.2; Figure 3.15A) in the present study. Interestingly, Pícková et al. 
found a nearly constant ATPAF1 mRNA level in all tissues investigated. This suggests that ATPAF1 
behaves like an housekeeping gene to provide constitutively low levels of this assembly factor. 
Very few studies of the effect of altered ATPAF1 expression have been published. A genetic 
association study found that sequence variation in ATPAF1 is significantly associated with asthma and 
asthma severity (Schauberger et al. 2011). This study also showed that ATPAF1 mRNA expression 
was markedly (50-fold) higher in bronchial biopsies from patients with asthma than controls, which 
validated the genetic association results. While the functional role of ATPAF1 as a novel asthma risk 
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factor is unclear, the authors speculated that it may involve altered ATP-signaling in 
bronchoconstriction. Another study highlighted ATPAF1 as genetic modifier of prostate cancer 
(Schinke et al. 2014); it was found that ATPAF1 mRNA is overexpressed in prostate cancer tissue. 
The relevance of the parkin-ATPAF1 interaction to neurodegeneration is supported by recent studies 
suggesting that dysfunction of the mitochondrial ATP synthase specifically may contribute to parkin-
linked PD. For example, a study by Kim et al. (2012) investigated the protective role of Drosophila 
glutathione S-transferase omega 1 (GSTO1) in a Drosophila model of PD. They found that 
overexpression of GSTO1 was able to rescue some of the phenotype of parkin mutants, including 
degeneration of dopaminergic neurons and muscle. Further investigation revealed that this rescue 
effect is dependent on the direct catalytic action of GSTO1 on its novel substrate, the β-subunit of F1-
ATP synthase.  
The total protein expression of the β-subunit was unaffected in parkin mutant and wild-type flies; 
however, the level of GSTO1-mediated glutathionylation of the β-subunit was marked decreased in 
the parkin mutant (Kim et al. 2012). Kim et al. found that increased glutathionylation of the β-subunit 
was correlated with an improved mitochondrial F1F0-ATP synthase efficiency and elevated ATP 
levels, both of which were significantly decreased in parkin-mutant flies. Importantly, they also 
investigated the assembly level of F1F0-ATP synthase in parkin mutants. It was found that the level of 
correctly assembled F1F0-ATP synthase was markedly decreased in parkin mutants, and that this could 
be restored by upregulation of GSTO1. It is currently unclear how glutathionylation of the β-subunit 
improves ATP synthase assembly efficiency. While the investigators could not suggest why parkin 
mutants had defects in ATP synthase assembly in the first place, it could be hypothesized that the 
newly-discovered interaction of parkin with ATPAF1 contributes to this. In the absence of parkin, the 
dysregulation of ATPAF1 may lead to an impairment of the ATPAF1-driven β-subunit incorporation 
into the ATP synthase complex, which manifests as the altered ATP synthase assembly seen by Kim 
et al. To our knowledge, no other study specifically looked at impairment of ATP synthase assembly 
in parkin-deficient models, but it can be gathered from the above-described results that such 
impairment would contribute to altered cellular energetics and neurodegeneration. 
Another insightful study investigated OGFOD1 (2-oxoglutarate and Fe2+-dependent oxygenase 
domain containing protein 1), and implicated this protein as a pro-apoptotic factor (Saito et al. 2010). 
OGFOD1 knockout HeLa cells, i.e. cells deficient in OGFOD1, demonstrated a survival advantage 
upon exposure to ischemic stress. Further investigation of the pro-apoptotic mechanism of OGFOD1 
revealed that OGFOD positively regulates ATPAF1 mRNA expression: silencing of OGFOD1 
downregulated ATPAF1 expression, whereas ATPAF1 expression was enhanced by re-introduction of 
OGFOD1. Saito et al. speculated that this transcriptional activation of ATPAF1 by OGFOD1 was 
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required for the promotion of cell death under ischemic conditions. In support of this, the 
overexpression of ATPAF1 in OGFOD1 knockout cells significantly increased ischemia-induced cell 
death compared to OGFOD1 knockout cells with endogenous expression of ATPAF1. This suggests 
that ATPAF1, acting downstream from OGFOD1, may participate in the ischemia-induced cell death 
pathway via an unknown mechanism (Saito et al. 2010).  
To our knowledge, the above-mentioned study represents the only investigation of the functional 
consequences of ATPAF1 overexpression performed to date. The strong suggestion that it is elevated 
ATPAF1 which mediated the pro-apoptotic effects of OGFOD1 during ischemic stress is of special 
relevance to the present study. Parkin, as part of its pro-survival function, may monitor the protein 
expression of ATPAF1 in order to counteract OGFOD1-ATPAF1 pro-apoptotic signaling. It is 
revealing that the study of Saito et al. used HeLa cells as an experimental model; HeLa cells do not 
express any parkin due to a chromosomal deletion (Denison et al. 2003). Hence, their choice of the 
widely-used HeLa cell line may have unwittingly provided an appropriately parkin-free model where 
the effects of ATPAF1 expression would be amplified.     
It is interesting to note that a recent exome sequencing study of 100 PD patients highlighted OGFOD1 
as a novel candidate risk gene for PD (Quadri et al. 2014). It could be speculated that the regulation of 
ATPAF1 protein expression by parkin (as seen in the present study), and ATPAF1 mRNA expression 
by OGFOD1 (as seen by Saito et al.), may represent two alternative routes to a common pathogenic 
pathway in PD. 
To summarize, the present study demonstrated that the mitochondrial F1F0-ATP synthase assembly 
factor ATPAF1 interacts with parkin, and that ATPAF1 accumulates in the absence of parkin. While 
there are very few functional studies on ATPAF1 available, it has been shown that impairment of 
F1F0-ATP synthase assembly is a feature of parkin-mutant Drosophila (Kim et al. 2012). Other 
studies have found that increased ATPAF1 is detrimental to cellular health. For example, upregulation 
of ATPAF1 expression is involved in OGFOD1-ischemic cell death signaling (Saito et al. 2010); 
increased ATPAF1 expression is also associated with asthma (Schauberger et al. 2011) and prostate 
cancer (Schinke et al. 2014). In light of these interesting findings, the interaction of parkin with 
ATPAF1 and its relevance to neurodegeneration should be investigated further.   
 
4.2.2.2 SEPT9 
The septins, a family of thirteen protein paralogs, are GTP-binding proteins with diverse roles in 
health and disease (Dolat et al. 2014). Septins form hetero-oligomeric complexes capable of 
assembling into higher ordered structures, including filaments and rings. As part of such non-polar 
filamentous structures, septins interact with both actin filaments and microtubules, and septins are 
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increasingly being recognized as an important and dynamic component of the cytoskeleton (Mostowy 
and Cossart 2012). A major function of septins is the control of cellular protein localization and 
trafficking, which contributes to the roles of septins in cytokinesis, cytoskeletal reorganization, cell 
motility, signaling cascades, vesicle trafficking and exocytosis (Peterson and Petty 2010).  
Septins are of particular interest to neurodegeneration, as the accumulation of two septins, SEPT4 and 
SEPT5, has been implicated in the cytotoxic process underlying parkin-linked PD. SEPT5 was the 
first parkin substrate to be identified (Zhang et al. 2000), and was found to accumulate in the midbrain 
of PD patients with parkin mutations (Choi 2003). Overexpression of SEPT5 in both Drosophila and 
rats induced dopamine-dependent neurodegeneration (Dong et al. 2003; Muñoz-Soriano et al. 2012), 
suggesting that the accumulation of SEPT5 in the absence of functional parkin contributes to PD. 
SEPT5 interacts with both the exocyst complex and the SNARE protein syntaxin, implicating SEPT5 
in the regulation of vesicle trafficking and exocytosis (Hsu et al. 1998; Beites et al. 1999). Hence, 
accumulation of SEPT5 may contribute to neurodegeneration by dysregulation of synaptic exocytosis. 
SEPT4 is also a substrate of parkin (Choi 2003). Interestingly, the two distinct splice isoforms of 
SEPT4 (SEPT4_v1 and SEPT4_v2, also known as ARTS) have divergent functions in neurons. 
SEPT4_v1 has a neuroprotective role and directly interacts with α-synuclein to prevent its aggregation 
(Ihara et al. 2007). This isoform is abundantly found in LBs of PD patients (Ihara et al. 2003; 
Shehadeh et al. 2009).  ARTS (Apoptosis-Related protein in the TGF-β Signaling pathway), on the 
other hand, is a mitochondrial pro-apoptotic protein (Larisch et al. 2000).  While parkin interacts 
equally with both isoforms, only ARTS is ubiquitinated and targeted for degradation by parkin 
(Kemeny et al. 2012). Hence, only the ARTS isoform of SEPT4 accumulates in the absence of parkin, 
and promotes neurodegeneration by the activation of apoptotic signaling (Kemeny et al. 2012). 
The present study demonstrated a novel interaction between parkin and SEPT9; furthermore, SEPT9 
accumulated in parkin-null fibroblasts. Of all the septins, dysfunction of SEPT9 is the most 
convincingly linked to disease. Heterozygous mutations in SEPT9 cause hereditary neuralgic 
amyotrophy, a rare form of neuropathy (Kuhlenbäumer et al. 2005), whereas SEPT9 overexpression is 
found in diverse cancers, including breast, kidney, liver, lung, ovary, pancreas, etc. (Scott et al. 2005). 
SEPT9 DNA methylation changes have been used as a biomarker in colorectal cancer (Grützmann et 
al. 2008), and MLL-SEPT9 fusion transcripts frequently occur in acute myeloid leukemia (Cerveira et 
al. 2011).     
SEPT9 is near ubiquitously expressed in tissues; however, it has complex transcriptional pattern 
resulting in seven different protein isoforms (Kalikin et al. 2000). These isoforms are differentially 
expressed in body tissues: isoform 1 (SEPT9_v1) is detected in all tissues except the brain and 
thymus, while the other isoforms are expressed to varying degrees in the brain, among other tissues 
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(McIlhatton et al. 2001; Hall et al. 2005). SEPT9 isoforms are structurally very similar, differing only 
at their far N-termini while retaining identical GTPase domains and C-termini. Despite their 
similarity, some of the isoforms have diverging functions, and the altered expression of particular 
isoforms is linked to disease (Connolly et al. 2014).  
It is noteworthy that, in the present study, the Y2H prey clone that demonstrated an interaction with 
the parkin bait (Section 3.2.1.6) did not encode the full SEPT9 peptide, but rather only for the region 
containing the GTPase domain and C-terminus of SEPT9  (Appendix X). This is not unexpected, as 
N-terminal domains are poorly represented in oligo(dT)-primed cDNA libraries such as the cDNA 
library used in this Y2H screen (Van Criekinge and Beyaert 1999). As the parkin bait interacted with 
a protein domain common to all SEPT9 isoforms, it can be concluded that the interaction is not 
isoform-specific, and that parkin can be expected to interact with whichever isoform is expressed in a 
particular cell type.        
While several SEPT9 isoforms are expressed in the CNS, very little is known about the function of 
SEPT9 in the brain. To date, only one study have looked at SEPT9 protein expression and distribution 
in various brain tissues, in the context of SEPT9’s possible role in traumatic brain injury in rats (Mao 
et al. 2013). This study found that SEPT9 is expressed in neurons, but not astrocytes or 
oligodendrocytes. SEPT9 protein expression (but not mRNA expression) was marked increased in 
neurons following traumatic brain injury, and that this increased expression was closely correlated 
with induction of caspase-3-mediated apoptosis. While these observations need to be investigated 
further, it is suggestive of a pro-apoptotic role for SEPT9 in neurons.  
As stated, all septins form hetero-oligomers which polymerize into filaments. Despite this important 
property, the native assembly states and hetero-oligomerization partners of septins have only recently 
been investigated (Sellin et al. 2011). Current knowledge suggests that septins exist predominantly in 
the context of hexamers and octamers (Sellin et al. 2011). Importantly, all septin octamers contain 
SEPT9 at each terminus, which mediates octamer polymerization in a microtubule-dependent manner 
(Kim et al. 2011). Overexpression of SEPT9 alters the ratio of hexamers to octamers, and modulates 
the higher-order arrangement of septin filaments (Sellin et al. 2012). Hence, SEPT9 expression levels 
alter cellular septin assemblies in a stoichiometric manner, suggesting that its overexpression may 
impact on the functioning of most other septins, including septins enriched at the synaptic terminals. 
Septin filaments are particularly important for proper synaptic function at the synaptic terminal 
(Tsang et al. 2011); the important role of SEPT9 in septin filament assembly could conceivably 
disrupt the regulated functioning of these septins. 
The identified interaction between parkin and SEPT9 could also have implications for oncogenesis, as 
both proteins have been implicated in cancer. SEPT9 positively regulates the hypoxic response 
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pathway, by interacting with and stabilizing hypoxia-inducible factor 1α (HIF-1α) (Amir et al. 2006). 
This activation of HIF-1α induces a diverse range of target genes, and plays a key part in the 
promotion of cell proliferation, tumor growth and angiogenesis (Semenza 2010). Cells overexpressing 
SEPT9 had enhanced HIF-1α activity and higher proliferation rates both in vitro and in vivo (Amir et 
al. 2009). Conversely, targeted knockdown of SEPT9 reduced HIF-1α expression, cell proliferation 
and tumorigenesis (Amir et al. 2010). Increased expression of SEPT9, possibly as a result of parkin 
dysfunction, therefore impairs cell cycle regulation and promotes oncogenesis via activation of the 
HIF-1α pathway. This interesting observation is in accordance with the established connection 
between parkin dysfunction and cancer (Section 1.16.5) 
One is then faced with a conundrum: is increased SEPT9-HIF-1α signaling in the absence of parkin 
also relevant in neurodegeneration? After all, increased HIF-1α in the brain has a neuroprotective 
effect: HIF-1α promotes dopamine release (Witten et al. 2009) and protects against MPTP-induced 
neurotoxicity (Lee et al. 2009). Hence, parkin dysfunction in neurons could, paradoxically, have a 
pro-survival effect via the positive effect of SEPT9 accumulation on HIF-1α induction. This puzzle is 
solved by numerous studies showing that the interaction of SEPT9 with HIF-1α is restricted to the 
SEPT9_v1 isoform. In fact, the first 25 amino acids of SEPT9_v1, which are uniquely different from 
the other septin isoforms, were found to be critical for HIF-1α activation (Amir et al. 2009; Golan and 
Mabjeesh 2013). As this isoform is not expressed in the brain (McIlhatton et al. 2001; Hall et al. 
2005), the SEPT9-HIF-1α effect is restricted to non-neuronal, mitotic tissues (Amir et al. 2006).   
In summary, the identified functional interaction of parkin with SEPT9 may be of relevance to PD, 
given that two other members of the septin protein family have been implicated in parkin-associated 
neurodegeneration. Moreover, previous studies have established that dysregulated SEPT9 expression 
can have numerous pathological, tissue- and isoform-specific effects. While the cellular consequences 
of SEPT9 accumulation have not been specifically examined in neurons, previous reports suggest that 
it may have a pro-apoptotic effect. The accumulation of SEPT9 in the absence of parkin could 
conceivably impair neuronal function in several ways, as SEPT9 plays a pivotal role in regulating the 
assembly dynamics of many other septins. Finally, the interaction of parkin with SEPT9 may be of 
particular relevance to cancer research, and provide novel answers as to how parkin mutations 
increase susceptibility to various cancers.      
 
4.2.2.3 14-3-3η 
14-3-3 proteins are a family of highly conserved regulatory proteins ubiquitously expressed in cells; 
they are particularly abundant in the brain (Berg et al. 2003). To date, seven isoforms (β, γ, ε, ζ, η, θ 
and σ) have been identified, where each isoform is different in its cellular distribution, function and 
pathological relevance (Mhawech 2005). 14-3-3 proteins act as chaperones by binding to 
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phosphorylated serine sites of interacting partners. This binding may have several effects, whether 
augmenting or inhibiting the activity of the interactor, acting as an adaptor/scaffold for multi-protein 
assemblies, protecting the interactor from dephosphorylation, or regulation the subcellular localization 
of the interactor. In this manner, 14-3-3 proteins play important roles in the regulation and 
coordination of numerous diverse pathways, including intracellular trafficking, signal transduction, 
cell cycle control, cell survival and apoptosis (Mackintosh 2004).  
14-3-3η, in particular, has been implicated in neuronal function and health. Polymorphisms in the 14-
3-3η gene (YWHAH) are genetic susceptibility factors for both schizophrenia and bipolar disorder 
(Toyooka et al. 1999; Wong et al. 2003; Grover et al. 2009). Furthermore, YWHAH was found to be 
downregulated in a dopaminergic neuronal cell line during oxidative stress, suggesting that the loss of 
the chaperone activity of 14-3-3η contributes to the oxidative signaling underlying oxidative damage 
in dopaminergic neurons (Anantharam et al. 2007). Conversely, YWHAH was shown to be 
upregulated in primary cortical neurons during in vitro development, indicating a role of 14-3-3η in 
neuronal growth and differentiation (Chen et al. 2005). Moreover, transient overexpression of 14-3-3η 
in AF5 neuronal cells protected the cells from N-methyl-D-aspartate (NMDA)-induced excitotoxic 
cell death (Chen et al. 2007).  
Of relevance to this dissertation, 14-3-3η has also been implicated in neurodegeneration and PD.  
Most 14-3-3 proteins are abundantly found in LB’s of PD brains (Kawamoto et al. 2002), while the 
14-3-3γ, -ε and η isoforms in particular are enriched at the synaptic junction and the synaptic 
membrane, similarly to α-synuclein (Berg et al. 2003). Interestingly, 14-3-3 proteins share amino acid 
sequence homology with α-synuclein (Ostrerova et al. 1999). Soluble α-synuclein and 14-3-3 protein 
complexes were observed in neurons of SNCA transgenic mice (Shirakashi et al. 2006), and a direct 
interaction of 14-3-3η with α-synuclein was confirmed by immunoprecipitating this complex from the 
SNpc of PD patients (Sato et al 2006). A recent and insightful study examined the relationship 
between 14-3-3η and α-synuclein, which found that the fibrillization and aggregation process of α-
synuclein is heavily influenced by the presence of 14-3-3η (Plotegher et al. 2014). Their study showed 
that, while 14-3-3η was unable to bind monomeric α-synuclein, it strongly interacted with oligomeric 
α-synuclein aggregation intermediates and diverted the aggregation process. However, when the level 
of α-synuclein was overwhelmingly higher than 14-3-3η, the fibrillization process in effect 
sequestered 14-3-3η. This sequestration of 14-3-3η by excessive α-synuclein may contribute to PD 
pathogenesis via the loss of appropriate 14-3-3η function. Indeed, 14-3-3η overexpression rescued the 
toxic effects of early-stage α-synuclein aggregation in cell models (Plotegher et al. 2014).     
LRRK2 has been shown to bind several 14-3-3 isoforms, especially 14-3-3η, where PD-causing 
mutations in LRRK2 abolished the interaction with 14-3-3η (Nichols et al. 2010; Li et al. 2011b). 
Moreover, disruption of the interaction between 14-3-3η and LRRK2 altered the cytoplasmic 
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localization of LRRK2, resulting in the accumulation of this normally diffusely-spread protein 
(Dzamko et al. 2010). Further evidence suggests that 14-3-3η mediates the extracellular release of 
LRRK2 in exosomes (Fraser et al. 2013). Hence, 14-3-3η regulates LRRK2 localization and sorting, 
while PD-linked mutations impair this regulatory action. This may be of considerable relevance as 
aberrant LRRK2 sorting has been implicated in PD pathogenesis (MacLeod et al. 2013). 
Of note, 14-3-3η has been previously shown to interact with parkin (Sato et al 2006). Sato et al. co-
immunoprecipitated parkin and 14-3-3η from mouse brain homogenates, and found that the 
association with parkin was specific to this isoform. Furthermore, they used parkin deletion constructs 
to demonstrate that the region containing parkin’s RING0 domain was critical for 14-3-3η binding. 
Upon investigation of the effect of 14-3-3η binding on parkin’s activity, it was discovered that 14-3-
3η suppressed parkin’s intrinsic auto-ubiquitination ability; 14-3-3η furthermore inhibited the 
interaction of parkin with its substrate synphilin-1. Surprisingly, Sato et al. found that wild-type α-
synuclein relieved this negative regulation of parkin activity via its interaction with 14-3-3η, while 
PD-causing A30P and A53T SNCA mutants could not rescue parkin activity. 
These insightful findings suggest that 14-3-3η-bound parkin is present in a latent state in the cells, 
where 14-3-3η functionally links parkin and α-synuclein. It could be that an imbalance of the three-
way interactions between parkin, 14-3-3η and α-synuclein may contribute to the neurodegenerative 
process. While this has not been properly explored, the interaction of 14-3-3η with parkin might 
protect parkin from cellular stresses, such as its previously-reported sensitivity to nitrosative stress 
(Yao et al. 2004). Furthermore, while 14-3-3η may negatively regulate parkin activity, it may 
paradoxically play a positive role in maintaining a large pool of parkin in the cell by inhibiting its 
auto-ubiquitination and subsequent degradation. Physiological α-synuclein might fine-tune this 
regulation by binding to 14-3-3η and activating the latent parkin-14-3-3η complex in an appropriate 
manner. In fact, immunoprecipitation of 14-3-3η from midbrain lysates showed that 14-3-3η-bound 
parkin is significantly decreased in PD patients compared to controls, whereas levels of 14-3-3η-
bound α-synuclein is clearly elevated in PD patients (Sato et al 2006). This supports the hypothesis 
that a disruption of the careful balance between the positive and negative regulation of parkin 
contributes to PD. Moreover, the demonstration that 14-3-3η interacts with numerous PD-associated 
proteins, including α-synuclein, LRRK2 and parkin, might suggest that 14-3-3η is involved in the 
regulation of multiple pathogenic processes in PD. 
The present study independently verified the previously-described interaction of parkin with 14-3-3η 
(Sato et al 2006). Furthermore, the protein expression levels of 14-3-3η was found to not differ 
significantly between parkin-null and wild-type parkin fibroblasts, which is consistent with the 
regulation of parkin by 14-3-3η, instead of vice versa. While the curious negative regulation of parkin 
by 14-3-3η was not investigated further, as this was beyond the scope of this study, future 
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investigation of the precise molecular mechanisms and consequences of this regulatory effect may be 
of interest to PD research. Also, modulating the regulation of parkin by 14-3-3η may be a novel target 
for the prevention and therapy of PD, as may be the interactions by 14-3-3η with α-synuclein or 
LRRK2. Recent efforts have discovered many natural and synthetic compounds that modulate the 
binding of 14-3-3 proteins with their targets (Zhao et al. 2011a; Milroy et al. 2013; Ottmann 2013); 
however, such compounds would need to selectively target specific 14-3-3 isoforms and isoform 
interactions before they can be used in vivo.     
   
4.2.2.4 Cytoskeletal actin 
β-Actin and γ-actin  are two ubiquitously-expressed cytoplasmic members of the actin protein family; 
this family includes four other actin paralogs that are predominantly expressed in muscle (Rubenstein 
1990). These two non-muscle cytoskeletal actins share an exceptionally high amino acid sequence 
similarity, differing by only four amino acids clustered at their respective N-terminals 
(Vandekerckhove and Weber 1978). In the present study, a Y2H screen identified an interaction 
between parkin and a cDNA clone encoding a large fragment of γ-actin. However, as the peptide 
sequence encoded by this clone is also found in β-actin, it can be assumed that parkin interacts with 
both actin paralogs. Hence, the relevance of the interaction between parkin and cytoskeletal actin will 
be discussed here.   
The cytoskeleton consists of the three essential components: actin filaments, tubulin-containing 
microtubules and intermediate filaments. Actin participates in many important cellular functions as 
part of the cytoskeleton, including cell signaling, vesicle trafficking, organelle movement, and 
structural organization (Pollard and Cooper 2009). Crucial to these roles is the ability of actins to self-
assemble into filaments (F-actin). The assembly of F-actin is a highly dynamic process which can be 
modulated by numerous actin-associated proteins in the cell, and perturbation of F-actin dynamics can 
impair proper cellular functioning.  
Numerous studies have highlighted a link between actin, vesicle trafficking and PD. For example, α-
synuclein is known to alter actin cytoskeletal structure and dynamics. Wild-type α-synuclein was 
found to interact with actin, slowing its polymerization and promoting its depolymeration (Sousa et al. 
2009). A30P mutant α-synuclein, on the other hand accelerated polymerization (Sousa et al. 2009). 
This interaction of α-synuclein and F-actin is thought to underlie α-synuclein’s role in synaptic vesicle 
trafficking and synaptic function (Bellani et al. 2010). Similarly, accumulating evidence also 
implicate LRRK2 in actin dynamics. It was shown that LRRK2 depolymerized F-actin in vitro, and 
that PD-causing LRRK2 mutations accelerated actin disassembly in SH-SY5Y cells (Chan et al. 
2011a; Meixner et al. 2011) Fibroblasts from PD patients with LRRK2 mutations had decreased F-
Stellenbosch University  https://scholar.sun.ac.za
169 
 
actin stability which were more susceptible to the F-actin depolymerizing agent Latrunculin A (Caesar 
et al. 2014). Moreover, such fibroblasts had a significant increase in F-actin bundles, possibly a 
compensatory mechanism to protect F-actin from the depolymerizing effect of mutant LRRK2 
(Caesar 2014.) LRRK2 also phosphorylates moesin, a protein that anchors F-actin to the plasma 
membrane (Jaleel et al. 2007); phosphorylation of moesin alters the arrangement of the actin 
cytoskeleton and modifies synaptic vesicular function (Parisiadou et al. 2009). This important role of 
LRRK2 in modulating synaptic transmission is increasingly being recognized as a key feature of PD 
(Belluzzi et al. 2012; Lee et al. 2012a). 
Parkin has been previously associated with the cytoskeleton in the literature. Huynh et al. (2000) used 
confocal microscopy to demonstrate that parkin co-localized with actin fibers in COS1 cells. To 
further differentiate whether parkin associated with actin filaments or microtubules, cells were treated 
with cytochalastin D, an actin depolymerizing agent, or nocodazole, which selectively destabilizes 
microtubules. Cytochalastin D treatment disrupted both actin and parkin staining behavior, further 
supporting parkin-actin co-localization. Nocodazole, however, had no effect on parkin staining, 
suggesting that parkin did not co-localize with microtubules. In contrast to this, Ren et al. (2003) 
found that parkin is a microtubule-binding protein. This study demonstrated that parkin co-
immunoprecipitated with both α- and β-tubulin and co-localized to α/β tubulin heterodimers in SH-
SY5Y cells. These contradictory findings by Huynh at al. and Ren et al. may be explained by 
differences in experimental conditions. Ubiquitination assays demonstrated that wild-type parkin 
ubiquitinated both monomeric α- and β-tubulin, and targeted these proteins for proteasomal 
degradation (Ren et al. 2003). The authors speculated that parkin may selectively ubiquitinate 
misfolded monomeric tubulins, which are cytotoxic upon accumulation in the cell. However, parkin 
also interacts with assembled tubulins, albeit in a non-enzymatic manner. It was demonstrated that 
parkin interacted with and stabilized microtubules independently of its E3 ligase activity, supporting 
the association of parkin and the microtubule cytoskeleton (Yang et al. 2005). 
There are other studies which support the functional association of parkin and actin. Parkin interacts 
with and ubiquitinates LIM kinase 1 (LIMK1), which then attenuates LIMK1-dependendent 
phosphorylation and inactivation of cofilin (Lim et al. 2007). Cofilin is known to bind to F-actin and 
promotes actin turnover (Lappalainen and Drubin 1997). Hence, parkin modulates the actin 
cytoskeleton indirectly via its interaction with LIMK1. A further study investigated the functional link 
between PINK1 and parkin, and found that RNAi-mediated PINK1 knockdown dramatically 
increased parkin’s interaction with F-actin (Kim and Son 2010). Further investigation demonstrated 
that loss of PINK1 induced F-actin bundling in neuronal cells via the increased inactivation of cofilin, 
which then promoted the recruitment of parkin to F-actin. Interestingly, induction of oxidative stress 
and treatment with rotenone similarly increased the association of parkin with F-actin (Kim and Son 
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2010). Collectively, these results support a model whereby parkin binds and stabilizes F-actin, and 
this stabilization is increased as a neuroprotective response to cellular stress. This is similar to the 
stabilizing binding of parkin to microtubules (Yang et al. 2005). 
Of note, this study by Kim and Son is the only report of the successful co-IP of parkin and actin prior 
to the present study. However, Kim and Son used overexpressed and FLAG-tagged parkin to perform 
the co-IP assay, whereas the present study demonstrates this interaction with endogenous parkin. 
Hence, the present study confirmed the interaction between parkin and actin in a more biologically 
relevant experimental setting. This is of importance as the presence of N-terminal epitope tags are 
known to alter the biochemical function of parkin by artificially inducing an auto-activated state 
(Burchell et al. 2012). It is strongly suggested that any results obtained using tagged parkin should be 
confirmed with endogenously-expressed parkin, as has been done for the parkin-actin interaction in 
the present study.    
The absence of parkin was found to have no effect on the steady-state level of total γ-actin (and β-
actin) protein. This suggests that the interaction of parkin with actin does not promote the turnover of 
actin, which is consistent with reports that the degradation of actin is instead mediated by the E3 
ligase TRIM23 (Kudryashova et al. 2005). However, it is conceivable that the absence of parkin may 
have an effect on the assembly state of F-actin, which would not have been reflected in denaturing 
western blot analyses as performed in the present study. While the functional relevance of this 
interaction is currently unclear, parkin’s association with actin may promote proper actin dynamics, 
which is supported by studies that suggest a stabilizing role of parkin at F-actin, similar to parkin’s 
role at microtubules. Alternatively, parkin may associate with actin as a general means of “anchoring” 
itself in various subcellular localizations. This would allow for the efficient ubiquitination of parkin 
substrates that are being transported along actin filaments. Further investigation of the interaction of 
parkin with actin may be fruitful, as the relevance of actin dynamics to PD has been highlighted by 
the numerous studies showing that α-synuclein and LRRK2 also interact with actin. The actin 
cytoskeleton may therefore represent a functional link between several PD-causing genes.  
 
4.3 FUNCTIONAL STUDIES IN A PARKIN-DEFICIENT CELLULAR MODEL 
Patient-derived fibroblasts with parkin mutations are valuable models for investigating the functions 
of parkin in an in vivo setting. However, published results of such investigations of parkin-mutant 
fibroblasts have not been wholly consistent (Mortiboys et al. 2008; Grunewald et al. 2010; Pacelli et 
al. 2011). Therefore, the present study aimed to functionally compare parkin-mutant fibroblasts from 
South African PD patients with wild-type control fibroblasts using a variety of assays of cellular 
health and function (Section 3.3). 
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It was shown that patient-derived fibroblasts have comparable cell viabilities (as detected by a MTT 
assay) to wild-type control fibroblasts under basal conditions. Surprisingly, it was also found that the 
cell growth (as measured by a CyQUANT® assay) is significantly higher in the parkin-mutant 
fibroblasts under basal conditions (p=0.0001). This is in contrast to the established literature. For 
example, Mortiboys et al. (2008) reported that both cell viability and growth rates were similar in 
fibroblasts from controls and patients with parkin mutations, whereas Pacelli et al. (2011) reported 
that parkin mutant fibroblasts displayed a significantly lower growth rate than control fibroblasts. 
Both of these studies reported cell viability and growth under basal, unstressed conditions. The 
increased cell growth detected in the present study may reflect methodological differences, as neither 
the study by Mortiboys et al. or Pacelli et al. used a CyQUANT® assay to determine cell growth. It is 
also conceivable that the increased cell proliferation in the absence of parkin is a result of a metabolic 
shift in response to parkin deficiency, which is known to promote cell proliferation in various cancers 
(Xu et al. 2014).   
In contrast to these observations, the cell growth of parkin-mutant fibroblasts is significantly inhibited 
after treatment with CCCP (p=0.0013), while wild-type fibroblasts demonstrate a much smaller 
response. This is indicative of an increased susceptibility to CCCP in the absence of parkin. Treatment 
with CCCP reduces the Δψm and promotes the recruitment of parkin from the cytoplasm to 
depolarized mitochondria (Narendra et al. 2008). Parkin is subsequently involved in the isolation and 
mitophagic clearance of CCCP-damaged mitochondria (Narendra et al. 2008). Hence, parkin 
deficiency in patient-derived fibroblasts may reduce cell growth after CCCP treatment via the failure 
to properly clear damaged mitochondria. The resulting accumulation of depolarized mitochondria in 
the absence of parkin may impair cell growth by being a significant source of oxidative stress 
(Henchcliffe and Beal 2008).  
The present study found interesting differences in the mitochondrial network morphologies of patient 
and wild-type fibroblasts (Section 3.3.4). Whereas the degree of mitochondrial elongation (aspect 
ratio) was comparable between patient-derived and wild-type fibroblasts, the amount of mitochondrial 
branching (form factor) was significantly decreased in patients (p=0.0306). This decrease in form 
factor is consistent with increased fragmentation of the mitochondrial network (Burbulla et al. 2010).  
Other studies which investigated mitochondrial network morphology in fibroblasts from patients with 
parkin mutations found conflicting results. In contrast to the results obtained here, Mortiboys et al. 
(2008) found that fibroblasts with parkin mutations had a marked increase in mitochondrial 
branching, as quantified by the form factor. This was suggestive of an increased mitochondrial fusion 
in the absence of parkin. Two other studies found that parkin mutant and wild-type fibroblasts 
demonstrated comparable form factors under basal conditions (Grunewald et al. 2010; Rakovic et al. 
2011). However, both studies found that treatment with mitochondrial stressors (paraquat and 
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valinomycin, respectively) decreased the form factor and induced mitochondrial network 
fragmentation in parkin mutant and wild-type fibroblasts; these decreases was only statistically 
significant in the fibroblasts with parkin mutations. These findings are supported by the results of 
Pacelli et al. (2011), who observed a noticeably more fragmented mitochondrial network in parkin-
mutant fibroblasts even under basal conditions; however, this difference was not quantified in terms 
of form factor. Hence, the majority of studies reported a decreased mitochondrial form factor, 
indicating increased fragmentation, in the absence of parkin. The results obtained here support these 
established findings, but not the contrasting findings of Mortiboys et al. (2008).  
Of note, all of the above-mentioned studies which quantified the mitochondrial network morphology 
reported that the degree of mitochondrial elongation (as expressed by the aspect ratio) was 
comparable in parkin-mutant and wild-type fibroblasts (Mortiboys et al. 2008; Grunewald et al. 2010; 
Rakovic et al. 2011). Hence, the similar mitochondrial aspect ratios observed in the present study is in 
concordance with the established literature. 
Several other studies have implicated increased mitochondrial fission in the pathogenesis of PD. For 
example, mutations in PINK1 and DJ-1 induce mitochondrial fragmentation in cultured neurons 
(Exner et al. 2007; Krebiehl et al. 2010). Similarly, overexpression of α-synuclein and LRRK2 were 
found to promote mitochondrial fragmentation (Wang et al. 2012b; Xie and Chung 2012). In addition 
to the above-described reports of fragmented mitochondrial networks in parkin mutant fibroblasts, 
RNAi-mediated knockdown of parkin in neuronal cells had a similar pro-fragmentation effect (Lutz et 
al. 2009). This enhanced mitochondrial fragmentation in the absence of parkin can be explained by an 
abrogation of parkin’s interaction with the mitochondrial fission factor Drp1. Parkin ubiquitinates and 
promotes the proteasomal degradation of Drp1 (Wang et al. 2011a); therefore, loss of parkin would 
reduce the level of Drp1 ubiquitination, resulting excessive mitochondrial fission and fragmentation 
of the mitochondrial network. In fact, the fragmented phenotype of parkin mutant cells was found to 
be dependent of Drp1, and Drp1 knockdown could rescue these morphological abnormalities (Lutz et 
al. 2009).  
However, this is contradicted by other studies demonstrating that, in Drosophila, wild-type parkin 
promotes fission, and loss of parkin resulted in increased mitochondrial fusion and branching, which 
can be rescued by Drp1 overexpression (Poole et al. 2008; Ziviani et al. 2010). In support of the 
relevance of these observations is the finding that parkin ubiquitinates Mfn1 and Mfn2 even in 
mammalian cells, promoting the degradation of these pro-fusion factors (Glauser et al. 2011; Sun et 
al. 2012). According to this model, wild-type parkin ubiquitinates Mfn1/2 in response to 
mitochondrial damage in order to inhibit fusion of damaged mitochondria with healthy mitochondria. 
This fission promotes the selective isolation and mitophagy of dysfunctional mitochondria (Rakovic 
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et al. 2011). In the absence of parkin, dysregulation of Mfn1/2 may contribute to increased 
mitochondrial fusion, as seen in some parkin-mutant fibroblasts (Mortiboys et al. 2008).  
It is difficult to reconcile the described pro-fusion (via Drp1 ubiquitination) and pro-fission (via 
Mfn1/2 ubiquitination) functions of parkin. It is likely that these contradictory roles of parkin reflect 
the complex nature of the regulation of mitochondrial dynamics, where a delicate balance between 
fusion and fission promotes optimal mitochondrial functioning. Hence, the enhanced fission and 
fragmentation in the absence of parkin, as seen in the present study, may indicate a disruption of 
mitochondrial dynamics that cannot be easily reduced to one-way interactions between parkin and 
fission/fusion proteins.    
Mitochondrial morphology is thought to be intimately connected to various parameters of 
mitochondrial health, including Δψm. However, the current study found that Δψm is similar in parkin-
mutant and wild-type fibroblasts, irrespective of the degree of mitochondrial branching (Section 
3.3.3). This lack of Δψm impairment is in contrast to the findings by Mortiboys et al. (2008), who 
reported a 30% decrease in Δψm in parkin-mutant fibroblasts relative to wild-type controls. The 
reported decrease in Δψm was even more pronounced when the fibroblast culture media was switched 
to include galactose as an energy source rather than glucose, which saw a 70% decrease in Δψm in 
fibroblasts with parkin mutations under these oxidative conditions (Mortiboys et al. 2008). Cultured 
fibroblasts predominantly use glycolysis to generate ATP, rather than oxidative phosphorylation 
(Benard et al. 2007). Culturing fibroblasts in glucose-deficient media obligates their use of oxidative 
phosphorylation for ATP production, which explains why possible mitochondrial impairments are 
enhanced under these conditions (Rossignol et al. 2004).  
Grunewald et al. (2010) found that Δψm was similar in parkin-mutant and wild-type fibroblasts under 
basal conditions, in concordance to the results of the present study. However, a decrease in Δψm was 
observed in the patient fibroblasts after the induction of oxidative stress by treatment with paraquat. 
While the present study only investigated Δψm under basal conditions, it is conceivable that possible 
impairments in Δψm in parkin-mutant fibroblasts may only be readily observable under highly 
oxidative conditions, where the cells are more reliant on mitochondria for ATP production. Hence, 
culturing the fibroblasts in glucose-free media may have unmasked impairments in Δψm which are not 
apparent under the experimental conditions used in the present study. 
Surprisingly, the present study found that the rate of mitochondrial respiration is increased in parkin-
mutant fibroblasts in comparison to wild-type fibroblasts (Section 3.3.2). Further investigation of 
respiratory activity after the addition of various inhibitory compounds demonstrated that, in addition 
to an increased mitochondrial respiratory rate under basal conditions (p=0.0355), patient fibroblasts 
have an elevated ATP-coupled respiration (p=0.0481), increased respiration due to passive proton 
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leak across the inner mitochondrial membrane (p=0.0273) and an increased maximal respiratory rate 
(p=0.0081).    
The unanticipated overall increase in mitochondrial respiration is in contrast to numerous studies 
which have reported decreased respiratory activity in fibroblasts from PD patients with parkin 
mutations. For example, Mortiboys et al. (2008) described significant impairment of mitochondrial 
complex I activity in parkin-mutant fibroblasts, which was linked to a loss of Δψm and decreased 
cellular ATP content. Similarly, Pacelli et al. (2011) reported that both the basal and maximal 
respiratory rate was significantly decreased in patient fibroblasts with parkin mutations. Further 
investigation of the specific respiratory complexes contributing to the decline in respiratory flux 
demonstrated that complex I, III and IV (but not complex II) activity was significantly reduced in 
patient fibroblasts (Pacelli et al. 2011).  
The paradoxically improved mitochondrial respiration in the absence of parkin seen in the present 
study is difficult to explain, but it likely reflects a compensatory response in these parkin-mutant 
fibroblasts. Indeed, the increase in respiration that is coupled to ATP strongly suggests an 
upregulation of mitochondrial function, which will be discussed in more detail below.  However, it is 
telling that the patient fibroblasts also had an increased passive proton leakage, and the resulting 
oxygen consumption from this leakage (which does not contribute to ATP production) is elevated to a 
higher extent than the ATP-linked oxygen consumption. This is reflected by the trend towards lower 
ATP coupling efficiency of the parkin-mutant fibroblasts, although this difference did not reach 
statistical significance (p=0.0983). It is possible that the increased proton leakage and lower ATP 
coupling efficiency points towards an underlying mitochondrial defect caused by parkin deficiency, 
which is then overcome and masked by a compensatory response.  
Conversely, it is also possible that the higher proton leakage is in itself a compensatory response 
aimed at lowering ETC-linked ROS production. Studies have demonstrated that the elevation of 
proton leakage can be induced by uncoupling proteins (UCPs) in response to oxidative stress (Brand 
2000; Porter 2001). Here, UCPs promote the passive movement of protons across the inner 
mitochondrial membrane which lowers Δψm in a controlled fashion; UCPs therefore decrease further 
ROS production at the expense of decreased ATP production (Toime and Brand 2010).      
As stated, it is speculated that the significant increase in basal and ATP-linked respiration in parkin-
mutant fibroblasts is due to a compensatory effect. In fact, several compensatory responses to parkin 
deficiency have been described in the literature. Pacelli et al. (2011) found that the defective ATP 
production by oxidative phosphorylation in parkin-mutant fibroblasts was compensated by an 
upregulation of the glycolytic pathway. They furthermore reported that the protein expression of 
PGC1-α was significantly higher in parkin-mutant fibroblasts; PGC1-α is a key promoter of the 
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compensatory increase in mitochondrial biogenesis (Kelly and Scarpulla 2004). However, the 
expression of several PGC1-α target genes directly involved in mitochondrial biogenesis (including 
NRF1, TFAM and COX II) were unchanged or even decreased in patient-derived fibroblasts. Pacelli et 
al. postulated that an unknown post-translational modification of PGC1-α modulated its function in 
parkin-mutant fibroblasts, preventing a compensatory increase in mitochondrial biogenesis. It is 
interesting to speculate that the genetic backgrounds of the patient-derived fibroblasts in the current 
study may allow for the PGC1-α-mediated increase in mitochondrial biogenesis, in contrast to 
fibroblasts used by Pacelli et al. This may, in part, explain the conflicting results obtained here and by 
Pacelli et al. Clearly, additional studies will be necessary to support such a mechanism. 
Other studies have also hinted at a compensatory increase in mitochondrial biogenesis in parkin 
deficient fibroblasts. Grunewald et al. (2010) investigated the citrate synthase activity of parkin-
mutant fibroblasts as an index of total mitochondrial mass, and found that such activity was 
significantly higher in parkin-mutant fibroblasts than wild-type controls. Indeed, Grunewald et al. did 
not observe any impairments of mitochondrial complexes I-IV under basal conditions. This in in 
contrast to Pacelli et al. (2011) who reported that citrate synthase activity was significantly decreased 
in parkin-mutant fibroblasts, suggesting a decrease in total mitochondrial content, which was 
associated with marked defects in complexes I, III and IV. Hence, increased citrate synthase activity, 
and elevated mitochondrial biogenesis in general, may explain the milder phenotype of parkin mutant 
fibroblasts observed by Grunewald et al. While markers of mitochondrial biogenesis were not 
specifically assayed in the present study, increased biogenesis may underlie the compensatory 
increase in mitochondrial respiration seen here. 
It is noted that a possible compensatory elevation of mitochondrial biogenesis in the parkin-deficient 
fibroblasts would be paradoxical: parkin is involved in the promotion of mitochondrial biogenesis; 
hence, these processes are expected to be decreased in the absence of parkin (Kuroda et al. 2006a). 
However, future investigation of the exact nature and mechanism of the respiratory compensation 
seen here in parkin-mutant fibroblasts may reveal a more complex and nuanced view of parkin and its 
interaction with mitochondria.  
It is furthermore found that patient fibroblasts have a higher maximal respiration, with this effect 
being particularly pronounced in the fibroblasts of patient P2 (Section 3.3.2). This is reflected in the 
significantly higher spare respiratory capacity of the P2 fibroblasts over the wild-type control 
fibroblasts, whereas the fibroblasts of patient P3 have a spare capacity comparable to the controls. 
These differences between the two patients’ fibroblasts may be explained by genetic differences, 
which results in additional compensatory mechanisms specific to the P2 fibroblasts. It is interesting to 
compare this to the results of the parkin interactor accumulation experiments (Section 3.2.4.2), which 
also suggested a compensatory response in the P2 fibroblasts. While the nature of this patient-specific 
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compensation is unclear, previous studies have found compensatory mitochondrial biogenesis and 
upregulation of lysosomal degradation pathways PINK1 knockout mice (Wood-Kaczmar et al. 2008), 
as well as upregulation of various RING and RBR E3 ubiquitin ligases in parkin knockout mice 
(Bhandari et al. 2014). It is interesting to speculate that P2 fibroblasts may be compensating for the 
loss of parkin by upregulating alternative mitochondrial and/or protein degradation pathways, which 
is not occurring in P3 cells to the same extent. Indeed, a clinical comparison of the PD phenotypes of 
patients P2 and P3 is suggestive of such a possible compensatory effect. P2 and P3 harbor identical 
parkin mutations and, as siblings, share approximately 50% of their genetic makeup; however, P2 has 
a markedly less severe PD phenotype and slower disease progression than her sibling (personal 
communication with research nurse, Sr. Debbie Joubert). The possible compensatory mechanism 
which attenuates PD severity and cellular impairments in P2 should be investigated in future studies.      
Spare respiratory capacity is the extent to which cells can increase oxidative phosphorylation in the 
case of a sudden increase in energy demand, and reflects the cells’ abilities to respond to stressful 
conditions (Nicholls 2009). The marked increase in maximal respiration and spare respiratory 
capacity of the P2 fibroblasts specifically is therefore unexpected, and may represent an “overshoot” 
of the compensatory response to the absence of parkin. However, is should be noted that 
compensatory adaptions due to the upregulation of parallel or alternative pathways are almost 
certainly less efficient, and may only result in a seemingly “improved” phenotype when the cells are 
not exposed to any additional sources of stress. Indeed, the fibroblasts in the present study were 
cultured under optimal growth conditions prior to respiratory rate analysis, and the perturbations with 
pharmacological stressors during analysis were performed in short time spans of minutes – hardly 
enough time for the ablation of compensatory responses under prolonged stress. It would be 
interesting to investigate whether similar respiratory compensation is in effect for cells cultured in 
glucose-free galactose media. 
These compensatory responses are likely dependent on cell- and tissue-specific metabolic capacity 
and adaptations (Akundi et al. 2013). Hence, the observations made here on patient-derived 
fibroblasts should not be extrapolated to possible effects in a neuronal environment, as neurons may 
be more restricted in their compensatory repertoire than dermal fibroblasts. In particular, the inability 
of neurons to upregulate glycolysis may increase their vulnerability to mitochondrial dysfunction 
(Bolaños et al. 2010). Furthermore, many of the described functional roles of parkin are cell-type 
specific which will result in different functional effects of parkin deficiency in fibroblasts and 
neurons. For example, it was found that parkin has anti-apoptotic and anti-oxidative properties in 
neuronal and myogenic cells, but not in COS-1 kidney cells (Kuroda et al. 2006b). Ideally, the 
observations made in this study should be verified in a neuronal model, such as iPSC-derived neurons 
with parkin mutations. 
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 4.4 VITAMIN K2 AS A POTENTIAL THERAPEUTIC MODALITY 
Patient-derived fibroblasts, with pre-defined genotypes, are particularly useful in the evaluation of the 
effects of various compounds on underlying disease mechanisms in human cells (Auburger et al. 
2012). In fact, fibroblasts from PD patients with parkin mutations have been successfully used to 
investigate the rescue effect of glutathione precursor compounds on mitochondrial impairment 
(Mortiboys et al. 2008). Similarly, it has been demonstrated that rapamycin partially rescued 
mitochondrial defects in parkin-mutant fibroblasts (Tain et al. 2009). Here, the effects of treatment 
with the potential therapeutic agent vitamin K2 on mitochondrial function were assessed in a cellular 
model of parkin deficiency.  
It was shown that vitamin K2 (in the form of MK-4) had no overall effect on cell growth when 
comparing vitamin K2-treated fibroblasts with untreated cells, either for patient-derived or wild-type 
control fibroblasts. Similarly, vitamin K2 co-treatment did not significantly alter overall cell growth of 
CCCP-stressed fibroblasts. Furthermore, vitamin K2 did not rescue the increased susceptibility to 
CCCP in parkin-mutant fibroblast discussed in Section 4.3. When considering assays of cell viability, 
it was found that vitamin K2 slightly decreased cell viability in comparison to untreated cells, but this 
effect was not significantly different between patient-derived and wild-type fibroblasts. In other 
words, the observed decrease in cell viability is a global effect not related to parkin mutation status. 
This decline in cell viability after vitamin K2 treatment may be explained by the previously-described 
pro-apoptotic effect of vitamin K2 (Yokoyama et al. 2008). It is unclear why similar effects on cell 
viability were not seen during the initial optimization of vitamin K2 treatment conditions (Section 
3.4.1).  
The effect of vitamin K2 on the morphology of the mitochondrial network had a similarly global, 
parkin-independent effect. Vitamin K2 increased both the mitochondrial length (aspect ratio; 
p<0.0001) and degree of branching (form factor; p<0.0001) of all investigated fibroblast cell lines. 
The observed increases in aspect ratio and form factor following vitamin K2 treatment are indicative 
of an increase in mitochondrial fusion and decrease in fission, respectively; hence, vitamin K2 is 
thought to promote a more interconnected mitochondrial network. Previous studies have shown that 
increased mitochondrial fusion has protective effects.  It was reported that enhanced fusion enabled 
equal distribution of mitochondrial proteins and metabolites, and reduced the accumulation of mtDNA 
mutations, thereby protecting against mitochondrial damage (Nakada et al. 2001; Ono et al. 2001). 
Thus, the elevation of mitochondrial fusion may serve to maintain bioenergetic function by acting as a 
“rescue” pathway (Twig and Shirihai 2011). Increased mitochondrial fusion was also found to be 
protective against ischemia in heart tissue (Ong et al. 2010). Interestingly, Rambold et al (2011) found 
that the fusion-driven elongation of mitochondria increased ATP production; this was ascribed to the 
enhanced cristae density and ATP synthase dimerization of elongated mitochondria.  
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Given these functional links between mitochondrial dynamics and bioenergetics, it can be speculated 
that the higher interconnectedness of mitochondria of vitamin K2-treated fibroblasts seen in the 
present study is associated with altered mitochondrial respiration. In fact, mitochondrial respiration 
analysis revealed that vitamin K2 increased the rates of basal respiration (p=0.0459), ATP-linked 
respiration (p=0.0465), the oxygen consumption due to proton leakage (p=0.025) and the maximum 
respiration (p=0.0331) of all fibroblasts cell lines. While treatment with vitamin K2 increased these 
measures of absolute respiration, it did not significantly affect ATP coupling efficiency or spare 
respiratory capacity. Importantly, the observed increases in basal and ATP-linked respiration were 
global effects of vitamin K2 treatment, irrespective of the parkin mutation status of the fibroblasts. It 
was speculated that the enhanced respiratory rates may be due to increased polarization of Δψm 
following treatment; however, further experiments found that vitamin K2 had no observable effect on 
Δψm .This suggests that vitamin K2 may act as a general promoter of mitochondrial respiration, which 
is in accordance to its previously-described role as a mitochondrial electron carrier in the ETC of 
Drosophila (Vos et al. 2012).  
It is interesting to contrast the results obtained here to those reported by Vos et al: while they found 
that vitamin K2 supplementation rescued mitochondrial dysfunction in PINK1-mutant flies, wild-type 
control flies did not experience any enhancement of mitochondrial function. For example, 
measurements of OCR and ATP synthesis were comparable between wild-type flies fed on vitamin K2 
and control media. Similarly, whereas vitamin K2 rescued the swollen, clumped mitochondrial 
phenotype of PINK1- and parkin-mutant flies, treatment had no effect on the mitochondrial 
morphology of wild-type Drosophila. This is in contrast to the increased interconnectedness of 
mitochondrial networks and elevated respiratory rates seen in even wild-type fibroblasts following 
vitamin K2 treatment. This discrepancy may point toward significant differences in the molecular 
action of vitamin K2 in Drosophila and human cells, which should be followed up in future studies.       
Some interesting disparities between patient and wild-type fibroblasts in their respective vitamin K2 
treatment responses were observed. For instance, the increase in proton leakage following treatment 
was significantly more pronounced in patients than the increase in wild-types (p=0.0082). Also, 
vitamin K2 increased the maximum respiratory rates of parkin-mutant fibroblasts to a greater extent 
than control fibroblasts (p=0.0105). Whereas it was originally anticipated that vitamin K2 may rescue 
defects in mitochondrial respiration in parkin-mutant fibroblasts, this study found a compensatory 
increase of respiratory rates in response to parkin deficiency (Section 4.3), which is enhanced by 
vitamin K2 treatment. The enhancement of this compensatory effect in parkin-mutant fibroblasts by 
vitamin K2 may point towards an interaction of vitamin K2 with the patient-specific compensatory 
response.  
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It is noted that the global effects of vitamin K2 seen in patient and unaffected control fibroblasts, such 
as elevated mitochondrial respiration and enhanced interconnectivity of mitochondrial network, may 
itself be indirect cellular responses to vitamin K2 treatment. This may repudiate the specific action of 
vitamin K2 as an ETC molecule in human fibroblasts, as seen in Drosophila (Vos et al. 2012). 
However, potentially promising therapeutic compounds do not necessarily have to target specific 
cellular pathways to prove beneficial: compounds which induce compensatory mechanisms may 
sufficiently overcome underlying cellular defects to provide a protective effect.  
While this study of parkin-deficient fibroblasts does not support a role for vitamin K2 to treat PD 
pathology specifically, vitamin K2 may have appeal as a general promoter of mitochondrial 
respiratory function. As such, vitamin K2 supplementation could potentially support the function of 
cells and tissues that are particularly reliant on proper mitochondrial function, including neurons. 
Hence, this compound may prove beneficial as a general neuroprotective agent. Other studies have 
described various neuroprotective effects of vitamin K2; for example, vitamin K2 was found to protect 
against oxidative stress-induced cell death in cultured neurons and oligodendrocytes (Li et al. 2003; 
Sakaue et al. 2011). Vitamin K2 is also known to promote neuroprotection via its activation of the 
anti-apoptotic protein Gas6 (Shankar et al. 2003).  Moreover, the vitamin K analog β-lapachone has 
been shown to enhance mitochondrial function in the brain and prevent motor function decline in aged 
mice (Lee et al. 2012b). In fact, low levels of vitamin K2 in the brain, as well as low dietary intake of 
vitamin K2, have been associated with an increased susceptibility to Alzheimer’s disease (Allison 
2001; Presse et al. 2008).  
Vitamin K2 may also be of benefit in PD therapy by targeting other neurodegenerative pathways. A 
recent study demonstrated that vitamin K2 can directly interact with α-synuclein and inhibit its 
fibrillization in vitro (da Silva et al. 2013). In contrast to the non-specific hydrophobic interactions 
exhibited by most other anti-fibrillogenic compounds, vitamin K2 delayed fibrillization via a specific 
interaction with α-synuclein residues, which promoted the formation of short fibrils rather than 
cytotoxic oligomers. These anti-fibrillogenic properties of vitamin K2, in combination with its 
enhancement of mitochondrial function seen in the present study, suggest that vitamin K2 has 
potential as a multi-target PD therapeutic agent.     
However, it should be emphasized that the interesting effects described in this pilot study were 
observed in cultured fibroblasts, and that these results cannot necessarily be extrapolated to neurons. 
Fibroblasts are markedly different from neurons in their bioenergetic requirements (Connolly 1998), 
and the increased mitochondrial respiration of fibroblasts in the presence of vitamin K2 may reflect 
cell-type specific responses. Therefore, the promising mitochondrial effects seen here should be 
verified in an appropriate neuronal environment to support the potential of vitamin K2 as a 
neuroprotective compound.  
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4.5 LIMITATIONS OF THE STUDY  
4.5.1 Limitations of the PD study group 
The major drawback of the study group used for parkin mutation screening is the limited number of 
South African PD patients available for inclusion. Furthermore, out of the 229 recruited PD patients, 
only seventeen were of Black African ancestry. This under-studied population group is therefore not 
adequately represented in the present study, which prohibits informed conclusions being made 
regarding the frequency of parkin mutations in the Black South African population. The limited 
number of Black PD patients may reflect a recruitment bias, as the majority of the study participants 
were recruited at the Movement Disorders clinic at Tygerberg Hospital (Cape Town, South Africa). 
This hospital mainly serves the predominantly Caucasian and mixed ancestry communities of the 
surrounding area, due to the complex socio-economic legacies of the apartheid regime. Black PD 
patients in rural areas may be under-diagnosed, as there are currently very few trained neurologists 
available to such rural communities. It is possible that this bias of ascertainment contributed to the 
low recruitment of Black PD patients in the present study. Despite intensive efforts, no additional 
Black patients could be recruited: this was due to a lack of contact details, loss of patients to follow-
up and a lack of willingness of family members to participate in the research.      
The South African Indian population is also under-represented amongst the study participants, with 
only four PD patients of Indian descent; however, this limitation is of less concern as the contribution 
of parkin mutations to PD in this population group has been well studied on the Indian subcontinent 
(Biswas et al. 2006; Vinish et al. 2010; Padmaja et al. 2012). While separate genetic screening for PD 
genes in the South African Indian population would be of benefit, this is perhaps not as urgent as 
investigations of the population groups that are predominantly found in South Africa. 
 
4.5.2 Limitations of mutation detection techniques  
HRM analysis is a fast, simple and cost-effective method to screen for genetic variants; however, 
HRM is susceptible to both false positive and false negative results. Several studies have established 
the sensitivity and specificity of this technique to be in the range of 90-100% (Dobrowolski et al. 
2007; Montgomery et al. 2007; Taylor 2009). Small insertions and deletions may be more difficult to 
detect than nucleotide substitutions, and homozygous substitutions or A>T substitutions may not 
significantly alter the melting profile (van der Stoep et al. 2009). Hence, all samples demonstrating 
altered melting behavior need to be verified, and their variants identified, by direct sequencing. This 
need for subsequent verification incurs additional costs on the HRM screening method.    
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The MLPA technique allows for the targeted, simultaneous analysis of many genomic regions for 
exonic rearrangements, using standard PCR and capillary electrophoresis equipment (Hömig-Hölzel 
and Savola 2012). However, MLPA is susceptible to false positive results, specifically false exonic 
deletions. Such false positives may arise from DNA sequence polymorphisms in the target sequence 
that are located close to the probe ligation site, which may interfere with proper probe annealing. This 
particular limitation is evident in the present study, as the presence of the M192L parkin 
polymorphism was shown to produce a false positive result (Section 3.1.2). Hence, it is advisable that 
all exonic rearrangements detected via MLPA analysis be verified using a second, independent 
experimental approach. This alternative exonic rearrangement detection method may introduce 
additional reagent and labor costs. Furthermore, probe signal analysis requires the proper binding of 
reference probes to their target sequences. While these reference probes are designed to target 
chromosomal regions that are not expected to harbor structural variants, probe design is mostly based 
on genomic data from Caucasian individuals. It is possible that the great genetic diversity observed in 
African populations may influence the binding of reference probes to target regions, which may yield 
false results. It is therefore important to independently verify MLPA results obtained for samples from 
non-Caucasian origin. 
 
4.5.3 Limitations of Y2H 
The Y2H method is a simple, inexpensive and powerful high-throughput genetic technique to detect 
interactions between bait and prey proteins in an in vivo environment (Fields and Song 1989). This 
makes Y2H a widely-used screening method with broad applications in the study of interactomics. 
However, this approach presents several limitations, particularly in regards to false positive and false 
negative results.  
False positive bait-prey interactions, i.e. detection of spurious interactions in the Y2H setting which 
are biologically meaningless, may arise for a number of reasons. Firstly, proteins observed to interact 
in yeast do so in a very artificial setting:  they are directed to the nucleus (forced co-localization), are 
overexpressed in the same cell (forced co-expression), are expressed as fusion proteins, and they 
interact in a non-native yeast environment, all of which may facilitate their interaction (Gietz 2006; 
Brückner et al. 2009). Hence, protein interactions observed in a Y2H setting need to be independently 
verified in more biologically appropriate environment. Secondly, bait or prey proteins may activate a 
reporter gene independently of an interacting partner: this limitation was mitigated in this study by 
testing for auto-activation of the parkin bait prior to Y2H analysis, the use of multiple reporter genes, 
and by performing rigorous interaction specificity testing of prey proteins after Y2H analysis. 
Nonetheless, false positives remain a serious drawback, with an estimated 25-45% false positive rate 
for the Y2H system (Deane et al. 2002; Huang et al. 2007).     
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While steps can be taken to mitigate the detection of false positive interactions, it is more difficult to 
address the high false negative rate, estimated at 45-96% (Edwards et al. 2004). A major source of 
false negatives, i.e. authentic protein interactions which were not detected in the Y2H setting, is the 
necessity of bait and prey proteins to enter the yeast nucleus. Membrane proteins, mitochondrial 
proteins and other proteins with strong localization signals may not appropriately translocate to the 
yeast nucleus, despite their fusion to a nuclear localization signal (Koegl and Uetz 2007). Moreover, 
bait and preys are expressed as fusion proteins, where the presence of fused domains may interfere 
with proper folding of the proteins or sterically obstruct protein interactions. Furthermore, relevant 
cofactors required for protein interaction, such as post-translation protein modifications or adaptor 
proteins, may not be present in the yeast host organism, leading to a false negative result (Sprinzak et 
al. 2003). Importantly, parkin requires PINK1-mediated phosphorylation to activate the mitophagy 
cascade (Shiba-Fukushima et al. 2012); important mitophagic targets of parkin may therefore have 
been overlooked due to the absence of the proper phosphorylation signal in the Y2H setting.  
False negatives may also arise from proteins that are toxic to the host cell when overexpressed (Suter 
et al. 2008). Although initial testing of the parkin bait showed no toxic effect on the host strain, one 
cannot rule out such an effect for certain prey proteins. Furthermore, the high stringency of the 
interaction specificity tests used to reduce false positives may have excluded authentic protein 
interactions. One of the heterologous bait controls used in the present study encodes murine p53; 
parkin is a known target of p53 (Zhang et al. 2011) Hence, parkin interactors which are likewise 
targets of p53 would have been spuriously excluded as false positives, including the often-reported 
interaction of parkin with itself (Zhang et al. 2000; Imai et al. 2001). 
These false negatives drastically affect the reproducibility of Y2H screens. Per illustration, two 
independent Y2H screens using identical methods showed less than 30% overlap and only 12% of 
known interactions were detected in each screen (Ito et al. 2001). This considerable limitation is the 
likely explanation for why most of the previously-described parkin interactors were not detected here. 
 
4.5.4 Limitations of verification techniques 
The current study used a combination of immunofluorescent and biochemical approaches to verify 
selected protein interactions. Independent verification of such interactions greatly supported their 
authenticity and biological relevance, as the interacting proteins were expressed under the influence of 
their native promoters (endogenous expression), in mammalian cells in their natural cellular 
compartments, and without the presence of artificial fusion domains. However, verification 
techniques are labor-intensive and can only be applied to a small number of interactions detected via 
Y2H. Hence, most of the interactions found in the Y2H screen remain to be verified in a future study.      
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In vivo co-localization was used to demonstrate that parkin and each of its interactors share 
subcellular environments, thereby supporting the biological relevance of these interactions. However, 
as fluorescence microscopy is limited by the optical resolution of the microscope (typically 200nm for 
confocal microscopy), apparent co-localization of proteins cannot be taken as evidence of physical 
interaction per se (Lalonde et al. 2008). The present study used vertical Z-stacking to acquire 
fluorescent signal in all three dimensions, which allowed for the resolution of signals that might have 
deceptively appeared to co-localize in two-dimensional analyses. Common problems when 
performing immunofluorescence experiments include cellular autofluorescence and spectral bleed-
through between different fluorescent signals (Zinchuk et al. 2007; Dunn et al. 2011). However, the 
present study used careful selection of appropriate fluorophores, suitable negative controls, and 
assessment of primary and secondary antibodies for cross-reactivity and specificity of fluorescent 
signals, to minimize such effects.   
Co-IP of endogenous proteins is generally considered to be the “gold standard” technique for the 
demonstration of protein interactions (Berggård et al. 2007). However, co-IP requires careful 
consideration and optimization in order to overcome the limitations of this approach. A commonly 
experienced problem is high background signals resulting from antibody cross-reactivity; here, 
antibodies were selected in such a way as to avoid cross-reactivity. Furthermore, co-
immunoprecipitation is less adept at detecting transient interactions, and detected interactions may 
represent the association of proteins in a common complex, rather than direct interactions. An 
additional consideration when using homogenized cell lysates is that proteins from different cellular 
compartments are likely to come into contact with each other; however, in this study, co-localization 
analyses did illustrate that parkin and each of its interactors share subcellular environments in vivo.   
Co-IP relies on proper antibody binding to isolate protein complexes. Hence, the 3D structure of an 
interacting pair may obstruct an antibody epitope, and prevent immunoprecipitation of that protein 
complex (Zhou and Veenstra 2007). This limitation was encountered in the co-IP of parkin and 
SEPT9 (Section 3.2.3.2), where the use of a different anti-parkin antibody (recognizing a different 
parkin epitope) circumvented this obstacle.    
 
4.5.5 Limitations of parkin-deficient cell models 
Originally, it was attempted to use siRNA-mediated gene knockdown in SH-SY5Y cells to create a 
parkin-deficient neuronal cell model. However, this approach was reconsidered after several technical 
issues were encountered. Firstly, of the four unvalidated parkin-targeted siRNA molecules tested, 
only two had any demonstrable effect on parkin mRNA expression. When considering the two siRNA 
molecules that did suppress parkin mRNA expression, this knockdown was limited to only 50% of 
parkin expression observed in non-silenced control cells. This partial knockdown effect would have 
Stellenbosch University  https://scholar.sun.ac.za
184 
 
been problematic in subsequent experiments, as cells from heterozygous parkin mutation carriers 
(with presumably 50% functional parkin) typically do not demonstrate significant functional 
impairments (Mortiboys et al. 2008; Pacelli et al. 2011). This is in accordance with the recessive 
inheritance pattern of parkin mutations, suggesting that a 50% loss of parkin is mostly insufficient to 
result in PD. Secondly, the two tested siRNA molecules had greatly inconsistent effects on the parkin 
protein expression, despite the fact that similar transfection conditions were used in all replicate 
experiments. Ultimately, the inconsistent knockdown efficiency at the protein level precluded 
downstream siRNA experiments, in which implicitly reliable parkin knockdown would be critical.   
Furthermore, the necessity for recurring transfections in all downstream applications made the 
transient siRNA-mediated gene knockdown approach impractical in the present study, which 
employed a large range of repeated functional assays. It is suggested that alternative approaches to 
transient siRNA-mediated gene knockdown, such as stable knockdown with small hairpin RNA 
(shRNA) or genomic editing with CRISPR (clustered regularly interspaced short palindromic 
repeats)/Cas9, may be more appropriate for future use (Lambeth and Smith 2013; Liu and Fan 2014).    
The current study used PD patient-derived parkin-null fibroblasts as a model of parkin deficiency. 
These patient-derived cell lines have the advantage of harboring predefined parkin mutations, without 
the need for genetic manipulation. Furthermore, such cell models reflect the cumulative cell damage 
at the age of the patients. However, the use of patient-derived fibroblasts has several limitations which 
need to be considered (Auburger et al. 2012). Firstly, the gene expression profile of dermal fibroblasts 
differs significantly from neurons, which limit their use as models of PD. SNCA in particular is 
expressed at a relatively low level in fibroblasts, and in addition fibroblasts are resistant to the 
mitochondrial toxin rotenone (Harper et al. 2007). Fibroblast models therefore do not recapitulate the 
neuronal environment, particularly not the susceptible dopaminergic neuronal environment. This 
limitation may be overcome by reprogramming patient-derived fibroblasts into induced pluripotent 
stem cells (iPSCs), after which they may be differentiated into an appropriate dopaminergic neuronal 
PD model (Beevers et al. 2013). 
Secondly, the use of derived cell models is significantly limited by the inherent genomic variability 
between cell lines from different individuals. It is therefore recommended that several biological 
replicate and control cell lines be investigated in any given study, which may improve the signal-to-
noise ratio caused by this variability. In the current study, fibroblasts could only be obtained from 
three patients with parkin-null mutations, of which one fibroblast culture was lost to microbial 
contamination. The results obtained here are therefore limited by the low number of biological 
replicates (two).  Furthermore, the two patients recruited for this study were siblings. The limited 
sample size is a major drawback of the study, and verification of the findings reporter here in a larger 
group of patients and controls would be necessary.   
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4.5.6 Limitations of functional assays 
MTT assays are widely used to assess cell viability (Berridge et al. 2005). These assessments are 
based on the capacity of cellular dehydrogenases to reduce MTT to insoluble formazan, which is 
limited to viable cells. However, MTT measurements are particularly susceptible to biochemical 
influences of added compounds, which may artificially inflate viability measurements (Ulukaya et al. 
2004; Ahmad et al. 2006; Ganapathy-Kanniappan et al. 2010). In fact, several studies have reported 
conflicting results from MTT-based cell viability assays and cell growth assays due to such MTT 
artefacts (Jabbar et al. 1989; Pagliacci et al. 1993; Belyanskaya et al. 2007). This limitation was also 
seen in the present study, as treatment of fibroblasts with CCCP greatly enhanced the ostensible 
viability measurements (Section 3.3.1). It has been suggested that MTT assays should be 
supplemented with additional assays of cellular health in order to detect such MTT-induced artefacts. 
This was done here, as CyQUANT® assays were performed in parallel with MTT assays. While 
CyQUANT® assays are based on measurements of total DNA content and are therefore not 
susceptible to the same artefacts as MTT assays, CyQUANT® assays are less adept at discriminating 
between viable and apoptotic cells. Hence, the simultaneous use of these two complementary assays 
provides a more reliable estimate of cellular health than either assay by itself. 
Mitochondrial respiration analysis using a Seahorse Extracellular Flux Analyzer provides a simple, 
accurate and high-throughput method to investigate respiratory flux in in intact cells (Ferrick et al. 
2008). However, it should be noted that the respiratory state of isolated dermal fibroblasts are not 
representative of cell respiration in more energetically-demanding cells such as neurons, as fibroblasts 
are known to have a lower metabolic rate than most cells (Connolly 1998). Furthermore, OCR 
measurements are very sensitive to inhibitor compound concentrations; therefore, these parameters 
were extensively optimized for the fibroblast cell lines prior to the experiment. It is particularly 
important that all OCR measurements should be normalized to account for quantitative differences 
between cell samples; in the present study, OCR measurements were normalized to cell number. 
While measurements of cell number or total protein content is generally regarded as a sufficient 
means of normalization (Perron et al. 2013; Wills et al. 2013), it should be noted that this does not 
correct for possible differences in mitochondrial densities between cells. Hence, cells may increase 
mitochondrial biogenesis as a compensatory response to mitochondrial impairment, which would 
greatly affect cellular respiration. This compensation would not be accounted for when only 
considering cell number or total protein concentration. Analyzing isolated mitochondria would allow 
for a respiratory analysis of comparable mitochondrial numbers; however, this approach is susceptible 
to several other limitations and artefacts (Brand and Nicholls 2011).   
Functional assays that employ fluorescent dyes, such as the JC-1 dye in Δψm analysis and the 
Mitotracker Red dye used for mitochondrial network analysis, should be carefully optimized in order 
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to minimize dye-induced cytotoxicity. Such dye-induced cytotoxicity may increase cellular stress and 
apoptosis, which may result in artefacts. In the present study, the JC-1 and Mitotracker Red live-cell 
staining conditions were first optimized in order to minimize dye-induced cytotoxicity in the 
fibroblast cell cultures. Additionally, care was taken to keep all dye incubation periods and 
fluorescence imaging procedures consistent between experimental runs.  
 
4.6 OVERVIEW AND FUTURE DIRECTIONS OF THE STUDY 
It was concluded from the present study that parkin mutations do not significantly contribute to the 
genetic etiology of PD in South African patients. This finding is consistent with parallel studies from 
our research group which found that mutations in the known PD genes are rare in the South African 
PD population. The large percentage of South African PD patients without any detected mutations in 
known PD genes raises the interesting possibility of the South African population harboring novel 
mutations or novel PD-causing genes. Hence, our research group is currently employing various 
approaches to identify new PD candidate genes for screening in the South African population. For 
example, a NGS-based exome sequencing approach is currently underway to identify candidate PD 
genes in an extended Afrikaner family. Alternatively, genes and proteins that contribute to PD may be 
identified by a hypothesis-driven approach, whereby proteins acting in common pathways with known 
PD genes are prioritized for investigation and genetic screening. This approach may identify new 
genetic risk factors of PD. The present study identified and verified four parkin-interacting proteins; 
future studies should be aimed at screening the genes encoding 14-3-3η, ATPAF1, β- and γ-actin and 
SEPT9 for variants in a group of South African PD patients. Ultimately, the identification of the genes 
and mutations underlying PD in the unique Black, Afrikaner and Mixed ancestry sub-populations of 
South Africa may reveal novel disease mechanisms underlying the etiology of PD in South Africa. 
Of the four parkin interactors, two are wholly novel and should be prioritized for future research. It 
was found that ATPAF1 and SEPT9 both accumulate in the absence of parkin, which strongly 
suggests that these proteins are substrates of parkin-mediated ubiquitination. The obvious next step 
would be to confirm that this is indeed the case, using either in vitro or in vivo ubiquitination assays. 
Furthermore, the ubiquitination signals should be analyzed with chain-specific anti-ubiquitin 
antibodies, which would establish the mode of ubiquitination (whether mono-, poly-, K48- or K63-
ubiquitination). This approach would provide further insight into the nature and consequences of these 
protein interactions.  
It is recommended that the functional consequences of parkin’s interaction with both ATPAF1 and 
SEPT9 should be investigated further, as these two proteins are novel and exciting members of the 
parkin interactome. For example, it should be determined whether the accumulation of ATPAF1 alters 
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the assembly of the F1-ATP synthase, as this has not been investigated to date. This may be performed 
by overexpressing ATPAF1 in an appropriate cell line and using non-denaturing PAGE and 
immunoblotting with an antibody directed against the β-subunit of F1-ATP synthase, which would 
indicate the incorporation of the β-subunit into various stages of ATP synthase assembly. This 
investigation should also be performed in parkin-deficient cell models, which accumulate ATPAF1 
without the need for transgenic overexpression. In terms of SEPT9, future studies should investigate 
how accumulating SEPT9, either as a result of overexpression or due to parkin deficiency, impacts on 
the assembly of septin filaments. Cell imaging approaches would be appropriate towards this end. The 
particular role of SEPT9 in neurons should also be investigated, as this is currently unknown. A 
previous study has suggested that SEPT9 accumulation in neurons may have a pro-apoptotic effect 
(Mao et al. 2013); this should be investigated further in the context of its interaction with parkin.    
This study also identified 25 other putative parkin-interacting proteins in a Y2H screen which were 
not prioritized for verification. However, these proteins may be authentic parkin interactors of 
significant relevance to PD, and should be verified in the future. Based on recent findings, three of the 
putative interactors could be prioritized for further verification and study: EXOC4, CCDC56 and 
HGS. EXOC4, also known as Sec8, is a component of the exocyst complex with important roles in 
vesicular trafficking (Heider and Munson 2012). Interestingly, it was recently reported that 
accumulation of EXOC4 activated the JNK pro-apoptosis signaling cascade (Tanaka et al. 2014). 
CCDC56 has only very recently been characterized as a mitochondrial transmembrane protein and 
essential factor in mitochondrial complex IV biogenesis (Clemente et al. 2013). This may be of 
significant relevance to neurodegeneration, and future studies should aim to verify this protein 
interaction. Lastly, the putative parkin interactor HGS is a component of the endosomal sorting 
complex required for transport (ESCRT), and has recently been implicated in xenophagy directed 
against mycobacterial pathogens (Mehra et al. 2013). Hence, parkin and HGS may interact in the 
mediation of xenophagy. While this is perhaps not related to PD, this interesting finding may have 
significant implications for research into cellular defense responses.    
The investigation of the functional effects of parkin deficiency in fibroblasts obtained from South 
African PD patients has delivered some surprising results. Whereas these parkin-mutant fibroblasts 
are more susceptible to CCCP-induced cytotoxicity and have more fragmented mitochondrial 
networks than wild-type control fibroblasts; the respiratory capacity of these fibroblasts are not 
impaired in the absence of parkin. In fact, measurements of respiratory rates were markedly enhanced 
in patient-derived fibroblasts, strongly suggesting a compensatory response in these cells. Future 
studies should aim at investigating the molecular mechanism of such mitochondrial compensation in 
the absence of parkin. In particular, it should be determined whether mitochondrial biogenesis is in 
fact increased in the patient-derived fibroblasts. This may be done by performing q-PCR to quantify 
mtDNA content, or by using western blotting to evaluate the protein expression of key mitochondrial 
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proteins. Alternatively, indirect measures of mitochondrial content (such as citrate synthase activity) 
may be performed, as has been done in previous studies (Grunewald et al. 2010; Pacelli et al. 2011).    
It is also suggested that future studies should confirm that the interesting impairments and 
compensatory effects observed in the patient-derived fibroblasts are due to parkin deficiency itself, 
rather than an unknown secondary mechanisms. For example, Mortiboys et al. (2008) used an RNAi 
approach to demonstrate the parkin-dependent nature of the mitochondrial impairments they initially 
observed in parkin-mutant fibroblasts, and which were recapitulated following parkin knockdown in 
wild-type fibroblasts. Similar RNAi approaches or genomic editing with CRISPR/Cas9 may be 
suitable to this end. Moreover, this study could be expanded to include fibroblasts from patients with 
sporadic PD, which may be more appropriate controls for the parkin-mutant fibroblasts than cells 
obtained from unaffected individuals.   
Importantly, all of the functional effects of parkin deficiency observed in this pilot study were 
performed on fibroblasts cultured under basal, unstressed conditions. Given parkin’s important role in 
the cellular stress response, future studies should aim to compare the results obtained here to 
fibroblasts cultured under more stressed or oxidative conditions. This may be achieved by exposing 
the cells to low concentrations of cytotoxic agents, or by culturing the fibroblasts in glucose-free 
galactose media.    
This study also evaluated the effects of vitamin K2 treatment on mitochondrial health in a parkin-
deficient cell model. It was found that vitamin K2 increased the interconnectedness of the 
mitochondrial network and enhanced respiratory rates of all the fibroblasts investigated, irrespective 
of parkin mutation status. This suggests that vitamin K2 may be a promising pro-mitochondrial 
compound, and its specific molecular action at the mitochondria should be investigated further. 
Particularly, it is still unclear whether vitamin K2 increases mitochondrial function by acting as an 
electron carrier in the fibroblasts (as it does in Drosophila) or whether respiratory rates are increased 
as a secondary cellular response to vitamin K2 treatment. It is therefore suggested that the action of 
vitamin K2 at the ETC should be determined in human cells. This may be done by isolating 
mitochondria and determining the effect of direct application of vitamin K2 on the rate of oxygen 
consumption or ATP production, as was done by Vos et al. (2012).   
Finally, the results obtained here from both the functional investigations of parkin deficiency and the 
evaluation of the effects of vitamin K2 treatment would benefit significantly from a more 
comprehensive analysis of cellular and mitochondrial function, and from using a larger sample size. 
Our results may be substantiated and informed by measurements of total ATP levels, ATP synthesis 
rates, activities of the individual ETC complexes, NADH/NADPH levels, glycolysis, and/or ROS 
generation. Furthermore, whole proteome or transcriptome analyses would provide valuable and 
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unbiased insights into cellular differences between parkin-deficient and wild-type cells, as well as 
between vitamin K2-treated and untreated cells.      
 
4.7 CONCLUSION 
This study has described several interesting findings on the parkin gene, its protein product and parkin 
deficiency, which provided valuable insight into how parkin dysfunction contributes to 
neurodegeneration. However, the reported findings, plausible explanations and proposed mechanisms 
may only be scratching the surface of the biological processes involved. It is almost inevitable that the 
exploratory approaches used in the current study raise more questions than provide answers; however, 
such questions are fertile ground for future research. Ultimately, it is hoped that a more 
comprehensive understanding of parkin and its role in PD would be translated into novel and more 
effective PD therapeutic approaches, in order to better treat patients suffering from this debilitating 
disorder.    
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APPENDIX I 
 
UK Parkinson’s Disease Society Brain Bank criteria for the diagnosis of PD 
Step 1: Diagnosis of parkinsonian syndrome 
Bradykinesia (slowness of initiation of voluntary movement with progressive reduction in speed and 
amplitude or repetitive actions) 
And at least one of the following: 
 Muscular rigidity 
 4–6 Hz rest tremor 
 Postural instability not caused by primary visual, vestibular, cerebellar, or proprioceptive 
dysfunction 
 
Step 2: Exclusion criteria for PD 
History of repeated strokes with stepwise progression of parkinsonian features 
History of repeated head injury 
History of definite encephalitis 
Oculogyric crises 
Neuroleptic treatment at onset of symptoms 
More than one affected relative* 
Sustained remission 
Strictly unilateral features after three years 
Supranuclear gaze palsy 
Cerebellar signs 
Early severe autonomic involvement 
Early severe dementia with disturbances of memory, language, and praxis 
Babinski sign 
Presence of a cerebral tumor or communicating hydrocephalus on CT scan 
Negative response to large doses of levodopa (if malabsorption excluded) 
MPTP exposure 
 
Step 3: Supportive positive criteria of PD 
Three or more required for diagnosis of definite PD: 
 Unilateral onset 
 Rest tremor present 
 Progressive disorder 
 Persistent asymmetry affecting the side of onset most 
 Excellent response (70%–100%) to levodopa 
 Severe levodopa-induced chorea 
 Levodopa response for five years or more 
 Clinical course of ten years or more 
*This criteria is no longer used (Hughes et al. 2001). Adapted from Gibbs & Lees (1988b).  
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APPENDIX II 
 
1. DNA EXTRACTION SOLUTIONS 
 
Cell lysis buffer 
Sucrose      109.54g 
Triton X-100     10ml 
MgCl2      476mg 
1M Tris-HCl stock solution, pH 8  10ml 
Add ddH2O to a final volume of 1 liter.  
 
3M Na-Ac solution 
Sodium acetate     40.81g 
ddH2O       50ml 
Adjust pH to 5.2 with glacial acetic acid. Add ddH2O to a final volume of 100ml.   
 
Na-EDTA solution 
4mM NaCl stock solution   18.75ml 
100mM EDTA stock solution   250ml 
 
Phenol-chloroform 
Phenol      50ml 
Chloroform     48ml 
8-hydroxyquinone    2ml 
Store at 4˚C. 
 
Chloroform-octanol (24:1) 
Chloroform     96ml 
Octanol      4ml 
Store at 4˚C. 
 
10X TE stock solution 
1M Tris-HCl stock, pH 8   10ml 
500mM EDTA stock solution, pH 8  20ml 
Add ddH2O to a final volume of 100ml.  
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1X TE buffer 
10X TE stock solution    10ml 
Add ddH2O to a final volume of 100ml.  
 
2. ELECTROPHORESIS SOLUTIONS 
 
20X SB stock solution 
Sodium tetraborate decahydrate   38.14g 
Add ddH2O to a final volume of 1 liter.  
 
1X SB buffer 
20X SB stock solution    50ml 
Add ddH2O to a final volume of 1 liter. 
 
4X SDS-PAGE resolving gel buffer 
Tris base     109.2g 
ddH2O      330ml 
10% SDS     24ml 
Adjust pH to 8.8 using 1M HCl. Add ddH2O to a final volume of 600ml. 
 
4X SDS-PAGE stacking gel buffer 
Tris base     36.3g 
ddH2O      330ml 
10% SDS     24ml 
Adjust pH to 6.8 using 1M HCl. Add ddH2O to a final volume of 600ml. 
 
10% Sodium dodecyl sulfate (SDS) 
SDS      50g 
Add ddH2O to a final volume of 500ml. 
 
10X SDS-PAGE running buffer 
Tris base     30g 
Glycine      144g 
10% SDS     100ml 
Add ddH2O to a final volume of 1 liter. 
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1X SDS-PAGE running buffer 
10X SDS-PAGE running buffer   100ml 
Add ddH2O to a final volume of 1 liter. 
 
10% Ammonium persulfate (APS) 
Ammonium persulfate    10g 
Add ddH2O to a final volume of 100ml. Mix well and store at 4oC. 
 
Transfer buffer 
Tris base     3.03g 
Glycine      14.4g 
Methanol     200ml 
Add ddH2O to a final volume of 1 liter. 
 
3. GELS 
 
1% Agarose gel 
Agarose      1g 
1X SB buffer     100ml 
Dissolve the mixture by microwaving for 1-2min on maximum power. Allow to cool to approximately 
55oC. Add 5μl ethidium bromide (10mg/ml). 
 
2% Agarose gel 
Agarose      2g 
1X SB buffer     100ml 
Dissolve the mixture by microwaving for 1-2min on maximum power. Allow to cool to approximately 
55oC. Add 5μl ethidium bromide (10mg/ml). 
 
3.75% SDS-PAGE stacking gel 
ddH2O      2.53ml 
10% SDS     40μl 
4X SDS-PAGE stacking buffer   1ml 
40% Acrylamide    390μl 
TEMED     6μl 
10% APS     30μl 
Makes two gels for the Bio-Rad Mini gel apparatus system (Bio-Rad Laboratories, Hercules, 
California, USA) 
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12% SDS-PAGE resolving gel 
ddH2O      5.57ml 
10% SDS     100μl 
4X SDS-PAGE resolving buffer   1.25ml 
40% Acrylamide    3ml 
TEMED     5μl 
10% APS     75μl 
Makes two gels for the Bio-Rad Mini gel apparatus system (Bio-Rad Laboratories, Hercules, 
California, USA) 
 
15% SDS-PAGE resolving gel 
ddH2O      4.82ml 
10% SDS     100μl 
4X SDS-PAGE resolving buffer   1.25ml 
40% Acrylamide    3.75ml 
TEMED     5μl 
10% APS     75μl 
Makes two gels for the Bio-Rad Mini gel apparatus system (Bio-Rad Laboratories, Hercules, 
California, USA) 
 
4. LOADING DYES  
 
Ethidium bromide stock (10mg/ml) 
Ethidium bromide    500mg 
ddH2O      50ml 
Stir well on a magnetic stirrer for 4h and store aliquots in a dark container at 4˚C. 
 
Bromophenol blue loading dye  
1% Bromophenol blue    10ml 
Glycerol     50ml 
Add ddH2O to a final volume of 100ml. Mix well and store aliquots at 4˚C.  
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2X SDS loading buffer 
10% SDS     600μl 
1M Tris-HCl (pH 6.8)    1.5ml 
1% Bromophenol blue    600μl 
DTT      464mg 
Glycerol     3ml 
Add ddH2O to a final volume of 15ml. Mix well and store aliquots at -20˚C.   
 
5X SDS loading buffer 
10% SDS     1.5ml 
1M Tris-HCl (pH 6.8)    3.75ml 
1% Bromophenol blue    1.5ml 
DTT      1.16g 
Glycerol     7.5ml 
Add ddH2O to a final volume of 15ml. Mix well and store aliquots at -20˚C.    
 
5.  BACTERIAL MEDIA 
 
Luria-Bertani (LB) media 
Bacto tryptone     5g 
Yeast extract     2.5g 
NaCl      5g 
Add ddH2O to a final volume of 500ml. Autoclave at 121˚C for 20min and allow cooling to 
approximately 55˚C. Add appropriate antibiotic (Ampicillin 25mg/liter; Kanamycin 5mg/liter). 
 
LB agar plates 
Bacto tryptone     5g 
Yeast extract     2.5g 
NaCl      5g 
Bacto agar     8g 
Add ddH2O to a final volume of 500ml. Autoclave at 121˚C for 20min and allow cooling to 
approximately 55˚C. Add appropriate antibiotic (Ampicillin 25μg/ml; Kanamycin 5μg/ml). Pour into 
plates and allow 2-3h to set. Store at room temperature for up to three weeks.  
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6. YEAST MEDIA 
 
YPDA media 
Difco peptone     10g 
Yeast extract     10g 
Glucose     10g 
0.2% L-adenine hemisulfate   7.5ml 
Add ddH2O to a final volume of 500ml. Autoclave at 121˚C for 20min. 
 
2X YPDA media 
Difco peptone     20g 
Yeast extract     10g 
Glucose     20 
0.2% L-adenine hemisulfate   1.5ml 
Add ddH2O to a final volume of 500ml. Autoclave at 121˚C for 20min. 
 
0.5X YPDA media 
Difco peptone     2g 
Yeast extract     1g 
Glucose     2g 
0.2% L-adenine hemisulfate   1.5ml 
Add ddH2O to a final volume of 200ml. Autoclave at 121˚C for 20min. 
 
YPDA agar plates 
Difco peptone     10g 
Yeast extract     10g 
Glucose     10g 
0.2% L-adenine hemisulfate   7.5ml 
Bacto agar     10g 
Add ddH2O to a final volume of 500ml. Autoclave at 121˚C for 20min and allow cooling to 
approximately 55˚C. Pour into plates and allow 2-3h to set. Store at room temperature for up to three 
weeks.  
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SD-Ade agar plates 
Glucose     12g 
Yeast nitrogen base without amino acids  4g 
SD-Ade amino acid supplement   0.4g 
Bacto agar     12g 
Add ddH2O to a final volume of 600ml. Autoclave at 121˚C for 20min and allow cooling to 
approximately 55˚C. Pour into plates and allow 2-3h to set. Store at room temperature for up to three 
weeks.  
 
SD-His agar plates 
Glucose     12g 
Yeast nitrogen base without amino acids  4g 
SD-His amino acid supplement   0.4g 
Bacto agar     12g 
Add ddH2O to a final volume of 600ml. Autoclave at 121˚C for 20min and allow cooling to 
approximately 55˚C. Pour into plates and allow 2-3h to set. Store at room temperature for up to three 
weeks.  
 
SD-Ura agar plates 
Glucose     12g 
Yeast nitrogen base without amino acids  4g 
SD-Ura amino acid supplement   0.4g 
Bacto agar     12g 
Add ddH2O to a final volume of 600ml. Autoclave at 121˚C for 20min and allow cooling to 
approximately 55˚C. Pour into plates and allow 2-3h to set. Store at room temperature for up to three 
weeks.  
 
SD-Leu media 
Glucose     12g 
Yeast nitrogen base without amino acids  4g 
SD-His amino acid supplement   0.4g 
Add ddH2O to a final volume of 600ml. Autoclave at 121˚C for 20min. 
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SD-Leu agar plates 
Glucose     12g 
Yeast nitrogen base without amino acids  4g 
SD-Leu amino acid supplement   0.4g 
Bacto agar     12g 
Add ddH2O to a final volume of 600ml. Autoclave at 121˚C for 20min and allow cooling to 
approximately 55˚C. Pour into plates and allow 2-3h to set. Store at room temperature for up to three 
weeks.  
 
SD-Trp media 
Glucose     12g 
Yeast nitrogen base without amino acids  4g 
SD-Trp amino acid supplement   0.4g 
Add ddH2O to a final volume of 600ml. Autoclave at 121˚C for 20min. 
 
SD-Trp agar plates 
Glucose     12g 
Yeast nitrogen base without amino acids  4g 
SD-Trp amino acid supplement   0.4g 
Bacto agar     12g 
Add ddH2O to a final volume of 600ml. Autoclave at 121˚C for 20min and allow cooling to 
approximately 55˚C. Pour into plates and allow 2-3h to set. Store at room temperature for up to three 
weeks.  
 
SD-Leu-Trp media 
Glucose     12g 
Yeast nitrogen base without amino acids  4g 
SD-Leu-Trp amino acid supplement  0.4g 
Add ddH2O to a final volume of 600ml. Autoclave at 121˚C for 20min. 
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SD-Leu-Trp agar plates 
Glucose     12g 
Yeast nitrogen base without amino acids  4g 
SD-Leu-Trp amino acid supplement  0.4g 
Bacto agar     12g 
Add ddH2O to a final volume of 600ml. Autoclave at 121˚C for 20min and allow cooling to 
approximately 55˚C. Pour into plates and allow 2-3h to set. Store at room temperature for up to three 
weeks.  
 
TDO media 
Glucose     12g 
Yeast nitrogen base without amino acids  4g 
SD-Leu-Trp-His amino acid supplement  0.4g 
Add ddH2O to a final volume of 600ml. Autoclave at 121˚C for 20min. 
 
TDO agar plates 
Glucose     12g 
Yeast nitrogen base without amino acids  4g 
SD-Leu-Trp-His amino acid supplement  0.4g 
Bacto agar     12g 
Add ddH2O to a final volume of 600ml. Autoclave at 121˚C for 20min and allow cooling to 
approximately 55˚C. Pour into plates and allow 2-3h to set. Store at room temperature for up to three 
weeks.  
 
QDO media 
Glucose     12g 
Yeast nitrogen base without amino acids  4g 
SD-Leu-Trp-His-Ade amino acid supplement  0.4g 
Add ddH2O to a final volume of 600ml. Autoclave at 121˚C for 20min. 
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QDO agar plates 
Glucose     12g 
Yeast nitrogen base without amino acids  4g 
SD-Leu-Trp-His-Ade amino acid supplement  0.4g 
Bacto agar     12g 
Add ddH2O to a final volume of 600ml. Autoclave at 121˚C for 20min and allow cooling to 
approximately 55˚C. Pour into plates and allow 2-3h to set. Store at room temperature for up to three 
weeks.  
 
X-α-galactosidase (X-α-gal) solution (5mg/ml) 
X-α-gal      25mg 
Dimethylformamide    1ml 
Makes a 25mg/ml stock solution. Dilute with dimethylformamide to a 5mg/ml working solution. Store 
in a dark container at -20˚C.  
 
7. MAMMALIAN CELL CULTURE MEDIA 
 
Fibroblast isolation media 
Amniochrome II complete media   95ml 
Chang Medium® D    95ml  
Non-essential amino acids (NEAA)  5ml 
Penicillin-streptomycin     5ml 
Pre-warm to 37˚C before use. Store at 4˚C. 
 
Fibroblast culture media 
DMEM (4.5g/liter glucose, with L-glutamine) 450ml 
Fetal bovine serum     50ml 
Penicillin-streptomycin     5ml 
Pre-warm to 37˚C before use. Store at 4˚C. 
 
SH-SY5Y culture media 
DMEM (4.5g/liter glucose, with L-glutamine) 222.5ml 
Ham’s F12 (with L-glutamine)   222.5ml 
Fetal bovine serum     50ml 
Penicillin-streptomycin     5ml 
Pre-warm to 37˚C before use. Store at 4˚C. 
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SH-SY5Y serum-free media 
DMEM (4.5g/liter glucose, with L-glutamine) 50ml 
Ham’s F12 (with L-glutamine)   50ml 
Pre-warm to 37˚C before use. Store at 4˚C. 
 
8. SOLUTIONS FOR THE GENERATION OF BACTERIAL COMPETENT CELLS 
 
CAP buffer 
CaCl2      2.21g 
Glycerol     37.5ml 
PIPES       0.76g 
Add ddH2O to a final volume of 250ml. Adjust pH to 7.0 and store at 4˚C. 
 
9. YEAST TRANSFORMATION SOLUTIONS 
 
1M Lithium acetate (LiAc) 
LiAc      5.1g 
Add ddH2O to a final volume of 50ml.  
 
100mM LiAc 
1M LiAc     5ml 
Add ddH2O to a final volume of 50ml.  
 
50% Polyethylene glycol (PEG) 
PEG 4000     25g 
Add ddH2O to a final volume of 50ml.  
 
10. YEAST PLASMID PURIFICATION SOLUTIONS 
 
Yeast lysis buffer 
10% SDS     10ml 
Triton X-100     2ml 
5M NaCl stock solution    2ml 
1M Tris-HCl stock solution, pH 8  1ml 
500mM EDTA stock solution, pH 8  200μl 
Add ddH2O to a final volume of 100ml.  
Stellenbosch University  https://scholar.sun.ac.za
251 
 
 
12. WESTERN BLOT SOLUTIONS 
 
Passive lysis buffer 
1M HEPES stock solution   10ml 
5M NaCl stock solution    4ml 
500mM EDTA stock solution, pH 8  4ml 
Triton X-100     2ml 
10mM Sodium pyrophosphate (NaPPi)  8ml 
1M Na3VO4     400μl 
Add ddH2O to a final volume of 200ml. Aliquot and store at 4˚C. Prior to use, add 100μl of 50mM 
PMSF and one quarter protease inhibitor tablet (Roche) to 5ml passive lysis buffer. 
 
Bradford protein reagent 
Coomassie Brilliant Blue   100mg 
Phosphoric acid     100ml 
96% Ethanol     50ml 
Add ddH2O to a final volume of 1 liter. Filter 2-5 times until solution is light brown in color. Store in 
lightproof container at room temperature.  
 
TBST 
5M NaCl stock solution    30ml 
1M Tris-HCl stock solution (pH 7.6)  20ml 
Tween-20     1ml 
Add ddH2O to a final volume of 1 liter. 
 
Membrane stripping buffer 
Glycine      15g 
10% SDS     10ml 
Tween-20     10ml  
Adjust pH to 2.2. Add ddH2O to a final volume of 1 liter. 
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13. CO-LOCALIZATION SOLUTIONS 
 
Phosphate buffered saline (PBS) 
NaCl      8g 
KCl      200mg 
Na2HPO4·2H2O     1.42g 
KH2PO4     200mg 
Add ddH2O to a final volume of 1 liter. 
 
4% Paraformaldehyde 
Paraformaldehyde    8g 
PBS      200ml 
Dissolve by adding 1ml of 1M NaOH and heating at 50˚C for 30min with constant stirring. Once 
dissolved, adjust final pH to 7.4-7.6.  
 
Mounting media 
Mowiol 4-88     12g 
Glycerol     30g 
ddH2O      30ml 
Add 60ml of a 0.2M Tris stock solution (pH 8.5) and stir overnight at room temperature. Dissolve 
remaining Mowiol by heating to 50˚C with constant stirring. Centrifuge at 5000g for 15 min. Aliquot 
and store supernatant at -20˚C. Prior to use, add a small quantity (<10mg) anti-fading agent (n-
propylgallate) to 1ml mounting media and dissolve by heating to 50˚C for 1h. Centrifuge at 5000g for 
2 min to remove residual sediment. Store in the dark at 4˚C for up to three weeks. 
 
14. SOLUTIONS FOR CELL FUNCTION ASSAYS 
 
5mg/ml MTT stock solution  
Thiazolyl blue tetrazolium bromide  10mg 
PBS      2ml 
Filter through a 0.2μm filter before use. Store in the dark at 4˚C for up to two weeks. 
 
0.1N Acidified isopropanol 
38% HCl     990μl 
Isopropanol     99.1ml 
Store at room temperature. 
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40mM MK-4 (Vitamin K2) stock solution   
MK-4      35.6mg 
Ethanol      2ml 
Vortex well. Aliquot and store in the dark at -20˚C. Stable at 4˚C for up to two weeks. 
 
40µM MK-4 (Vitamin K2) working solution   
MK-4 stock solution    20µl 
Fibroblast culture media   20ml 
Make up fresh before each use. 
 
40mM CCCP stock solution 
Carbonyl cyanide m-chlorophenyl hydrazone 16.2mg 
DMSO      2ml 
Aliquot and store in the dark at -20˚C. Stable at 4˚C for up to two weeks. 
 
10μM CCCP working solution 
40mM CCCP stock solution   5µl 
Fibroblast culture media   20ml 
Make up fresh before each use. 
 
5mg/ml JC-1 stock solution 
Tetraethyl benzimidazolyl carbocyanine iodide  5mg 
DMSO      1ml 
Aliquot in 40µl volumes and store in lightproof container at -20˚C.  
 
0.5μg/ml JC-1 working solution 
5mg/ml JC-1 stock solution    2μl 
Fibroblast culture media   20ml 
Make up fresh before each use. Keep in a lightproof tube. 
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APPENDIX III 
 
1. YEAST CALCULATIONS (obtained from Clontech Manual) 
 
Library titer 
Count number of colonies on all plates with 30-300 colonies after four days 
 #colony forming units (cfu)/ml = 
#cfu x 1000μl/1ml
volume plated (μl) x dilution factor
 
 
Yeast mating efficiency 
Number of cfu/ml on SD-Leu plates indicates viability of prey partner 
Number of cfu/ml on SD-Trp plates indicates viability of bait partner 
Number of cfu/ml on SD-Leu-Trp plates indicates viability of diploids 
The lowest number of cfu/ml on SD-Leu or SD-Trp plates indicates which of the bait or prey partners is 
the limiting partner 
Mating efficiency = 
#cfu/ml of diploids  x 100
#cfu/ml of limiting partner
  
 
Number of clones screened 
#clones screened = #cfu/ml of diploids x resuspension volume (ml) 
 
2. HEMOCYTOMETRIC CELL COUNT  
A hemocytometric yeast cell count was performed in order to obtain a bait culture titer prior to the use 
of the culture in Y2H library mating. Hemocytometric cell counting was also used to obtain the 
correct mammalian cell count for the accurate seeding of SH-SY5Y cells. A glass coverslip was 
placed on the counting surface of a Neubauer hemocytometer (Superior, Berlin, Germany) after both 
the coverslip and the hemocytometer were cleaned with ethanol. Approximately 50μl of a 1 in 10 
dilution of cell suspension was loaded onto the counting surface, which filled the area underneath the 
coverslip through capillary action. The counting chamber was viewed under a microscope (Nikon 
TMS, Nikon Instruments, New York, USA) and the number of cells in the large central quadrant was 
counted. The number of cells per milliliter was calculated as follows: 
#cells/ml = #cells in central quadrant x dilution factor x 104 (a constant used as the volume of the 
central quadrant is 10-4ml) 
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APPENDIX IV 
 
BACTERIAL STRAIN PHENOTYPES 
E. coli strain DH5α 
Φ 80d lacZΔM15 recA1, endA1, Gry A96 thi-1, hsdR17 supE44, relA1, deoR Δ(lacZYA argF)u169 
 
YEAST STRAIN PHENOTYPES  
S. cerevisiae strain AH109 
MATa, trp1-901, leu2-3, ura3-5, his3-200, gal4Δ, gal80Δ, LYS::GAL1UAS-GALTATA-HIS3, GAL2UAS-
GA2TATA-ADE2, URA3:: MEL1UAS-MEL1TATA-lacZ (James et al. 1996) 
S. cerevisiae strain Y187 
MATα, ura3-52, his3-200, ade2-101, trp1-901, leu2-3, 112, gal4Δ, met-, gal80Δ, URA3:: GAL1UAS-
GAL1TATA-lacZ (Harper et al. 1993) 
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APPENDIX V 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pGBKT7 restriction map and multiple cloning site (MCS). This vector expresses proteins fused to 
amino acids 1-47 of the GAL4 DNA binding domain (DNA-BD) as well as a c-Myc epitope tag. 
Expression in yeast is driven by the constitutive ADH1 promoter (PADH1) whereas transcription is 
terminated by the T7 and ADH1 transcription termination sequence (TT7&ADH1). The vector also 
contains a T7 RNA polymerase promoter. Unique restriction sites in the MCS are indicated in bold. 
The vector replicates from pUC ori and 2µ ori in E. coli and S. cerevisiae, respectively. The 
kanamycin resistance gene (Kanr) and the TRP1 nutritional marker respectively facilitate selection in 
E. coli and S. cerevisiae. (Taken from Clontech MATCHMAKER™ vector handbook) 
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pGADT7 AD restriction map and multiple cloning site (MCS). This vector expresses proteins 
fused to amino acids 768-881 of the GAL4 DNA activation domain (DNA-AD), a SV40 nuclear 
localization signal (SV40 NLS) and a haemagglutinin (HA) epitope tag. Expression in yeast is driven 
by the constitutive ADH1 promoter (PADH1) whereas transcription is terminated by the ADH1 
transcription termination sequence (TADH1). The vector also contains a T7 RNA polymerase promoter. 
Unique restriction sites in the MCS are indicated. The vector replicates from pUC ori and 2µ ori in E. 
coli and S. cerevisiae, respectively. The ampicillin resistance gene (Ampr) and the LEU2 nutritional 
marker respectively facilitate selection in E. coli and S. cerevisiae. (Taken from Clontech 
MATCHMAKER™ vector handbook) 
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APPENDIX VI 
 
Complete list of clones illustrating scoring of HIS3, ADE2 and MEL1 reporter genes activation 
during Y2H analysis 
Clone ID 
Growth on TDO    
(HIS3 activation) 
Growth on QDO 
(ADE2 activation) 
X-α-galactosidase assay                    
(MEL1 activation) 
1 ++++ +++ Pale blue 
2 +++ + No blue 
3 +++ - - 
4 ++++ ++++ Pale blue 
5 ++++ ++++ Dark blue 
6 ++++ +++ Pale blue 
7 +++ - - 
8 ++++ ++++ Medium blue 
9 ++ ++ Medium blue 
10 ++++ - - 
11 +++ ++ Pale blue 
12 +++ - - 
13 + - - 
14 ++++ +++ Dark blue 
15 ++ - - 
16 + - - 
17 ++ + Dark blue 
18 + - - 
19 ++++ ++ Pale blue 
20 ++++ +++ Dark blue 
21 ++++ ++++ Dark blue 
22 ++++ ++++ Dark blue 
23 ++++ +++ Dark blue 
24 ++++ +++ Dark blue 
25 ++ - - 
26 +++ + Pale blue 
27 +++ +++ Pale blue 
28 ++++ +++ No blue 
29 +++ ++ Medium blue 
30 +++ + Medium blue 
31 + - - 
32 ++++ ++++ Pale blue 
33 +++ + Pale blue 
34 + - - 
35 +++ ++ No blue 
36 ++++ +++ Pale blue 
37 ++++ ++++ Pale blue 
38 ++++ ++++ Pale blue 
39 ++ - - 
40 ++ ++ Pale blue 
41 ++ - - 
42 + - - 
43 ++++ ++++ Dark blue 
44 + - - 
45 ++++ ++++ Pale blue 
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Clone ID 
Growth on TDO    
(HIS3 activation) 
Growth on QDO 
(ADE2 activation) 
X-α-galactosidase assay                    
(MEL1 activation) 
46 ++++ ++++ Pale blue 
47 ++++ ++++ Pale blue 
48 ++++ ++++ Dark blue 
49 +++ - - 
50 +++ ++ Pale blue 
51 + - - 
52 ++ - - 
53 + - - 
54 +++ +++ Pale blue 
55 ++ - - 
56 ++ ++ Medium blue 
57 + + Pale blue 
58 + - - 
59 ++++ ++ Medium blue 
60 ++ - - 
61 ++ + Pale blue 
62 ++++ ++++ Dark blue 
63 +++ ++ Medium blue 
64 ++++ +++ Dark blue 
65 ++++ +++ Dark blue 
66 +++ +++ Dark blue 
67 ++++ +++ Dark blue 
68 ++ ++ Pale blue 
69 ++++ ++ Dark blue 
70 ++ + Dark blue 
71 ++++ +++ Dark blue 
72 ++++ + Medium blue 
73 ++++ + Dark blue 
74 +++ + Dark blue 
75 ++++ +++ Dark blue 
76 ++ + Medium blue 
77 ++ + Medium blue 
78 +++ + Dark blue 
79 ++ + Dark blue 
80 ++ ++ Medium blue 
81 ++++ + Dark blue 
82 ++ - - 
83 + - - 
84 +++ - - 
85 ++ - - 
86 +++ ++ Medium blue 
87 +++ + Medium blue 
88 + - - 
89 + - - 
90 ++++ ++++ Dark blue 
91 +++ + Pale blue 
92 +++ + Medium blue 
93 ++ - - 
94 + - - 
95 ++ - - 
96 ++ - - 
97 + - - 
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Clone ID 
Growth on TDO    
(HIS3 activation) 
Growth on QDO 
(ADE2 activation) 
X-α-galactosidase assay                    
(MEL1 activation) 
98 +++ - - 
99 +++ +++ Pale blue 
100 ++++ ++++ Dark blue 
101 ++++ ++++ Dark blue 
102 ++++ ++++ Dark blue 
103 ++++ ++ Medium blue 
104 ++++ ++++ Dark blue 
105 ++++ +++ No blue 
106 ++++ ++++ Dark blue 
107 + - - 
108 +++ ++ Medium blue 
109 +++ + Medium blue 
110 ++ + Pale blue 
111 ++ + Pale blue 
112 + - - 
113 ++++ ++++ Dark blue 
114 ++ - - 
115 + - - 
116 ++++ +++ Dark blue 
117 + - - 
118 ++ - - 
119 ++ - - 
120 + - - 
121 +++ +++ Pale blue 
122 +++ ++ Pale blue 
123 ++++ +++ Dark blue 
124 +++ + Medium blue 
125 +++ +++ Pale blue 
126 +++ +++ No blue 
127 +++ +++ Pale blue 
128 ++++ +++ No blue 
129 ++ + Medium blue 
130 +++ +++ Pale blue 
131 ++ ++ Pale blue 
132 ++ ++ No blue 
133 ++ + Medium blue 
134 +++ ++ Pale blue 
135 ++ + Pale blue 
136 +++ +++ Pale blue 
137 + - - 
138 ++++ ++++ Pale blue 
139 ++++ ++ Medium blue 
140 ++++ +++ Dark blue 
141 ++++ ++ Dark blue 
142 ++++ ++++ Medium blue 
143 ++ ++ Medium blue 
144 ++ + Pale blue 
145 + - - 
146 ++ ++ Medium blue 
147 +++ +++ Dark blue 
148 ++ - - 
149 ++++ +++ Dark blue 
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Clone ID 
Growth on TDO    
(HIS3 activation) 
Growth on QDO 
(ADE2 activation) 
X-α-galactosidase assay                    
(MEL1 activation) 
150 +++ +++ Dark blue 
151 ++++ ++++ No blue 
152 ++ - - 
153 ++ ++ No blue 
154 ++++ ++++ No blue 
155 + - - 
156 +++ + Medium blue 
157 ++ - - 
158 ++ + Dark blue 
159 ++++ + Dark blue 
160 ++ ++ Medium blue 
161 ++++ ++++ Dark blue 
162 ++++ +++ Dark blue 
163 ++ - - 
164 ++++ ++++ Dark blue 
165 ++++ ++++ Dark blue 
166 +++ ++ Dark blue 
167 ++++ - - 
168 ++++ ++++ No blue 
169 ++ - - 
170 + - - 
171 ++++ +++ Dark blue 
172 ++++ ++ Pale blue 
173 ++++ + Medium blue 
174 ++++ +++ Dark blue 
175 +++ + Medium blue 
176 +++ + Pale blue 
177 ++ + Pale blue 
178 ++ + Pale blue 
179 ++++ + Pale blue 
180 ++++ + Medium blue 
181 ++ + Pale blue 
182 ++ + Pale blue 
183 +++ +++ Pale blue 
184 +++ +++ Pale blue 
185 +++ + Medium blue 
186 ++++ +++ Pale blue 
187 +++ +++ Pale blue 
188 ++++ +++ Dark blue 
189 +++ + Medium blue 
190 +++ +++ No blue 
191 ++ - - 
192 + - - 
193 + - - 
194 ++ ++ Medium blue 
195 ++++ + Dark blue 
196 +++ - - 
197 +++ ++ Medium blue 
198 ++++ +++ Dark blue 
199 ++++ +++ Dark blue 
200 ++ - - 
201 ++ - - 
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Clone ID 
Growth on TDO    
(HIS3 activation) 
Growth on QDO 
(ADE2 activation) 
X-α-galactosidase assay                    
(MEL1 activation) 
202 ++++ +++ Dark blue 
203 ++++ ++ Medium blue 
204 ++++ +++ Dark blue 
205 ++++ ++ Medium blue 
206 + - - 
207 ++++ ++++ Dark blue 
208 ++++ +++ Dark blue 
209 ++ - - 
210 + - - 
211 + - - 
212 ++ - - 
213 ++ - - 
214 +++ +++ Pale blue 
215 +++ ++ Medium blue 
216 + - - 
217 ++++ + Dark blue 
218 ++++ +++ Dark blue 
219 +++ ++ Medium blue 
220 ++++ ++ Medium blue 
221 ++++ ++++ Dark blue 
222 ++++ ++++ Dark blue 
223 ++++ ++++ Dark blue 
224 ++++ +++ Dark blue 
225 ++++ +++ Dark blue 
226 ++ - - 
227 + - - 
228 + - - 
229 + - - 
230 ++++ ++++ Pale blue 
231 +++ - - 
232 ++++ ++++ Dark blue 
233 ++ + Medium blue 
234 ++ - - 
235 ++ ++ Dark blue 
236 +++ +++ Pale blue 
237 ++ - - 
238 + - - 
239 +++ +++ Pale blue 
240 ++ - - 
241 ++ - - 
242 ++++ ++++ Medium blue 
243 ++ - - 
244 +++ + Pale blue 
245 + - - 
246 +++ +++ Pale blue 
247 ++ + Pale blue 
248 ++ + Pale blue 
249 +++ + Pale blue 
250 + - - 
251 ++++ +++ Pale blue 
252 ++++ ++++ Medium blue 
253 ++ ++ Pale blue 
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Clone ID 
Growth on TDO    
(HIS3 activation) 
Growth on QDO 
(ADE2 activation) 
X-α-galactosidase assay                    
(MEL1 activation) 
254 +++ ++ Pale blue 
255 ++++ ++ Pale blue 
256 ++++ ++++ Dark blue 
257 ++++ ++++ Dark blue 
258 ++++ ++++ Dark blue 
259 ++++ ++++ Medium blue 
260 ++++ ++++ Pale blue 
261 +++ +++ Pale blue 
262 + - - 
263 ++ ++ Pale blue 
264 ++ - - 
265 + - - 
266 + - - 
267 + - - 
268 ++ - - 
269 +++ +++ Pale blue 
270 + - - 
271 ++++ +++ Dark blue 
272 + - - 
273 ++ - - 
274 +++ +++ Dark blue 
275 ++++ ++++ Dark blue 
276 ++++ ++++ Dark blue 
277 ++++ ++++ Dark blue 
278 ++++ ++++ Medium blue 
279 ++++ ++ Medium Blue 
280 ++ ++ Medium blue 
281 ++ - - 
282 ++ ++ Medium blue 
283 ++ - - 
284 +++ ++ Pale blue 
285 ++++ ++ Pale blue 
286 ++ ++ Pale blue 
287 +++ +++ Pale blue 
288 ++ + Medium blue 
289 ++ ++ Pale blue 
290 +++ ++ Pale blue 
291 ++++ ++++ No blue 
292 + - - 
293 +++ +++ Pale blue 
294 +++ +++ Pale blue 
295 +++ +++ Pale blue 
296 ++++ +++ No blue 
297 ++++ ++++ No blue 
298 ++++ +++ No blue 
299 + - - 
300 + + No blue 
301 +++ +++ Pale blue 
302 +++ +++ Pale blue 
303 +++ ++ Pale blue 
304 + - - 
305 ++ ++ Pale blue 
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Clone ID 
Growth on TDO    
(HIS3 activation) 
Growth on QDO 
(ADE2 activation) 
X-α-galactosidase assay                    
(MEL1 activation) 
306 +++ + Medium blue 
307 ++ + Pale blue 
308 ++++ ++++ No blue 
309 +++ +++ Pale blue 
310 ++++ ++++ Pale blue 
311 +++ ++ Medium blue 
312 +++ ++ Medium blue 
313 +++ ++ Pale blue 
314 +++ ++ Pale blue 
315 ++++ ++ Pale blue 
316 ++++ ++++ Pale blue 
317 ++++ ++++ Dark blue 
318 +++ +++ Dark blue 
319 +++ +++ Dark blue 
320 +++ +++ Dark blue 
321 ++++ +++ Dark blue 
322 + - - 
323 ++ - - 
324 ++++ +++ Pale blue 
325 ++ - - 
326 ++ - - 
327 ++ - - 
328 + - - 
329 ++++ ++++ Dark blue 
330 ++++ ++++ Dark blue 
331 ++++ ++ Pale blue 
332 ++++ +++ Dark blue 
333 ++++ +++ Dark blue 
334 ++++ ++++ Dark blue 
335 ++ - - 
336 ++ - - 
337 ++++ +++ Dark blue 
338 + - - 
339 + - - 
340 ++++ +++ Dark blue 
341 ++ - - 
342 +++ ++ Pale blue 
343 ++ + Medium blue 
344 ++++ ++ Medium blue 
345 ++++ +++ Dark blue 
346 + - - 
347 ++++ ++++ Dark blue 
348 ++++ ++++ Dark blue 
349 ++ - - 
350 + - - 
351 + - - 
352 ++ + Pale blue 
353 + - - 
354 + - - 
355 + - - 
356 ++ - - 
357 ++ ++ Pale blue 
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Clone ID 
Growth on TDO    
(HIS3 activation) 
Growth on QDO 
(ADE2 activation) 
X-α-galactosidase assay                    
(MEL1 activation) 
358 +++ ++ Pale blue 
359 + - - 
360 ++++ ++++ No blue 
361 ++++ ++++ Dark blue 
362 ++ + Pale blue 
363 ++++ ++++ Pale blue 
364 ++ - - 
365 ++ - - 
366 + - - 
367 + - - 
368 + - - 
369 + - - 
370 +++ +++ Pale blue 
371 ++++ +++ Pale blue 
372 + - - 
373 + - - 
374 ++ ++ No blue 
375 + - - 
376 + - - 
377 ++++ ++++ Dark blue 
378 ++++ +++ Dark blue 
379 ++++ ++++ Dark blue 
380 ++ - - 
381 ++++ ++++ Dark blue 
382 ++++ ++++ Dark blue 
383 ++ - - 
384 ++ - - 
385 + - - 
386 +++ ++++ Dark blue 
387 ++++ ++++ Dark blue 
388 ++ - - 
389 +++ - - 
390 ++++ ++++ Dark blue 
391 ++ - - 
392 + - - 
393 ++++ + Dark blue 
394 ++ - - 
395 ++ ++++ Dark blue 
396 ++ - - 
397 +++ - - 
398 ++++ ++++ No blue 
399 ++ - - 
400 + - - 
401 +++ +++ No blue 
402 ++++ ++++ Dark blue 
403 ++ - - 
404 ++ - - 
405 +++ - - 
406 + - - 
407 ++ - - 
408 ++ - - 
409 ++ - - 
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Clone ID 
Growth on TDO    
(HIS3 activation) 
Growth on QDO 
(ADE2 activation) 
X-α-galactosidase assay                    
(MEL1 activation) 
410 + - - 
411 + - - 
412 + - - 
413 ++++ + Pale blue 
414 ++ - - 
415 + - - 
416 ++++ ++++ Pale blue 
417 ++ - - 
418 +++ - - 
419 + - - 
420 ++ - - 
421 ++ - - 
422 + - - 
423 ++++ ++++ Dark blue 
424 ++ - - 
425 ++ - - 
426 + - - 
427 + - - 
428 +++ +++ Pale blue 
429 +++ - - 
430 + - - 
431 + - - 
432 ++++ ++++ Dark blue 
433 ++++ +++ Dark blue 
434 ++++ +++ Pale blue 
435 ++++ +++ Dark blue 
436 ++++ +++ Dark blue 
437 ++++ ++++ Dark blue 
438 +++ - - 
439 ++++ ++++ Dark blue 
440 ++ + Pale blue 
441 ++++ +++ Dark blue 
442 ++++ +++ Dark blue 
443 ++++ +++ Dark blue 
444 ++++ + Medium blue 
445 ++ - - 
446 + - - 
447 ++++ ++ Pale blue 
448 ++ - - 
449 ++ - - 
450 + - - 
451 + - - 
452 ++++ +++ Dark blue 
453 + - - 
454 + - - 
455 + - - 
456 + - - 
457 ++ - - 
458 ++ - - 
459 + - - 
460 ++ - - 
461 +++ - - 
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Clone ID 
Growth on TDO    
(HIS3 activation) 
Growth on QDO 
(ADE2 activation) 
X-α-galactosidase assay                    
(MEL1 activation) 
462 ++++ ++++ Dark blue 
463 +++ - - 
464 + - - 
465 ++++ ++++ Dark blue 
466 ++ - - 
467 ++ - - 
468 ++ - - 
469 ++ - - 
470 + - - 
471 + - - 
472 ++++ ++++ Dark blue 
473 + - - 
474 ++ - - 
475 + - - 
476 +++ +++ Dark blue 
477 ++ - - 
478 ++++ ++++ No blue 
479 + + No blue 
480 + + No blue 
481 ++ + Pale blue 
482 + - - 
483 ++++ +++ Dark blue 
484 + - - 
485 + - - 
486 ++ - - 
487 ++ ++ Medium blue 
488 +++ ++ Pale blue 
489 ++++ +++ Dark blue 
490 +++ +++ Dark blue 
491 +++ ++ Medium blue 
492 + - - 
493 ++ - - 
494 ++++ ++++ Dark blue 
495 +++ +++ Dark blue 
496 ++++ ++++ Dark blue 
497 ++++ ++ Pale blue 
498 ++ - - 
499 + - - 
500 + - - 
501 + - - 
502 ++ - - 
503 +++ - - 
504 ++ ++ Medium blue 
505 ++ - - 
Clones in blue font were designated as primary clones. Abbreviations: ++++, excellent growth; +++ fair growth; 
++ weak growth; +, very weak growth; -, no growth; QDO, quadruple dropout (SD media lacking tryptophan, 
leucine, histidine and adenine); TDO, triple dropout (SD media lacking tryptophan, leucine and histidine); Y2H, 
yeast two-hybrid 
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APPENDIX VII 
 
Complete list of clones scored for bait-prey interaction specificity 
Clone ID pGBKT7-parkin pGBKT7 pGBKT7-53 pGBKT7-TTN 
5 ++++ +++ + + 
8 ++++ + - + 
14 ++++ - + - 
20 ++++ ++ - + 
21 ++++ - +++ - 
22 ++++ ++ - ++ 
23 ++++ + - - 
24 ++++ + - + 
43 +++++ + - + 
48 ++++ + + + 
62 ++++ + + - 
64 ++++ + - + 
65 ++++ ++++ + +++ 
66 ++++ + + + 
69 ++++ + + + 
71 +++++ ++++ +++ ++ 
75 +++++ ++++ + + 
90 ++++ +++ + + 
100 ++++ + + + 
101 ++++ - - + 
102 ++++ + - + 
104 ++++ + ++++ - 
113 +++++ + +++ + 
116 ++++ + ++++ - 
123 ++++ ++ +++ +++ 
140 ++++ + ++++ + 
141 ++++ + + - 
142 ++++ + + + 
147 +++++ + - - 
149 ++++ +++ - - 
150 +++++ - +++ + 
161 ++++ + + + 
162 +++++ + +++ + 
164 ++++ + + + 
165 ++++ + + + 
166 ++++ + - + 
171 ++++ - ++++ ++++ 
174 +++++ - + + 
188 ++++ + + + 
198 ++++ + + + 
199 ++++ + - +++ 
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Clone ID pGBKT7-parkin pGBKT7 pGBKT7-53 pGBKT7-TTN 
202 ++++ +++ - - 
204 ++++ + + + 
207 ++++ +++ - + 
208 ++++ + - + 
218 ++++ + - + 
221 +++++ + + - 
222 ++++ - - - 
223 ++++ ++ + + 
224 ++++ + - + 
225 ++++ + + + 
232 ++++ + ++++ + 
242 ++++ + - - 
252 ++++ - + + 
256 ++++ + +++ ++ 
257 ++++ + + + 
258 +++++ + - - 
259 ++++ + + + 
271 +++++ + + ++++ 
274 ++++ + + + 
275 ++++ + ++++ + 
276 ++++ + + + 
277 ++++ + + + 
278 ++++ + + + 
317 ++++ + - + 
318 ++++ + + + 
319 +++++ + + + 
320 ++++ +++ +++ + 
321 ++++ + - + 
329 ++++ + + + 
330 ++++ + + + 
332 ++++ +++ + + 
333 ++++ + +++ ++++ 
334 ++++ ++++ + + 
337 ++++ + + + 
340 ++++ ++ + + 
345 ++++ + +++ + 
361 ++++ ++ ++ ++ 
372 ++++ - + + 
377 ++++ + + + 
378 ++++ ++ +++ - 
379 ++++ + - + 
386 ++++ ++ +++ ++ 
387 ++++ ++ ++ ++ 
390 ++++ ++ ++ ++ 
395 ++++ + + + 
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Clone ID pGBKT7-parkin pGBKT7 pGBKT7-53 pGBKT7-TTN 
423 ++++ - + - 
432 ++++ + + + 
433 +++++ ++++ ++++ ++++ 
435 ++++ - + + 
436 ++++ + - + 
437 +++++ + + + 
439 ++++ + + + 
441 ++++ +++ + ++++ 
442 ++++ ++ ++++ - 
443 ++++ + + + 
452 ++++ + + + 
462 ++++ - ++++ + 
465 ++++ ++ - ++ 
472 ++++ +++ - + 
476 +++++ + + + 
483 ++++ + - + 
489 ++++ - + + 
490 ++++ ++++ ++++ - 
494 ++++ + + + 
495 ++++ - - - 
496 ++++ + + + 
Clones in blue font were considered to demonstrate specific parkin-bait interactions. All colonies were scored 
after 7 days on QDO plates. Abbreviations: ++++, excellent growth; +++ fair growth; ++ weak growth; +, very 
weak growth; -, no growth; QDO, quadruple dropout (SD media lacking tryptophan, leucine, histidine and 
adenine 
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APPENDIX VIII 
 
SEPT9 
 
 
 
 
ATPAF1 
 
 
 
 
 
γ-Actin 
 
 
 
 
14-3-3η 
 
 
 
 
 
Protein expression of parkin interactors in parkin-null and wild-type fibroblasts over three 
experimental runs. Relative protein expression of SEPT9, ATPAF1, γ-actin and 14-3-3η were 
assayed with western blots in fibroblasts from parkin-null patients (P2 and P3) and wild-type controls 
(WT2, WT3, WT4). Expression of interactors (top lanes) was normalized to GAPDH expression 
(bottom lanes). Experiments were performed in triplicate (N=3) and western blots of all three replicate 
runs are shown. Numbers on the side of western blots denote protein sizes (in kiloDalton).  
 
 
 
 
  P2       P3      WT2     WT3   WT4         P2       P3      WT2    WT3    WT4          P2       P3     WT2   WT3    WT4 
 
 
  P2       P3      WT2     WT3   WT4         P2       P3      WT2    WT3    WT4          P2       P3     WT2   WT3    WT4 
 
 
  P2       P3      WT2    WT3    WT4          P2       P3    WT2   WT3    WT4           P2       P3      WT2    WT3   WT4 
 
 
  P2        P3     WT2    WT3   WT4          P2       P3    WT2   WT3    WT4             P2        P3     WT2   WT3    WT4 
 
 
65 -  
36 -  
36 -  
36 -  
36 -  
28 -  
42 -  
36 -  
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APPENDIX IX 
 
GRAPHICAL OUTPUTS OF FUNCTIONAL ASSAYS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell growth in patient-derived and wild-type fibroblasts under basal and CCCP-stressed 
conditions, with and with Vitamin K2 treatment. Cell growth was assessed by a CyQUANT® 
assay. Box-and-whisker plots depict measurements for each fibroblast cell line for three experimental 
runs. A, cell growth in different cell lines under each treatment category. B, comparison of cell 
growth under different treatments within a given cell line.  
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Cell viability in patient-derived and wild-type fibroblasts under basal and CCCP-stressed 
conditions, with and with Vitamin K2 treatment. Cell viability was assessed by a MTT assay. Box-
and-whisker plots depict measurements for each fibroblast cell line for three experimental runs. A, 
cell viability in different cell lines under each treatment category. B, comparison of cell viability 
under different treatments within a given cell line.  
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Parameters of respiratory control in patient-derived and wild-type fibroblasts. Box-and-whisker 
plots depict values for each fibroblast cell line, with 6 replicate measurements.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Relative Δψm of untreated patient-derived and wild-type fibroblasts, with and with Vitamin K2 
treatment. Relative Δψm was determined by JC-1 red:green fluorescent emission ratios, across 3 
experimental runs. Red:green ratios for each fibroblast cell line is shown in the left panel, whereas the 
effect of treatment with vitamin K2 (MK-4) on the red:green ratio of each cell line is shown in the 
right panel.  
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Mitochondrial network analysis of patient-derived and wild-type fibroblasts, with and with 
Vitamin K2 treatment. Mitotracker Red and live-cell microscopy was used to visualize the 
mitochondrial network. All images were assessed in regards to the degree of mitochondrial branching 
(form factor) and degree of mitochondrial elongation (aspect ratio), with approximately 40 cell 
analyzed per fibroblast cell line. The distribution of these parameters in each fibroblast cell line are 
represented on logarithmic scale in box-and-whisker-plots.  
 
Untreated 
MK-4 
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APPENDIX X 
 
SEPT9_v1      MKKSYSGGTRTSSGRLRRLGDSSGPALKRSFEVEEVETPNSTPPRRVQTPLLRATVASST 60 
SEPT9_v2      MSDP------AVNAQLDG-IISDFEALKRSFEVEEVETPNSTPPRRVQTPLLRATVASST 53 
SEPT9_v3      ------------------MERDRISALKRSFEVEEVETPNSTPPRRVQTPLLRATVASST 42 
ORF           ------------------------------------------------------------ 0 
                                                                           
 
SEPT9_v1      QKFQDLGVKNSEPSARHVDSLSQRSPKASLRRVELSGPKAAEPVSRRTELSIDISSKQVE 120 
SEPT9_v2      QKFQDLGVKNSEPSARHVDSLSQRSPKASLRRVELSGPKAAEPVSRRTELSIDISSKQVE 113 
SEPT9_v3      QKFQDLGVKNSEPSARHVDSLSQRSPKASLRRVELSGPKAAEPVSRRTELSIDISSKQVE 102 
ORF           -------------------------------------------------LSIDISSKQVE 11 
                                                               *********** 
 
SEPT9_v1      NAGAIGPSRFGLKRAEVLGHKTPEPAPRRTEITIVKPQESAHRRMEPPASKVPEVPTAPA 180 
SEPT9_v2      NAGAIGPSRFGLKRAEVLGHKTPEPAPRRTEITIVKPQESAHRRMEPPASKVPEVPTAPA 173 
SEPT9_v3      NAGAIGPSRFGLKRAEVLGHKTPEPAPRRTEITIVKPQESAHRRMEPPASKVPEVPTAPA 162 
ORF           NAGAIGPSRFGLKRAEVLGHKTPEPAPRRTEITIVKPQESAHRRMEPPASKVPEVPTAPA 71 
              ************************************************************ 
 
SEPT9_v1      TDAAPKRVEIQMPKPAEAPTAPSPAQTLENSEPAPVSQLQSRLEPKPQPPVAEATPRSQE 240 
SEPT9_v2      TDAAPKRVEIQMPKPAEAPTAPSPAQTLENSEPAPVSQLQSRLEPKPQPPVAEATPRSQE 233 
SEPT9_v3      TDAAPKRVEIQMPKPAEAPTAPSPAQTLENSEPAPVSQLQSRLEPKPQPPVAEATPRSQE 222 
ORF           TDAAPKRVEIQMPKPAEAPTAPSPAQTLENSEPAPVSQLQSRLEPKPQPPVAEATPRSQE 131 
              ************************************************************ 
 
SEPT9_v1      ATEAAPSCVGDMADTPRDAGLKQAPASRNEKAPVDFGYVGIDSILEQMRRKAMKQGFEFN 300 
SEPT9_v2      ATEAAPSCVGDMADTPRDAGLKQAPASRNEKAPVDFGYVGIDSILEQMRRKAMKQGFEFN 293 
SEPT9_v3      ATEAAPSCVGDMADTPRDAGLKQAPASRNEKAPVDFGYVGIDSILEQMRRKAMKQGFEFN 282 
ORF           ATEAAPSCVGDMADTPRDAGLKQAPASRNEKAPVDFGYVGIDSILEQMRRKAMKQGFEFN 191 
              ************************************************************ 
 
SEPT9_v1      IMVVGQSGLGKSTLINTLFKSKISRKSVQPTSEERIPKTIEIKSITHDIEEKGVRMKLTV 360 
SEPT9_v2      IMVVGQSGLGKSTLINTLFKSKISRKSVQPTSEERIPKTIEIKSITHDIEEKGVRMKLTV 353 
SEPT9_v3      IMVVGQSGLGKSTLINTLFKSKISRKSVQPTSEERIPKTIEIKSITHDIEEKGVRMKLTV 342 
ORF           IMVVGQSGLGKSTLINTLFKSKISRKSVQPTSEERIPKTIEIKSITHDIEEKGVRMKLTV 251 
              ************************************************************ 
 
SEPT9_v1      IDTPGFGDHINNENCWQPIMKFINDQYEKYLQEEVNINRKKRIPDTRVHCCLYFIPATGH 420 
SEPT9_v2      IDTPGFGDHINNENCWQPIMKFINDQYEKYLQEEVNINRKKRIPDTRVHCCLYFIPATGH 413 
SEPT9_v3      IDTPGFGDHINNENCWQPIMKFINDQYEKYLQEEVNINRKKRIPDTRVHCCLYFIPATGH 402 
ORF           IDTPGFGDHINNENCWQPIMKFINDQYEKYLQEEVNINRKKRIPDTRVHCCLYFIPATGH 311 
              ************************************************************ 
 
SEPT9_v1      SLRPLDIEFMKRLSKVVNIVPVIAKADTLTLEERVHFKQRITADLLSNGIDVYPQKEFDE 480 
SEPT9_v2      SLRPLDIEFMKRLSKVVNIVPVIAKADTLTLEERVHFKQRITADLLSNGIDVYPQKEFDE 473 
SEPT9_v3      SLRPLDIEFMKRLSKVVNIVPVIAKADTLTLEERVHFKQRITADLLSNGIDVYPQKEFDE 462 
ORF           SLRPLDIEFMKRLSKVVNIVPVIAKADTLTLEERVHFKQRITADLLSNGIDVYPQKEFDE 371 
              ************************************************************ 
 
SEPT9_v1      DSEDRLVNEKFREMIPFAVVGSDHEYQVNGKRILGRKTKWGTIEVENTTHCEFAYLRDLL 540 
SEPT9_v2      DSEDRLVNEKFREMIPFAVVGSDHEYQVNGKRILGRKTKWGTIEVENTTHCEFAYLRDLL 533 
SEPT9_v3      DSEDRLVNEKFREMIPFAVVGSDHEYQVNGKRILGRKTKWGTIEVENTTHCEFAYLRDLL 522 
ORF           DSEDRLVNEKFREMIPFAVVGSDHEYQVNGKRILGRKTKWGTIEVENTTHCEFAYLRDLL 431 
              ************************************************************ 
 
SEPT9_v1      IRTHMQNIKDITSSIHFEAYRVKRLNEGSSAMANGMEEKEPEAPEM   586 
SEPT9_v2      IRTHMQNIKDITSSIHFEAYRVKRLNEGSSAMANGMEEKEPEAPEM   579 
SEPT9_v3      IRTHMQNIKDITSSIHFEAYRVKRLNEGSSAMANGMEEKEPEAPEM   568 
ORF           IRTHMQNIKDITSSIHFEAYRVKRLNEGSSAMANGMEEKEPEAPEM   477 
              ********************************************** 
 
Protein alignment of translated ORF sequence of Y2H clone 318 with SEPT9 isoforms. Three 
representative SEPT9 isoforms (SEPT9_v1, SEPT9_v2 and SEPT9_v3) were selected; clone 318 had 
a 100% identity to all isoforms. Hence, clone 318 encodes a peptide common to all SEPT9 isoforms. 
The isoform-variable region of SEPT9 is shown in red font, whereas the GTPase domain-containing 
region is shown in blue font. In silico alignment was performed with CLUSTAL O 1.2.1 
(http://www.ebi.ac.uk/Tools/msa/clustalo). 
Stellenbosch University  https://scholar.sun.ac.za
277 
 
 
Stellenbosch University  https://scholar.sun.ac.za
